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  Abstract 1 
Abstract 
 
Action potentials are an essential process for signal transmission in excitable cells. At chemical 
synapses, the action potential triggers the release of neurotransmitters from synaptic vesicles to 
transmit the signal to the target cells. After signal transmission, the neurotransmitters are 
refilled into synaptic vesicles. The uptake mechanism of the primary excitatory 
neurotransmitter glutamate is mediated by the vesicular glutamate transporter (VGLUT).[1,2] 
However, the efficiency of glutamate transport by VGLUT is tightly regulated by the 
extravesicular and luminal Cl- concentrations.[3,4] Despite many years of research, quantitative 
measurements of the Cl- conductance through VGLUT and the regulation of neurotransmitter 
uptake are still under discussion. For unravelling of the complex dependence between Cl- and 
glutamate transport, fluorescent Cl- sensors were developed, which allow measurements of the 
intravesicular Cl- concentration. The sensor was labelled with a Cl- sensitive BAC fluorophore 
and the insensitive AlexaFluor 647 dye. This combination of dyes allows a ratiometric 
measurement of the Cl- concentrations, independent of the experimental parameters.[5–7] The 
BAC fluorophore, thereby, has the advantage of Cl- sensitivity within the physiological range, 
pH insensitivity as well as prolonged excitation and emission wavelengths compared to Cl- 
sensitive protein reporters. The backbone of the sensor, which connects both fluorophores, is 
composed of a PNA-DNA scaffold (PNA = peptide nucleic acid), combining the sensing, 
normalising and stabilisation module.[5,6,8] The PNA-DNA backbone was further modified with 
membrane anchors, for enhanced incorporation of the Cl- sensor into the luminal site of the 
liposome. Modification with a protease cleavage sequence or affinity tag allows the specific 
removal of extravesicular orientated sensors from the liposome. For VGLUT dependent 
measurements of Cl- concentration, liposomes were co-reconstituted with a bacterial proton 
pump (TF0F1) and VGLUT. Therefore, incorporation of the Cl
- sensor allows direct 








Apart from investigations of Cl- dependence during the neurotransmitter uptake of glutamate 
through VGLUT, an attempt of specific blockage of voltage-gated sodium (NaV) channels was 
studied in chapter two of this thesis. NaV channels are key players of the initiation and 
propagation of action potentials. Dysfunctions of the nine different isoforms are linked to 
diseases of the nervous system, heart rhythm and skeletal muscles contraction.[9,10] However, 
especially malfunctions of the NaV1.2 channel subtype are associated with neurological 
disorders.[11] For further understanding of the disease development and progression, improved 
visualisation of the NaV1.2 channels are essential. Therefore, new fluorescently labelled 
inhibitors with high affinity and specificity are required. Screening studies of neurotoxins from 
venomous cone snails revealed the µ-conotoxin SIIIA, which blocks the NaV1.2 channel with 
nanomolar affinity and the skeletal NaV1.4 channel with submicromolar affinity.
[12–14] The 
synthesis and challenging folding of the µ-conotoxin SIIIA could be improved by using a 
regioselective folding strategy with orthogonal thiol-protecting groups. After the successful 
formation of the native µ-SIIIA, the molecule was labelled with an AlexaFluor 488 fluorophore 
enabling channel visualisation. For activity measurements with the µ-conotoxin SIIIA, a caging 
approach was developed, which precisely allows NaV channel inhibition upon photocleavage 
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1 Synthesis of Chloride-Sensors to Investigate 
Neurotransmitter filling in Synaptic Vesicles 
 
1.1 Introduction - Synaptic Vesicle 
The communication between neurons and their target cells occurs at the synapse and is 
regulated by action potentials. In a synapse, an incoming action potential results in the release 
of neurotransmitters from synaptic vesicles to transmit the signal to the target cell. Synaptic 
vesicles (SV) are lipid bilayer compartments with a small size 40 nm diameter, which are 
restricted to the uptake, storage and release of neurotransmitters.[1,2,15]  
The neurotransmitter release process, induced by an action potential, is called exocytosis and 
proceeds in three distinct steps: docking, priming and fusion. In the docking step, the SV is 
recruited to the active zone (see figure 1.1). This zone is a specialised region close to the 
presynaptic membrane characterised by an accumulation of cytoskeleton-associated 
proteins.[1,16,17] The docking process is mediated by the soluble N-ethylmaleimide-sensitive-
factor attachment receptors (SNAREs) proteins, ensuring the fusion of synaptic vesicles with 
the presynaptic membrane. Next, the synaptic vesicles must be converted into a ready-to-fuse 
state. All docked and fused synaptic vesicles belong to the readily releasable pool (RRP), 
allowing immediate vesicle fusion upon electrical stimulation.[18–20] 
The incoming action potential depolarises the synapse, resulting in the activation of voltage-
gated Ca2+ channels. The Ca2+ influx triggers the fusion of synaptic vesicles with the presynaptic 
nerve terminal, releasing neurotransmitters into the synaptic cleft. These neurotransmitters 
activate the postsynaptic receptors and therefore induce an ion influx in the postsynaptic 
membrane, which generates a new action potential.[1,21] After fusion, the synaptic vesicles are 
endocytosed, recycled by clathrin-coated proteins and refilled with neurotransmitters for a new 
round of exocytosis.[1,20]
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Figure 1.1: Cycling of Neurotransmitters and Synaptic vesicles. Neurotransmitter filled synaptic vesicles are 
transported to the active zone in the nerve terminal. After docking and priming, the neurotransmitters are released 
into the synaptic cleft, triggered by Ca2+ influx. The synaptic vesicles are recycled by endocytosis and refilled with 
neurotransmitters. Reprinted with permission from R. JAHN et al., Nature 2012, 490, 201–207. 
Vesicular neurotransmitter transporters regulate the refilling of neurotransmitters in 
endocytosed synaptic vesicles. All vesicular transporters are secondary active transporters that 
require an electrochemical gradient (ΔµH+), which is generated by a vacuolar-type H+-ATPase 
(V-ATPase) in the membrane of the SVs. The V-ATPase hydrolyses cytosolic ATP and pumps 
the corresponding H+ into the vesicle lumen, building a pH gradient (ΔpH) as well as a positive 
membrane potential (ΔΨ) across the vesicle membrane. The pH gradient, as well as ΔΨ, 
contribute to the electrochemical gradient (ΔµH+) which can be calculated by the       
equation:[22–24] 
ΔµH+ = ΔΨ +(2.3 RT/zF) log ([H+]in/[H
+]out)    (1.1) 
R = gas constant, T = temperature, z = ion valence, F = Faraday constant 
 
1.1.1 Vesicular Neurotransmitter Transporters 
So far, four different vesicular neurotransmitter transporters have been discovered and can be 
classified depending on the neurotransmitters they transport.[25] The first identified group were 
vesicular monoamine transporters (VMATs), which transport monoamines like dopamine, 
serotonin, noradrenaline or adrenaline. VMATs exhibit a submicromolar affinity for their 
substrates due to the low cytosolic concentration of monoamines.[26,27] Uptake of monoamine 
in SVs is driven by an antiport mechanism, exchanging two luminal H+ for one positively 
charged monoamine. This transport mechanism mainly depends on the ΔpH component of 
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ΔµH+.[28,29] The vesicular acetylcholine transporter (VAchT) is closely related to the VMATs, 
showing a similar transport mechanism by exchanging luminal protons for one positively 
charged acetylcholine.[28,30]  
The third group is the vesicular inhibitory amino acid transporter (VIAAT or VGAT) 
responsible for the uptake of γ-aminobutyric acid (GABA) and glycine in the synaptic vesicle. 
The transport of non-charged GABA and glycine is believed to be mediated by an H+-antiport 
mechanism requiring both components of ΔµH+.[31,32]  
The transport of the primary excitatory neurotransmitter glutamate is mediated by the vesicular 
glutamate transporter (VGLUT). The main driving force for the negatively charged glutamate 
uptake is the membrane potential ΔΨ (see figure 1.2).[33] The transport of glutamate is highly 
complex and was extensively investigated over the last years.[34,35] 
 
Figure 1.2: Proton-dependent neurotransmitter transport into vesicles. Refilling and storing of different 
neurotransmitters into synaptic vesicles, driven by the ΔµH+ electrochemical gradient generated by the V-ATPase. 
Reprinted with permission from N. PIETRANCOSTA et al., Mol. Neurobiol. 2020, 57, 3118–3142. 
 
1.1.2 The Vesicular Glutamate Transporters  
The requirement of VGLUT for brain function and their involvement in different neurological 
pathologies was demonstrated in various mice studies.[35–38] Analysis of heterozygous VGLUT 
knock-out mice revealed not only issues in the sensory processing, learning as well as the 
memory, they also suffered from neuropathic pain and anxiety.[39] Furthermore, psychiatric and 
neurological disorders like depression, Alzheimer’s disease, epilepsy or schizophrenia can be 
traced back to an imbalance in glutamatergic neurotransmission.[40–43] Most of these 
neurological diseases are not curable and the only available treatment option is the reduction of 
symptoms or delay of progression. Especially psychiatric medications are strictly controlled 
due to the variety of off-target effects.[44] Consequently, a better understanding of the complex 
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processes of glutamatergic transmission in synaptic vesicles is required to develop new 
psychoactive drugs with a higher specification and fewer side effects. 
The VGLUTs are members of solute carrier transmembrane transporters (SLC17) and were first 
described as Na+-dependent inorganic phosphate transporter. The first experiments that showed 
a contribution of VGLUT in transmitting glutamate were performed in the 1980s with purified 
synaptic vesicles.[45] Remarkably, VGLUT has a relatively low affinity for glutamate (1-2 mM) 
but an inability to transport structurally similar amino acids like glutamine or aspartate.[33,46] 
Current estimations suggest a glutamate concentration between 60 and 120 mM in synaptic 
vesicles.[47] 
So far, three different isoforms of the vesicular glutamate transporters (VGLUT1-3) have been 
described, which exhibit a high sequence homology in mammals.[35,48,49] VGLUT1 is the most 
abundant isoform in the CNS and is expressed in the cerebral cortex, hippocampus and the 
amygdala, whereas VGLUT2 is primarily found in subcortical excitatory neurons.[36,50] 
Compared to VMATs and VAchT, the expression of VGLUTs is limited to nerve endings where 
they constantly control the glutamate transport between plasma membrane, endosomes and 
synaptic vesicles.[51,52]  
Surprisingly, VGLUT3 is expressed in non-glutamatergic neurons, disproving DALE’S principle 
that neurons release only one type of neurotransmitters. These findings indicated that glutamate 
act as a co-transmitter in these cells.[50] However, the consequences and mechanism of co-
release for vesicle filling and neurotransmitter release are still under discussion.[53,54] 
 
1.1.3 Structure of Vesicular Glutamate Transporters  
For further insights into the mechanism of glutamate transport, structural informations of 
VGLUTs are required. Recently, LI et al. report the first cryo-electron microscopy structure of 
rat VGLUT2 at 3.8 Å resolution, facilitated by an antigen-binding fragment (Fab) (see figure 
1.3 A).[55] Since VGLUT1 and VGLUT2 exhibit a sequence homology of 75 %, it is assumed 
that both transporters share structural similarities.[55] Analysis of the cryo-EM structure 
revealed that VGLUT2 consists of 12 transmembrane helices, as predicted by modelling studies 
and hydropathy plots.[56] The helices are connected by cytoplasmic loops and are organised into 
an N- and C-domain (see figure 1.3 B and 1.3 C).[55] 
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Figure 1.3: Structure of VGLUT. A) Cryo-EM structure of the VGLUT2. The N-domain is coloured in blue, the 
C-domain is presented in red and Fab is coloured in yellow. B) Schematic presentation of the transmembrane 
domains of VGLUT2. C) Structure of VGLUT2. The helices are highlighted in the colours according to the display 
in B. Reprinted with permission from F. LI et al., Science 2020, 368, 893–897. 
The central cavity of VGLUT consists of positively charged residues ensuring the transport of 
the negatively charged glutamate. The glutamate-binding site is formed by the two domains 
consisting of the residues Arg88, H128, Glu191 (N-Domain) as well as Arg322, His487, 
Glu396, Cys321 (C-Domain) (Figure 1.4 A). Especially the Arg88 residue is highly conserved 
in transporters of the SLC17 family, forming a salt bridge with one carboxyl-group of the 
glutamate. The residue Glu191 and His128 are part of the N-Domain and protonation of the 
Glu191 residue liberates the adjacent Arg88, which subsequently can interact and transport 
glutamate. If no substrate is bound to the Glu191 residue, the channel is blocked by a charged 
pair formed with Arg88 (see figure 1.4 B and 1.4 C).[55] 
The residue Arg322 faces Arg88 from the opposite side of the binding pocket and recognises 
the glutamate substrate's second carboxy group. The relevance of both arginine residues was 
illustrated in mutation studies, showing that R88A reduced the glutamate transport, whereas the 
mutation of R322A eliminates the transport. The residues of the C-Domain His487, Glu396 as 
well as C321 are in proximity to the Arg322 and exclusively conserved along VGLUT and not 
in the SLC17 family, indicating an essential role of the second carboxyl group in the binding 
process of glutamate (Figure 1.4 D).[55,57]  
A B 
C  
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Figure 1.4: Functional residues of VGLUT. A) Electrostatic surface of VGLUT2. The central cavity consists of 
two domains. The N-domain is highlighted in cyan and the C-domain in pink. B) Top view of N-domain, showing 
the essential residues and distances between the sidechains (Å). C) Side-view of the N-Domain. D) Top view of 
the C-domain. Reprinted with permission from F. LI et al., Science 2020, 368, 893–897. 
 
1.1.4 Transport Mechanism of VGLUT  
Over the last years, enormous efforts have been made to understand the transport mechanisms 
and the charge movements in the process of the neurotransmitter filling by VGLUT. The charge 
neutrality for each glutamate transport cycle is especially essential due to the small volume of 
synaptic vesicles. An imbalance of only one charge can result in a change of the membrane 
potential of 2 mV. Also, a single free proton in the lumen of synaptic vesicles leads to a decrease 
in the pH from 7.4 to 4.[3,58] Consequently, the efficient loading of glutamate into synaptic 
vesicles requires different exit or entry pathways for ions to ensure a charge and pH balance.  
The luminal H+ is transported by the V-ATPase into the synaptic vesicle and allosterically 
activate VGLUT to transport glutamate. The main driving force for glutamate transport is the 
membrane potential (ΔΨ), which was demonstrated by specific inhibition of the ΔpH 
component. Measurements with the electroneutral cation antiporter nigericin, which exchanges 
luminal H+ with extravesicular K+, showed no difference in the glutamate transport.[59,60] 
During the transport, the negative charge of glutamate is balanced by the luminal H+, causing 
glutamic acid formation.[33,61] After exhausting the buffering capacity of the synaptic vesicles, 
a cation-H+ exchanger (NHE) catalyses the replacement of luminal H+ for external Na+ or K+ 





 Transport Mechanism of VGLUT 9 
Remarkably, PREOBRASCHENSKI et al. and ERIKSEN et al. presented that VGLUT itself also has 
a K+/H+ exchange activity, enabling a charge-neutral H+ exit pathway to prevent an over-
acidification of the lumen by accumulating high glutamic acid concentrations. Consequently, 
their measurements with reconstituted liposomes showed a significant increase in the glutamate 
uptake in the presence of extravesicular K+.[3,63] Treatment with the VGLUT inhibitor Evans 
Blue reduces the glutamate uptake, indicating a blockage of the K+/H+ exchange.[3]  
Additionally, NAITO and UEDA reported that the efficiency of the glutamate uptake shows a 
biphasic dependency on the extravesicular Cl- concentration. A substantial increase in the 
glutamate uptake in synaptic vesicles was measured at low chloride concentrations (4-6 mM), 
whereas high extravesicular Cl- concentrations (> 20 mM) lead to an inhibitory effect (see 
figure 1.5).[33,50,64] The inhibition of the glutamate uptake at high Cl- levels was explained by 
an increased influx of Cl-, causing an enhanced ΔpH due to the generation of HCl and the 
dissipation of ΔΨ. The stimulating effect at low Cl- concentrations are attributed to an allosteric 
Cl- binding site on the cytoplasmic side of the transporter.[59,64–66] 
 
Figure 1.5: Cl- dependence of vesicular glutamate uptake. At low Cl- concentrations the glutamate uptake 
(black line) and ΔΨ (blue line) are maximal whereas ΔpH (red line) between the vesicular lumen and the cytoplasm 
is low. High extravesicular Cl- concentration increases the ΔpH due to the formation of HCl and subsequently 
decreases ΔΨ and the glutamate accumulation. Reprinted with permission from S. EL MESTIKAWY et al., Nat. Rev. 
Neurosci. 2011, 12, 204–216. 
 
1.1.4.1 Mediation of Chloride Transport into Synaptic Vesicles 
Since Cl- plays an essential role in the regulation of the glutamate transport, the question 
remained, whether Cl- conductance is mediated by chloride transporters, like ClC3 or by 
VGLUT itself.[4,67] ClC3 is a Cl-/H+ exchanger with a 2:1 stoichiometry, which is localised in 
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demonstrated, that ClC3 facilitates acidification of lysosomes and endosomes by an 
accumulation of luminal chloride.[69–72] Also, the disruption of ClC3 in rodent models causes 
neurodegeneration represented by the disability of synaptic vesicle acidification.[67,73] However, 
investigations of synaptic vesicles isolated from ClC3 knock-out mice revealed no difference 
in the biphasic Cl- dependence. The glutamate uptake was still increased at low Cl- 
concentrations and inhibited at high Cl- concentrations. These results indicated that other 
proteins or transporters are involved in the chloride uptake in synaptic vesicles.[3,4] 
Schenck et al. performed similar experiments with VGLUT1 knock-out mice, showing a strong 
reduction in the Cl- and glutamate-dependent acidification, identifying VGLUT as Cl- 
transporter.[4] These results were confirmed by measuring a Cl- induced acidification in 
liposomes co-reconstituted exclusively with VGLUT1 and the bacterial proton pump TF0F1-
ATPase (see figure 1.6 A).[3] Furthermore, PREOBRASCHENSKI et al. fused purified synaptic 
vesicles with large liposomes, including the TF0F1-ATPase to exclude differences in the 
behaviour of VGLUT in a native environment. The hybrid vesicles contained all endogenous 
proteins in the correct orientation. They showed chloride-dependent acidification and chloride-
stimulated glutamate uptake, indicating that Cl- conductance is mediated by VGLUT and not 
the ClC3 channel (see figure 1.6 B).[3] CHANG et al. revealed by measuring endosome currents, 
that extravesicular Cl- directly competes with glutamate for permeation through VGLUT, 
independent of ΔΨ. Therefore, the inhibition of the glutamate uptake at high Cl- concentrations 
can be explained by a compeptitive binding and not exclusively by the dissipation of the driving 
force ΔΨ.[34,74] 
 
Figure 1.6: Proteoliposome model for Cl- transport mechanism. A) Reconstituted liposomes with TF0F1-
ATPase and VGLUT to measure Cl- transport through VGLUT during acidification. B) Formation of hybrid 
vesicles, by SNARE-mediated fusion of TF0F1 liposomes and native synaptic vesicles. Interference with unfused 
synaptic vesicles was excluded by blocking the endogenous V-ATPase activity with bafilomycinA1.[3]. 
A B 
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1.1.4.2 Allosteric Activation of VGLUT by Luminal Chloride 
SCHENCK et al. could further discover that not only extravesicular Cl- influences the glutamate 
transport but also high intravesicular Cl- concentrations allosterically activate the glutamate 
uptake. Measurements in reconstituted liposomes, preloaded with 100 mM KCl, showed a 
threefold increased glutamate uptake compared to the negative control. These results indicated 
one or several allosteric Cl- binding sides that are accessible from the luminal as well as the 
cytoplasmic site.[3,4,63] These findings are in line with the assumption that synaptic vesicle are 
regenerated and filled with high levels of Na+ and Cl- (~ 130 mM) during the process of 
endocytosis.[46] The export of luminal Cl- into the cytoplasm can also drive the glutamate uptake 
exclusively, which was reported by MARTINEAU et al., performing live-cell imaging 
experiments of hippocampal neurons with a pH- and Cl- sensitive fluorophores.[47,63] 
Additionally, CHANG et al. presented electrophysiological recordings of VGLUT-associated 
currents, independent of an H+ pump, ion gradients or ΔΨ. Their measurements in endosomes 
also confirmed an allosteric activation of the glutamate transport by luminal Cl-.[74]  
For more in-depth insights into the relationship between allosteric activation and Cl- 
permeation, CHANG et al. performed mutation studies, revealing that the luminal activation of 
the glutamate transport depends on the interaction of Cl- with a highly conserved arginine 
residue in transmembrane helix 4. Further, they presented that neutralisation of the arginine 
residue by interaction with luminal Cl- is sufficient to initiate the allosteric activation required 
for glutamate transport and Cl- conductance.[74,75] The mutations studies, in which the arginine 
residue was replaced by an uncharged alanine, caused a permanent influx of glutamate and Cl- 
even in the absence of luminal Cl-.[74] 
Based on these findings, EDWARDS and colleagues proposed a mechanism for the glutamate 
uptake within the synaptic vesicle cycle (see figure 1.7). After endocytosis, the high luminal 
Cl- concentration trapped in synaptic vesicles activate the glutamate transport by neutralising 
the positive charge of the Arg residue in TM 4. The efflux of luminal Cl- along its concentration 
gradient generates the membrane potential necessary for the glutamate uptake. The 
glutamate/Cl- exchange mechanism allows an electroneutral filling without affecting the 
osmotic pressure. As the luminal Cl- concentration decreases, the glutamate uptake is driven by 
the membrane potential generated by the V-ATPase pumping H+ in the vesicle lumen. The 
glutamate filling stops when the membrane potential dissipates and the luminal pH decreases, 
resulting in an inactivation of VGLUT. This process prevents the leakage of glutamate from 
filled vesicles. Finally, the filled synaptic vesicles release the glutamate in the synaptic cleft 
during the process of exocytosis. [47,55,74,75] 
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Figure 1.7: Proposed mechanism of glutamate uptake in the synaptic vesicle. Top: Glutamate is released into 
the synaptic cleft. Left: After endocytosis, the synaptic vesicles contain high luminal Cl- concentrations and their 
efflux promotes the glutamate uptake by VGLUT. The glutamate influx is also driven by the ΔΨ generated by 
V-ATPase, pumping H+ in the vesicle. The entry of glutamate causes a decrease in the luminal pH. Right: In the 
late stage of the cycle, the acidified synaptic vesicles are filled with glutamate and the efflux of Cl- maintains 
ΔΨ.[55,75] 
 
1.1.4.3 VGLUT Model for Ion Transport across Vesicular Membranes  
The fundamental role of VGLUT for glutamate uptake was discovered in the recent years, 
showing that VGLUT not only transports glutamate into the synaptic vesicles, it also controls 
the transport of Cl- and functions as K+/H+ antiporter. These different binding modes allow 
VGLUT to control ionic- or charge changes tightly and to optimise the uptake of glutamate into 
synaptic vesicles.[3,74] PREOBRASCHENSKI et al. developed a detailed model of the VGLUT 
transport mechanism, assuming that VGLUT consists of two anionic and at least one cationic 
binding site. VGLUT can also switch between two conformational states, in which it is either 
open to the cytoplasmic (state I) or luminal side (state II) (see figure 1.8).[3]  
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Figure 1.8: Model of the VGLUT transport mechanism. VGLUT has two anionic and one cationic binding site 
and can be open to either the cytoplasmic (state I) or luminal side (state II).[3]  
When VGLUT is open to the cytoplasmic side, one of the anionic binding sites specifically 
binds Cl- with a millimolar affinity (see figure 1.9). The high millimolar Cl- concentration, 
which is present under physiological conditions, leads to a constantly occupied binding 
position. Thus, no net Cl- transport occurs independently of the conformational state of the 
transporter. When the transporter is open to the cytoplasmic side, glutamate can bind with a 
higher affinity to the second anionic binding site compared to Cl-. The binding of glutamate can 
already trigger a conformational change of VGLUT, opening the binding pocket to the luminal 
side, where glutamate dissociates. When VGLUT is open to the luminal side (state II), the 
glutamate binding site is occupied by Cl-, due to much higher luminal Cl- concentration 
compared to glutamate. Consequently, the conformational switch from state II to state I results 
in the efflux of Cl- from the synaptic vesicle. The conformational change of VGLUT in both 
directions is accelerated when the Cl- binding pocket is also occupied, indicating that Cl- 
binding lowers the activation energy for the conformational switch. The glutamate uptake is 
maximal when chloride is present on the luminal as well as the cytoplasmic side.[3,74]  
In the late stages of the synaptic vesicle cycle, when the luminal Cl- concentration is strongly 
reduced, the accumulation of glutamate in the vesicle causes an acidification of the lumen. For 
an efficient glutamate loading in the vesicle even at low intravesicular pH (~5.5), an H+ efflux 
pathway is required. This exit strategy is provided by the K+/H+ antiporter function of VGLUT, 
which transports H+ from the luminal to the cytoplasmic site, whereas K+ is transported in the 
reverse direction. This K+/H+ exchange mediates the glutamate uptake by maintaining ΔΨ and 
decreasing ΔpH. This model shows that VGLUT exhibit Cl- and H+ binding sites, which are not 
tightly coupled to the glutamate transport. This allows adjustments of the changing ionic 
concentrations during the transport mechanism resulting in an efficient glutamate 
loading.[3,44,62] 
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Figure 1.9: Elevated model of the VGLUT transport mechanism. When VGLUT is open to the cytoplasmic 
site (state I), it is loaded with glutamate, Cl- and K+. After the conformational change glutamate and K+ are 
dissociated into the lumen (state II). Next, the glutamate binding site is loaded with Cl- and the cationic site binds 
an H+, which are transported to the cytoplasm.[3]  
 
1.1.5 Development of Fluorescent Chloride Sensor Molecules  
The physiological importance of Cl- is not only limited to the process of glutamate uptake into 
synaptic vesicles, but it is also involved in numerous cellular functions like regulation of cell 
volume and charge balance as well as stabilisation of the resting membrane potential.[76,77] 
However, mutations in Cl- channels or transporters can lead to an imbalance in the chloride 
homeostasis, which is associated with the occurrence of several diseases like cystic fibrosis, 
lysosomal storage disease, osteoporosis or epilepsy.[78,79] For further understanding of these 
disease progression, more profound insights into the Cl- channel activity are essential. 
Consequently, there is a great need for measuring intracellular Cl- concentrations to characterise 
channel activity and cellular processes further. This physiological studies can be addressed by 
using Cl- sensor molecules.[8] 
The first measurements of intracellular chloride concentrations were presented by NEILD and 
THOMAS in 1974, by using a chloride-sensitive microelectrode to measure currents in giant 
neurons of the snail Helix aspersa. However, this method revealed major drawbacks regarding 
the restriction to large cells, the time-consuming preparation and the limited selectivity for 
chloride.[80] Also, radioactive tracers showed only insufficient sensitivity and limited time 
resolution.[81] Sensor molecules based on optical methods were developed, providing the 
 Development of Fluorescent Chloride Sensor Molecules 15 
advantage of spatially and temporally resolved measurements of the Cl- concentration. Over the 
last years, an enormous variety of fluorescent Cl--sensors have been developed, which can be 
categorised into two groups: Cl--sensitive fluorescent proteins and Cl--sensitive small molecule 
dyes.[8,82] 
 
1.1.5.1 Chloride Sensitive Protein Reporters  
Generally, protein-based sensors provide the advantage of subcellular targeting and cellular 
retention compared to small molecule sensors. One of the first Cl- sensitive fluorescent proteins 
was presented by WACHTER and REMINGTON showing that the fluorescence of the yellow 
fluorescent protein (YFP) is quenched in the presence of halide or nitrate ions 
(KD = 777 mM).
[83] YFP is a homolog of the green fluorescent protein (GFP), containing the 
S65G, V68L, S72A and T203Y mutations. Recognising the opportunity to transform YFP into 
a Cl- sensor for intracellular measurements, several mutation studies were performed to increase 
the Cl- affinity and brightness. Especially, the mutant YFP-H148Q-I152L revealed an improved 
KD for Cl
- from 777 mM to 88 mM as well as an accelerated response.[84,85] 
However, the YFP sensors exhibit a pH-dependence under physiological conditions, which 
strongly affects the Cl- sensitivity (at pH 6.0 KD = 32 mM, pH 7.5 KD = 777 mM), limiting the 
in vitro or in vivo application. Furthermore, YFP provides only a single optical signal which is 
influenced by the local probe concentration, optical path length, light scattering, illumination 
intensity or photobleaching.[82] Consequently, quantitative measurements of the Cl- 
concentration with YFP are highly laborious and imprecise. To overcome these downsides, a 
ratiometric sensor was developed, combining YFP with a second Cl- insensitive fluorophore, 
enabling the normalisation of the YFP distribution. Based on the emission ratio of both 
fluorophores, the intracellular Cl- concentration and changes in the local environment can be 
precisely calculated.[8,82] 
One of the first ratiometric YFP-based chloride sensors was CL-SENSOR, which consists of the 
previously described YFP mutant and the chloride-insensitive cyan fluorescent protein (CFP) 
connected by a flexible peptide linker (see figure 1.10).[86] Due to the overlap between the CFP 
emission (λEm. = 485 nm) and YFP excitation spectrum, the fluorophores form a FÖRSTER 
resonance energy transfer (FRET) pair. High Cl- concentrations quench the emission of the YFP 
fluorophore without affecting the Cl- insensitive CFP fluorophore. Recordings of the emission 
ratio of YFP to CFP provides an absolute measurement of the Cl- concentration theoretically. 
Compared to other ratiometric reporters, CL-SENSOR exhibit a high Cl- affinity (KD =30 mM) 
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and can be applied to monitor Cl- concentrations under physiological conditions 
(3-60 mM).[86,87] However, the CL-SENSOR exhibit the crucial disadvantage of pH sensitivity, 
which affects the Cl- affinity. The FRET readout is thereby distorted, resulting in imprecise 
chloride measurements.[86] 
 
Figure 1.10: Schematic representation of CL-SENSOR. The Cl- insensitive CFP (cyan) and the Cl- sensitive YFP 
(yellow) mutant are forming a FRET pair.[86] 
To overcome these limitations, AROSIO et al. developed a non-FRET based sensor, called 
CLOPHENSOR, which allows simultaneous measurements of the intracellular pH and Cl- 
concentration.[88] A specific halogen-binding site was introduced into the pH-sensor protein 
E2GFP by a single substitution mutation T203Y.[89] To perform ratiometric measurements, the 
E2GFP is fused with the normalising red fluorescent protein (DsRed), which is insensitive to 
variations of Cl- as well as H+ concentration (see figure 1.11). The pH and Cl- concentration 
can be calculated by measuring the ratio of green-to-cyan fluorescence of E2GFP, because Cl- 
quenches both cyan and green fluorescence, whereas H+ exclusively quenches the green 
fluorescence of E2GFP.[88,90]  
 
Figure 1.11: Schematic presentation of the CLOPHENSOR. The sensor consists of the Cl- and pH-sensitive 
E2GFP and the normalising DsRed protein. Binding of Cl- to the E2GFP quenches the fluorescence.[88] 
 Development of Fluorescent Chloride Sensor Molecules 17 
Besides all advantages, CLOPHENSOR still exhibits some limitations regarding their complex 
analysis, low photostability, aggregation of the DsRed fluorophore and they are not applicable 
to all physiological chloride concentrations.[5,8] Since all protein-based Cl- sensors do not fulfil 
the criteria required for precise intracellular Cl- measurements, Cl- sensitive small molecule 
dyes were extensively investigated. This group of Cl- sensors has the major advantage of pH 
insensitivity and Cl- sensitivity across the entire physiological range (3-60 mM).[82,91,92] 
 
1.1.5.2 Small Molecule Chloride Sensors 
The idea of measuring intracellular chloride concentration with small fluorescent molecules 
was inspired by the success of pH- and Ca2+ sensors, providing a sensitive and non-invasive 
method.[93,94] For the design of fluorescent indicators used for specialised biological 
applications, the sensors must fulfil different criteria. The fluorescence of the Cl- sensitive 
indicator must be sensitive to changes in the physiological range of Cl- (3-60 mM). 
Furthermore, they need to respond selectively to changes in the Cl- concentration, be nontoxic, 
insensitive to pH-changes and cell impermeable. Also, high excitation and emission 
wavelengths (>400 nm), as well as a high quantum yield of the sensor, are required to minimise 
phototoxicity and autofluorescence from UV excitation.[8,95,96] 
Based on the mentioned criteria, VERKMAN and colleagues synthesised the first generation of 
chloride-sensitive dyes 6-methoxy-N-(3-sulfopropyl)quinolinium (SPQ, 1), N-
(ethoxycarbonylmethyl)-6-methoxyquninolinium bromide (MQAE, 2) and 6-methoxy-N-
ethylquinolinium iodide (MEQ, 3) as well as the second generation 10,10’-bis[3-
carboxypropyl]-9,9’biacridinium dinitrate (BAC, 4) (see figure 1.12 and table 1.1).[95,97–99]  
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Figure 1.12: Examples for the first-generation Cl--sensitive small molecules. A) SPQ (1), B) MQAE (2), C) 
MEQ (3) and D) the second-generation Cl- sensor BAC (4).[7,95] 
Table 1.1: Overview of the fluorescent Cl--sensitive small molecule dyes. SPQ, MQAE, MEQ and BAC 
presenting their absorption and emission maxima, extinction coefficient as well as KSV.[7,95,98,99]  
Name Generation Abs [nm] Em [nm] ε [M-1‧cm-1] KSV [M-1] 
SPQ (1) 1 344 443 3700 12 
MQAE (2) 1 350 460 2800 25 
MEQ (3) 1 344 442 3900 19 
BAC (4) 2 434 505 12500 56 
 
All these sensors undergo dynamic collisional quenching which occurs when the excited sensor 
molecule collides with Cl- and returns to the ground state through a non-radiative transition. 
The resulting decrease in the fluorescence intensity and lifetime is directly related to the 
chloride concentration, which can be calculated by the STERN-VOLLMER equation (1.2). 
Thereby, the STERN-VOLLMER quenching constant (KSV) describes the Cl
- concentration that 
quenches half of the fluorescence and is a crucial parameter to define the optimal working range 




     (1.2) 
F0 = fluorescence in the absence of Cl-; F = fluorescence in the presence of Cl-; KSV = STERN-VOLLMER quenching 
constant. 
The first generation sensors, SPQ (1), MQAQ (2) and MEQ (3) have been used for 
measurements of the Cl- concentrations in neurons, glia, epithelial cells or fibroblasts.[100–102] 
A B C D 
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However, the small molecule Cl- sensors revealed some critical limitations regarding 
photobleaching, cell impermeability, self-quenching, UV-excitation and especially the absence 
of ratiometry. Due to the lack of a second emission wavelength, the fluorescence readout 
depends on the sensor uptake, cellular distribution and optical thickness. Therefore, they cannot 
provide an accurate measurement of the chloride concentration.[8] 
 
1.1.5.3 Second Generation Sensor – Development of Ratiometric Quantification 
To overcome all these limitations, VERKMAN and colleagues developed a ratiometric sensor 
based on the second-generation Cl- sensitive dye BAC (4).[7] Compared to the previously 
described quinolinium based sensors, the BAC fluorophore (4) exhibits significant advantages 
and fulfils all criteria of a fluorescent indicator for biological applications. Especially the 
increased chromophore size by the tricyclic acridine structure shifts the excitation and emission 
spectra of BAC to longer wavelengths, reducing phototoxicity. Furthermore, BAC (4) also 
revealed a high chloride sensitivity in the physiological range (3-60 mM), a pH insensitivity, 
intracellular stability and membrane impermeability.[7] Similar to the quinolinium sensor, BAC 
(4) is also collisionally quenched by Cl- or other halides. Due to the low concentration of other 
halides in living systems, this influence can be neglected.[103–105]  
For ratiometric measurements, the green fluorescent BAC fluorophore (4) was conjugated to 
the chloride insensitive red fluorescent tetramethylrhodamine (TMR), connected by an amino 
dextran linker (40 kD) (see figure 1.13). With the ratiometric BAC-TMR-dextran sensor (5), 
SONAWANE et al. measured the dependence between chloride accumulation and acidification in 
endosomes and Chinese hamster ovary cells.[7] However, the BAC-TMR-construct (5) varies 
from batch-to-batch when used for intracellular measurements, as the stoichiometry of the BAC 
and TMR binding to the dextran scaffold cannot be controlled. This leads to inconsistent 
measurements due to the unequal loading densities of both fluorophores. Furthermore, direct 
conjugation of the BAC fluorophore to proteins, lead to a reduced fluorescence by 90%, despite 
the introduction of long spacers.[8,106]  
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Figure 1.13: Structure of a ratiometric Cl- sensor (5). The chloride sensitive BAC and TMR fluorophores are 
conjugated to a dextran scaffold.[7]  
 
1.1.5.4 Chloride Sensor conjugated to a DNA Scaffold 
Interestingly, KRISHNAN and colleagues presented an approach, which combined two 
fluorophores in a precise 1:1 stoichiometry, enabling them to target organelles or cellular 
pathways.[107,108] The fluorophores were conjugated to a DNA scaffold, which provides the 
advantage of a modular structure, making the scaffold targetable, programmable as well as 
biocompatible. The first application of a fluorophore labelled DNA nanodevice was a pH 
sensor, called I-switch, used to investigate cellular processes. The sensor was labelled at the 3’ 
and 5’ position with the fluorophores AlexaFluor 488 and AlexaFluor 647, which can form a 
FRET pair after conformational changes caused by protonation of the cytosine-rich region in 
the DNA scaffold (see figure 1.14). Due to a specific double-strand (ds) DNA sequence d(AT)4, 
the I-switch can target to the lumen of endocytic organelles in Drosophila haemocytes.[107–109] 
 
Figure 1.14: Structure of the I-switch sensor. The I-switch is present in the open state at high pH (low FRET) 
and in a closed state at low pH (high FRET).[107] 
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Inspired by the concept of the I-switch sensor and the synthesis of the Cl- sensitive BAC 
fluorophore (4), KRISHNAN and co-workers developed a ratiometric DNA nanodevice to 
measure intracellular Cl- concentrations in specific organelles.[7,107] The BAC fluorophore (4) 
was conjugated to a Cl- insensitive normalising AlexaFluor 647 fluorophore, by linking both 
fluorophores to a single-stranded DNA sequence (BAC-ssDNA) in a 1:1 stoichiometry (see 
figure 1.15).[6,108] Accordingly, the BAC fluorescence intensity (G) is linearly reduced with 
increasing Cl- concentration, whereas the fluorescence intensity (R) of AlexaFluor 647 remains 
constant. Based on the ratio of the emission intensities (R/G), the Cl- concentration can be 
calculated. However, conjugation of BAC to the DNA scaffold significantly decreases the 
fluorescence intensity, chloride sensitivity (KSV = 33.6 M
-1), as well as fluorescence lifetime 
(5.5 ns), compared to the free BAC (4) (see table 1.1).[6] 
This reduction can be explained by a photoinduced electron transfer (PET) between guanine 
and BAC, quenching the fluorescence. The efficiency of PET-based quenching from guanine 
is firmly distance-dependent and reduces with increasing distance. Thus, guanine is placed ten 
nucleotides (nt) apart from BAC and the formation of BAC-double-stranded DNA prevented 
the development of globular structures that bring guanine and BAC close together.[6] 
Surprisingly, the duplexation showed no significant increase in the fluorescence intensity or 
chloride sensitivity. This could be explained by intercalation of BAC into the dsDNA, which 
limits the accessibility of BAC to chloride.[6] 
To investigate the effect of groove binding and intercalation of BAC into the ds-DNA, various 
ds-DNA scaffolds were synthesised, bearing BAC internally (BAC-dsDNAB0) or creating 
bulges of different sizes around BAC (BAC-dsDNAB1). The bulges were designed to enhance 
the conformational flexibility of BAC or to place BAC away from the helical scaffold to 
enhance the accessibility for chloride. However, determination of the chloride sensitivity 
revealed for all constructs no significant increase in sensitivity compared to BAC-single 
stranded (ss) DNA (see table 1.2). These results indicate a strong interaction between the 
positively charged acridine core of BAC and the negatively charged DNA backbone, leading 
to increased PET-based quenching and intercalation due to the proximity.[6] 
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Figure 1.15: Schematic structure of various DNA based sensor. A) BAC-ssDNA B) BAC-dsDNA C) BAC-
dsDNA with bulges. The BAC fluorophore is shown in green, whereas Alexa Fluor 647 is presented in red.[6] 
To overcome the limitation of electrostatic interaction between BAC and the negatively charged 
phosphate backbone, the DNA scaffold was replaced by a peptide nucleic acid (PNA) oligomer. 
The PNA consists structurally of purine and pyrimidine bases, which are linked to a non-
charged peptidic backbone and can form stable PNA/PNA as well as PNA/DNA strands. 
Measurements of a synthesised BAC-dsPNA oligomer revealed an increased chloride 
sensitivity, fluorescence lifetime (9.2 ns) as well as Cl- sensitivity (KSV = 71 M
-1) which are 
comparable with the sensitivity of free BAC (4) (lifetime: 9.2 ns, KSV = 56 M
-1).[6]  
Nevertheless, the application of BAC-dsPNA for intracellular Cl- sensing is limited. Precise 
ratiometric measurements require a spacing of at least 40 nt (10 nm) between the sensing BAC 
as well as normalising AlexaFluor 647 fluorophores to preserves photophysical characteristics 
of both fluorophores and to exclude FRET effects.[110] Since the synthesis of PNA oligomers is 
still limited to a length of 20 nt, a BAC-dsPNA nanodevice would lead to imprecise 
measurements.[111] Furthermore, the specific targeting of the nanodevice sensors to pathways 
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Table 1.2: Overview of the photophysical characteristics of different BAC-labelled constructs. STERN-
VOLLMER constant (KSV), average lifetime (τ0 Avg), fold change in fluorescence intensity 24.4-90.9 mM [Cl-]. 
Construct KSV (M-1) τ0 Avg (ns) Fold change (R/G) 
BAC (4) 56.4 ± 0.6 9.15 ± 0.01 2.89 
BAC-ssDNA 33.6 ± 0.8 5.47 ± 0.25 1.24 
BAC-dsDNAB0 33.6 ± 1.8 5.16 ± 0.19 1.21 
BAC-dsDNAB1 3.9 ± 0.5 2.68 ± 0.11 1.3 
BAC-dsDNAB2 7.7 ± 1.1 3.57 ± 0.26 1.3 
BAC-ssPNA 64.3 ± 1.1 7.35 ± 0.06 1.82 
BAC-dsPNA 70.8 ± 0.2 7.80 ± 0.08 2.72 
CLENSOR 58.6 ± 0.3 7.40 ± 0.01 1.82 
 
Consequently, to combine the benefits of the specific intracellular targeting of the ds-DNA and 
the improved chloride sensitivity of the PNA, the KRISHNAN group designed a nanodevice, 
called CLENSOR, consisting of three different modules.[6,92] The sensing module is a 12-mer 
PNA sequence (P) carrying the chloride-sensitive BAC fluorophore (4). The normalising 
module is a 38-mer DNA sequence (D2) conjugated with a chloride insensitive AlexaFluor 647 
fluorophore and the targeting sequence, which is a 26-mer DNA sequence (D1) bearing a 
recognition sequence for endosomal targeting (see figure 1.16). The P and D1 module hybridise 
with the complementary DNA strand D2 to form a DNA-PNA hybrid duplex. The ds-DNA part 
of CLENSOR, consisting of D1 and D2, can also be linked with different recognition sequences 
to target specific organelles, for example, with an RNA aptamer to investigate human 
transferrin receptors.[5]  
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Figure 1.16: Schematic presentation of CLENSOR. A) Structure of the CLENSOR: the sensing module (P, pink) 
consists of PNA and BAC (4), the normalising DNA module (D2, grey) bears the AlexaFluor 647 and the targeting 
DNA module (D1, grey). In the presence of Cl-, BAC (4) is collisional quenched, whereas the AlexaFluor 647 is 
Cl- insensitive. B) Modified Clensor with an RNA aptamer structure (R, blue) to target the human transferrin 
receptor.[92] 
Measurements with the CLENSOR molecule under physiological conditions showed a 33 % 
improved fluorescence intensity compared to the BAC-dsDNA. Fluorescence lifetime and 
chloride titration experiments revealed a lifetime of 8.3 ns and a KSV value of 58.6 M
-1, which 
is comparable with characteristics of free BAC (4), showing similar sensitivity. Subsequently, 
CLENSOR was applied to measure characteristics of Cl- concentrations along the endolysosomal 
pathway in Drosophila melanogaster.[5] 
Compared to protein-based Cl- sensors, the CLENSOR molecule, provides the advantage of a 
high Cl- sensitivity in the physiological range, a rapid response (< 1 ms) and insensitivity to 
physiological changes in pH. Due to conjugation of the BAC and AlexaFluor 647 fluorophore 
to the PNA-DNA scaffold, the sensor is also ratiometric and can specifically target intracellular 
pathways or organelles. In addition, the modular structure of CLENSOR allows the introduction 
of modifications for special transport and storage in the desired compartment.[6,92]  
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1.2 Design and Synthesis of PNA-DNA based Chloride Sensors  
Vesicular neurotransmitter transporters play an essential role in neurological processes, by 
filling neurotransmitters in synaptic vesicles. Especially, imbalance in the glutamatergic 
neurotransmission can be linked to various neurological diseases, which are currently not 
curable and the available treatment with psychiatric therapeutics can cause various off-target 
effects.[40–43] Consequently, for the development of highly specific therapeutics, more in-depth 
insights into the glutamate transport mechanism are required. One decisive question is how 
different Cl- concentrations can influence the dynamics and mechanisms of glutamate uptake 
by VGLUT. For answering this question, a fluorescent Cl- sensor was developed, to measure 
the Cl- influx through VGLUT during the glutamate transport.  
For kinetic measurements of the Cl- influx, the sensor was encapsulated into the lumen of the 
proteoliposomes. The Cl- sensor was thus modified with a hydrophobic membrane anchor to 
ensure that the sensor remains in the liposome during reconstitution. Due to the conjugation of 
the membrane anchor, the Cl- sensor incorporates to the luminal as well as extravesicular site 
of the proteoliposomes. However, the extravesicular orientated sensors disturb the 
measurements of the Cl- influx through VGLUT since the fluorescence signals from luminal 
and extravesicular sensors cannot be differentiated. To overcome this limitation, a Cl- sensor 
has to be synthesised, consisting of a membrane anchor and a cleavage sequence, which allows 
the removal of all outside orientated sensors of the reconstituted liposome. The Cl- sensitive 
fluorophore has to be conjugated to an insensitive fluorophore, to perform ratiometric 
measurements.  
To fulfil these criteria, a new Cl- sensor was developed, based on the design of the CLENSOR 
molecule from KRISHNAN and colleagues.[5,6] The BAC fluorophore (4) was selected as Cl- 
sensitive fluorophore due to its sensitivity in the physiological range of Cl- from 3 to >100 mM, 
pH insensitivity and prolonged excitation as well as emission wavelength.[7,92] For the 
ratiometric design, the BAC fluorophore (4) was linked to a Cl- insensitive AlexaFluor 647 
fluorophore in a 1:1 stoichiometry by a PNA-DNA scaffold, consisting of three modules. The 
sensing module is a 12-mer peptide nucleic acid (PNA) oligomer conjugated to the BAC 
fluorophore (4), whereas the normalising AlexaFluor 647 fluorophore is linked to a 38-mer 
DNA (D2) sequence. For spatial separation between sensing and normalising dye, a stabilising 
26-mer DNA (D1) module is introduced, which hybridises with the PNA and the D2 module 
(see figure 1.17). To target the Cl- sensor in the lumen of the proteoliposomes, a peptidic linker 
sequence was attached to the PNA scaffold. This linker sequence allows, on the one hand, the 
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conjugation of a palmitoyl or cholesterol anchor for membrane incorporation and on the other 
hand the introduction of a protease cleavage site. Consequently, treatment with a protease leads 
to a cleavage between the sensor and the membrane anchor, removing all extravesicular 
orientated sensors from the proteoliposomes. The intravesicular orientated sensors is not 
affected by the protease cleavage due to their membrane impermeability. 
 
Figure 1.17: Structure and function of the Cl- sensors. The PNA strand is labelled with the Cl- sensitive BAC 
fluorophore (4), which is modified with a membrane anchor and a cleavage site. The D2 strand is the normalising 
module, containing a Cl- insensitive AlexaFluor 647 fluorophore. D1 is the stabilising module, which hybridises 
with D2. Incorporation of the Cl- sensor in proteoliposomes leads to luminal and extravesicular orientated sensors. 
All outside orientated sensors can be removed by addition of a protease, cleaving the linker sequence between the 
sensor and membrane anchor.  
 
1.2.1 Synthesis of PNA based Sensing Module 
In this chapter, the synthesis of a ratiometric PNA-DNA based Cl- sensors is described, which 
are modified with a membrane anchor and a protease cleavage sequence to measure 
intravesicular Cl- concentrations in proteoliposomes. Therefore, the protease recognition 
motive was conjugated to the peptidic backbone of the 12-mer PNA sensing module and the 
membrane anchor was linked to a side chain residue of the protease recognition motif at the 
C-terminal part of the peptide-PNA oligomer. The Cl- sensitive BAC fluorophore (4) was 
coupled to a lysine residue at the N-terminal part of the oligomer (see figure 1.18). Since the 
formation of PNA oligomers and their labelling with the BAC fluorophore (4) are challenging, 
an optimised synthesis strategy for PNA coupling as well as fluorophore labelling was 
introduced in the first step (part I). Following, different membrane anchors (part II) and 
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protease recognition sequences (part III) were incorporated into the PNA sequence, to identify 
efficient liposome incorporation and cleavage conditions for the Cl- sensor.  
 
Figure 1.18: Target structure of Cl- sensitive PNA module. The structure consists of three parts: the PNA 
sequence and the Cl- sensitive BAC fluorophore (4) (green; I), the membrane anchor (orange; II) as well as a 
protease cleavage sequence (blue; III). The PNA residues are shown in lowercase letters. The C-terminus of the 
peptide-PNA oligomer is amidated. 
 
1.2.2 Optimised Synthesis Strategy for PNA Oligomers (molecule part I) 
PNA oligomers are artificially synthesised polymers, which were developed by NIELSEN, 
EGHOLM, BERG and BUCHARDT as DNA mimics.[112] Over the last years, PNA strands were 
frequently used in diagnostic assays, as tools for molecular biology or as drug leads.[113–116] In 
contrast to the DNA structure, the sugar-phosphate backbone is replaced in the PNA scaffold 
by a synthetic peptide backbone consisting of N-(2-aminoethyl)-glycine (aeg) units (see figure 
1.19). The PNA monomers are linked by peptide bonds and the corresponding nucleobases are 
attached to the backbone by methylene carbonyl linkages.[117] Due to the lack of electrostatic 
repulsion, PNA oligomers can form stronger interactions with the complementary DNA or 
RNA strands than the corresponding DNA/DNA or RNA/RNA strands. They are also stable 
over a wide temperature and pH range as well as resistant towards proteases or nucleases due 
to their unnatural backbone.[118,119]  
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Figure 1.19: Structure of the aeg-PNA. Duplexation of PNA strands according to WATSON-CRICK base pairing.  
In the first step, the PNA oligomer sequence of the sensing module was synthesised by solid-
phase peptide synthesis (SPPS). The simple structure of the unmodified PNA scaffold allows 
the optimisation of coupling and labelling conditions since the formation of PNA oligomers is 
limited by the low solubility of the monomers in DMF and their poor coupling efficiency.[111,119] 
Previous PNA synthesis protocols from SAHA et al. or MIDDEL et al. reported a manual double-
coupling method for PNA monomers for 1 h at rt.[5,120] The deprotection of the N-terminal 
Fmoc-group was performed with 20 % piperidine for two times 10 min at rt. Due to the long 
coupling and deprotection times, the synthesis of the 12-mer PNA oligomer lasted three to four 
days. To reduce the time needed for PNA synthesis, an optimised coupling protocol for PNA 
monomers was developed, using automated SPPS on a peptide synthesiser.  
For increasing the coupling efficiency and reduction of the reaction times, a microwave-assisted 
coupling method was developed using N,N’-diisopropylcarbodiimide (DIC) as activator and 
ethyl cyanohydroxyiminoacetate (Oxyma) as activator base. Higher coupling temperatures of 
50 °C lead thereby to a reduced coupling time of 25 min. Further attempts to increase the 
coupling temperature to 75 °C lead to no product formation. The deprotection conditions were 
also enhanced by applying 2 % piperazine at 50 °C for 5 min. Furthermore, the formation of 
side products was reduced by blocking unreacted amino acids with acetic anhydride after the 
coupling process. Since acetic anhydride in the capping solution can acetylated nucleobases, 
the resin-bound peptide-PNA hybrids were washed with 5 % DIPEA, which reverse the nucleo-
acetylation and reduces the formation of side-products. The optimised SPPS protocol for the 
synthesis of peptide-PNA oligomers lead to enhanced yields and purity as well as significantly 
reduced reaction times compared to the manually coupled PNA protocol.[121] The amino acids 
were coupled by standard Fmoc-chemistry using DIC and Oxyma as coupling reagents and 
elevated reaction temperatures of 90 °C for 8 min at 30 W.  
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Based on these findings, the 12-mer PNA sequence, which was adopted from the CLENSOR 
molecule, was synthesised on a Rink Amide resin with low loading density, to prevent 
aggregation of the oligomers during synthesis (see figure 1.20 A).[5] As a first amino acid, an 
additional lysine residue was coupled to increase the solubility of the oligomer. For the 
introduction of the BAC fluorophore (4), an orthogonal Alloc-protected lysine residue was 
attached to the N-terminal part of the PNA sequence, which can be selectively deprotected by 
addition of Tetrakis(triphenylphosphine)palladium (0) (Pd(PPh3)4). However, the free amine 
group of the lysine residue caused cleavage of the adjacent N-terminal Fmoc group, leading to 
unspecific binding of the BAC fluorophore (4) to the lysine and N-terminal amine group. To 
overcome this limitation, an additional Boc protected alanine residue was introduced to the 
N-terminal position. The Boc group is stable towards nucleophilic attack from the ε-amine of 
the lysine and can be removed under acidic conditions. After completion of the coupling 
process, a test cleavage confirmed the successful formation of the PNA oligomer (6) sequence 
by HPLC and mass spectrometry analysis (see figure 1.20 B). Consequently, the Cl- sensitive 
BAC fluorophore (4) was synthesised in the next step, to perform labelling experiments of the 
PNA oligomer.  
 
 
Figure 1.20: Synthesis and analysis of PNA oligomer. A) Structure of the PNA oligomer (6), bearing an Alloc-
protecting group for selective introduction of the BAC-fluorophore (4). B) U-HPLC chromatogram of the PNA 
oligomer (6) after test cleavage. U-HPLC gradient: 1-30 % MeCN in 15 min. 
The BAC fluorophore (4) was synthesised over three steps, according to the literature procedure 
from SONAWANE et al. (see figure 1.21).[7] First, the acridone (7) was heated under basic 
conditions in γ-butyrolactone (8), forming the 10-[carboxypropyl]-9(10H)-acridone (9), which 
was subsequently dimerised in a MCMURRY reaction by addition of zinc and HCl in ethanol. In 
B 
A 
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the last step, the 10,10’-bis[3-caboxypropyl]-9,9’biacridylidene (10) was dissolved and heated 
in nitric acid (2 M) producing BAC (4) with an overall yield of 12 % over three steps.  
 
Figure 1.21: Synthesis of the Cl- sensitive BAC fluorophore (4). The synthesis was performed over three steps, 
starting from the acridone (7). 
 
1.2.2.1 Synthesis of BAC Modified Peptide-PNA Oligomer 
Before the BAC fluorophore (4) can be conjugated to the PNA oligomer, the Alloc protecting 
group of the N-terminal lysine residue was removed with Pd(PPh3)4 and phenylsilane under 
microwave irradiation for 5 min at 38 °C and 15 W.[122] This method allows a complete 
cleavage of the Alloc-group with significantly reduced reaction times, compared to previous 
procedures.[123] Following, the BAC fluorophore (4) was coupled to the free ε-amine group of 
the lysine side chain residue according to the protocol from SAHA et al.[6,106] The BAC 
fluorophore (4) was activated by N-hydroxysuccinimide (NHS) as well as 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) for 2 h at rt, followed by incubation with the resin-
bound PNA oligomer (6) for 24 h at rt. After cleavage of the PNA sequence from the resin with 
trifluoroacetic acid (TFA), triisopropylsilane (TIS), H2O (95/2.5/2.5, v/v/v), the labelling 
process was analysed by LC-MS revealing no product formation. 
In a second approach, a labelling method for fluorescent Ca2+-sensors to β-peptides was tested. 
For the activation of the BAC fluorophore (4), a mixture of ((7-azabenzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate) (PyAOP), 1-hydroxy-7-
azabenzotriazole (HOAT), N,N-diisopropylethylamine (DIPEA) in DMF was used. The 
labelling reaction was performed under microwave irradiation at an elevated temperature of 
70 °C for 3 h at 15 W (see figure 1.22 A).[124] Compared to the frequently used 
1-(bis(dimethylamino)methylene)-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluoro-
phosphate (HATU), PyAOP provides the advantage of no deactivation of free amine groups by 
guanidinylation.[124,125] After fluorophore labelling, the PNA oligomer and alle acid sensitive 
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protecting groups were removed by addition of TFA/TIS/H2O (95/2.5/2.5, v/v/v). The 
successful synthesis of the BAC labelled PNA oligomer (11) was confirmed by HPLC and mass 
spectrometry analysis showing a complete conversion of the starting material (see figure 1.22 B 
and 1.22 C). 
 
 
Figure 1.22: Synthesis and Analysis of BAC labelled PNA oligomer. A) Synthesis of BAC modified peptide-
PNA oligomer (11). B) HPLC chromatogram of the of PNA oligomer (11) after BAC labelling. The isolated 
product peak is highlighted with an arrow. HPLC gradient: 1-30 % MeCN in 30 min. C) U-HPLC chromatogram 
of the purified PNA-BAC sensor (11). U-HPLC gradient: 1-30 % MeCN in 15 min. 
 
1.2.3 Synthesis of Membrane Anchor Modified PNA Sensors (Molecule Part II) 
After optimisation of the PNA coupling protocol and BAC labelling conditions, a membrane 
anchor had to be incorporated, for encapsulation of the sensor in the liposome. For identification 
of optimal anchoring conditions, a modified cholesterol derivate and a palmitoyl linker were 
selected, due to previous studies with modified β-peptides, showing a successful accumulation 
in membranes for both modifications.[126,127]  
 
tr = 22.2 min 
B C 
A 
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1.2.3.1 Synthesis of Cholesterol-Modified Peptide-PNA Oligomer 
Starting with the incorporation of the cholesterol anchor, an amine-modified cholesterol 
derivate was synthesised, which can be linked to a free carboxyl group of the resin-bound PNA 
sequence. The synthesis of the amine-modified cholesterol derivate was performed over three 
steps according to the synthesis protocol from SUN et al. (see figure 1.23).[128] In the first step, 
the hydroxyl group of cholesterol (12) was converted into a good leaving group by adding 
methanesulfonyl chloride forming the cholesteryl mesylate (13). Following, the cholesteryl 
mesylate (14) was treated with trimethylsilyl azide (TMSN3) and boron trifluoride etherate 
(BF3‧OEt2) to produce the azido-5-cholestene (14). In the final step, the azide group was 
reduced by the addition of lithium aluminium hydride to form the amino-5-cholestene (15) with 
an overall yield of 18 %.  
 
Figure 1.23: Synthesis of amino-5-cholestene (15). The reaction was performed over three steps, starting from 
cholesterol (12). 
For the incorporation of the amine-modified cholesterol anchor (15), a PNA oligomer sequence 
(16) with an allyl protected glutamic acid residue at the C-terminal part was synthesised by the 
optimised PNA coupling protocol (see chapter 1.3.2). After synthesis of the oligomer, the 
allyl-group was cleaved with Pd(PPh3)4 and the amine-modified cholesterol anchor (15) was 
conjugated to the free carboxyl group by addition of the activators (1-cyano-2-ethoxy-2-
oxoethyliden-aminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate 
(COMU) and DIPEA (see figure 1.24). The reaction process was analysed after 24 h by a test 
cleavage and LC-MS analysis, revealing no conversion of the deprotected PNA oligomer. Also 
different coupling reagents, like HOAt/HATU, DIC/Oxyma or DIC/HOAt and longer reaction 
times lead to no product formation. These findings can probably be explained by the steric 
structure of the cholesterol molecule and their tendency to aggregate. Different approaches from 
HÖGER, to directly incorporate cholesterol modified aspartic acid building block by SPPS, lead 
to no conversion of the starting material.[127] 
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Figure 1.24: Synthesis approach of cholesterol modified peptide-PNA oligomers (17).  
As a consequence, a strategy for cholesterol coupling in solution was developed, by 
synthesising the PNA sequence on the RAMAGE linker modified chlorotrityl resin (18) (see 
figure 1.25).[129] This approach allows the cleavage of the fully protected peptide-PNA oligomer 
(19) from the resin with 10 % acetic acid and the coupling of the sterically demanding 
cholesterol anchor to the PNA oligomer in solution. Nevertheless, cholesterol (15) coupling 
with COMU and DIPEA as well as HOAt/HATU lead to no product (17) formation, indicating 
that the bulky cholesterol structure is incompatible for coupling to PNA oligomers. Based on 
these findings, it was assumed that another membrane anchor with a reduced steric demand was 
required. 
 
Figure 1.25: Synthesis approach of cholesterol modified peptide-PNA oligomer (17) in solution.  
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1.2.3.2 Synthesis of a Palmitoyl-Modified Peptide-PNA Oligomer 
Besides the cholesterol motif, palmitoyl anchors are frequently used for the incorporation of 
peptides in membranes, providing the advantage of a reduced steric structure and increased 
solubility. An effective strategy for the incorporation of palmitoyl anchors in peptide sequences 
is the synthesis of a palmitoyl modified aspartic acid residue by the formation of an ester bond, 
which can directly be used for SPPS.[130] 
The synthesis of the palmitoyl modified aspartic acid building block for SPPS was performed 
in two steps according to the literature procedure (see figure 1.26).[130] First, Fmoc-
Asp(palmitoyl)-OtBu (22) was obtained by esterification of the palmityl alcohol (21) and the 
protected Fmoc-Asp-OtBu (20) using 1-(2-mesitylensulfonyl)-3-nitro-1H-1,2,4-triazole 
(MSNT) as well as 1-methylimidazole (MeIm) as activators. In the second step, the C-terminal 
tert-butyl ester group was cleaved with TFA in DCM afforded Fmoc-Asp(palmitoyl)-OH (23) 
with an overall yield of 71 %.  
 
Figure 1.26: Synthesis of Fmoc-Asp(palmitoyl)-OH (23) over two steps.  
Standard microwave coupling conditions achieved the incorporation of the palmitoyl-modified 
aspartic acid building block (23) into the C-terminal part of the PNA oligomer (24) at an 
elevated temperature of 90 °C (see figure 1.27 A). To increase the solubility of the palmitoyl 
modified PNA oligomer (24), two additional lysine residues were introduced at the C-terminal 
part. After completion of the coupling process, a test cleavage was performed, confirming the 
successful synthesis of the PNA oligomer modified with a palmitoyl anchor. Following, the 
Alloc protecting group of the N-terminal lysine residue was removed with Pd(Ph3)4 and the 
BAC fluorophore (4) was coupled under microwave irradiation for 3 h at 70 °C and 15 W. 
Verification of the labelling process by HPLC and mass spectrometry analysis, revealed the 
formation of the palmitoyl modified PNA-BAC sensor (25) (see figure 1.27 B and 1.27 C).  
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Figure 1.27: Synthesis and analysis of palmitoyl and BAC modified PNA oligomer. A) BAC labelling of the 
palmitoyl-modified PNA oligomer (25). B) HPLC chromatogram of palmitoyl-PNA oligomer (25) after BAC 
labelling. The isolated product peak is highlighted with an arrow. HPLC gradient: 10-60 % MeCN in 30 min. C) 
U-HPLC chromatogram of the purified palmitoyl -PNA-BAC sensor (25). U-HPLC gradient: 1-30 % MeCN in 
15 min. 
 
1.2.4 Introduction of Cleavage Sites in Modified PNA Sensors (molecule part III)  
After successful synthesis and purification of the palmitoyl modified PNA-BAC sensor (25), 
the optimised synthesis strategy was applied for the introduction of a protease recognition motif 
(see figure 1.18). The cleavage sequence was incorporated between the palmitoyl modified 
aspartic acid and the PNA part, allowing the cleavage of extravesicular orientated sensors on 
the liposome. To ensure an efficient cleavage process, different proteases were tested.  
 
1.2.4.1 TEV Protease Cleavage Site 
Screening of different proteases and their cleavage conditions revealed the tobacco etch virus 
(TEV) protease, which is frequently used for the cleavage of fusion proteins or affinity 
tags.[131,132] The TEV protease recognises the sequence Glu-Asn-Leu-Tyr-Phe-Gln-Gly/Ser and 
cuts specifically between the Gln and Gly/Ser residues. Additionally, the TEV protease 
tR = 23.5 min 
B C 
A 
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demonstrated a high cleavage activity over a broad pH (4-9) and temperature range (4 °C-
37 °C), without the formation of non-specific proteolysis side products.[133,134] 
For investigations of the cleavage efficiency, a TEV recognition sequence was introduced 
between the palmitoyl anchor and the PNA part of the sensing module, to allow cleavage 
between the anchor and the sensor (see figure 1.28). To prevent blockage of the TEV protease 
by the highly flexible palmitoyl chain, a linker sequence was incorporated, separating the C-
terminal palmitoyl chain from the TEV recognition sequence. The linker sequence consists of 
a repetitive glycine serine motive. The synthesis of the peptide-PNA sensor (26) with a 
palmitoyl anchor and the TEV recognition site was performed by optimised PNA coupling 
protocol (see chapter 1.3.2). After deprotection of the Alloc group, the BAC fluorophore (4) 
was coupled under microwave irradiation and the peptide-PNA oligomer was cleaved from the 
resin. HPLC purification of the crude oligomer yielded the palmitoyl modified peptide-PNA 
sensor (27) with a TEV recognition sequence in high purity.  
 
Figure 1.28: Synthesis of palmitoyl, TEV and BAC modified peptide-PNA oligomer (27). The protease 
cleavage site is highlighted in grey. 
In the next step, the TEV protease-mediated cleavage of the synthesised PNA sensor (27) was 
investigated (see figure 1.29). The purified peptide-PNA sensor (27) was dissolved in the 
reaction buffer (50 mM Tris-HCl, 0.5 mM EDTA, 1 mM DTT, pH 8.0), heated to 37 °C and 
the TEV protease (3000 U/mg) was added in a ratio of 100:1 (v/v). The cleavage process was 
monitored after incubation times of 6 h, 12 h and 24 h by U-HPLC, showing no conversion of 
the starting material (27). Also, increased concentrations of the TEV protease (50:1 or 20:1 
(v/v)) and reduced incubation temperatures (20 °C, 4 °C) lead to no cleavage of the peptide-
PNA sensor.  
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Figure 1.29: TEV-protease cleavage experiments of the palmitoyl modified PNA sensor (27). This experiment 
was analysed by U-HPLC after incubation times of 0 min, 6 h, 12 h and 24 h at 37 °C. U-HPLC gradient: 10-60 % 
MeCN in 15 min. 
These findings indicate a blockage of the TEV protease activity, caused either by the PNA 
structure or by the palmitoyl anchor. Consequently, different test peptides were synthesised 
without the PNA structure (28) and with increased Gly-Ser linker length to reduce possible 
blockage from the palmitoyl linker (29) (see table 1.3). To exclude micelle formation of the 
peptide-PNA oligomers, which would limit the accessibility of the cleavage sequence, a peptide 
sequence (30) lacking the hydrophobic palmitoyl anchor was also synthesised (see figure 
1.30 A). For verification of the cleavage activity, a peptide (31) consisting exclusively of the 
recognition sequence and two additional lysine residues was tested as a positive control. After 
the synthesis of different test peptides, the cleavage process was investigated. The peptides 
were dissolved in the reaction buffer and the TEV protease was added (100:1, v/v) at 37 °C. 
The cleavage process was analysed by U-HPLC after 1 h, 3 h, 5 h and 24 h, showing no 
cleavage for any of the tested peptides. Also, testing of various protease concentrations (10:1 
or 1000:1, v/v) and reaction temperatures (4 °C, 20 °C), revealed no conversion of the test 
peptides under these conditions. The activity of the TEV protease was verified with a control 
protein (provided by RASHI GOEL, Group of Prof. REINHARD JAHN), showing a complete 
cleavage after 2 h (see figure 1.30 B). These results indicated that the TEV protease is 
unsuitable for the cleavage of short peptide sequences since these are probably unable to enter 
the TEV protease binding pocket. Thus, a different protease is required with higher catalytic 
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Table 1.3: Overview of the different test peptides with the TEV recognition sequence. 
 
Figure 1.30: TEV-cleavage experiments of different test peptides. A) TEV-protease cleavage experiments of 
the palmitoyl-modified peptide sequence (29) with increased Gly-Ser linker length analysed by U-HPLC after 
incubation times of 1 h, 3 h, 5 h and 24 h at 37 °C. U-HPLC gradient: 10-60 % MeCN in15 min. B) TEV-protease 
cleavage experiments of a control protein by U-HPLC after incubation times of 2 h at 37 °C. U-HPLC gradient: 
10-60 % MeCN in 15 min. 
 
1.2.4.2 Factor Xa Protease Cleavage Site 
Screening of proteases, which have been successfully used for the cleavage of small peptides, 
revealed the Factor Xa protease. This site-specific endoprotease cleaves the C-terminal peptide 
bond after the recognition motif Ile-Glu-Gly-Arg with high specificity.[135] To investigate the 
cleavage conditions of the Factor Xa protease, a test peptide (32) with the recognition motif 
was synthesised (see figure 1.31 A). For the cleavage experiments, the peptide was dissolved 
in the reaction buffer, incubated at 37 °C and subsequently, the Factor Xa protease (20 U/mg) 
was added in a ratio of 50:1 (v/v). The cleavage process was analysed by U-HPLC after 5 h, 7 h 
and 12 h, showing a complete conversion of the starting material (32) under these conditions 
after 12 h (see figure 1.31 B). 
 
Peptide Sequence Comment 




Palmitoyl-anchor, increased linker 
length and TEV-recognition sequence 
30 H2N-A-K-S-Q-F-Y-L-N-E-S-G-S-G-S-G-S-G-D-V-V-
CONH2 
Increased linker length and TEV-
recognition sequence 
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Figure 1.31: Structure and cleavage of Factor Xa test peptides. A) Sequence of the Factor Xa test peptide (32) 
with the recognition motif I-E-G-R. The protease cleavage site is highlighted in grey. B) Factor Xa-protease 
cleavage experiments of 32 analysed by U-HPLC after incubation times of 3 h, 5 h and 12 h. U-HPLC gradient: 
10-60 % MeCN in 15 min. 
Consequently, the Factor Xa cleavage sequence was incorporated into the palmitoyl-modified 
PNA sensor. The synthesis of the peptide-PNA oligomer (33) was performed as previously 
described by the optimised coupling conditions (see chapter 1.2.2). After labelling with the 
BAC fluorophore (4) and HPLC purification, the palmitoyl modified peptide-PNA sensor (34) 
with a Factor Xa recognition sequence was obtained in high purity (see figure 1.32 A). Next, 
the cleavage properties were investigated, by dissolving the peptide-PNA sensor (34) in 
protease reaction buffer with the Factor Xa protease (50:1, v/v) at 37 °C. However, analysis of 
the cleavage process revealed only the starting material (34) after 2 h, 4 h, 16 h and 48 h (see 
figure 1.32 B). Different cleavage conditions with higher protease concentration (25:1 or 10:1, 
v/v) and reduced incubation temperatures (23 °C, 4 °C) also revealed no cleavage under all 
conditions. Based on these findings, it was assumed that the PNA scaffold probably blocks the 
activity of the Factor Xa protease. Since the preliminary results from the test peptide showed a 
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Figure 1.32: Synthesis and Factor Xa cleavage of palmitoyl-modified PNA sensors.  A) Synthesis of palmitoyl 
modified peptide-PNA sensor (34) with a Factor Xa recognition sequence. The protease cleavage site is highlighted 
in grey. B) Factor Xa-protease cleavage experiments of the Factor Xa modified peptide-PNA sensor (34) analysed 
by U-HPLC after incubation times of 2 h, 4 h, 16 h and 48 h at 37 °C. HPLC gradient: 10-60 % MeCN in 15 min. 
 
1.2.4.3 Cathepsin B Protease Cleavage Site 
In a third approach, the highly active lysosomal cathepsin B protease was tested, which is 
upregulated under pathological conditions like in metastatic tumours.[136] Several cancer drugs 
are conjugated with cathepsin B cleavable linkers, allowing a controlled release of the drug in 
the targeted tissue to reduce off-target effects.[137,138] Commonly used recognition motifs are 
the dipeptides valine-citrulline or phenylalanine-lysine, which are stable under physiological 
conditions but rapidly hydrolysed by addition of cathepsin B. 
Consequently, a palmitoyl modified peptide-PNA sensor (35) with a cathepsin B recognition 
sequence was synthesised by the optimised coupling protocol and purified by HPLC (see figure 
1.33 A). For the cleavage experiments, the cathepsin B protease was activated by a mixture of 
DTT and EDTA for 15 min at rt. The activated cathepsin B (10 U/mg) was then transferred to 
the dissolved peptide-PNA oligomer (36) and the mixture was incubated at 37 °C. The cleavage 
efficiency was measured after 30 min, 60 min, 90 min and 20 h by U-HPLC as well as mass 
A 
B 
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spectrometry analysis showing a complete conversion of the starting material after 30 min (see 
figure 1.33 B).  
 
 
Figure 1.33: Synthesis and cathepsin B cleavage of palmitoyl-modified PNA sensors. A) Synthesis of 
palmitoyl modified peptide-PNA sensor (36) with a cathepsin B recognition sequence. The protease cleavage site 
is highlighted in grey. B) Cathepsin B protease cleavage experiments of the cathepsin B modified peptide-PNA 
sensor (36), analysed by U-HPLC after incubation times of 0 min, 30 min, 60 min, 90 min and 20 h at 37 °C. 
HPLC gradient: 10-60 % MeCN in 15 min. 
1.2.4.4 Membrane Incorporation of Palmitoyl Modified PNA Sensors 
After successful cleavage experiments with the cathepsin B protease, the membrane 
incorporation efficiency of the palmitoyl modified PNA sensor was determined by density-
gradient centrifugation performed by RASHI GOEL. The peptide-PNA sensors (36) were 
therefore incorporated into liposomes (DOPC/DOPS/DOPE/cholesterol, 63/10/2/25) by 
manual extrusion and the proteoliposomes were overlaid with a Nycodenz gradient (40 %, 30 % 
and 0 %) as well as a buffer layer on top. During centrifugation, the low-density 
proteoliposomes with incorporated peptide-PNA oligomers migrate to the top buffer fraction 
(see figure 1.34). Contrary, unbound free peptide-PNA sensors (36) accumulate in the lower 
fractions, due to their higher density. After centrifugation, the separation between the different 
Nycodenz fractions was analysed by fluorescence measurements. 
A 
B 
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Figure 1.34: Separation of incorporated sensors by density-gradient centrifugation. Incorporation of 
palmitoyl modified peptide-PNA sensors into liposomes by manual extrusion. The efficiency of the incorporation 
process was analysed by density-gradient centrifugation.  
Analysis of the co-flotation assay revealed for the palmitoyl modified PNA sensors (36) 
inefficient incorporation in liposomes in the top fractions compared to the Texas Red 
fluorophore, which was used as the positive control (see figure 1.35). The floating properties 
of the palmitoyl modified peptide-PNA sensor (36) without liposomes (free BAC) were 
analysed, to exclude accumulation of the sensor itself in the top fractions. Based on these 
findings, it was assumed that the hydrophobic effect of one palmitoyl moiety is not sufficient 
to anchor the hydrophilic PNA strand in the membrane. The formation of liposomes was further 
hampered, due to aggregation of the palmitoyl-modified sensors.  
 
Figure 1.35: Incorporation of the palmitoyl-modified PNA sensor in liposomes. The relative BAC 
fluorescence intensity (λEx = 450 nm, λEm = 520 nm) was measured in the different fractions of the density gradient 
centrifugation. The fractions for the palmitoyl-PNA sensor with the liposomes are highlighted in black, liposomes 
incubated with Texas Red are shown in red and only sensor without liposomes is presented in grey. The experiment 
was performed by RASHI GOEL. 
1.2.5 Synthesis of TMD Modified PNA Sensors 
As the incorporation of the palmitoyl modified PNA sensors into the liposome was 
comparatively low, a more hydrophobic membrane anchor for improved incorporation had to 
be identified. Different studies of SNARE peptide model systems and spin labelled 
Partitioning of BAC in liposomes
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transmembrane peptides, revealed efficient incorporation of the transmembrane domain (TMD) 
modified peptides into liposomes.[139,140] The transmembrane domains are a part of membrane-
spanning protein domains, consisting predominantly of nonpolar amino acid residues. 
Screening of different transmembrane domains revealed the lysine-flanked model peptide 
(KALP), which is frequently used for anchoring of peptides into the membrane.[141] The KALP 
TMD consists of an alternating leucine and alanine core as well as two lysine residues at the 
N- and C-terminus. The amine group of the lysine side chains can interact with the polar lipid 
head groups and therefore enhances the solubility. Structurally, the KALP domain forms a 
stable α-helical structure and is incorporated into the membrane in a transmembrane orientation.  
The TMD-modified PNA oligomer (37) was synthesised by the optimised PNA coupling 
protocol (see figure 1.36 A). To improve the coupling efficiency of the hydrophobic TMD 
domain, the amino acids were coupled with increased DIC (0.1 M) and Oxyma (0.2 M) 
concentration as well as prolonged reaction times (10 min at 90 °C). The recognition sequence 
for the cathepsin B protease and a short Gly-Ser linker sequence were placed between the TMD 
and the PNA sequence. After synthesis of the TMD-PNA oligomer (37), the Alloc protecting 
group was removed and the BAC fluorophore was conjugated under microwave irradiation. 
HPLC purification of the crude mixture yielded the TMD-PNA sensor (38) with a cathepsin B 
recognition motif, which was directly used for cleavage experiments. The cathepsin B protease 
was activated and transferred to the TMD modified PNA sensor. The cleavage process was 
monitored by U-HPLC after 30 min and 60 min, revealing a complete conversion of the starting 
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Figure 1.36: Synthesis and Cathepsin B cleavage of TMD-modified PNA sensors. A) Synthesised of a TMD 
modified peptide-PNA sensor (38) with a cathepsin B recognition sequence. The recognition sequence is 
highlighted in grey. B) Cathepsin B protease cleavage experiments of the cathepsin B modified TMD-PNA sensor 
(38) analysed by U-HPLC after incubation times of 0 min, 30 min, 60 min at 37 °C. U-HPLC gradient: 10-60 % 
MeCN in15 min.  
 
1.2.5.1 Membrane Incorporation and Distribution of TMD-Modified PNA Sensors 
Following the successful cathepsin B cleavage experiments, the incorporation efficiency of the 
TMD-modified PNA sensor (38) into liposome DOPC/DOPS/DOPE/cholesterol (63/10/2/25) 
by manual extrusion was analysed by density-gradient centrifugation (performed by RASHI 
GOEL). Measurements of the BAC fluorescence intensity in the different fractions revealed a 
high BAC fluorescence intensity in the top fraction of the density gradient (4). In contrast, 
marginal BAC signals were detected in the bottom fractions (1 and 2) (see figure 1.37). These 
results confirmed highly efficient incorporation of the BAC labelled TMD-PNA oligomer into 
the liposomes. The fluorophore Texas Red was again used as positive control and the floating 
properties of the TMD-PNA sensor without liposomes were analysed, revealing a low 
accumulation in the top fraction.  
B 
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Figure 1.37: Incorporation assay of the TMD-modified PNA sensor in liposomes. The relative BAC 
fluorescence intensity (λEx = 450 nm, λEm = 520 nm) was measured in the different fractions of the density gradient 
centrifugation. The fractions for TMD-PNA sensor with the liposomes are highlighted in black, liposomes 
incubated with Texas Red are shown in red and only sensor without liposomes is presented in grey. The experiment 
was performed by RASHI GOEL. 
After incorporation experiments of the TMD-PNA sensors (38) into liposomes, the 
incorporation efficiency between intra- and extravesicular orientated sensors was determined. 
The TMD part of the sensor was synthesised and labelled with the 7-nitro-2-1,3-benzoxadiazole 
(NBD)-fluorophore. The fluorescence of the NBD dye can be quenched by addition of sodium 
dithionite (Na2S2O4
2-), which induces a reduction of the electron-withdrawing nitro group (39) 
to an electron-donating amine group (40) (see figure 1.38 A). The sodium dithionite is unable 
to cross the membrane due to the charges. Thus, only the NBD fluorescence of the 
extravesicular orientated sensors are quenched, whereas the intravesicular NBD fluorescence 
signals are not affected (see figure 1.38 B). 
       
Figure 1.38: Quenching experiments in fluorophore labelled TMD peptides. A) Reduction of the 7-nitro-2,1,3-
benzoxoadiazol-4-yl (NBD) fluorophore (39) to the corresponding 7-amino-2,1,3-benzoxoadiazol-4-yl (40) by 
addition of sodium dithionite. B) The sodium dithionite quenches all extravesicular orientated NBD-labelled 
KALP-TMD oligomers, whereas intracellular sensors are not quenched.  
The NBD-labelling of the TMD sequence was performed according to the literature procedure 
(see figure 1.39 A).[123] In the next step, the Alloc protecting group was removed and the NBD-
Cl was coupled to the N-terminal lysine residue with a mixture of DIPEA in DMF at rt for 24 h. 
Co-flotation assay

























R = KALP-TMD 
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After cleavage from the resin and subsequent HPLC purification, the NBD-labelled TMD 
oligomer (42) was incorporated into liposomes by manual extrusion. The incorporation 
efficiency of the NBD labelled TMD oligomer was measured before and after treatment with 
sodium dithionite. The proteoliposomes were incubated with 50 mM Na2S2O4 for 5 min at rt. 
Fluorescence measurements revealed an NBD fluorescence reduction of about 55 % after 
quenching with sodium dithionite (see figure 1.39 B). These results highlight the nearly equal 
intra- and extravesicular integration of the NBD labelled TMD oligomer (42).  
 
 
Figure 1.39: Synthesis and incorporation assay of NBD labelled TMD peptides. A) Synthesis of NBD 
modified TMD sequence (42). B) Fluorescence change after treatment of lipid vesicles containing NBD-labelled 
TMD oligomers with sodium dithionite. The experiment was performed by FREDERIKE MAAß. 
 
1.2.5.2 Formation of the Chloride Sensitive PNA-DNA Complex 
After successful incorporation of the TMD-PNA sensors (38) into liposomes, with 
complementary DNA oligomers (D1: stabilizing module, D2: normalizing module) was 
investigated next. The formation of the TMD modified PNA sensors (38) and the commercially 
available D1 and D2 strands were analysed by a gel mobility shift assay on a native 
polyacrylamide gel (see figure 1.40; see table 1.4). First, all three components were mixed in 
equimolar ratios and were annealed at 90 °C for 5 min, decreasing the temperature every 15 min 
by 5 °C. Analysis of the TMD-Cl- sensor formation revealed only a complexation of the D1-D2 
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preformed D1-D2 complex was tested, to optimize process conditions (lane 5-7). However, 
only for the annealing temperature of 35 °C, small amounts of the TMD-Cl- sensor were 
observed (lane 7). 
Further improvement of complex formation by increasing the concentration of TMD-PNA 
strand could not be achieved (data not shown). The BAC labelled PNA oligomer (11) without 
a TMD was used as a positive control, revealing the PNA-DNA complex formation and only 
small amounts of D1-D2 (lane 3).  
 
Figure 1.40: Gel mobility shift assay for visualisation of the Cl- sensor formation. The captured band detection 
results from the emission of the AlexaFluor 647 fluorophore. Lane 1: D1, Lane 2: D2, Lane 3: D1+D2+11, Lane 
4: D1+D2+38 at 90 °C, Lane 5: D1+D2+38 at 70 °C, Lane 6: D1+D2+38 at 60 °C, Lane 7: D1+D2+38 at 35 °C. 
The experiment was performed by BENJAMIN IDE. 
Table 1.4: Sequence of the peptide-PNA and DNA oligomers.. 
 
Name Sequence Comment 
D1 5′CAC CAG ACA GCA AGA TCC TAT ATA TA3′ DNA strand: stabilizing module 
(M = 7996 g/mol) 
D2 5′TAT AT(AlexaFluor 647)A TAG GAT CTT GCT GTC TGG 
TGT GCA GTG TTG AT3′ 
DNA strand: normalizing module 
(M = 12571 g/mol) 
38 H2N-A-K(BAC)-a-t-c-a-a-c-a-c-t-g-c-a-K-L-F-K-F-K-K-L-A-
L-A-L-A-L-A-L-A-L-A-L-A-L-A-K-K-CONH2 
PNA strand: sensing module       
(M = 6580 g/mol) 
11 H2N-A-K(BAC)-a-t-c-a-a-c-a-c-t-g-c-a-K- CONH2 PNA strand: sensing module      
(M = 4057 g/mol) 
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This inefficient Cl- sensor complex formation of the TMD-modified PNA oligomer (38) with 
the complementary DNA strands might be caused by the hydrophobic TMD, which avoid 
interactions with the charged DNA backbone. Also, the steric hindrance and rigidity of the 
α-helical structure from the TMD can block the interaction with the DNA strands. Due to the 
incomplete complex formation, the Cl- sensor cannot be used for precise measurements. This 
might cause the batch-to-batch variability between the Cl- sensitive BAC fluorophore and the 
Cl- insensitive AlexaFluor 647 fluorophore. Based on these results, a new Cl- sensor with 
improved complex formation as well as efficient encapsulation and cleavage of the 
extravesicular orientated sensors was required. 
 
1.2.6 Synthesis of His-Tag Modified PNA Sensors 
Since the hydrophobic TMD hinders the interaction of PNA and complementary DNA, a new 
membrane anchoring system for the Cl- sensor was required. The demanded characteristic of 
reduced hydrophobicity and efficient removal of extravesicular orientated sensors could be 
found in affinity tags. VASIC et al. firstly presented this interesting approach of protein 
incorporation into liposomes, by introducing an affinity tag to the substrate and thereby 
increasing their encapsulation efficient during liposome formation.[142] Therefore, a 
polyhistidine sequence can be introduced to the N- or C-terminus of the target protein. The 
benefit of the polyhistidine sequence (His-tag) is the strong interaction with Ni2+, which can be 
incorporated as Ni2+-nitrilotriacetic acid (NTA) labelled phospholipids in liposomes (see figure 
1.41). The addition of imidazole leads to efficient removal of the histidine-Ni2+ interaction, 
which is a crucial requirement for the elimination of the extravesicular orientated sensors. Thus 
a His-tag modified PNA sensor was synthesised for improving the sensor complex formation. 
The protease cleavage site is no longer required, as the extravesicular orientated sensors can be 
removed by imidazole. 
 
 Synthesis of His-Tag Modified PNA Sensors 49 
 
Figure 1.41: Strategy for a more effective Cl--sensor encapsulation. For this approach, Ni2+-NTA labelled 
liposomes were used. The His-tagged Cl--sensor was incorporated in Ni2+-NTA modified liposomes. After 
detergent removal, the Cl--sensors were coupled to the intra-and extravesicular site of the membrane. Following, 
treatment with imidazole cleaves the extravesicular bound sensors. 
 
1.2.6.1 Synthesis of a His14-Tag PNA Sensors 
Polyhistidine tags are widely disseminated for protein purification and consist of six or more 
consecutive histidine residues, which guarantee a high selectivity due to the rare occurrence of 
oligohistidine segments in proteins. The tag can be introduced to the C- or N-terminus of the 
target protein by polymerase chain reaction (PCR) or encoding the target protein in a vector. 
The synthesis of histidine sequences by SPPS is challenging due to their tendency to epimerise 
during the coupling step (see figure 1.42.). The free electron pair of the imidazole Nπ thereby 
deprotects the α-carbon (43), forming an achiral ester enolate (44), which can be converted to 
the L- or D-isomer (44).[143] Analysis of different histidine protecting groups revealed that 
coupling of histidine with the frequently used trityl (Trt) group at 50 °C for 10 min lead to an 
elevated formation of the D-isomer (5.8 %). However, Boc-protected histidine revealed a 
reduced D-isomer formation of 0.18 % under the same conditions. The Fmoc-His(Boc)-OH also 
showed a low tendency to epimerize (1.2 %) at higher coupling temperatures of 90 °C for 2 min 
compared to Fmoc-His(Trt)-OH (22 %).[144] This can be explained by the decreased basicity 
caused by the electron-withdrawing effect of the carbamate group.  
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Figure 1.42: Epimerization of Fmoc-His(PG)-OH during SPPS activation. 
Previous experiments from LATA et al. demonstrated that longer polyhistidine-tags (His10) 
possess 10-fold higher affinity compared to the frequently used His6-tag.
[145–147] Further studies 
from VASIC revealed a high encapsulation efficiency of proteins modified with a His14 sequence 
in Ni2+ containing liposomes.[142] The His14 sequence consists of four polyhistidine segments 
with three or four residues each, which are connected by flexible glycine, serine or threonine 
linkers. The structure of the His14 sequence allows the preferred interaction of two histidine 
residues (i and i+2/i and i+5) with the Ni2+. 
To develop efficient SPPS conditions for the synthesis of the His14 PNA sensor, the Boc-
protected histidine residues were used and the coupling was performed at a reduced temperature 
of 50 °C to minimize epimerization (see figure 1.43 A).[144] Further increased coupling times of 
two times 25 min and higher activator concentrations (DIC: 0.1 M, Oxyma: 0.2 M) lead to an 
improved crude purity compared to initial coupling conditions (10 min, 75 °C). The PNA part 
of the oligomer was synthesised by the optimised coupling conditions. After completion of the 
coupling process, a test cleavage and LC-MS analysis were performed, revealing a successful 
synthesis of the His14-PNA oligomer (46). In the final step, the Alloc protection group of the 
N-terminal lysine residue was cleaved, and the BAC fluorophore (4) was introduced. HPLC 
purification and mass analysis revealed the formation of the BAC-labelled His14-PNA sensor 













Figure 1.43: Synthesis and analysis of His14-PNA sensors. A) Synthesis of BAC-labelled His14-PNA oligomer 
(47). B) HPLC chromatogram of the crude His14-PNA oligomer (47) after BAC labelling. The isolated product 
peak is highlighted with an arrow. HPLC gradient: 1-40 % MeCN in 30 min. C) U-HPLC chromatogram of the 
purified BAC-labelled-His14-PNA oligomer (47). HPLC gradient: 1-40 % MeCN in 15 min.  
 
1.2.7 Characterisation of His14-Tag Chloride Sensor 
1.2.7.1 Formation studies of the His14-Tag Chloride Sensor 
The BAC-labelled His14-PNA oligomer (47) was characterised by JENNIFER STRUCK and RASHI 
GOEL (Group of PROF REINHARD JAHN). In the first step, the Cl- sensor formation of the BAC-
labelled His14-PNA oligomer (47) with the complementary DNA strands was analysed by a gel 
shift assay on a native polyacrylamide gel (PAGE) (see figure 1.44). Mixing of equimolar ratios 
of the PNA and DNA strands lead to the formation of the desired Cl- sensor, with a low amounts 
of free D1 and D2 complex (lane 4). To achieve a full complexation, an increased ratio of 1.25 
of the His14-PNA oligomer (47) was used, showing the formation of the His14-Cl
- sensor without 
free DNA complexes (lane 5). Further increase of the PNA sensor ratio to 1.5 did not achieve 
A 
B C 
tR = 18.4 min 
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an improvement of the complex formation (lane 6). Consequently, the following experiments 
were performed in a molar ratio of 1:1:1.25.  
 
Figure 1.44: Gel mobility assay visualizing the His14 Clensor formation. The captured band is indicated by the 
emission of the AlexaFluor 647 fluorophore. Lane 1: D2, Lane 2: D1+D2, Lane 3: D1+D2+11 (molar ratio: 1:1:1), 
Lane 4: D1+D2+47 (molar ratio: 1:1:1), Lane 5: D1+D2+47 (molar ratio: 1:1:1.25), Lane 6: D1+D2+47 (molar 
ratio: 1:1:1.5). The experiment was performed by JENNIFER STRUCK. 
In the next step, the sensitivity of the His14 modified sensor towards Cl
- was evaluated, by 
measuring the emission spectra of the BAC- and AlexaFluor 647 fluorophore in the 
physiological range of Cl- (0-75 mM). The fluorescence intensity of the BAC fluorophore was 
reduced in a dose-dependent manner with increasing Cl- concentrations when measured at the 
wavelength of 505 nm (G) (see figure 1.45 B). However, the fluorescence intensity of the 
AlexaFluor 647 fluorophore (R), measured at a wavelength of 670 nm, remained constant (see 
figure 1.45 C). For quantification of the Cl- concentration, the STERN-VOLLMER quenching 
constant (KSV) of the His14 Cl
- sensor was calculated. A Cl- calibration profile was created, 
fitting the R/G ratios dependent on the Cl- concentration, according to the STERN-VOLLMER 
equation (see figure 1.45 D). Based on the Cl- calibration profile, an apparent KSV of 
21.15 ± 0.33 M-1 for the His14 Cl
- sensor was calculated.  
 
 




Figure 1.45: Cl- sensitivity measurements of the His14-Cl- sensor. A) Structure of the His14-Clensor, PNA 
sensing module (pink) contains the His14 tag (blue) and the BAC fluorophore (green), D1 stabilizing module (grey) 
and D2 normalizing module (grey) containing the AlexaFluor 647 fluorophore (red). B) BAC fluorescence 
emission spectra at [Cl-] ranging from 0-75 mM using λEx = 434 nm. C) AlexaFluor 647 fluorescence emission 
spectra at [Cl-] ranging from 0-75 mM using λEx = 650 nm. D) Calibration profile of His14-Clensor visualizing 
AlexaFluor 647 and BAC fluorescence intensity ratio (R/G) versus [Cl-]. The R/G values were normalized to 
blank. The experiments were performed by JENNIFER STRUCK. 
 
1.2.7.2 His14-Tag Chloride Sensor Encapsulation into Liposomes  
After successful complex formation and measurements of the Cl- sensitivity, the encapsulation 
efficiency of the His14-Cl
- sensor into liposomes and further their cleavage from the 
extravesicular site was evaluated in the following steps. For efficient removal of the 
extravesicular incorporated sensors, three different approaches were developed using imidazole 
to remove the His-tag, a DNase I to degrade the sensor or a combination of imidazole and the 
enzyme.  
Before the cleavage experiments can be performed, the integrity of the His14-Cl
- sensor towards 
imidazole and DNase I was verified by gel mobility assay, to exclude denaturation of the sensor 
A B 
D C 
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by imidazole or blockage of the DNase activity by the PNA structure (see figure 1.46). The 
results of the gel mobility assay revealed no affection of the His14-Cl
- sensor integrity after the 
treatment with 400 mM imidazole, whereas treatment with DNase I (1 U/µL) resulted in the 
degradation of the sensor. Surprisingly, the combination of both compounds leads to incomplete 
degradation of the DNA strands, presumably caused by the reduced enzymatic activity of the 
DNase induced by imidazole. Interestingly, incubation of the BAC fluorophore with imidazole 
revealed a quenching effect for the BAC fluorescence, whereas the emission spectrum of the 
AlexaFluor 647 fluorophore remains unaffected (data not shown). Based on these findings, it 
is essential to incorporate a dialysis step in the encapsulation procedure to exclude falsification 
of the BAC fluorescence by imidazole. 
 
Figure 1.46: Integrity analysis of His14 Cl- sensor by gel mobility shift assay. The sensor was incubated with 
imidazole, DNase I or with a combination. Lane 1: D2, Lane 2: D1 and D2, Lane 3: His14-Cl- sensor, Lane 4: His14-
Cl- sensor treated with 400 mM imidazole, Lane 5: His14-Cl- sensor treated with DNase I, Lane 6: His14-Cl- sensor 
treated with imidazole and DNase I. Experiment was performed by JENNIFER STRUCK. 
After the assessment of His14-Cl
- sensor integrity towards imidazole and DNase, the 
incorporation efficiency and the cleavage of extravesicular orientated sensors by imidazole or 
DNase were analysed. Therefore, liposomes (DOPC 63 %, DOPS 10 %, cholesterol 25 %) 
modified with DGS-NTA(Ni2+) lipids (2 %) were prepared and the His14-Cl
- sensor was 
incorporated by manual extrusion. The incorporation of the sensors into the liposomes was 
evaluated by density gradient centrifugation, measuring the fluorescence intensity of the top 
fractions. The AlexaFluor 647 emission intensity was used as a readout for the incorporation 
and cleavage efficiency, as the BAC fluorescence is quenched by imidazole.  
The results from the co-flotation experiments revealed a 3.7 times higher His14-Cl
- sensor 
incorporation in liposomes containing 2 % DGS-NTA (Ni2+) lipids, compared to liposomes 
without Ni2+ lipids (see figure 1.47 A). Treatment of Ni2+ modified liposomes with imidazole 
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resulted in a decrease of the AlexaFluor 647 fluorescence intensity by approximately 50 %, 
compared to Ni2+ liposome without imidazole. However, the fluorescence intensity for Ni2+ free 
liposome remained constant after imidazole addition. These results confirm successful 
incorporation of the His14-Cl
- sensor in Ni2+ modified liposomes and the cleavage of 
extravesicular orientated sensors. The reduced fluorescence intensity of 50 % after imidazole 
treatment indicates an equal intra- and extravesicular integration of the sensor, similar to 
previous investigations with the TMD based sensors (see chapter 1.3.5.1). Despite the 
successful encapsulation, the incorporation efficiency of the His14-Cl
- sensor into the liposome 
was relatively low, probably caused by steric hindrance of the PNA-DNA scaffold or low 
accessibility of the His14 tag to the Ni
2+-NTA lipids.  
On the contrary, the results for DNase mediated cleavage of extravesicular orientated His14-Cl
- 
sensor revealed a reduced fluorescence intensity of AlexaFluor 647, whereas the BAC emission 
intensity was increased (see figure 1.47 B; BAC data not shown). This effect can probably be 
explained by the resistance of the PNA structure towards the DNase, which only degrades the 
D1 and D2 strands by cleaving their phosphate backbone. Considering the outcome of these 
experiments, imidazole was used as cleavage reagent for the extravesicular orientated sensor in 
further experiments.  
 
Figure 1.47: Encapsulation and cleavage of His14-Cl- sensor in Ni2+ modified liposomes. Relative AlexaFluor 
647 fluorescence intensity of the top fractions from density gradient centrifugation normalized to the control 
fluorescence intensity. A) Top fractions of density gradient centrifugation for liposomes with or without Ni2+ and 
imidazole. B) Top fractions of density gradient centrifugation for liposomes with or without Ni2+ and DNase. The 
experiments were performed by JENNIFER STRUCK. 
 
1.2.7.3 Purification and Chloride Measurements of Sensor Modified Liposomes  
After successful encapsulation of the sensor into liposomes, the His14-Cl
- sensor was separated 
from the cleaved free sensor by gel filtration chromatography. The reduced interaction with the 
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free sensor (data not shown). The structural integrity of the liposome was subsequently verified 
by dynamic light scattering (DLS) measurements. 
Next, the efficiency of the separation process was analysed. The fractions of the purified 
liposomes were therefore separated by density gradient centrifugation, revealing a high 
fluorescence intensity in the top fractions (8-10) and only minor amounts of the unbound sensor 
(fractions 1-5) (see figure 1.48 A). The purified liposomes were used to determine the chloride 
sensitivity of the encapsulated His14-Cl
- sensors. Measurements of the AlexaFluor 647 (R) and 
BAC (G) ratio of intact liposomes with encapsulated sensor showed no response to increasing 
Cl- concentrations. Contrary, disruption of the liposomes with Triton X-100 caused a dose-
dependent increase of the R/G ratio due to the release of the BAC fluorophore from the luminal 
liposome site (see figure 1.48 B). Calculations of the apparent STERN-VOLLMER quenching 
constant revealed for the intact liposomes a KSV of 0.99 M
-1
 and after disruption a quenching 
constant of KSv = 13.58 M
-1. These results approved the successful encapsulation and efficient 
cleavage of the extravesicular orientated His14-Cl
- sensors. The sensors still reveal a dose-
dependent response towards Cl- concentration after liposome reconstitution. The difference in 
KSV compared to the free His14-Cl
- sensor (KSV = 21.15 M
-1) might be caused by the lipid 
environment changes in the buffer composition or by imidazole, which was not completely 
removed during the dialysis steps. 
 
Figure 1.48: Purification and Cl- measurements of encapsulated His14 sensors in liposomes. A) Density 
gradient chromatography profile of purified liposomes containing the His14-Clensor. The fractions were analysed 
and the relative fluorescence intensity was calculated based on the total fluorescence intensity of all fractions. B) 
Measurements of the Cl- calibration profile of liposomes containing the His14-Cl- sensor either treated with or 
without Triton X-100. The emission spectra of BAC and AlexaFluor 647 were measured at Cl- concentrations 
ranging from 0-75 mM. The R/G values at different Cl- concentrations were normalized to 0 mM Cl-, equation of 
linear fit R/G = 1 + 0.99 M-1 ‧ [Cl-]; plus Triton X-100 R/G = 1 + 13.58 M-1[Cl-]. The experiments were performed 
by JENNIFER STRUCK. 
A B 
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1.2.7.4 Functional Assays of the His14-Tag Chloride Sensor 
To measure the intravesicular Cl- concentrations in the liposomes, the His14-Cl
- sensor has to 
be encapsulated in Ni2+ modified liposomes together with VGLUT1 and TF0F1 (ATP synthase 
for thermophilic Bacillus PS3). In preliminary experiments, the activity of VGLUT and TF0F1 
in reconstituted Ni2+ modified liposomes was confirmed, showing ATP-induced acidification 
and influx of external Cl- as a counter ion (data not shown). Changes of the luminal pH were 
measured with pH-sensitive dye Acridine Orange (AO). Furthermore, acidification experiments 
were performed in the presence of imidazole, which revealed no effect on the VGLUT1 and 
TF0F1 activity. 
Based on these data, Cl- concentrations were measured in proteoliposomes by the His14-Cl
- 
sensor. Liposomes with encapsulated His14-Cl
--sensor were formed by manual extrusion and 
VGLUT as well as TF0F1 were reconstituted by detergent removal (see figure 1.49 A). All 
extravesicular orientated sensors were removed by addition of imidazole and the liposomes 
were purified by gel filtration chromatography. The excess of imidazole was removed by 
dialysis, to prevent quenching of the BAC fluorophore. The purity of the liposomes was verified 
by density gradient centrifugation and the integrity of the liposomes was confirmed by DLS 
measurements (see figure 1.49 B).  
Further, the successful incorporation of VGLUT and TF0F1 was proven by density gradient 
centrifugation analysed by SDS-PAGE or Western Blot (see figure 1.49 C). Next, the activity 
of VGLUT and TF0F1 in the presence of His14-Cl
- sensor was analysed by measuring the ATP-
mediated acidification with 30 mM external Cl-. These results revealed strong acidification of 
the liposomes (Δ% of 61.14 %), similar to previous acidification assays, confirming the activity 
of VGLUT1 and TF0F1 in the presence of the sensor (see figure 1.49 D).  
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Figure 1.49: Activity measurements of encapsulated VGLUT, TF0F1 and His14-Cl- sensors in liposomes. A) 
Structure of the liposomes containing VGLUT, TF0F1, His14-Cl- sensor and the pH-Sensor Acridine Orange. B) 
Density gradient chromatography profile (fraction 1: 40 % Nycodenz, fraction 10: 0 % Nycodenz) of purified 
liposomes after size exclusion chromatography. The fractions were analysed by the relative fluorescence intensity, 
which was calculated based on the total fluorescence intensity of all fractions. C) Top: Silver stained SDS PAGE 
after density gradient centrifugation, showing co-migration of TF0F1 with liposomes in top-fractions. Down: 
Western Blot analysis after density gradient centrifugation, showing co-migration of VGLUT in top fractions. D) 
Cl- dependent acidification of proteoliposomes lacking or containing VGLUT. Experiments were performed with 
2 mM ATP and 30 mM KCl. The experiment was performed by JENNIFER STRUCK. 
Finally, the Cl- conductance in liposomes containing VGLUT, TF0F1 and encapsulated 
His14-Cl
- sensor were measured by monitoring the BAC fluorescence intensity. Surprisingly, 
stepwise addition of Cl- (30 mM) lead to no drastic decrease in the BAC fluorescence in the 
millisecond range, as observed for the Cl- calibration curves (see figure 1.50). The 
measurements of the BAC fluorescence intensity were disturbed by long stabilisation times and 
bleaching of the fluorophore caused by prolonged irradiation periods. During the fluorescence 
recordings, it was not possible to measure the fluorescence intensity of BAC and 
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BAC fluorescence intensity were also not considered. Thus, further measurements of the Cl- 
conductance will be performed with total internal reflection fluorescence (TIRF) microscopy 
or fluorescence cross-correlation spectroscopy (FCCS), which allows the simultaneous 
monitoring of the BAC and AlexaFluor 647 fluorescence. 
 
Figure 1.50: Time-dependent BAC fluorescence intensity of His14-Cl--sensor. After signal stabilization, 
30 mM Cl- was added each. The fluorescence intensity was normalized to the time point of signal stabilization. 
The experiment was performed by JENNIFER STRUCK. 
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1.2.8 Development of an ALFA-Tag Modified Chloride Sensor  
Besides the synthesis of His14-modified PNA sensors, an approach for in vivo measurements of 
Cl- concentrations was developed. The idea of linking a sensor molecule to the luminal 
synaptotagmin 1 domain, described by MARTINEAU et al., was used for this strategy.[47] 
Synaptotagmin is a transmembrane protein in synaptic vesicles, which is interacting with the 
SNARE complex, regulating the process of vesicle docking and fusion. Expression of the sensor 
in cultured hippocampal neurons leads to efficient incorporation in synaptic vesicles. However, 
MARTINEAU et al. used the CLOPHENSOR (see chapter 1.1.5.1), which produces imprecise 
measurements as it does not cover all physiological Cl- concentrations and the Cl- recordings 
require a complex pH correction factors.[5,88] 
A bispecific monoclonal nanobody was engineered, which can simultaneously address the 
luminal synaptotagmin domain and binds specifically an epitope tag, which is conjugated to a 
Cl- sensor. This tag can be introduced into the PNA sensing module, allowing specific 
interaction with the nanobodies and incorporation of the PNA-DNA based Cl- sensor in synaptic 
vesicles during endocytosis. Since nanobodies are antibody fragments with reduced molecular 
weight (12-15 kDa compared to 150-160 kDa), the synaptic vesicle can incorporate a higher 
number of Cl- sensors.[148,149] 
 
Figure 1.51: Strategy for Cl--sensor incorporation in synaptic vesicles. Thereby, the luminal domain of 
synaptotagmin is addressed with a nanobody. Fusion with a second nanobody allows specific interaction with an 
epitope tag, which can be incorporated in PNA-DNA based Cl- sensors. 
Screening of highly specific and potent epitope tags for protein purification or detection 
revealed the ALFA-tag, which is recognized by the ALFA nanobody (NbALFA) with ~26 pM 
affinity. The ALFA-tag was already successful conjugated to fluorophores, enzymes and 
biomolecules, applicable for super-resolution microscopy, immunoprecipitations or detection 
of proteins in living cells.[150] The sequence of the ALFA-tag (SRLEEELRRRLTE) was 
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forms a stable α-helical structure in solution.[151] Furthermore, the ALFA tag sequence is 
compatible with protein functions and can be either incorporated at the N- or C-terminus of a 
protein or between two domains. Other advantages of the ALFA tag are the low reactivity, as 
it lacks free amine or thiol groups, as well as reduced influence on protein conformation, as it 
is flanked by proline residues, which break secondary structures. 
After engineering of a bispecific nanobody fairy, which targets, on the one hand, the luminal 
synaptotagmin domain and on the other hand the ALFA tag sequence, first incorporation 
experiments were performed (see figure 1.52). Therefore, an ALFA-tag modified GFP 
fluorophore and the nanobody fairy were incubated in primary cultured hippocampal neurons, 
showing a successful encapsulation after 10 min (experiment performed by RASHI GOEL). For 
removal of all extravesicular orientated nanobodies, a TEV protease cleavage site was 
introduced into the nanobody sequence to measure the intravesicular Cl- concentration 
exclusively. Despite so far unsuccessful experiments using the TEV protease, no hindrance was 
expected for this approach since previous studies revealed only limited TEV activity for the 
cleavage of small peptides.  
 
Figure 1.52: Structure of the nanobody fairy. The construct consists of a recognition unit against the luminal 
synaptotagmin domain and the ALFA tag sequence. The nanobodies are connected by a TEV recognition sequence 
to remove extracellular orientated sensors and a FLAG linker to increase the flexibility of both nanobodies.  
Based on the successful encapsulation experiments of the GFP fluorophore, the ALFA tag 
sequence was introduced in the PNA sensing module of the Cl- sensor, to ensure incorporation 
in synaptic vesicle and measurements of the Cl- concentration. The ALFA tag recognition 
sequence was incorporated in the C-terminal part of the sensing module and the ALFA-PNA 
oligomer (48) was synthesised by the previously described optimised PNA coupling conditions 
(see chapter 1.2.2). To increase spatial separation, a short Gly-Ser linker, as well as proline 
residues, were introduced between the ALFA tag and the PNA oligomer (see figure 1.53 A). 
For the coupling of the Arg residue in the ALFA tag sequence, reduced reaction temperatures 
of 75 °C and enhanced reaction times (10 min) were applied, to prevent δ-lactam formation 
during the coupling process. After cleavage of the Alloc protection group, the BAC fluorophore 
(4) was coupled under microwave irradiation and the crude oligomer was purified by HPLC 
(see figure 1.53 B). U-HPLC and mass spectrometry confirmed the successful formation of the 
ALFA-tag PNA sensor (49) (see figure 1.53 C). 
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Figure 1.53: Synthesis and analysis of ALFA-tag modified PNA sensor. A) Synthesis of the ALFA-tag 
modified PNA sensor (49) for Cl- measurements in synaptic vesicles. B) HPLC chromatogram of the of ALFA-
PNA oligomer (49) after BAC labelling. The isolated product peak is highlighted with an arrow. HPLC gradient: 
1-30% MeCN in 45 min. C) U-HPLC chromatogram of the purified ALFA-PNA-BAC sensor (49). U-HPLC 
gradient: 1-30% MeCN in 20 min. 
Following, the synthesised ALFA-PNA sensor (49) was hybridized with the complementary 
DNA strands, by annealing all three components for 5 min at 90°C. The successful formation 
of the ALFA-tag modified Cl- sensor was confirmed by gel mobility shift assay (data not 
shown) and the sensor was directly incubated with the ALFA nanobody at rt for 15 min. The 
complex formation of the nanobody and the Cl- sensor was analysed by gel mobility shift assay 
visualized by silver staining, revealing only bands for the nanobody and the ALFA-Cl--sensor, 




tR = 16.0 min 
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Figure 1.54: Gel mobility shift assay of the ALFA-Cl--sensor formation with the ALFA-nanobody. For 
visualisation, silver staining was used. Lane 1: Marker, Lane 2: ALFA nanobody, Lane 3: GFP as the positive 
control, Lane 4: ALFA- Cl--sensor, Lane 5: ALFA nanobody and GFP, Lane 6: ALFA-Cl--sensor and ALFA 
nanobody. The experiment was performed by RASHI GOEL. 
These findings indicated a blockage of the ALFA nanobody recognition process, probably 
caused by the bulky PNA-DNA structure, which hinders the accessibility of the ALFA-tag 
sequence. The complex formation of a simplified ALFA-tag peptide, lacking the PNA structure, 
with the nanobody was investigated. The ALFA-tag peptide consists of the recognition 
sequence and a fluorophore to visualise complexation with the nanobody and possible uptakes 
in synaptic vesicles. For facilitation of the binding process, an increased Gly-Ser linker 
sequence was introduced between the fluorophore and the ALFA recognition side (see figure 
1.55). The peptide sequence (50) was synthesised by SPPS and the Arg residues were coupled 
at a reduced temperature of 75 °C. In the next step, the Alloc protecting group of the N-terminal 
Lys residue was cleaved and an NHS-activated AlexaFluor 488 fluorophore was conjugated to 
the resin-bound peptide with a mixture of DIPEA and DMF at rt for 24 h. After labelling, the 
peptide was cleaved from the resin with TFA, TIS, H2O (95/2.5/2.5, v/v/v) and the crude peptide 
(51) was purified by HPLC (data not shown). The fluorophore AlexaFluor 488 was selected, 
due to its stability, small size and high quantum yield.  
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Figure 1.55: Synthesis of AlexaFluor 488 labelled ALFA-tag peptides (51). 
The fluorophore labelled ALFA peptide (51) was used for complexation studies with the ALFA 
nanobody, which were analysed by gel mobility shift assay and visualised by the fluorescence 
emission of the AlexaFluor 488 fluorophore. The complexation experiments revealed for the 
AlexaFluor 488 labelled ALFA peptide (51) and the nanobody a band at approximately 40 kDa 
as expected for the complex (see figure 1.56). However, similar bands were detected for the 
labelled ALFA peptide (51) itself, indicating the formation of aggregates and no complexation 
with the ALFA nanobody. This effect might be explained by the structure of the ALFA-tag 
sequence, which has a high tendency to oligomerise, caused by the charged arginine and 
glutamic acid residues. When conjugated to proteins, the tendency to oligomerise is reduced 
due to the small size of the ALFA-tag sequence compared to protein structures.  
 
Figure 1.56: Gel mobility shift assay visualizing the AFLA-peptide nanobody formation. Lane 1: Nanobody, 
Lane 2: ALFA modified GFP (as positive control), Lane 3: AlexaFluor488-labelled peptide (high conc.), Lane 4: 
AlexaFluor488-labelled peptide after centrifugation to disrupt secondary structures (high conc.), Lane 5: 
AlexaFluor488-labelled peptide, Lane 6: AlexaFluor488-labelled peptide after centrifugation, Lane 7: 
AlexaFluor488-labelled peptide and the nanobody, Lane 8: AlexaFluor488-labelled peptide and nanobody after 
centrifugation, Lane 9: ALFA-GFP and nanobody. The experiment was performed by RASHI GOEL. 
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Since the interaction between the ALFA tag modified peptides (51) and the nanobody are 
hindered, the ALFA-tag approach was replaced by HaloTag, which is frequently used for 
visualisation of the cellular process by super-resolution microscopy. The HaloTag is a 
self-labelling protein, which forms a covalent bond with reactive chloralkane linker, conjugated 
to fluorophores or sensors.[152,153] Consequently, the HaloTag protein was fused with the 
nanobody against the luminal synaptotagmin domain, which allows the incorporation of 
chloralkane-modified PNA-DNA sensors into synaptic vesicles. Further incorporation 
experiments with the Halo fusion protein and modified PNA-DNA sensors are still pending. 
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1.3 Discussion and Conclusion 
 
The transmission of signals is managed by a complex network of neurons, which send signals 
along axons and thereby releasing neurotransmitters into the synaptic cleft. After signal 
transmission, the neurotransmitters are recycled and refilled into synaptic vesicles.[1,2] Mainly, 
the reuptake process of the excitatory neurotransmitter glutamate was studied over the last 
years, as several neurological diseases can be linked to glutamate imbalance.[40,41] The transport 
of glutamate into synaptic vesicles by VGLUT is proton gradient dependent. This gradient is 
generated by the V-ATPase. However, the efficiency of glutamate transport by VGLUT is 
tightly regulated by the extravesicular and luminal Cl- concentrations.[3,4,74] For more in-depth 
insights into the Cl- dependence, a fluorescent Cl- sensor was developed to pursue the kinetics 
of the Cl- influx through VGLUT during the glutamate transport.  
To complete this task, a ratiometric PNA-DNA based Cl- sensor was developed, which consists 
of three modules: a PNA sensing module (PNA) conjugated to the Cl- sensitive BAC 
fluorophore, a normalizing DNA module bearing the Cl- insensitive AlexaFluor 647 
fluorophore and a stabilizing DNA module (see figure 1.57). For encapsulation of the Cl--sensor 
into the lumen of the proteoliposomes, the PNA sensing module was modified with a 
hydrophobic membrane anchor and protease cleavage sequence. The incorporation of the 
cleavage motif allows the specific removal of extravesicular orientated sensors on the liposome 
by addition of a protease.  
 
Figure 1.57: Structure of the PNA-DNA based Cl- sensor.  The sensor consists of the normalizing and stabilizing 
DNA strands as well as the Cl- sensitive PNA module. Furthermore, the PNA strand is modified by a membrane 
anchor and a cleavage sequence, to encapsulate sensors in the liposome.  
Peptide-PNA sensors, equipped with a palmitoyl membrane anchor and different protease 
recognition sequences, were synthesised by an optimised PNA coupling strategy. This method 
allows automated SPPS of the PNA monomers with significantly reduced reaction times (2 x 
25 min at 50 °C) compared to manually coupling protocols (2 x 1 h, rt).[5,120,121] For further 
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improvements of the synthesis process, the reaction temperature could be increased to 65 °C 
and therefore, the coupling times could be reduced to 15 min. These new coupling conditions 
would allow the synthesis of a 12-mer PNA oligomer in almost half of the time. PAfter 
synthesis of the different peptide-PNA sensors, the cleavage process was analysed. Oligomers 
with a TEV or Factor Xa protease recognition sequence revealed no cleavage under different 
digestion conditions. In contrast, peptide-PNA oligomers with a cathepsin B recognition motif 
were completely cleaved after 30 min. Despite efficient cleavage, cathepsin B protease revealed 
a reduced cleavage specificity compared to the TEV or Factor Xa protease. The cathepsin B 
protease cleaves the recognition motif Phe-Lys preferentially. Still, it is also able to cleave the 
sequence Phe-Arg or Gly-Phe-Leu-Gly. Therefore, removal of extravesicular sensors by 
cathepsin B could also affect the activity of VGLUT or the TF0F1, since both proteins exhibit 
cathepsin B cleavage motifs. The cathepsin B protease is still applicable for in vitro 
measurements, however, removal of the extravesicular sensors has to take place before the 
proteins are incorporated into the liposomes. For further improvements of the cleavage process, 
a protease with higher specificity is required, which is also applicable for the cleavage of small 
peptide structures. The protease cleavage sequence could also be replaced by disulphide- or 
pH-sensitive linker systems, which have been used for the synthesis of antibody-drug 
conjugates.[154–156]  
The membrane incorporation of palmitoyl modified PNA sensors was analysed by density 
gradient centrifugation. However, the results demonstrated inefficient incorporation of the 
sensor, presumably the hydrophobic effect of one palmitoyl moiety is not sufficient to anchor 
the PNA strand in the membrane. 
The palmitoyl anchor was replaced by a hydrophobic transmembrane domain (TMD), which 
was introduced into the PNA sequence by an optimised SPPS coupling protocol. Further 
investigations of the TMD-modified PNA sensor revealed a fast cleavage by cathepsin B and 
efficient incorporation into the liposomes, showing an equal intra- and extravesicular 
distribution (see figure 1.58). However, annealing of the TMD-PNA sensor with the 
complementary DNA strands revealed no formation of the Cl- sensor, probably caused by the 
hydrophobic TMD, which hinders the interaction with the charged DNA backbone. To 
overcome this limitation, the distance between the TMD and PNA scaffold could be increased, 
by the introduction of a highly flexible PEG linker, which is frequently used for the application 
of drugs and biomolecules.[157] The introduction of the PEG-linker would also increase the 
water solubility of the TMD-PNA sensor and therefore enhance the interaction with the DNA 
strands.  
Discussion and Conclusion 68 
 
Figure 1.58: Overview of the results of the TMD and Cathepsin B modified PNA sensor. After synthesis of 
the sensor, the cleavage by the cathepsin B protease (left) and incorporation experiments (right) were performed.  
Based on these findings, the TMD anchor was replaced by a hydrophilic polyhistidine sequence, 
which can specifically interact with Ni2+-NTA labelled phospholipids in liposomes. A protease 
cleavage sequence was no longer required since the addition of imidazole leads to efficient 
removal of extravesicular orientated sensors. Previous incorporation experiments revealed a 
higher encapsulation efficiency for more extended polyhistidine tags compared to the 
frequently used His6-tag.
[142,145] Therefore, a His14-PNA sensor was synthesised by optimised 
SPPS conditions. Further characterisations of the His14-PNA oligomer presented a successful 
complexation with the complementary DNA strands and a Cl- sensitivity of the BAC 
fluorophore (KSV = 21.15±0.33 M
-1) in the physiological range of Cl- (see figure 1.59).  
Following, the incorporation efficiency and the removal of extravesicular orientated His14-Cl
- 
sensor was verified. The results from the co-flotation experiments revealed a 3.7 times higher 
His14-Cl
- sensor incorporation in liposomes modified with Ni2+ lipids and efficient removal of 
all outside orientated sensors by treatment with imidazole. However, the incorporation 
efficiency of the His14-Cl
- sensor into liposomes was relatively low, probably caused by steric 
demand. In future experiments, different Ni2+ lipid or Cl- sensor concentrations have to be 
investigated, to identify optimal conditions to encapsulated a maximum number of sensors in 
the liposomes. Another improvement of incorporation might be achieved by replacing the His14 
sequence by a His6-tag, as reduced steric demand increase the incorporation amount. 
Preliminary experiments with a His6-tag modified PNA sensor presented already a successful 
Cl- sensor formation and further incorporation studies are under investigation.  
After the encapsulation studies, the His14-Cl
- sensor was incorporated into Ni2+ modified 
liposomes together with VGLUT and an ATPase (TF0F1), to measure the kinetics of Cl
- influx 
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through VGLUT in liposomes. First experiments revealed the successful incorporation of 
VGLUT and TF0F1 in Ni
2+ modified liposomes and their activity in the presence of encapsulated 
His14-Cl
- sensor. Surprisingly, recordings of the Cl- conductance in liposomes containing 
VGLUT, TF0F1 and encapsulated His14-Cl
- sensor revealed no decrease in the BAC 
fluorescence intensity after addition of Cl-. However, the measurements were hampered by 
bleaching of the BAC fluorophore, caused by long irradiation times. Further experiments will 
be performed by TIRF or FCCS measurements, which allows the simultaneous monitoring of 
the AlexaFluor 647 and BAC fluorescence intensity. The AlexaFluor 647 emission intensity 
can be used to normalise the emission intensity of BAC.  
 
Figure 1.59: Overview of the results of the His14-PNA sensor.  First, the His14-sensor was formed and the Cl- 
sensitivity was measured (left). Afterwards, the incorporation and cleavage efficiency of the Cl- sensor were 
analysed (right).  
Additionally, one approach for in vivo measurements of the Cl- concentration was developed. 
An ALFA tag nanobody was used to target the luminal synaptotagmin domain in synaptic 
vesicles. Simultaneously, the nanobody binds to a short ALFA-tag sequence, which consists of 
15 amino acids.[150] This ALFA sequence was introduced into the PNA sensing module of the 
Cl- sensor by SPPS. However, incubation of the ALFA-tag modified Cl- sensor and the 
nanobody lead to no complexation, presumably caused by the bulky PNA-DNA structure or 
oligomerisation of the ALFA-tag sequence. The ALFA-tag was replaced by a HaloTag protein, 
which can specifically interact with a chloralkane modified PNA-DNA sensor. The simple 
structure of the chloralkane linker might lead to improved interaction with the HaloTag and a 
more efficient complex formation. The chloralkane linker was introduced to the 3’ end of the 
D1 strand instead of the PNA module, which might improve the accessibility of the linker 
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towards the HaloTag protein. Complexation and encapsulation studies of the Halo fusion 
protein and the sensor is under current investigation.  
Combining these results, different PNA-DNA based Cl--sensors were synthesised with an 
optimised coupling strategy. This approach allows the successful incorporation of various 
membrane anchoring systems into the PNA sequence. Especially the introduction of the 
His14-tag presented an elegant approach for efficient encapsulation in liposomes and controlled 
removal of all extravesicular orientated sensors by incubation with imidazole. Noteworthy, the 
strategy of liposome encapsulation of the His14-PNA-DNA sensors is not only limited to Cl
- 
sensing and presents, therefore a useful tool for measurements of ion concentrations. This will 
provide new opportunities to study transmembrane proteins and their transport mechanisms. 
One exciting application of the sensor is the profound examination of SNARE-mediated 
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2 Investigation of Voltage-Gated Sodium 
Channels by modified Conotoxins 
 
2.1 Structure and Function of Voltage-Gated Sodium Channels 
Voltage-gated sodium channels (VGSC or NaV channels) are integral membrane proteins that 
initiate electrical signalling in excitable cells and control a variety of physiological processes. 
The activity of NaV channels is tightly controlled by changes of the membrane potential, which 
causes a channel opening and therefore an influx of Na+ along their electrochemical 
gradient.[158,159] The NaV channels were first discovered by HODGKIN and HUXLEY in 1952, by 
analysing action potentials of giant squid axons with voltage-clamp measurements. Their work 
revealed that signals in nerves are initiated by voltage-dependent activation of Na+ influx.[160,161] 
After inactivation (1-2 ms) of the NaV channels, ionic balance is reestablished by potassium 
channels, initiating a K+ efflux.[159] 
The first basic structural investigations of VGSCs were reported by BENESKI, CATTERALL and 
HARTSHORNE in the 1980s, using azidonitrobenzoyl mono[125I]iodo, a photoactive derivate of 
the scorpion toxin, to identify subunits of rat brain sodium channels.[162,163] More precise 
structural information and visualization of different functional states were revealed with 
recently published X-ray crystal structures of the bacterial NaV channels from the marine 
bacterium Magnetoccus sp. (strain MC-1).[164] Although the crystal structure of the mammalian 
NaV channels is still unknown, homology models were developed based on the sequences of 
human NaV channels and bacterial crystallographic data. These models provided further 
insights into the functionality of these channels on a molecular level.[165,166]  
The human NaV channels consist of a large pore-forming α-subunit of 260 kDa, associated with 
auxiliary β1- and β2-subunit of 30-40 kDa. The α-subunit is a single-chain polypeptide with a 
length of 2000 amino acids, organized in four homologous domains, each containing the six 
transmembrane segments S1-S6 (see figure 2.1 A).[9,167,168] The S1-S4 transmembrane 
segments form the voltage-sensing domain, in which the conserved S4 segment acts as the 
channel's voltage sensor, consists of positively charged arginine or lysine residues in every third 
position.[9,168] The voltage sensors from each domain are organized around the channel pore, 
which is formed by the S5-S6 segments of all domains as well as the extracellular connecting 
pore loops. (see figure 2.1 B and 2.1 C).[169,170] Upon depolarization, the S4 segment moves 
forward to the extracellular surface, inducing a conformational change which allows the 
opening of the channel and a Na+ influx. During the depolarization process, the inactivation
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gate, formed by the short intracellular loop between S3 and S4, folds into the channel pore 
resulting in an inactivation of the channel and a refolding of the S4 segment to the resting 
position.[171]  
The selectivity of the channel is ensured by a filter that distinguishes between Na+ and other 
competing ions which differ in charge and radii. The negative charge of the channel attracts 
only cations, interacting with the narrowest part of the pore, which just fits for a Na+ ion 
conjugated with one water molecule.[172] The narrowest part of the pore is formed by a salt 
bridge between a lysine and glutamate or aspartate residue. Destruction of the salt bridge by 
replacing the lysine with an alanine residue destroys the selectivity of the channel and makes it 
permeable towards K+, Ca2+ and Ba2+.[9,173] 
 
 
Figure 2.1: Structure of NaV channels. A) Transmembrane folding diagram of the α-subunit of the human 
voltage-gated sodium channel. The channel consists of four homologous domains with six transmembrane 
segments each. The plus signs in the S4 segment represents the positively charged amino acids in the voltage-
sensing domain. B) View of the open-channel pore, from a crystal structure of bacterial NaV channel. C) Side-
view of NaV channel in the open state. Reprinted with permission from M. DE LERA RUIZ et al., J. Med. Chem. 
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2.1.1 Voltage-Gated Sodium Channel Isoforms 
Currently, nine different isoforms of the NaV channels (1.1-1.9) have been described with 
similar functionality and a high sequence homology over 50% in the transmembrane segments 
and extracellular loop regions. The NaV 1.1, 1.2, 1.3 and 1.6 are expressed in the central nervous 
system (CNS), whereas NaV 1.7-1.9 is restricted to the peripheral nervous system (PNS). The 
NaV1.4 and 1.5 channels occur predominantly in skeletal and cardiac muscles (see figure 
2.2).[174] Mutations or dysfunctions in the different NaV channels cause various diseases like 
chronic pain, neuromuscular disorders, cardiovascular diseases or psychiatric disorders.[10,175–
177]  
 
Figure 2.2: Tissue expression of the nine different voltage-gated sodium channel subtypes.[9] 
Especially, dysfunction of the neuronal NaV1.2 channel, which is expressed in the axon initial 
segment and dendrites, is linked to psychiatric diseases like epilepsy, autism, Asperger 
syndrome or febrile seizures.[11,178,179] Therefore, NaV1.2 might be a suitable target structure to 
address new treatment options for these diseases. The current used NaV inhibitors, like 
phenytoin carbamazepine or lamotrigine, can cause various off-target effects, due to subtype 
unspecific NaV channel binding.
[180,181] Consequently, there is a great interest in the 
development of specific inhibitors for the NaV1.2 channel to gain deeper insights into their 
molecular mechanisms as well as their localization and activity during different stages of the 
diseases. These findings would contribute to the development of new effective therapeutics 
with a higher specification and fewer side effects. 
Different approaches already tried to determine the density and localization of the NaV1.2 
channels with fluorophore-labelled antibodies for the α-subunit of the channel.[182–184] However, 
the usage of antibodies for immunostaining of NaV channels has significant drawbacks. The 
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bulky size of the antibody distorts the precise localisation of NaV channels by enlarging the 
distance of the fluorophore to the channel. Furthermore, the labelled antibodies address 
intracellular epitopes, requiring an uptake into the neurons. Therefore, the cells have to be 
fixated and permeabilised, which makes them only applicable for in vitro studies.[185] Also, 
several fluorophores can bind to one antibody and several antibodies can bind to one channel, 
making precise immunofluorescence measurement unfeasible.[182] Therefore, new inhibitors 
have to be identified, which fulfil the following criteria: the inhibitor requires a high affinity 
and specificity for the NaV1.2 channels, it has to be compatible with fluorophore labelling 
strategies and it must bind to the extracellular site of the channel in a precise 1:1 stoichiometry. 
 
2.1.2 Inhibition of NaV-channels by Conotoxins 
Over the last years, different high-affinity inhibitors of the NaV channels have been described, 
which mostly are produced by venomous animals or poisonous plants.[9] Depending on their 
structure, the inhibitors can be categorized into two main groups of peptidic- or non-peptidic 
toxins. In the group of non-peptidic inhibitors, especially the alkaloid neurotoxins tetrodotoxin 
(TTX) (52) was extensively studied (see figure 2.3 A). The toxin is produced by the pufferfish, 
showing a nanomolar affinity for the NaV1.1-1.4, NaV1.6 and NaV1.7. Therefore, their 
application as a tool for channel investigations as well as their therapeutic potential is limited 
due to the lack of selectivity among different NaV subtypes.
[186,187] Also, other members of the 
group of non-peptidic toxins, like Batrachotoxin (53), revealed a high affinity for NaV channels 
but no subtype specificity (see figure 2.3 B).[9,188] 
 
Figure 2.3: Non-peptidic toxins inhibiting the NaV channels. A) Tetrodotoxin (52) extracted from pufferfish. 
B) Batrachotoxin (53) isolated from the skin secretion of the Phyllobates frog. Reprinted with permission from M. 
DE LERA RUIZ et al., J. Med. Chem. 2015, 58, 7093–7118. 
A B 
 Inhibition of NaV-channels by Conotoxins 75 
Hence, the search for highly selective NaV inhibitors was focussing on the group of venom 
peptides produced by spiders, scorpions, molluscs or marine cone snails. Although spiders, 
scorpions and sea anemones species produce up to 10 million bioactive peptides from which 
only 0.01% have been characterized, the highest potency, as well as subtype-selectivity for the 
NaV1.2 channel, was found in peptides isolated from the marine cone snail (see figure 
2.4).[9,189,190]  
 
Figure 2.4: Peptidic toxins that inhibit NaV channels. A) Anthopleurin B isolated from the sea anemones. B) 
ProTX-II isolated from tarantulas. C) OD1 extracted from the scorpion. D) µ-Conotoxin KIIIA extracted from 
cone snails. Reprinted with permission from M. DE LERA RUIZ et al., J. Med. Chem. 2015, 58, 7093–7118. 
Cone snails are distributed throughout tropical and subtropical waters, where they are hunting 
fish, worms or molluscs. Since the cone snails are slow-moving, they use a venomous harpoon 
to inject their toxins to capture faster-moving preys.[191,192] First investigations of the cone snail 
venoms were done in the 1960s due to several human deaths, caused by cone snail stings. In 
the following years, many researchers tried to unravel the pharmacological effects of the cone 
snail toxins. Their studies showed that the venom consists of a mixture of at least 100-200 
neuroactive peptides, so-called conotoxins. These toxins cause an almost immediate paralysis 
of the prey by blocking ion channels, G-protein coupled receptors or neurotransmitter 
transporters.[193,194] Structurally, conotoxins are small peptides with a length of 10-40 amino 
acid and well-defined secondary structures, which are stabilized by multiple conserved 
disulphide bonds. Additional post-translational modifications (PTMs) increase the stability 
towards degradation by proteases.[194,195] Today, around 750 different species of the cone snails 
have been discovered, producing up to 70.000 neuroactive peptides from which only 0.1 % 
have been characterized pharmacologically.[194,196] The so far revealed conotoxins can be 
organized into superfamilies based on similarities of the N-terminal precursor sequences (see 
figure 2.5). Further, the superfamilies can be classified into families based on their cysteine 
framework, conotoxin family and target receptor, according to the International Union of Basic 
B C D 
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and Clinical Pharmacology (IUPHAR) nomenclature.[197] The conotoxin nomenclature can be 
explained exemplary for the α-conotoxin PnIA: α indicates the targeting of the nicotinic 
acetylcholine receptor, Pn signifies the origin Connus pennaceus, I determines the framework 
one and A denotes the order of discovery.[192,198,199] 
 
Figure 2.5: Classification of conotoxins. Conotoxins are categorized into superfamilies based on their conserved 
signal sequence homology. The different organisation in families depends on their cysteine frameworks and target 
structures. Reprinted with permission from K. B. AKONDI et al., Chem. Rev. 2014, 114, 5815–5847. 
Due to the large number of neuroactive peptides produced by cone snails, the conotoxins exhibit 
a tremendous potential as lead molecules for the development of new therapeutics as well as 
tools for channel and receptor examination under physiological and pathological 
conditions.[194,195] The ω-conotoxin MVIIA (ziconotide) from the cone snail Conus magnus, 
was already approved by the Food and Drug Administration (FDA) in 2004 and is clinically 
used as an analgesic for the treatment of chronic pain. Ziconotide acts on the voltage-gated Ca2+ 
channel, by blocking neurotransmitter and substance P release, which is associated with 
inflammatory processes and pain.[200] Compared to morphine, ziconotide is 1000 times more 
potent and causes less tolerance and addiction. However, ziconotide must be administered 
directly into the spinal fluid because of the lack of efficacy when ingested orally or 
intravenously. Based on this limitation ziconotide is used exclusively as an alternative therapy 
for chronic pain or opiate-resistant patients.[200,201]  
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2.1.2.1 Neuronal-Subtype Binding µ-Conotoxins 
Analysis of the characterized conotoxin families revealed four families (µ-, µO-, δ-, i-) which 
are explicitly affecting the functions of NaV channels. The µ-conotoxins block the sodium 
conductance by direct blockage of the extracellular pore, whereas the µO-conotoxins inhibit 
the sodium current by interfering with the voltage-sensors in domain 2.[202,203] On the contrary 
δ-and i-conotoxins disturbs the process of channel inactivation by modifying the voltage sensor 
domain D4.[204] 
Among the conotoxins targeting NaV channels, the µ-conotoxins are the most numerous and 
best-characterized class of conotoxins. They consist of 16-26 amino acids and their three-
dimensional structure is stabilized by three conserved disulphide bridges arranged in a class III 
framework (Cys1-Cys4, Cys2-Cys5, Cys3-Cys6).[205] The net charge of the µ-conotoxins (+2 
to +7) allows them to electrostatically bind and block the negatively charged channel pore of 
the NaV channels (see table 2.1).
 Although the binding site of µ-conotoxins overlap with the 
TTX binding site, the µ-conotoxin interacts with more residues of the NaV-channel, resulting 
in the subtype selectivity.[203] 
The first isolated and characterized µ-conotoxin was the µ-GIIIA from the venom of Conus 
geographus, consisting of 22 amino acids. Structure-activity studies of the µ-GIIIA revealed 
that all three disulphide bridges, as well as the positively charged arginine residue in the second 
intercysteine loop, are essential for the blockage of the NaV channel.
[206,207] Furthermore, 
measurements with µ-GIIIA indicated for the first time a NaV channel subtype selectivity, by 
showing specificity for the skeletal muscle channel NaV1.4 (IC50 = 0.019 µM) over the neuronal 
subtypes (IC50 = 0.2-18 µM). Measurements of the related µ-conotoxins PIIIA and SmIIIA also 
revealed a preference for the muscular NaV1.4 channel.
[207] 
Shortly after the identification of µ-GIIIA, µ-PIIIA and µ-SmIIIA, the first inhibitors of the 
neuronal NaV channels were identified by BULAJ et al., presenting the µ-conotoxin SIIIA from 
Conus striatus and KIIIA from Conus kinoshitai.[12] Characterisation of these toxins revealed 
for the µ-SIIIA (IC50 = 0.05 µM) as well as µ-KIIIA (IC50 = 0.005 µM) a low nanomolar affinity 
for the NaV1.2 channel. Beside their inhibition of the NaV1.2 channel, both conotoxins block 
the NaV1.4 as well as NaV1.6 channel in submicromolar concentration.
[12,208,209] Structurally, 
the µ-SIIIA and µ-KIIIA exhibit a strong sequence homology, with µ-SIIIA having four 
additional residues in the N-terminal part. Further investigations of µ-SIIIA analogues also 
revealed an analgesic potency by blocking action potentials in mice sciatic nerves, leading to a 
reduction of inflammatory pain.[14,210] These results underline the therapeutic potential of µ-
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SIIIA as a potent inhibitor of the mammalian NaV1.2 channels. Furthermore, the four additional 
residues, which do not influence the overall activity of the µ-SIIIA, makes it a powerful tool 
for research studies by introducing modifications.[210] 
Table 2.1: µ-Conotoxin sequences and characteristics. Summary of the sequence, net charge, favoured NaV 
channels of selected µ-conotoxins. The disulphide framework is observed between Cys1-Cys4, Cys2-Cys5, Cys3-
Cys6. Z= pyroglutamate and O = hydroxyproline. Table adapted from [14]. 
 
Structurally, the µ-SIIIA consists of 20 amino acids with a net charge of +2 and three disulphide 
bridges, which are buried in the core of the peptide. The N-terminus is cyclized by the formation 
of pyroglutamate, which increases the stability against enzymatic degradation by 
exopeptidases.[211] The C-terminal is posttranslationally modified by amidation, which affects 
the isoelectric point and enhances the binding to the negative surface of the NaV channel. 
Furthermore, the amidation protects the µ-SIIIA against degradation by 
carboxypeptidase.[14,207] Investigations of the 3D-structure by NMR studies revealed a compact 
α-helix (residues 11-16) compared to the muscle subtype binding µ-conotoxins which form 
distorted helices (see figure 2.6 A).[208] Further structure-activity studies showed that the 
residues in the helical structure are most important for the channel interaction. Especially, 
replacement of the residues Lys11, Trp12, Arg14, His16 and Arg18 caused a significantly 
reduced binding affinity to the channel (see figure 2.6 B).[13,14] However, for all mutations, a 
preference for the neuronal NaV1.2, compared to the NaV1.4 channel was still measurable. 
Interestingly, the mutation H16A leads to a disruption in the α-helical motif, causing a 
significant decrease in the binding affinity for neuronal as well as muscle subtypes.[13,14]  









PIIIA ZRLCCGFOKSCRSRQCKOHARCC +6 1.4>1.6=1.1>1.2>1.3 
SmIIIA ZRACCNGRRGCSSRWCRDHSRCC +5 1.4>1.2>1.1>1.3>1.6 
SIIIA ZNACCNGAaGCSSKWCRDHARCC +2 1.2>1.4>1.6>1.1 
KIIIA AAACCNaaaAACSSKWCRDHSRCC +3 1.2>1.4>1.6>1.7 
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Figure 2.6: Structure and sequence of µ-conotoxin SIIIA. A) Three-dimensional structure of µ-SIIIA. The 
disulphide bridges are highlighted in yellow, the α-helix in blue and the crucial residues for channel interaction 
are shown in orange (BMRB ID code: SMS20025). The graphic was created with USCF Chimera package.[212]. 
B) Results of amino acid replacement on NaV1.2 and NaV1.4 subtype selectivity. () indicates improved potency 
against NaV1.2 or NaV1.4 subtypes, whereas () indicates a decreased potency.[207] 
To improve the therapeutic potential of µ-SIIIA, different synthetic analogues were developed 
to increase the stability under cellular conditions as well as specificity and affinity to the NaV1.2 
channel. Therefore, the disulphide bonds were replaced by diselenide bridges, which revealed 
greater thermodynamic stability under reductive conditions and enhanced oxidative folding but 
decreased binding affinity to the NaV1.2 channel.
[213,214] Furthermore, stabilisation of the 
µ-SIIIA structure by introduction of a lactam bridge causes a decrease in the affinity for NaV1.2 
compared to native µ-SIIIA.[215] Interestingly, studies from GREEN et al. revealed that replacing 
the non-essential Asn, pGlu or Gly residues, by non-peptidic backbone spacers lead to a higher 
analgesic effect in mice models.[207] These results indicate the potential of the non-essential 
positions for the introduction of modifications, without affecting the overall affinity and 
selectivity. 
 
2.1.3 Oxidative Folding of Disulphide-Rich Peptides 
One major drawback includes the limited availability of the µ-conotoxin SIIIA for the research 
as well as a clinical application when extracted from the cone snail venom.[194] Therefore, 
different approaches to produce sufficient amounts of µ-SIIIA have been developed. On the 
one hand, conotoxins can be produced by recombinant expression in heterologous expression 
systems like E. coli or yeast.[216] This method provides rapid production of µ-SIIIA. However, 
purification of the conotoxin, as well as the incorporation of unnatural amino acids and different 
posttranslational modifications, are still challenging in recombinant expression systems.[194] On 
B A 
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the other hand, chemical synthesis provides more control over the introduction of modifications 
such as backbone cyclization or disulphide replacement to increase the stability of µ-SIIIA 
against proteases. Therefore, the chemical synthesis of the conotoxin can be performed by solid-
phase peptide synthesis (SPPS), producing the linear precursor peptide. The folding of the 
conotoxin is induced by oxidation of the cysteine residues, which can be achieved by either 
oxidative folding or orthogonal protecting group strategy, leading to the formation of disulphide 
bridges.[194,217]  
The oxidative folding strategy provides the advantage of only one cysteine protecting group for 
SPPS and one purification step (see figure 2.7). The conformation of the conotoxin depends 
mainly on the folding information encoded in the sequence and the number of disulphide 
bridges and isomers, which can be calculated by the equation (2n)!/(2nn!) with n being the 
number of disulphide bonds.[194] Accordingly, the µ-SIIIA consists of three disulphide bridges 
and can theoretically form 15 isomers excluding topological isomers. However, only one 
isomer corresponds to the bioactive conformation, indicating the relevance of the folding 
process.[192]  
 
Figure 2.7: Formation possibilities in a peptide containing two-disulphide bonds. Reprinted with permission 
from K. B. AKONDI et al., Chem. Rev. 2014, 114, 5815–5847. 
The successful formation of the native µ-SIIIA by oxidative folding was achieved by the 
addition of reduced and oxidized glutathione (GSH/GSSG) in the basic buffer (pH 7.5-8.5) and 
high dilution to prevent dimer or oligomer formations.[12,210,218] Furthermore, the folding of the 
µ-SIIIA can also be induced in ionic liquids (1-ethyl-3-methylimidazolium acetate), providing 
higher yields and accelerated reaction times.[219]  
However, the limitations of the oxidative folding strategies were reported by RADZEY, showing 
that introduction of non-natural amino acids for fluorophore labelling, drastically disturb the 
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folding process.[220] A variety of different folding conditions, including GSH/GSSG in a 
Tris/HCl buffer or ionic liquids, were analysed, leading to multiple disulphide isomers, non-
native structures or low yields.[210,213] To overcome these limitations, a regioselective oxidation 
strategy was developed, allowing a controlled formation of the disulphide bonds. 
 
2.1.3.1 Regioselective Folding of Disulphide-Rich Peptides  
The regioselective synthesis approach is based on orthogonal cysteine-protecting groups, which 
ensure a selective deprotection and a stepwise formation of the disulphide bonds. This strategy 
forms the desired disulphide connectivity and reduces the number of isomers during the folding 
process to a few topological isomers (see figure 2.8).[221,222] For a controlled step-by-step 
formation of multiple disulphide bonds, cleavage and oxidation conditions are required, which 
prevent breaking and reshuffling of already formed disulphide bridges. Therefore, alkaline 
conditions, thiols or nucleophiles have to be avoided during all deprotection and disulphide 
formation steps. 
 
Figure 2.8: Comparison of oxidative one-step folding and regioselective synthesis strategy. 
For the synthesis of conotoxins with multiple disulphide bridges, different approaches were 
reported using the following protecting groups: tert-butylthio (StBu), trityl (Trt), 
acetamidomethyl (ACM), tert-butyl (tBu) and methoxybenzyl (MeOBzl) (see table 2.2).[223,224] 
However, the order of cleavage and deprotection, as well as reaction conditions, strongly affects 
the success and yields of the synthesis. For example, the StBu group is cleaved reductively; 
therefore, it must be removed in the first folding step, to prevent a reduction of already 
preformed disulphide bridges. The Trt group is a frequently used thiol protecting group because 
it is labile towards TFA and is removed in the cleavage process of the peptide from the resin. 
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Furthermore, the Trt-group is often combined with the orthogonal Acm group, which is stable 
against TFA and can be removed by iodine or mercury salts. However, the Acm cleavage 
conditions can cause oxidation of sensitive side chains like methionine, histidine, tryptophan or 
tyrosine residues.[194] Commonly protecting groups for the formation of the 3rd disulphide 
bridge are the tBu and MeOBzl group. The tBu group can be removed in a DMSO/TFA mixture 
at room temperature whereas MeOBzl is cleaved in DMSO/TFA at 60 °C.[225]  
Table 2.2: Overview of frequently used thiol protecting groups for SPPS. The structure, stability and standard 
cleavage conditions for the different protecting groups are shown.[194,223]  
Protecting group Structure Stabile Cleavage 
Triphenylmethyl (Trt) 
 








TFA, base, RSCl RSH, Bu3P, (HOOCCH2CH2)3P 
Tert-Butyl (tBu) 
 
TFA, HF (0 °C), base, 
Ag(I), I2 








base diluted TFA (0.5 %), Hg2+, Ag+, I2, 
Ti3+ 
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2.2 Design and Synthesis of Modified µ-Conotoxin SIIIA 
Voltage-gated sodium channels are involved in all physiological processes by controlling the 
influx of Na+ across the membrane.[11,178,179] Especially mutations and dysfunctions in the 
neuronal NaV1.2 channel are associated with various neurological diseases.
[11,178,179] However, 
for the development of new specific therapeutics, a deeper understanding of the molecular 
mechanisms and the expression levels of these channels are fundamental. A potent inhibitor of 
the NaV1.2 channel is required, which can be conjugated to a fluorescent dye, to visualize the 
localization and distribution of these channels by fluorescence microscopy. 
For identification of potent inhibitors of the NaV1.2 channels, a screening approach was 
performed. Thereby, the µ-conotoxin SIIIA and KIIIA, which were isolated from the venomous 
cone snails, were identified to preferentially block the NaV1.2 channel with low nanomolar 
affinity and further the skeletal NaV1.4 channel with submicromolar affinity.
[12,207] Comparison 
of the sequence of both conotoxins revealed additional pyroglutamate and asparagine residues 
at the N-terminus as well as two glycine residues in the first loop for the µ-SIIIA. Since these 
residues are non-essential for the channel interaction, they are suitable positions for a chemical 
substitution of a fluorophore, without affecting the binding affinity of the conotoxin.[210,220] 
Consequently, the µ-SIIIA was selected as a lead structure for fluorophore labelling and channel 
investigations.  
Commonly used labelling strategies, addressing amine or thiol groups in the protein of interest, 
cannot be applied for the µ-SIIIA.[226–228] On the one hand, labelling of a newly introduced 
amine group would lead to unspecific labelling of the native lysine residue in the α-helix, which 
is essential for the conotoxin channel interaction.[207] On the other hand, the introduction of 
another thiol group by a cysteine would result in misfolding of the µ-SIIIA, by the formation 
of a non-native disulphide bond. To overcome these limitations, the µ-SIIIA can be labelled by 
a biorthogonal copper-catalysed azide-alkyne cycloaddition (CuAAC). Therefore, an alkyne 
linker is introduced into the sequence of µ-SIIIA, which can be conjugated to an azide modified 
fluorophore.  
In previous studies from RADZEY, different positions in the µ-SIIIA sequence were modified 
with a fluorophore and analysed regarding their binding affinity towards NaV1.2 in patch-clamp 
measurements.[220] The µ-SIIIA derivative, which was labelled at the Gly6 position, revealed 
the highest blocking activity compared to C- or N-terminal labelled derivates.[220] However, 
accurate determination of the NaV1.2 channel distribution by fluorescence microscopy and 
kinetic measurements of the labelled µ-SIIIA were not performed. The measurements from 
Design and Synthesis of Modified µ-Conotoxin SIIIA 84 
RADZEY also revealed that the AlexaFluor 647 fluorophore exhibit a tendency of sticking to 
membranes and the charges of the fluorophore disturb the channel interaction.[220] The 
fluorophore was therefore replaced with the AlexaFluor 488 fluorophore, which was attached 
to an alkyne linker in the position of the Gly6 of the modified µ-SIIIA (see figure 2.9).[229] 
 
Figure 2.9: 3D Structure of the µ-SIIIA modified with AlexaFluor 488. The fluorophore was attached to an 
alkyne linker in the position of the Gly6. The fluorophore is highlighted in green, the disulphide bridges in yellow 
and main residues for the channel interaction are presented in orange (BMRB ID code: SMS20025). The graphic 
was created with USCF Chimera package.[212] 
 
2.2.1 Synthesis of Native µ-Conotoxin SIIIA 
In the following chapter, the synthesis of native and fluorophore labelled µ-conotoxins SIIIA 
are described to target NaV channels (see figure 2.10). Previous results from RADZEY revealed 
the formation of multiple disulphide isomers when using the oxidative folding strategy for the 
synthesis of an alkyne modified µ-SIIIA derivative.[220] A regioselective folding strategy for 
the synthesis of an alkyne-modified µ-SIIIA was developed, based on the work from 
RADZEY.[179] This synthesis strategy ensures the correct folding of three disulphide bridges and 
induces the native topology by a stepwise deprotection of orthogonal cysteine protecting 
groups. After folding of the disulphide bridges, the µ-SIIIA can be labelled with a fluorophore 
by CuAAC reaction.[220]  
First, the unmodified µ-SIIIA was synthesised to verify whether the regioselective folding 
strategy forms the native conformation of the toxin. Therefore, the synthesised µ-SIIIA was 
characterised by patch-clamp measurements and the blocking activity was compared with 
literature data for the native µ-SIIIA.[13,202,222] The simple structure of the unmodified µ-SIIIA 
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was used to optimize reaction and folding conditions, which can be later applied for the 
synthesis fluorophore labelled µ-SIIIA derivatives.  
 
Figure 2.10: Schematic overview of the µ-SIIIA synthesis into a fluorescent labelled toxin. In the first step, a 
linear peptide was synthesised, containing an alkyne linker for biorthogonal labelling (A). After the formation of 
the disulphide bridges (B), the fluorophore is attached to the folded peptide (C), allowing visualisation of the NaV 
channel distribution (D).  
The linear precursor sequence of the unmodified µ-SIIIA was synthesised on a 2-chlorotrityl 
chloride resin, using Fmoc-based solid-phase peptide synthesis (SPPS) on a peptide synthesizer. 
The chlorotrityl resin was modified with a RAMAGE-linker to introduce a C-terminal amide 
group to the peptide sequence.[129] To avoid peptide aggregation during SPPS, a resin with low 
loading (< 0.35 mmol/g) density was used. The peptides can be cleaved from the resin under 
mild conditions with 10 % acetic acid, producing the protected peptide in solution (see figure 
2.11). Disulphide bonds can be built in high dilution, which prevents dimer or oligomer 
formation caused by intermolecular disulphide bridges.[194] Coupling of the Fmoc-protected 
amino acids was performed under microwave irradiation at 50 °C for 10 min, due to the 
sensitivity of the chlorotrityl resin towards elevated temperatures.[231] Activation of the amino 
acids was achieved with DIC as activator and Oxyma as activator base.  
A controlled folding process of the three disulphide bonds is essential for the synthesis of the 
µ-SIIIA since studies of the disulphide isomers of the µ-conotoxin PIIIA revealed either no or 
a reduced (30-50 %) channel blockage activity compared to the native toxin.[230] The formation 
of the first disulphide bridge is crucial and the yields can be enhanced by activation of the first 
cysteine residue.[220] The resin-bound peptide (54) was treated with 20 % 2-mercaptoethanol in 
DMF to remove the StBu protecting group, forming the free thiol group at Cys3 (see figure 
2.11). Following, the thiol group was activated by introduction of an electron-withdrawing 
2-thiopyridine (SPyr) substituent, which promotes the formation of a disulphide bond in the 
following step. The protected peptide (55) was cleaved from the resin with 10 % acetic acid 
(AcOH) and the monomethoxytrityl (Mmt) protecting group at Cys13 was removed with 0.5 % 
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TFA in DCM under high dilution. The first disulphide bridge (56) was formed under basic 
conditions in a mixture of triethylamine (10 %) and DCM, causing deprotonation of the free 
thiol group which can attack, as a nucleophile, the activated Cys(SPyr). 
 
Figure 2.11: Formation of the first disulphide bridge of the native µ-SIIIA. After deprotection of the StBu 
group, the free thiol group was activated by 2,2’-dithiodipyridine. Afterwards, the peptide (54) was cleaved from 
the resin and the Mmt protecting group was removed, forming the first disulphide bridge (56) under basic 
conditions. Z represents pyroglutamate. 
After the formation of the first disulphide bridge (56), all acid-sensitive protecting groups were 
removed with a mixture of TFA, TIS and H2O, leading to the crude µ-SIIIA (57) with two Acm 
protected cysteine residues (see figure 2.12). The oxidation of the second disulphide bridge was 
induced by DMSO, which can be applied over a broad pH range from 1 to 8. Especially acidic 
conditions accelerate the oxidation rates and prevent reshuffling of already built disulphide 
bridges.[232] However, low pH (< 3) or high DMSO concentrations (> 50 %) can oxidize 
sensitive side-chain residues like histidine or tryptophan.[194] The formation of the second 
disulphide bridge was performed under mild oxidizing conditions with 20 % DMSO in acetate 
buffer at pH 6. The crude peptide (58) was purified by HPLC yielding one major product 
fraction.  
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Figure 2.12: Formation of the second disulphide bridge of the native µ-SIIIA. After cleavage of all acid 
protecting groups, the second disulphide bridge (58) was formed in acetate buffer with 20 % DMSO at pH 6. The 
C-terminus is amidated.  
Finally, the two Acm protecting groups were oxidatively cleaved by addition of iodine, which 
simultaneously induced the formation of the third disulphide bridge. Iodine-mediated cleavage 
can also cause oxidation of the sensitive residues histidine or tryptophan in the µ-SIIIA 
sequence and longer reaction times (> 4 h) can lead to a reshuffling of already formed 
disulphide bridges.[233] Consequently, the purified µ-SIIIA with two disulphide bonds was 
dissolved in a mixture of AcOH/H2O, whereby the scavenger Ac-Trp-OMe was added to 
prevent oxidative side reactions.[233] After the addition of iodine, the reaction mixture was 
stirred for 1 h and the addition of ascorbic acid quenched the excess of iodine. HPLC 
purification and mass spectrometry analysis of the crude reaction mixture showed the formation 
of four main product species (59), which have the same mass but show different retention times 
on the HPLC-column (isomer 59.1.1-59.1.4, see figure 2.13). Due to the regioselective 
synthesis strategy, the different product fractions are most likely topological isomers, which 
form the same disulphide linkage with different conformations. Detailed structural analysis of 
these isomers by NMR spectroscopy was not carried out so far, due to the small amounts of the 
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Figure 2.13: Formation of the third disulphide bridge of the µ-SIIIA. A) Cleavage of the Acm protecting 
groups of the µ-SIIIA (58) by addition of iodine in AcOH/H2O. B) HPLC chromatogram of the crude µ-SIIIA (59) 
with three disulphide bridges. The four product peaks (59.1.1-59.1.4) are highlighted with numbers. HPLC 
gradient: 1-40 % MeCN in 30 min. 
 
2.2.1.1 Optimised Folding Conditions of µ-Conotoxin SIIIA 
The observed formation of topological isomers by the regioselective approach was already 
reported for the synthesis of the enterotoxin and the conotoxin PnID B. Patch-clamp 
measurements of these topological isomers revealed a significant reduction of the biological 
activity compared to the native conformation.[234,235] ESPIRITU explained these differences of 
activity by the formation of distinct contortions or knots within the structure of the isomers.[234] 
Further analysis of the enterotoxin folding process by the three disulphide bridges (Cys1-Cys4, 
Cys2-Cys5, Cys3-Cys6) revealed a dependence between the order of disulphide bond formation 
and the proportion of topological isomers. The overall conformation is thereby strongly 
influenced by the formation of the last disulphide bond.[236] Thus, an optimised synthesis 
strategy for the µ-SIIIA is required to not only reduce the number of topological isomers but 
also to increase the yields for the native conformation to create a cost-effective product.  
Based on these findings, an optimised folding strategy for the µ-SIIIA was developed by 
analysing the 3D structure of µ-SIIIA. The analysis revealed two disulphide bonds (A: 
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the surface (C: Cys8-Cys20) (see figure 2.14 A). The synthesis strategy based on the work from 
RADZEY forms firstly one core disulphide bridge followed by the surface disulphide bridge. The 
last bridge is formed in the core between the Cys4-Cys19. This procedure results in four 
topological isomers potentially caused by the more variable core orientation of the cysteine 
residues. Changing the order of disulphide formation by rearranging the position of the 
protecting groups can affect the number of topological isomers. By firstly forming the interior 
disulphide bonds Cys3-Cys13 and Cys4-Cys19 of the µ-conotoxin SIIIA, the globular structure 
is preformed (see figure 2.14 B). In the last step, the disulphide bond on the surface is built 
between the Cys8 and Cys20 without affecting the overall conformation.  
 
Figure 2.14: Folding strategy of disulphide bonds. A) 3D Structure of the µ-SIIIA. The disulphide bridge C8-
C20 is highlighted in yellow, Cys3-Cys13 in orange and Cys4-Cys19 in green (BMRB ID code: SMS20025). The 
graphic was created with USCF Chimera package.[212] B) Comparison of the folding strategy for the synthesis of 
the µ-SIIIA developed by Radzey and in this work.  
Based on these assumptions, a new folding pattern for the synthesis of the native µ-conotoxin 
SIIIA (60) by an interchange of the cysteine protecting groups to Cys3-StBu, Cys13-Mmt, 
Cys4,19-Trt, Cys8,20-Acm was established (see figure 2.15 A). Similar to the previously 
described method, first the StBu, as well as Mmt group, were cleaved and the Cys3-Cys13 
disulphide bridge was built (see chapter 2.2.1). After removal of all acid-sensitive protecting 
groups, the second core disulphide bridge was formed, and the crude peptide (61) was purified 
by HPLC obtaining one isomer. Finally, the Acm groups were cleaved with iodine for 1 h, 
leading to the formation of only two instead of four topological isomers (59.2.1 and 59.2.2), 
which were separated by HPLC (see figure 2.15 B and 2.15 C). These results highlight the 
A 
B 
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importance of the order of disulphide bond formation as the presumable number of non-active 
topological isomers could be reduced from three to one.  
 
  
Figure 2.15: Synthesis and purification of native µ-SIIIA. A) Synthesis of the native µ-SIIIA (59). Compared 
to the synthesis approach from RADZEY, the Acm protected cysteine residues are placed in the positions Cys8 and 
Cys20 (60). B) HPLC chromatogram of crude native µ-SIIIA (59). The improved folding strategy received the 
isomers 59.2.1 and 59.2.2. HPLC gradient: 1-40% MeCN in 30 min. C) U-HPLC chromatogram of the purified 
isomers of the µ-SIIIA. HPLC gradient: 1-40% MeCN in 15 min. 
 
2.2.1.2 Patch Clamp Measurements of Native µ-SIIIA 
Whole-cell patch-clamp experiments carried out measurements of the NaV channel blocking 
activity by the topological isomers 59.2.1 and 59.2.2. Previous measurements of the 
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µ-conotoxin SIIIA (59) revealed a micromolar potency for NaV1.2 channels as well as a 
blockage of the NaV1.4 channels with a submicromolar potency.
[12,13,202] These 
electrophysiological characteristics can be used as a reference for the verification of the native 
µ-SIIIA isomer. 
Since expression and patch-clamp measurements of the NaV1.2 channel in cells are challenging, 
the blocking experiments of both isomers were performed by measuring currents through the 
NaV1.4 channel. Furthermore, the interaction of the µ-SIIIA and the NaV1.4 channel was 
intensively investigated, providing detailed information about the toxin-channel interaction as 
well as the association and dissociation process. These data support the characterisation of 
newly synthesised isomers and modified µ-SIIIA derivates.[202]  
Patch-clamp experiments of the isomer 59.2.1 and 59.2.2 of the µ-SIIIA were performed by 
VIVIEN KISTMACHER (Group of Prof. ENRICO LEIPOLD, University Lübeck). The inhibition 
studies were conducted with HEK 293 cells, which were transfected with rat NaV1.4-channel 
expression plasmids. The measurements of the sodium currents were performed 24-48 h after 
transfection and the µ-SIIIA isomers were locally applied with a glass pipette. The channel 
availability was monitored every 3 sec with a pulse, consisting of hyperpolarization to –80 mV 
and depolarization to 60 mV.  
Measurements of isomer 59.2.1 of the µ-SIIIA at a concentration of 1 µM revealed an 88 % 
inhibition of the NaV1.4 current reaching a steady-state phase after 350 sec (see figure 2.16 A). 
A 10-fold increase of the isomer 59.2.1 concentrations resulted in an increase of current 
inhibition up to 90 % after 80 sec. Saturating concentration of 100 µM µ-SIIIA leads to a 
maximal blocking activity of 93 %, reaching a steady-state phase after 25 sec. Analysis of the 
dissociation process revealed an almost irreversible binding, showing a sustained blocking 
activity of 80% after a washout time of 20 min (τoff = 6816 ± 85 sec). These results revealed a 
strong interaction between isomer 59.2.1 and the NaV1.4 channel but no complete blockage of 
the sodium currents, similar to previous experiments with the native µ-SIIIA.[202]  
To compare the efficiency of the binding process of the isomer 59.2.1 with the native µ-SIIIA, 
the dissociation constant (KD) has to be calculated. The KD value can be derived from the 
association rate (kon), which are dependent on the toxin concentration, and the independent 
dissociation rate (koff). The koff value (1.5 ‧ 10
-4 s-1) was recorded in the blocking experiments, 
whereas kon cannot directly be measured and has to be calculated from the experimentally 
observed association rate (kobs). The kobs rate is the sum of kon and koff depending on the analyte 
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concentration, which describes the association and dissociation of the toxins from the channel 
during the experiment (see equation 2.1).  
𝑘obs =  𝑘on ∙ [cµ−SIIIA] + 𝑘off   (2.1) 
The kobs were plotted against the corresponding concentration of isomer 59.2.1 and the kon rate 
(5.4 ‧ 10-3 µM-1 s-1) was calculated from the slope of the linear regression (see figure 2.16 B). 
Based on the kon and koff kinetics, a KD (KD = koff/kon) value of 28 ± 5 nM was calculated for the 
isomer 59.2.1. Comparable KD values were measured for the native µ-SIIIA by YAO et al. in 
Xenopus oocytes.[208,237] Based on the slow dissociation process and the KD value, the isomer 
59.2.1 were identified to form the native conformation of µ-SIIIA. 
 
Figure 2.16: Patch-clamp measurements of isomer 2.1. A) Blocking and wash-off kinetics of the isomer 59.2.1 
of µ-SIIIA at 1 µM, 10 µM and 100 µM concentration. The data points are highlighted in black. The SEM is 
indicated by grey shading and the red lines are single-exponential fits. The number of experimental replicates is 
shown in parentheses. B) Dose-response curve shows the association and dissociation kinetics (top) and 
percentage of sodium current inhibition as a function of the µ-SIIIA concentration (bottom). Straight lines are 
data fits; dashed lines are extrapolations of data fits. The experiment was performed by VIVIEN KISTMACHER. 
The patch-clamp measurements of isomer 59.2.2 of µ-SIIIA (10 µM) showed a reduced 
blocking activity of 58 % at a steady-state level after 80 sec, compared to a blocking activity of 
90 % for isomer 59.2.1 (see figure 2.17 A). Also, a 10-times higher concentration caused only 
a maximal inhibition of 87 % of the sodium currents after 25 sec. Measurements of the 
dissociation kinetics showed a fast wash-off from the NaV1.4 channel and a full recovery of the 
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isomer 59.2.2 yielded 140 times higher KD value (5.1 ± 1.2 µM) compared to isomer 59.2.1 (see 
figure 2.17 B). The fast dissociation process and the increased KD value indicate a reduced 
binding affinity between the channel and the toxin probably caused by a non-native 
conformation of the isomer 59.2.2. Since the toxins were synthesised by a regioselective 
synthesis strategy, the isomer 59.2.2 is probably forming a topological isomer, with correct 
disulphide linkage but non-native overall conformation. 
 
Figure 2.17: Patch-clamp measurements of isomer 59.2.2. A) Blocking and wash-off kinetics of isomer 59.2.2 
of µ-SIIIA at 10 µM and 100 µM concentration. The data points are highlighted in black. The SEM is indicated 
by grey shading and the red lines are single-exponential fits. The number of experimental replicates is shown in 
parentheses. B) Dose-response curve shows the association and dissociation kinetics (top) and percentage of 
sodium current inhibition as a function of the µ-SIIIA concentration (bottom). Straight lines are data fits; dashed 
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2.2.2 Synthesis of Labelled µ-Conotoxin SIIIA 
After the successful synthesis and identification of the native µ-SIIIA (59), the optimised 
folding strategy was applied for the development of fluorophore-labelled µ-SIIIA. A 
propargylglycine residue was incorporated at the position of Gly6 via SPPS, allowing the 
coupling of the fluorophore by copper(I)-catalysed alkyne-azide cycloaddition (CuAAC). The 
synthesis of the linear peptide (62) and the formation of the first and second disulphide bridge 
was performed analogously to the synthesis of the native µ-SIIIA (59) (see chapter 2.2.1.1). 
After HPLC purification, the µ-SIIIA (63) with two disulphide bonds and the Acm protecting 
groups at Cys8 and Cys20 was isolated. Compared to the synthesis protocol of the native 
µ-SIIIA (59), optimised reaction conditions are required for the cleavage of the Acm groups, 
as the alkyne linker is sensitive towards iodine. However, other cleavage conditions of the Acm 
groups were already examined by RADZEY, revealing that mercury(II) acetate or silver(I) 
trifluoroacetate lead to a reduction of the disulphide bridges.[220] Thus, the iodine mediated 
cleavage process was analysed by LC-MS to identify whether Acm deprotection or iodination 
of the alkyne group occurred first. The results showed an efficient cleavage of the Acm groups 
after 10 min and first traces of iodated side product after 20 min. The formation of the third 
disulphide bridge was induced with a mixture of iodine in AcOH/H2O and the reaction was 
stopped after 15 min (see figure 2.18 A). HPLC and mass spectrometry analysis of the reaction 
process revealed the formation of the desired alkyne-modified µ-SIIIA (64) as main product 
(fraction 1, see figure 2.18 B) and only small amounts of the starting material (fraction 2) as 
well as iodated side product (fraction 3). The purified alkyne-modified µ-SIIIA (64) was used 
for fluorophore labelling studies.  
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Figure 2.18: Synthesis and purification of alkyne modified µ-SIIIA. A) Synthesis of propargylglycine modified 
µ-SIIIA (64) by the optimised synthesis strategy. B) HPLC chromatogram of crude alkyne-modified µ-SIIIA (64). 
The product fraction (1) was separated from the starting material (2) and the diiodated side product (3). HPLC 
gradient: 1-40 % MeCN in 30 min. 
For imaging, the channel distribution, the alkyne modified µ-SIIIA (64) was labelled with the 
AlexaFluor 488 fluorophore as it exhibits a small size, high stability and quantum yield as well 
as reduced membrane interaction.[238] The labelling reaction was performed by a biorthogonal 
CuAAC reaction. Compared to other labelling strategies, the CuAAC reaction exhibits a higher 
specificity as the reaction only takes place at the alkyne linker. The CuAAC also shows a high 
tolerance towards functional groups, can be performed under mild reaction conditions and 
yields an irreversible bond.[239] However, CuAAC reaction has some restrictions regarding its 
prolonged reaction times for peptides as substrates as well as the formation of reactive oxygen 
species, which can cause oxidation of sensitive side-chain residues.[240,241] As a consequence, 
the reaction has to be performed under exclusion of oxygen and in the presence of stabilising 
ligands like tris(3-hydroxypropyltriazolylmethyl)amine (THPTA). The addition of stabilizing 
agents preserves the catalytic active copper(I) species and thus, enhances the reaction process 
significantly.[239] 
The fluorophore labelling of the µ-SIIIA was first performed according to a protocol from 
EMPTING et al.[242] The azide modified AlexaFluor 488 fluorophore and alkyne modified 
µ-SIIIA (64) were treated with copper(II) sulphate pentahydrate, THPTA and sodium ascorbate 
as reducing agent in degassed water. DIPEA was added to increase the formation of the active 
copper acetylide complex and accelerate the reaction time.[242] However, analysis of the reaction 
progress by LC-MS revealed no conversion of the starting material after 48 h. 
Consequently, a recently reported method from RINK and THOMAS was tested.[241] They 
presented an efficient method for fluorophore and tag labelling of coiled-coil peptides by 
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fluorophore and CuSO4/THPTA/sodium ascorbate as the catalytic system. The reaction was 
performed in degassed tert-butanol/PBS under inert gas atmosphere and was incubated at 35 °C 
for 48 h (see figure 2.19 A). Analysis of the labelling reaction by LC-MS revealed the 
conversion of the starting material and successful formation of AlexaFluor 488 labelled µSIIIA 
(65). After HPLC purification 33 nmol of the desired product were isolated (see figure 2.19 B). 
To conclude, the labelled µ-SIIIA (65) was successfully synthesised by a regioselective 
approach and conjugated to a fluorophore by CuAAC. The affinity and selectivity of the 
labelled µ-SIIIA (65) is currently investigated by patch-clamp experiments and further imaging 
experiments will be performed in near future. 
 
 
Figure 2.19: Synthesis and purification of AlexaFluor 488 labelled µ-SIIIA. A) Synthesis of the AlexaFluor 
488 labelled µ-SIIIA (65) by CuAAC. B) HPLC chromatogram of the crude µ-SIIIA (65) after fluorophore 
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2.2.3 New Synthesis Strategies for Labelling µ-Conotoxin SIIIA 
Despite the successful synthesis of the fluorophore labelled µ-SIIIA (65), low yields and the 
complicated synthesis route limit its application for NaV channel investigations. Especially the 
deprotection of the Acm group with iodine and therefore the formation of the third disulphide 
bridge proceeded insufficiently. The iodine also caused side reactions with the sensitive alkyne 
linker, which restricts the accessibility of the alkyne for the CuAAC reaction. To overcome 
these synthetic limitations, various folding strategies were investigated, including new thiol 
protecting groups as well as a rearrangement of the utilised protecting groups. 
 
2.2.3.1 Synthesis of Allocam Protected Alkyne Modified µ-SIIIA 
The first approach was inspired by the work of KONDASINGHE et al., who reported the synthesis 
and application of a new thiol protecting group allyloxycarbonyl aminomethyl (Allocam).[243] 
The Allocam group can be removed by Pd(0), I2, N-chlorosuccinimide or high concentrations 
of TFA whereas it is stable at low TFA concentrations (< 30 %) which are required for Trt or 
Mmt cleavage.[243] Furthermore, Allocam is compatible with the StBu group, showing no 
removal or oxidation after addition of 2-mercaptoethanol and dithiodipyridine.[244] Based on 
these results, a synthesis strategy for µ-SIIIA (66), including the StBu, Mmt, Trt and Allocam 
group, was developed (see figure 2.20). After deprotection of the StBu/Mmt groups and creation 
of the first disulphide bridge, the Trt-groups, as well as all acid sensitive protecting groups, 
were cleaved with a mixture of DCM, TFA, TIS and H2O (65/30/2.5/2.5, v/v/v/v). HPLC 
purification of the crude peptide yielded two isomers with two disulphide bridges and the 
remaining Allocam protecting groups (67.1-67.2). The formation of a second isomer indicates 
a disturbance of the folding process caused by the Allocam groups. In the last step the Allocam 
groups were removed with Pd(OAc)2, 5 % AcOH, 3 % NMM in DMSO for 48 h. However, 
analysis of the reaction progress by LC-MS revealed only the starting material and no product 
formation (64).  
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Figure 2.20: Synthesis strategy for the Allocam-protected alkyne-modified µ-SIIIA.  
 
2.2.3.2 Synthesis of tert-Butyl and MeOBzl Protected Alkyne Modified µ-SIIIA 
In a second approach, the Acm protecting group was replaced with the tert-butyl group as 
described in the work of WU et al., presenting a regioselective synthesis of peptides containing 
four disulphide bonds.[245] The tert-butyl group is orthogonal to the StBu, Mmt and Trt groups 
and can be cleaved with strong acids. Following, the tert-butyl group protected modified alkyne 
µ-SIIIA (68) was synthesised and the first, as well as second disulphide bridge (69), was formed 
as described previously (see chapter 2.2.1). The removal of the tert-butyl group and formation 
of the last disulphide bridge was performed in a mixture of TFA, methyl trichlorosilane and 
diphenylsulphoxide at 4 °C (see figure 2.21). After a reaction time of 30 min, 2 h and 12 h, the 
process was analysed by LC-MS revealing no product formation (64). Different cleavage 
conditions with 5 % DMSO in TFA at rt were tested, showing removal of the tert-butyl groups 
after 2 h. However, the isolated product showed a mass difference Δm/z of +16, indicating a 
hydroxylation of the sensitive Trp or His residue. Due to the essential function of both residues 
for the channel interaction, this approach was not pursued further.  
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Figure 2.21: Synthesis strategy of tert-butyl-protected and alkyne modified µ-SIIIA. 
In a third approach, the Acm groups were substituted by MeOBzl protecting groups, which 
have been successfully used for the synthesis of fluorescent labelled zinc finger peptides.[246] 
The MeOBzl group is stable under TFA-cleavage conditions and can be deprotected with 
trifluoromethanesulfonic acid (TFMSA). Thus, MeOBzl protected Cys8 and Cys20 were 
incorporated into an alkyne-modified µ-SIIIA (70) and the first, as well as second disulphide 
bridge, were formed (see figure 2.22). Purification of the crude peptide by HPLC yielded two 
isomers (70.1-70.2). In the last step, the remaining MeOBzl groups were cleaved in a mixture 
of 10 % TFMSA, 88 % TFA and 2 % Thioansiole. The cleavage progress was analysed after 
2 h, 4 h and 6 h by LC-MS, revealing only traces of the desired product (64). An improved 
product formation was detected by using 98 % TFA and 2 % TIS for 12 h at 37 °C.[247] 
Unfortunately, this method caused oxidation of sensitive side-chain residues as well. 
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Figure 2.22: Synthesis strategy of MeOBzl-protected and alkyne modified µ-SIIIA. 
Summarizing, all investigated protecting groups for replacing the Acm groups revealed 
limitations. Investigation of the Allocam modified µ-SIIIA showed no cleavage of the 
protecting groups by addition of Pd(OAc)2 in DMSO. Introduction of the Allocam groups 
disturbed the folding process of the µ-SIIIA, causing two topological isomers (67.1-67.2) after 
the formation of the second disulphide bridge, which reduced the overall yield. Analysis of the 
deprotection experiments for tert-butyl and MeOBzl modified µ-SIIIA displayed either no 
cleavage of the protecting groups or oxidation of the sensitive side chain residues. These results 
indicate that cleavage conditions for tert-butyl or MeOBzl protecting group are incompatible 
for peptides containing sensitive Trp or His residues.[248,249] The introduction of the bulky 
MeOBzl group also interferes with the folding process, causing the formation of two topological 
isomers (70.1-70.2), similar to the Allocam protected µ-SIIIA.  
Therefore, new synthesis strategies were developed, in which the alkyne linker for CuAAC 
mediated fluorophore labelling was replaced by either a lysine or cysteine residue. These 
residues can be labelled with NHS ester or maleimide activated fluorophores, providing the 
advantage of reduced sensitivity compared to the alkyne linker. These labelling approaches are 
compatible with the StBu, Mmt, Trt and Acm protecting groups, which have successfully been 
used for the synthesis of µ-SIIIA, without oxidizing sensitive side chain residues.  
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2.2.3.3 Synthesis of Thiol Modified µ-SIIIA 
A frequently applied fluorophore labelling strategy for peptides and proteins is the thiol-
maleimide conjugation. This reaction requires a free thiol group which can selectively react 
with a maleimide activated fluorophore in the presence of a base.[250] To achieve controlled 
labelling of the µ-SIIIA at a specific position, an additional cysteine residue, which is not 
involved in the formation of the disulphide bonds, has to be introduced into the sequence. The 
newly introduced cysteine residue will be cleaved after the formation of the third disulphide 
bond. A new synthetic route for the formation of the three disulphide bridges was developed 
using the orthogonal StBu, Mmt and Trt protecting groups exclusively. The additional cysteine 
residue was protected with an Acm group and was introduced in the position of the Gly6 (72).  
In the first step, the StBu protecting groups of Cys3 and Cys13 were removed with 
2-mercaptoethanol in DMF and the peptide was cleaved from the resin with 10 % acetic acid 
(see figure 2.23). The first disulphide bridge was formed between the Cys3 and Cys13 in DCM 
with triethylamine (10 %). Following, the two Mmt groups were cleaved with 0.5 % TFA and 
the second disulphide bridge (73) was formed in acetate buffer (pH 6, 20 % DMSO). The Trt-, 
as well as all acid-sensitive protecting groups, were cleaved in a mixture of TFA/TIS/H2O and 
the last disulphide bridge was formed in acetate buffer (pH 6, 20 % DMSO). After HPLC 
purification, two topological isomers of the Acm protected µ-SIIIA (74.1-74.2) with three 
disulphide bonds were obtained in high yields. Due to lack of an alkyne moiety, the Acm 
cleavage with iodine in AcOH/H2O was performed with prolonged reaction times of 1 h. 
However, LC-MS analysis of the crude peptide revealed the formation of an intermolecular 
disulphide bridge conjugating two µ-SIIIA molecules (75). Cleavage of the intermolecular 
disulphide bridge by addition of reducing agents would also cause a breakage of the three 
intramolecular disulphide bonds, leading to an unfolding of the toxin and loss of activity. These 
limitations required a different approach for fluorophore labelling. 
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Figure 2.23: Synthesis approach for Cys(Acm)-modified µ-SIIIA.  
 
2.2.3.4 Synthesis of Amine Modified µ-SIIIA 
Since the introduction of an additional cysteine residue for fluorophore labelling causes the 
formation of intermolecular disulphide bridges, the Cys6 was replaced by an additional lysine 
residue. The ε-amino group of the lysine side chain can be conjugated with an NHS activated 
fluorophore, forming a stable amide bond with high yields.[226,228,251] The successful labelling 
with NHS-activated fluorophores was recently reported for Hsp1a, a short cysteine-rich peptide, 
which selectively inhibits NaV1.7 channels.
[252] However, fluorophore labelling of the folded 
µ-SIIIA could also cause unspecific labelling of the Lys11, which is essential for the channel 
interaction. Thus, the introduction of the fluorophore in the position of the Lys11 would 
drastically decrease the affinity towards NaV channel. To overcome these limitations, an Alloc-
protected Lys residue was placed in the position of Gly6, whereby the Alloc protecting group 
is orthogonal to the StBu, Mmt as well as Trt groups and can be removed with Pd(PPh3)4. The 
initial cleavage of the Alloc-protecting group prevents the labelling of the still protected Lys11.  
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Consequently, a linear Lys(Alloc)-modified µ-SIIIA (76), bearing the StBu, Mmt and Trt 
protecting groups, was synthesised. After the formation of the first and second disulphide bridge 
(77) by deprotecting the StBu and Mmt groups (see chapter 2.2.3.3), the Alloc group was 
cleaved with Pd(PPh3)4 and phenylsilane under an argon atmosphere (see figure 2.24 A). In the 
next step, an NHS activated fluorophore was coupled to the free amine group of the Lys6, 
producing the fluorophore-labelled, protected µ-SIIIA with two disulphide bonds (78). For the 
first labelling experiments, tetramethylrhodamine (TMR) was used as a fluorophore, as it can 
easily be activated with N-hydroxysuccinimid, producing activated TMR with high yields. In 
the last step, the Trt, as well as all acid-sensitive protecting groups, were cleaved and the third 
disulphide bridge (79) was formed in acetate buffer. The reaction mixture was purified by 
HPLC, yielding two topological isomers (79.1-79.2) of the TMR labelled µ-SIIIA with 
significantly higher yields compared to the CuAAC labelling strategy (see figure 2.24 B). 
Further examination of the TMR labelled µ-SIIIA isomers (79.1-79.2), regarding their affinity 
and selectivity for NaV channels, have to be performed by patch-clamp experiments and 
fluorescence microscopy.  
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Figure 2.24: Synthesis and purification of TMR labelled µ-SIIIA. A) Synthesis approach for TMR modified 
µ-SIIIA (79). B) HPLC chromatogram of TMR modified µ-SIIIA (79), yielding two topological isomers (79.1-
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2.2.4 Synthesis of Caged µ-Conotoxin SIIIA 
Besides the visualisation of the NaV1.2 channel distribution with fluorophore labelled µ-SIIIA, 
there is a great interest in controlling the activity of the NaV channels on a cellular level in 
specific neuronal compartments. This specific control could provide more in-depth insight into 
channel mechanisms and how dysfunctions of the NaV1.2 are linked to neurological diseases. 
For controlled measurements of the channel activity, a highly specific inhibitor is required, 
which is modified with a caging group, reducing the channel blocking the activity of the 
inhibitor. A spatially and temporally controlled cleavage of the caging group switches the 
inhibitor from an inactive to an active state, allowing regulation of the NaV channel activity. 
For controlled blockage experiments of the NaV1.2 channel, the µ-conotoxin SIIIA was selected 
as an inhibitor and was modified with a photocleavable protecting group (PPG). The PPG is 
conjugated to an amino acid residue, which is crucial for interaction with the NaV and therefore 
prevents the binding of the caged µ-SIIIA to the channel (see figure 2.25). A controlled 
blockage of the channel activity can be induced by irradiation of the caged µ-SIIIA, causing 
cleavage of the PPG, which regenerates the blocking activity of the µ-SIIIA.  
 
Figure 2.25: Overview of the synthesis and application of caged neurotoxins. The linear µ-SIIIA bearing a 
PPG was synthesised (A) and folded to its 3D structure (B). The caged µ-SIIIA provides a tool for channel 
investigations and for controlling the action potential propagation. The caged conotoxin can be switched from an 
inactive state to (C) an active state by UV-irradiation. Only the active state of the conotoxin can inhibit the NaV 
channel activity (D).  
 
2.2.4.1 Characteristics of Photocleavable Protecting Groups  
Over the last years, PPG became a powerful tool to study dynamic intracellular processes or 
pathways in biological systems. The PPG can temporarily mask one of the functional groups in 
the caged molecule, which is responsible for the bioactivity. Thereby, the cleavage of the PPG 
by UV irradiation triggers the activation of the caged molecule. Photo-induced cleavage allows 
a precise spatial and temporal control over the release of the compound under mild conditions, 
B A C D 
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without the addition of other chemicals or invasive methods.[253–255] For in vitro and in vivo 
application, the PPGs require a strong absorption at λ > 340 nm as well as rapid photo-cleavage 
kinetics to prevent phototoxicity caused by prolonged illumination. Additional requirements of 
the PPG strategy are the stability towards cellular conditions and biocompatibility of the 
cleavage products.[256] 
 
2.2.4.2 Caging Experiments of the µ-Conotoxin SIIIA  
For controlled blocking experiments of the NaV1.2 channel activity, the µ-SIIIA was selected 
as the target molecule. Therefore, a PPG is conjugated to one of the essential residues for 
channel blocking to ensure no interaction between the PPG modified µ-SIIA and the channel. 
As previously described, several structure analysis studies of the µ-SIIIA have been performed, 
revealing a crucial role of the residues in the α-helix Lys11, Trp12, Arg14, Asp15, His16 and 
Arg18 for the interaction with the channel. From these residues, especially the Lys11 is an 
attractive position for covalent linkage of modifications, as the lysine ε-amine is nucleophilic. 
Further substitutions of the Asp15 with positively charged or aromatic residues significantly 
decreases the affinity towards NaV1.2.
[13] Conjugation of a bulky PPG could effectively 
decrease the channel blocking, making Asp15 an exciting position for the introduction of a 
caging group (see figure 2.26). Based on the structural analysis of the µ-SIIIA, lysine and 
aspartic acid were selected as target residue for conjugation and incorporation of a PPG into the 
µ-SIIIA sequence by SPPS. 
 
Figure 2.26: 3D Structure of the µ-conotoxin SIIIA. The residues Lys11 and Asp15 were selected for the 
introduction of a caging group and are highlighted in orange (BMRB ID code: SMS20025). The graphic was 
created with USCF Chimera package.[212]  
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2.2.4.3 Synthesis of Nvoc Protected Lysine  
The most frequently used photocleavable protecting groups are the o-nitrobenzyl, due to their 
simple structure and synthesis. They can also be attached to different functional groups in the 
target molecule and a variety of substitutions patterns for the nitrobenzyl moiety have been 
reported.[257] Depending on these substitutions, the photochemical properties of the caging 
groups, like absorption spectrum, quantum yield and cleavage efficiency, can be adjusted.[257] 
Significantly, the 6-nitroveratryloxycarbonyl (Nvoc) group is used for in vitro or in vivo 
measurements because of their two electron-donating methoxy groups, which increase the 
absorbance to longer wavelengths (λ > 350 nm compared to 265 nm for o-nitrobenzyl).[256–258] 
Photo-induced cleavage of the Nvoc group though leads to the formation of cytotoxic 
nitrosoaldehyde side products, limiting the application of the Nvoc group.[257] Nevertheless, the 
straightforward synthesis of the Nvoc protecting group allows the investigation of cleavage 
conditions for caged peptides.  
A lysine building block, modified with the Nvoc group for SPPS, was synthesised over two 
steps (see figure 2.27).[259] First, the 4-nitrophenyl chloroformate (80) reacted with 
4,5-dimethoxy-2-nitrobenzyl alcohol (81) to form the activated 6-nitrovertaryl-4’-nitrophenyl 
carbonate (82). In the second step, the activated carbonate was converted with Fmoc-Lys-OH 
in a substitution reaction to form the target compound Fmoc-Lys(Nvoc)-OH (83) with an 
overall yield of 60 %.  
 
Figure 2.27: Synthesis of the caged Fmoc-Lys(Nvoc)-OH building block for SPPS over two steps. 
After synthesis of Fmoc-Lys(Nvoc)-OH, the building block was incorporated into a short test 
peptide by SPPS to examine the coupling conditions as well as the photocleavage properties. 
The sequence of the test peptide construct consists of two serine residues, which increase the 
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solubility, as well as hydrophobic residues to prevent side reactions with the cleaved 
nitrosoaldehyde by-products. Additionally, a phenylalanine residue was incorporated, to 
estimate the peptide concentrations for the uncaging experiments. The peptide was synthesised 
automatically by SPPS on a Rink amide resin (see figure 2.28 A). Fmoc-Lys(Nvoc)-OH was 
coupled at a reduced temperature of 50 °C and an extended reaction time of 10 min at 15 W. 
After HPLC purification of the desired product, the photocleavage of the caged peptide (84) 
was investigated. Therefore, the peptide was dissolved in MilliQ, transferred into a quartz 
cuvette and irradiated with a mercury UV lamp at 650 W and 300–400 nm.[260] The uncaging 
progress was analysed after exposure times of 1 min, 3 min, 5 min, 10 min and 15 min by 
U-HPLC, revealing incomplete uncaging progress even after 15 min (see figure 2.28 B). These 
long cleavage times limit the in vivo applications, due to photodamage as well as photo-induced 




Figure 2.28: Structure and uncaging experiments of Nvoc modified peptides. A) Synthesis of Nvoc caged test 
peptide (84) to investigate cleavage conditions. B) Photocleavage experiment of the Nvoc caged peptide (84), 
analysed by U-HPLC after irradiation for 0 min, 1 min, 3 min, 5 min and 10 min. HPLC gradient: 1-40 % MeCN 
in 15 min. 
 
2.2.4.4 Synthesis of Nitrobenzyl Based Protected Aspartic Acid  
Based on the insufficient cleavage process of the Nvoc-protecting group, a PPG with higher 
cleavage efficiency is required, to reduce the irradiation times. Analysis of several nitrobenzyl-
based PPG revealed the 3-(4,5-dimthoxy-2-nitrophenyl)-2-butyl (DMNPB) as a suitable 
protecting group since it can be conjugated to glutamic or aspartic acid.[262] Measurements of 
the DMNPB protecting group revealed a higher quantum yield and an increased cleavage 
process at 354 nm, compared to the Nvoc protecting group. Additionally, the DMNPB group 
can be applied in biological systems as it forms the less reactive and non-toxic acetophenone 
B A 
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side product.[263,264] The Asp15 residue of the µ-SIIIA was selected for an introduction of the 
DMNPB group as it is essential for the conotoxin channel interaction. 
The synthesis of a DMNPB protected aspartic acid building block for SPPS was performed 
according to SPECHT et al. in five steps (see figure 2.29).[263] First, the 3,4-dimethoxyphenyl 
acetone (85) was selectively methylated by methyl iodide and sodium hydride leading to 3-
(3,4-dimethoxyphenyl)-butan-2-one (86). Next, the nitro group was incorporated at the ortho 
position of the aromatic ring using acetic acid and nitric acid yielding 3-(3,4-dimethoxy-2-
nitrophenyl)-butan-2-one (87). Reduction of the ketone by addition of sodium borohydride 
produces the alcohol 3-(4,5-dimethoxyphenyl)-butan-2-ol (88). Esterification of the alcohol 
(88) and the unprotected side chain of Fmoc-Asp-OtBu was achieved by activation with 
dimethylaminopyridine (DMAP) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 
yielding Fmoc-Asp(DMNPB)-OtBu (89). In the final step, the tert-butyl group was removed by 
TFA leading to the Fmoc-Asp(DMNPB)-OH (90) with an overall yield of 34 %. 
 
Figure 2.29: Synthesis of the caged Fmoc-Asp(DMNPB)-OH building block for SPPS. 
To analyse the cleavage properties of the DMNPB protecting group compared to Nvoc group, 
the DMNPB protected aspartic acid (90) was incorporated into the test peptide sequence (91) 
(see figure 2.30 A). The peptide was synthesised by SPPS and the Fmoc-Asp(DMNPB)-OH 
(90) was coupled at 50 °C for 10 min at 15 W. After HPLC purification, the cleavage process 
of the DMNPB caged peptide (91) was investigated after irradiation times of 1 min, 3 min, 
5 min, 10 min, 15 min and 20 min. Analysis of the HPLC chromatograms revealed an 
incomplete cleavage of the DMNPB group after 10 min as well as side product fractions (see 
figure 2.30 B). Thus, a new PPG structure lacking a nitrobenzyl scaffold might lead to higher 
photocleavage rates and consequently, a complete uncaging process.  
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Figure 2.30: Structure and uncaging experiments of DMNPB modified peptides. A) Synthesis of DMNPB 
caged test peptide (91). B) Photocleavage experiment of the DMNPB caged peptide (91), analysed by HPLC after 
irradiation for 1 min, 3 min, 5 min, 10 min, 15 min and 20 min. HPLC gradient: 1-40 % MeCN in 15 min. 
 
2.2.4.5 Synthesis of Coumarin Protected Lysine  
After a screening of several PPG structures with different cleavage properties, the coumarin 
based PPGs were identified, revealing a challenging synthesis but a fast photocleavage 
compared to the nitrobenzyl derivatives. They exhibit a high absorption coefficient at 
wavelengths above 350 nm, visible light sensitivity and biocompatibility.[255] The coumarin 
groups also provided different substitution possibilities to adjust the absorption wavelengths 
(λmax = 310–490 nm).
[257] Especially, the (7-(diethylamino)coumarin-4-yl)methyl (DEACM) 
group conjugated to cAMP, ATP or GABA have been extensively used for studying cellular 
processes, showing an efficient photocleavage, high quantum yields and intense absorptivity at 
> 300 nm.[265–267] 
Since the DEACM group can be conjugated to free amine groups, the DEACM protected lysine 
(95) was synthesised over three steps, according to the method from SCHÖNLEBER et al. and 
KOTZUR et al. (see figure 2.31).[268,269] In the first step, the methyl group of 7-diethylamino-4-
methyl-coumarin (92) was oxidized by selenium dioxide and reduced to the corresponding 
alcohol (93) by NaBH4. The isolated 7-diethylamino-4-hydroxymethyl-coumarin (93) was 
activated by 4-nitrophenyl chloroformate (80), DMAP and NEt3 to form the activated carbonate 
(94). In the final step, the carbonate was reacted with Fmoc-Lys-OH to yield the desired Fmoc-
Lys(DEACM)-OH (95) under basic conditions with an overall yield of 14 %. 
B A 
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Figure 2.31: Three-step synthesis of Fmoc-Lys(DEACM)-OH building block for SPPS.  
Next, the photocleavage process of the DEACM protected Lys was analysed, by incorporating 
the building block in the previously described test peptide sequence by SPPS (see figure 
2.32 A). The coupling of the Fmoc-Lys(DEACM)-OH (95) was performed two-times for 
10 min at 50 °C and 15 W. After HPLC purification, the DEACM protected peptide (96) was 
dissolved in MilliQ and irradiated by a handheld laser (200 mW, 405 nm) for 30 sec, 1 min, 
2 min, 3 min as well as 5 min (see figure 2.32 B). The cleavage progress was monitored by 
HPLC, revealing a complete deprotection of DEACM group after 3 min. The formation of the 
uncaged peptide was confirmed by mass spectrometry. Compared to the nitrobenzyl based 
Nvoc and DMNPB caging groups, the DEACM group revealed a fast photocleavage without 
the formation of side products. Therefore, the DEACM group was incorporated in the µ-SIIIA 
sequence, to perform controlled blocking experiments of the NaV channels. 
 
Figure 2.32: Structure and uncaging experiments of DEACM modified peptides. A) Synthesis of DEACM 
caged test peptide (96). B) Photocleavage experiment of the DEACM caged peptide (96), analysed by HPLC after 
irradiation for 0 min, 30 sec, 1 min, 2 min, 3 min and 5 min. HPLC gradient: 1-40 % MeCN in 15 min. 
B A 
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2.2.5 Synthesis of DEACM Caged µ-Conotoxin SIIIA 
After the successful synthesis and preliminary uncaging experiments, the Fmoc-Lys(DEACM)-
OH (95) building block was integrated into the µ-SIIIA sequence at the position of the Lys11. 
Since the sensitive alkyne-linker is missing in this sequence, the cysteine protecting groups 
StBu, Mmt, Trt and Acm were selected, for the regioselective formation of the three disulphide 
bonds. The synthesis of the linear peptide (97) was performed by SPPS on a RAMAGE-Linker 
modified chlorotrityl-resin (see chapter 2.2.1.1). The first disulphide bridge was formed after 
cleavage of the StBu and Mmt group under basic conditions (see figure 2.33 A). Subsequently, 
the Trt and all acid-sensitive protecting groups were cleaved in a mixture of TFA, TIS, H2O 
and the second disulphide bridge was formed in acetate buffer in 20 % DMSO at pH 6. HPLC 
purification of the crude peptide yielded one major product (98) with two disulphide bonds and 
the DEACM as well as Acm protection groups still attached. In the last step, the Acm groups 
were cleaved and the third disulphide bond, on the surface of the µ-SIIIA structure, was formed 
after the addition of iodine. Shortening of the reaction time to 20 min prevented possible side 
reaction of iodine with the DEACM group. HPLC and mass spectrometry analysis revealed a 
full conversion of the starting material and the formation of four topological isomers (99.1-
99.4) of the DEACM protected µ-SIIIA (99) (see figure 2.33 B). Interestingly, the incorporation 
of the bulky DEACM group disturbs the folding process of the conotoxins, causing two 
additional topological isomers compared to the folding of the native µ-SIIIA (59).  
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Figure 2.33: Synthesis and purification of the DECAM caged µ-SIIIA. A) Synthesis of DEACM caged µ-SIIIA 
(99). B) HPLC chromatogram of DEACM modified µ-SIIIA (99), yielding four topological isomers (99.1-99.4). 
HPLC gradient: 1-40 % MeCN in 30 min. 
 
2.2.5.1 Uncaging Experiments of DEACM Modified µ-SIIIA 
Since irradiation of conotoxins or disulphide rich peptides can destroy formed disulphide bonds, 
the photocleavage process of the DEACM modified µ-SIIIA (99) was evaluated.[261] Therefore, 
isomer 99.1 of the DEACM protected µ-SIIIA was diluted in MilliQ to a concentration of 
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(see figure 2.34). The deprotection process was monitored by HPLC and analysed by mass 
spectrometry, showing a reduction of the starting material (retention time of 13 min) as well as 
the formation of the uncaged native µ-SIIIA (59), which elutes after 8 min. The HPLC results 
revealed an almost complete deprotection after an irradiation time of 3 min, without the 
formation of side products or destruction of disulphide bridges. Detailed structural analysis of 
the conformation of the isomers by NMR spectroscopy was not carried out, due to the small 
amounts. Characterisation experiments of the different isomers (99.1-99.4) were analysed in 
patch-clamp measurements. 
 
Figure 2.34: Photocleavage experiments of DEACM caged µ-SIIIA. This experiment was analysed by HPLC 
after irradiation for 30 sec, 1 min, 2 min, 3 min and 5 min. The DEACM caged µ-SIIIA (99.1) revealed a retention 
time of 13 min, whereas the uncaged µ-SIIIA (59) elutes after 8 min. HPLC gradient: 1-40 % MeCN in 15 min. 
 
2.2.5.2 Patch Clamp Measurements of DEACM Caged µ-SIIIA 
To perform controlled inhibition studies of the NaV channel, the blocking activity and affinity 
of the DEACM protected µ-SIIIA (99) after irradiation has to be investigated. Patch-clamp 
experiments of the irradiated isomers (99.1-99.4) were performed and analysed by 
V. KISTMACHER and E. LEIPOLD (University Lübeck). Similar to the inhibition studies of the 
native µ-SIIIA isomers (59.2.1-59.2.2), the measurements were performed in HEK 293 cells 
transfected with rat NaV1.4-channel expression plasmid (see chapter 2.2.1.2). Measurement on 
the NaV1.4 channel facilitates the characterisation of the caged µ-SIIIA isomers (99.1-99.4), 
due to the comparative data from the native µ-SIIIA (59). After identification of the bioactive 
isomer and efficient cleavage conditions, further measurements have to be performed on the 
NaV1.2 channel.  
Before the measurements were carried out, the DEACM caged µ-SIIIA isomers (99.1-99.4) 
were diluted to a concentration of 10 µM and were irradiated with a 40 mW LED light source 
uncaged 
caged 
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(CooLED PE300) at 400 ± 25 nm. Since the LED light source has a reduced power compared 
to the handheld laser (200 mW), which was used in the preliminary uncaging experiments (see 
chapter 2.2.5.1), various irradiation periods were tested. After irradiation, the µ-SIIIA isomers 
were used for whole-cell voltage-clamp experiment to measure the NaV1.4 currents of the 
HEK 293 cells.  
Patch-clamp measurements of the isomer 99.1 of the DEACM protected µ-SIIIA revealed for 
the non-irradiated sample no blockage of the NaV1.4 current (see figure 2.35 A). This confirms 
that blockage of the ε-amino group of the Lys side chain by conjugation of a PPG, disperse the 
interaction of the µ-SIIIA and the NaV-channel. Recordings of the first uncaging experiment 
showed a maximal blocking activity of 38 % after an irradiation time of 5 min. These results 
confirmed a successful reactivation of the caged µ-SIIIA after irradiation. However, the reduced 
blocking activity of the isomer 99.1 compared to the native µ-SIIIA indicate an incomplete 
uncaging process. Therefore, the exposure time was extended to 20 min, 35 min and 60 min, 
showing an increased channel inhibition with longer irradiation times. A maximum of the 
blocking activity of 80 % was reached after 35 min, whereas longer exposure times of 60 min 
lead to no significant increase in the channel blocking. Recordings of the dissociation process 
for the isomer 99.1 after an irradiation time of 35 min, revealed a slow dissociation (τDiss = 
1690 ± 183 s) of the uncaged µ-SIIIA from the channel, similar to the isomer 59.2.1 of the 
native µ-SIIIA (τDiss = 3640 ± 163 s). Based on the similar dissociation kinetics of the isomers 
99.1 and the isomer 59.2.1 of the native µ-SIIIA, the efficiency of the uncaging process was 
calculated from the blocking activity, using the native µ-SIIIA data as a reference (see figure 
2.35 B). The effective concentration of reactivated µ-SIIIA (10 µM) after an exposure time of 
35 min corresponded to 300 nm of the native µ-SIIIA, representing a cleavage efficiency of 
only 3 %. Despite the leaky channel blocking, the slow dissociation of the uncaged toxin from 
the channel, indicate that isomer 99.1 forms a native conformation and the reduced blocking 
activity is caused by an incomplete uncaging process. 
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Figure 2.35: Patch-clamp experiments of isomer 4.1. A) Blocking and wash-off kinetics of isomer 99.1 of 
DEACM-protected µ-SIIIA (10 µM) after irradiation for 0 min, 5 min, 20 min, 35 min and 60 min. The data points 
are highlighted in black. The SEM is indicated by grey shading and the red lines are single-exponential fits. The 
number of experimental replicates is shown in parentheses. B) Dose-response curve shows the association and 
dissociation kinetics and percentage of sodium current inhibition as a function of the native µ-SIIIA (59.2.1) 
concentration (red dashed lines). Data points from 10 µM DEACM-caged µ-SIIIA after irradiation are highlighted 
in grey. The experiment was performed by VIVIEN KISTMACHER. 
The results of the uncaging studies showed for isomer 99.1 the highest blocking activity after 
an irradiation time of 35 min. Thus, the isomer 99.2 was irradiated for 35 min and the blocking 
activity was measured (see figure 2.36 A). Recordings of the sodium current revealed a 
marginally reduced blocking activity of 60 % compared to the isomer 99.1. Measurements of 
dissociation kinetics showed a slow wash-off from the channel (τDiss = 2520 ± 855 s), remaining 
a blocking activity of 50 % after a washout time of 17 min, similar to the isomer 99.1 of the 
native µ-SIIIA. Consequently, the effective concentration of the uncaged isomer 99.2 (10 µM) 
was estimated after irradiation, revealing a cleavage efficiency of only 0.6 % (see figure 
2.36 B). Based on the slow dissociation kinetics, it can be assumed that the isomer 99.2 also 
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Figure 2.35: Patch-clamp experiments of isomer 4.2. A) Blocking and wash-off kinetics of isomer 99.2 of 
DEACM-protected µ-SIIIA (10 µM) after irradiation for 35 min. B) Dose-response curve shows the association 
and dissociation kinetics and percentage of sodium current inhibition as a function of the native µ-SIIIA (59.2.1) 
concentration (red dashed lines). Data points from 10 µM of the second isomer after 35 min irradiation are 
highlighted in grey. The experiment was performed by VIVIEN KISTMACHER. 
Patch-clamp measurements of isomer 99.3 of the DEACM protected µ-SIIIA (10 µM) showed 
a reduced blocking activity of about 16 % after an exposure time of 35 min compared to the 
isomer 99.1 and 99.2 (see figure 2.37 A). Additionally, the dissociation kinetics revealed a fast 
wash-off from the NaV1.4 channel and an almost full recovery of the sodium current after 5 min 
(τDiss = 214 ± 36 s), compared to the isomer 99.1 and 99.2 (see figure 2.37 B). These results 
suggest that the isomer 99.3 forms a non-native conformation with a reduced affinity for the 
NaV1.4 similar to isomer 59.2.2 of the native µ-SIIIA. The patch-clamp measurements of 
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Figure 2.36: Patch-clamp experiments of isomer 4.3. A) Blocking and wash-off kinetics of isomer 99.3 of 
DEACM-protected µ-SIIIA (10 µM) after irradiation for 35 min. B) Dose-response curve shows the association 
and dissociation kinetics and percentage of sodium current inhibition as a function of the native µ-SIIIA (59.2.2) 
concentration (red dashed lines) and non-native µ-SIIIA (black dashed lines). Data points from 10 µM of the 
second isomer after 35 min irradiation are highlighted in grey. The experiment was performed by VIVIEN 
KISTMACHER. 
 
2.2.5.3 Verification of the Uncaging Process by U-HPLC 
Since isomer 99.1 and 99.2 revealed slow dissociation kinetics, it can be assumed that both 
isomers form the native conformation. However, the significantly reduced blocking activity, 
compared to the native µ-SIIIA, indicates an incomplete uncaging process of the DEACM 
group and therefore limited inhibition of the sodium currents. To verify the efficiency of the 
cleavage process for both isomers, the toxins were analysed by U-HPLC and mass spectrometry 
after irradiation of 35 min with the 40 mW LED light source (CooLED PE300) at 400 ± 25 nm. 
The U-HPLC chromatogram of the isomer 99.1 revealed the formation of the uncaged µ-SIIIA 
(59) with a retention time of 6.2 min, but also significant amounts of the DEACM caged 
µ-SIIIA (99) (15.7 min) (see figure 2.38 A). Beside the caged and uncaged µ-SIIIA, several 
side product fractions were detected, probably caused by the long exposure times. This 
prolonged UV irradiation can induce photolysis of the disulphide bonds as well as heat-related 
denaturation of the conformation. Investigation of the isomer 99.2 after irradiation for 35 min, 
showed only minor amounts of the uncaged µ-SIIIA (59) and a reduced uncaging efficiency 
compared to the isomer 99.1 (see figure 2.38 B). These results are consistent with the data from 
59.2.2 (µM) 
A B 
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the patch-clamp measurements, in which a reduced blocking activity was measured for isomer 
99.2. Furthermore, the caged µ-SIIIA (99), as well as side products, were detected with 
substantial higher concentrations. Based on the U-HPLC chromatograms, the relative peak area 
of the uncaged µ-SIIIA isomers were calculated and related to the caged µ-SIIIA as well as side 
product peaks. The calculations revealed a cleavage efficiency for the isomer 99.1 of 20 % and 
4 % for the 99.2, showing minimal higher deprotection rates as for the patch-clamp 
measurements.  
 
Figure 2.37: HPLC analysis of irradiated isomer 99.1 and 99.2. A) U-HPLC chromatogram of isomer 99.1 of 
the DEACM-protected µ-SIIIA after irradiation for 35 min. The uncaged µ-SIIIA (59) was detected after 6.2 min 
and the caged µ-SIIIA (99) elutes after 15.7 min. HPLC gradient: 1-40% MeCN in 15 min. B) U-HPLC 
chromatogram of isomer 99.2 after irradiation for 35 min. The uncaged µ-SIIIA (59) was detected after 6.1 min 
and the caged µ-SIIIA (99) elutes after 15.6 min. HPLC gradient: 1-40% MeCN in 15 min. 
In summary, analysis of the U-HPLC chromatograms for the isomers 99.1 and 99.2 after an 
exposure time of 35 min, showed an incomplete cleavage of the DEACM group and the 
formation of several side products, causing the reduced blocking activity. The long irradiation 
times with the LED light source are likely to destroy the disulphide connectivity or 
conformation of the conotoxin. Therefore, patch-clamp measurements of isomer 99.1 and 99.2 
should be performed again with optimised cleavage conditions, using low substrate 
concentrations and a quartz cuvette with a large surface area as well as a diameter ≤ 1 mm for 
optimal exposure conditions. The LED light source should also be replaced by the handheld 
laser, which was used in previous uncaging studies (see chapter 2.2.5.1), showing full cleavage 
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2.3 Discussion and Conclussion 
Voltage-gated sodium channels are involved in the initiation and propagation of action 
potentials and control a variety of different physiological processes.[166,171] From the nine 
different NaV channel isoforms, especially dysfunctions and mutations in the NaV1.2 subtype 
are linked to different neurological diseases.[171] For the development of specific therapeutics, 
more profound insights into the molecular mechanisms and expression levels of the NaV1.2 
channels are required. Fluorescent labelled neurotoxins were used to address NaV channels 
distribution and activity. Compared to labelled antibodies, the neurotoxins revealed higher 
selectivity for the different channel subtypes and a 1:1 binding stoichiometry.[182] In screening 
studies, the disulphide-rich µ-conotoxin SIIIA was identified, which inhibits the NaV1.2 
channel with low nanomolar affinity and the skeletal NaV1.4 channel with submicromolar 
affinity.[12,13,209] By contrast with µ-conotoxins, the µ-SIIIA (59) exhibit additional residues, 
which are non-essential for the channel interaction and therefore are suitable positions for 
fluorophore introduction.[14,207]  
For the synthesis of µ-SIIIA derivatives, a regioselective synthesis strategy was developed to 
ensure the correct disulphide connectivity and native conformation. An optimisation of the 
folding strategy, by rearranging the order of disulphide bridges, lead to the formation of only 
two topological isomers (59.2.1-59.2.2), instead of four (see figure 2.39). The isomers were 
separated by HPLC and analysed by patch-clamp measurements, revealing for isomer 59.2.1 a 
high blocking activity (93 %) as well as slow dissociation kinetics, indicating that the isomer 
59.2.1 forms the conformation of the native µ-SIIIA. The results for the isomer 59.2.2 revealed 
a reduced channel blocking activity and a fast dissociation process. Based on these results, it 
was assumed that isomer 59.2.2 forms a topological isomer with a non-native structure. Further 
structural analysis of 59.2.2 could help to investigate whether the reduced blocking activity is 
either based on different topological structure or disulphide connectivity caused by a reshuffling 
of the disulphide bonds. For clarification of the disulphide connectivity, NMR spectroscopy or 
MS/MS analysis can be performed. For the MS/MS measurements, the peptides get partially 
reduced and alkylated by addition of iodoacetamide. Following, a different combination 
between 2-, 4- and 6- alkylated peptides were obtained, which can be analysed by MALDI 
MS/MS.[230] More structural in-depth analysis was not carried out as only a limited amount of 
material was synthesised.  
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Figure 2.38: Overview of the results of the native µ-SIIIA. After synthesis and purification of the native 
µ-SIIIA, patch-clamp measurements were performed.  
After the successful formation of the native µ-conotoxin SIIIA (59), the regioselective folding 
strategy was applied for the synthesis of a fluorophore labelled µ-SIIIA derivative. The 
commonly used NHS-fluorophore labelling method, described by HONE et al. or GONZALES 
et al., revealed limitations for our approach, as the introduction of NHS-fluorophore would lead 
to a site unspecific binding to all nucleophilic lysine residues and N-terminal amine group in 
the folded peptide. For the specific introduction of the fluorophore, an alkyne linker was 
introduced into the position of the Gly6, which is non-essential for channel interaction. 
Following, the three disulphide bridges were formed and the alkyne-modified µ-SIIIA was 
labelled with an AlexaFluor 488 fluorophore via copper(I)-catalysed azide-alkyne 
cycloaddition (CuAAC) reaction, producing one isomer (see figure 2.40). The affinity and 
selectivity of the labelled µ-SIIIA (65) for the NaV1.2 will be analysed by patch-clamp 
measurements, followed by fluorescence microscopy experiments.[227,270,271] 
 
Figure 2.39: Overview of the results of the AlexaFluor 488 labelled µ-SIIIA. After folding of the alkyne-
modified µ-SIIIA, the AlexaFluor 448 fluorophore was introduced and purified by HPLC. 
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Despite the successful labelling of the µ-SIIIA, different folding strategies and cysteine 
protecting groups were investigated to facilitate the folding protocol and to increase the yields. 
Therefore, the Acm protecting group, which requires harsh cleavage conditions, was substituted 
with the Allocam group, tert-butyl or MeOBzl group. All tested protecting groups were either 
not cleavable or caused oxidation of sensitive side chain residues in the µ-SIIIA sequence. To 
overcome these limitations, various labelling strategies were analysed to eliminate the reactive 
alkyne linker for CuAAC. In a first approach, an additional Cys residue was introduced at the 
position of the Gly6, which can be labelled with maleimide activated fluorophores. The newly 
introduced cysteine residue was not involved in the formation of disulphide bridges and was 
deprotected after the formation of the last disulphide bridge. Unfortunately, deprotection of the 
cysteine lead to the formation of intermolecular disulphide bonds. In a second approach, an 
Alloc-protected lysine residue was introduced in the position of Gly6, which can be selectively 
deprotected and labelled with an NHS-activated TMR fluorophore. At the same time, all other 
nucleophilic groups were still protected. After the formation of the third disulphide bridge, two 
isomers (79.1-79.2) of the TMR-labelled µ-SIIIA were isolated with significantly higher yields 
compared to the CuAAC labelling strategy. Patch-clamp measurements and fluorescence 
microscopy will be performed for further characterisations of the isomers. Theses results will 
provide deeper insights into the folding process and how the introduction of the bulky TMR 
groups influences the overall conformation, compared to the AlexaFluor 488 labelled µ-SIIIA 
For addressing the scientific challenge of channel activity monitoring, a µ-SIIIA derivative 
modified with a photocleavable protecting group (PPG) was synthesised. This labelling strategy 
allows the controlled blockage of the NaV channel activity. The introduction of the PPG 
effectively prevented the interaction of the µ-SIIIA derivatives with the NaV channel. A 
controlled blockage of the channel activity was achieved by UV irradiation, as the PPG is 
cleaved from the µ-SIIIA enabling the binding and therefore blocking of the channel. 
Investigations of different PPGs displayed the DEACM group as PPG with the highest 
photocleavage rates compared to the Nvoc or DMNPB group. The DEACM group was 
incorporated into the µ-SIIIA sequence by conjugation to the ε-amino group of the lysine 
residue. After successful synthesis and purification of caged µ-SIIIA, four different isomers 
were isolated and analysed by patch-clamp measurements. Recordings of two caged isomers 
(99.1-99.2) revealed no blockage of the channel currents. As expected, irradiation by a LED 
light source lead to an increased channel inhibition, reaching a maximum of blocking activity 
of 70 % after an exposure time of 35 min. Measurements of the dissociation kinetics revealed 
a slow wash-off from the channel, similar to the native µ-SIIIA. These findings highlight the 
 Discussion and Conclussion 123 
potent blocking of the NaV channel by the two isomers after the uncaging process. Nevertheless, 
a reduced blocking activity could be recorded caused by an incomplete uncaging process. These 
findings were confirmed by U-HPLC, showing an incomplete cleavage of the DEACM group 
and the formation of several side product fractions. For further investigations of the caged µ-
SIIIA, a more powerful UV light is indispensable to achieve complete cleavage of the µ-SIIIA 
as shown in preliminary experiments.   
 
Figure 2.40: Overview of the results of the PPG modified µ-SIIIA.  After the introduction of the DEACM 
group, uncaging and patch-clamp experiments were performed.  
Summarizing these results, different µ-conotoxin SIIIA derivates were synthesised with an 
optimised regioselective folding strategy, which allows the controlled formation of three 
disulphide bridges and the introduction of different modifications in the µ-SIIIA sequence. 
Compared to previously reported toxin labelling strategies, the incorporation of the fluorophore 
by biorthogonal CuAAC reaction enables the specific introduction in the folded µ-SIIIA 
without the formation of side products.[227,270,271] Furthermore, the uncaging experiments 
presented for the first time, the successful synthesis and reactivation of a PPG modified 
conotoxin to control NaV channel activity. Notably, the folding strategy as well as labelling 
approach are not µ-SIIIA specific and can therefore be transferred to other toxins consisting of 
three disulphide bonds. This opens new possibilities for channel characterization and 
consequently, further investigations of channel dysfunction based disorders.  
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3 Experimental Part 
 
3.1 General  
Solvents 
Dry solvents were purchased from SIGMA-ALDRICH (Taufkirchen, Germany) and ACROS 
ORGANICS (Geel, Belgium). Technical solvents were distilled before use. Solvents of analytical 
and HPLC grade were purchased from FLUKA (Taufkirchen, Germany), VWR INTERNATIONAL 
(Fontenay-sous-Bois, France), ACROS ORGANICS (Geel, Belgium) and SIGMA-ALDRICH 
(Taufkirchen, Germany). Solvents for the NMR measurements were supplied by DEUTERIO 
(Kastellaun, Germany). Ultra-pure water was obtained by purifying demineralized water with 
the purification device arium mini lab water system by SARTORIUS (Göttingen, Germany). 
 
Reagents 
All reagents were purchased in the highest grade available and were used as supplied. Amino 
acid derivatives, resins and coupling reagents for solid-phase peptide synthesis were obtained 
from NOVABIOCHEM (Darmstadt, Germany), BACHEM (Bubendorf, Switzerland), GL BIOCHEM 
(Shanghai, China), IRIS BIOTECH (Marktredwitz, Germany), BLD PHARMATECH LTD. 
(Shanghai, China) as well as VWR (Darmstadt, Germany). Other chemicals were purchased 
from MERCK (Darmstadt, Germany), FISHER SCIENTIFIC (Nidderau, Germany), ALFA AESAR 
(Karlsruhe, Germany), BACHEM (Bubendorf, Switzerland), TCI (Eschborn, Germany), VWR 
(Darmstadt, Germany), NOVABIOCHEM (Darmstadt, Germany), ACROS ORGANICS (Geel, 
Belgium) and SIGMA-ALDRICH (Taufkirchen, Germany). DNA Oligomers were purchased from 




Air as well as water-sensitive reactions were carried out under argon (> 99.996 %) atmosphere 
using standard SCHLENK-technique in dry solvents. The glass apparatus was heated under 
reduced pressure and flushed with argon. The solution was added through a septum and solids 
in a counter stream of argon.  
 
 Experimental Part 125 
Freeze-drying 
Freeze-drying of peptides or synthesised building blocks was performed by an Alpha-2-4-LD 
plus benchtop freeze-dryer from CHRIST (Osterode am Harz, Germany) connected to a 
Vacuubrand chemistry hybrid pump RC5 high vacuum pump (Wertheim, Germany). Aqueous 
samples with minor amounts of acetonitrile collected from the HPLC device were frozen with 
liquid nitrogen and dried under reduced pressure (< 1 mbar). Small amounts (< 2 mL) were 
freeze-dried using an evacuable RVC 2-18 CD plus vacuum centrifuge from CHRIST. 
 
3.2 Chromatography 
Thin-layer chromatography (TLC) 
Analytical TLC was performed on TLC 60 F254 silica gel coated aluminium sheets from MERCK 
(Darmstadt, Germany). The substances were detected via fluorescence quenching (254 nm, 
366 nm) or by the following TLC stains: ninhydrin solution (1.5 g ninhydrin, 3 mL acetic acid 
in 100 mL n-butanol) or potassium permanganate (1.5 g KMnO4, 10 g K2CO3 and 1.25 mL 
10 % NaOH in 200 mL water) 
 
Flash column chromatography 
Flash column chromatography was performed using silica gel 60 F254 (particle size: 40-63 µm) 
purchased from MERCK (Darmstadt, Germany). Columns were packed with wet silica gel (50-
100 fold weight excess) and the sample was loaded as a concentrated solution or onto silica gel. 
The column was run at an overpressure of 0.5-1.0 bar. Elution of the product fractions was 
identified by TLC.  
 
High-Performance Liquid Chromatography (HPLC) 
Analytical or semi-preparative reversed-phase HPLC purifications were performed with a 
system from JASCO (Tokyo, Japan), consisting of two pumps PU-2020Plus, a 3-line degasser 
DG2080-53 and a diode array detector MD-2010Plus. Substances were eluted with a linear 
gradient MilliQ + 0.1 % TFA to MeCN + 0.1 % TFA. The following columns from MACHEREY-
NAGEL (Düren, Germany) were used for purification:  
Analytical: MN Nucleodor 100-5-C18, 250 nm x 4.6 mm, 5 µm, flow rate: 1 mL/min. 
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Semipreparative: MN Nucleodor 100-5-C18, 250 mm x 10 mm, 5 µm, flow rate: 3 mL/min. 
Preparative: MN Nucleodor 100-5-C18, 250 mm x 21 mm, 5 µm, flow rate: 10 mL/min. 
UV-detection was measured at 215 nm, 254 nm, 280 nm for non-labelled peptides. For peptides 
labelled with BAC, NBD, AlexaFluor 488 or TMR the UV-absorbances was recorded at 
368 nm, 464 nm, 488 nm, or 540 nm Before usage, the samples were dissolved in a mixture of 
MilliQ and MeCN, followed by filtration through a Chromafil RC-45/15 MS filter from 
MACHEREY-NAGEL. 
 
Ultra-High-Performance Liquid Chromatography (U-HPLC) 
An UltiMate 3000 from THERMO-FISCHER SCIENTIFIC (two pumps LPG-3400, autosampler 
WPS-3000SL, column compartment TCC-3000SD, Detector DAD-3000, interface 
Chromeleon) were used for analyses of uncaging-, enzyme cleavage experiments as well as 
peptide synthesis. Substances were eluted with MilliQ (0.085 % TFA) and MeCN (0.1 %TFA). 
The UV-absorption was detected with a photodiode arrays in a range of 200 to 450 nm.  
Analytical: ACE ExelTM 2 C18, 100 nm x 2.1 mm, 2 µm, flow rate: 0.3 ml/min. 
Prior analysis, the samples were dissolved in MilliQ and MeCN, followed by filtration.  
3.3 Characterisation 
Nuclear magnetic resonance spectroscopy (NMR) 
1H-NMR spectra were recorded at 300 MHz on a VNMRS-300 or a Mercury-VX 300 
spectrometer from VARIAN (Palo Alto, USA). 13C-NMR spectra were measured at 126 MHz on 
an Inova-500 from VARIAN (Palo Alto, USA). The sample temperature was 35 °C for DMSO-
d6 andCD3OD, whereas samples in CDCl3 were measured at 27 °C. The residual proton signals 
of the solvents served as an internal standard (DMSO-d6: δ = 2.50 ppm for 
1H-NMR, δ = 
39.5 ppm for 13C-NMR; CDCl3: δ = 7.26 ppm for 
1H-NMR, δ = 77.16 ppm for 13C-NMR; 
CD3OD: δ = 3.31 and 4.78 ppm for 
1H-NMR, δ =49.15 and 54.00 ppm for 13C-NMR). Chemical 
shifts δ are given in parts per million (ppm) and the coupling constants J were given in Hertz 
(Hz). The following abbreviations for the multiplicities were used: s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet) and br (broad). The coupling constant nJX,Y is indicated in 
Hertz (Hz) (n = number of bonds between the coupling nuclei; X,Y = coupling nuclei). 
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Mass Spectrometry 
Electrospray ionization (ESI) mass spectra and high-resolution ESI (HR-MS) spectra were 
recorded at a maXis or MicroTOF spectrometer by BRUKER DALTONIK GMBH (Bremen, 
Germany). The data were analysed with Compass Data analysis software (version 4.0) by 
Bruker. The samples were dissolved in MilliQ/MeOH (1:1), MeOH or DCM. The values are 
given in m/z ratio, along with the relative intensity of the peak.  
 
Liquid Chromatography Mass Spectrometry 
Analytical LC-MS measurements were performed on an UltiMate 3000 system Scientific (two 
pumps LPG-3400, autosampler WPS-3000SL, column compartment TCC-3000SD, Detector 
DAD-3000, interface Chromeleon) from THERMO FISHER SCIENTIFIC GMBH and an ACE 
ExelTM 2 column (C18, 100 nm x 2.1 mm, 2 µm) at 50 °C with a flow rate of 0.45 mL/min. 
Substances were eluted with MilliQ (0.1 % FA) and MeCN (0.1%FA) in 15 min, coupled to an 
LTQ XL ion trap spectrometer from THERMO FISHER SCIENTIFIC GMBH. The UV-absorption 
was detected with a photodiode arrays in a range of 200 to 450 nm.  
 
UV/Vis Spectroscopy 
UV spectra for determination of resin loading efficiency and peptide concentration was 
measured with a V-550 spectrometer from JASCO (Tokyo, Japan) or the THERMO SCIENTIFIC 
nanodrop ND-2000c spectrophotometer. Peptide concentrations were calculated by using 
LAMBERT-BEER law: 
c =  
A
𝜀∙d
       (4.1) 
c = concentration (mmol/l), A = absorption (nm), ε = molar extinction coefficient in (cm-1 
‧mmol-1), d = pathlength (in cm) 
The absorption was estimated either at 260 nm for peptide-PNA oligomers or at 280 nm for 
peptides containing tryptophan. The molecular absorption coefficients were calculated by 
summation of the single coefficients at a set wavelength. For fluorophore marked molecules, 
the absorption was measured for the maximum of the fluorophores (see table 4.1). 
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Table 3.1: The extinction coefficients used for concentration estimations. Depicted for tryptophan, 
phenylalanine and the used fluorophores as well as PNA monomers to estimate the overall ε peptide-PNA hybrids. 
 λabs [nm] ε [M-1‧cm-1] 
Trp 280 5500 
Phe 280 1490 
Phe 280 200 
NBD 466 22000 
AlexaFluor 488 495 73000 
AlexaFluor 647 650 270000 
S-S 280 125 
TMR 540 91000 
PNA-a 260 13700 
PNA-c 260 6600 
PNA-g 260 11700 
PNA-t 260 8600 
 
BCA Assay 
The concentration of DEACM-modified µ-conotoxin SIIIA was determined by BCA assay. 
Therefore, the following reagents were used: micro-BCA assay reagent A (645 mM Na2CO3, 
70 mM NaK Tatrat tetrahydrate, pH 11.25), micro-BCA assay reagent B (116 mM 
Bicinchoninic acid), micro-BCA assay reagent C (160 mM copper(II)sulphate pentahydrate), 
micro-BCA assay solution (reagent A/B/C (49:49:2, v/v/v).  
All samples (100 µL) were mixed with the micro-BCA assay solution (100 µL) and were 
incubated at 60 °C for 15 min. Following, the samples were cooled to room temperature and 
the absorbance at 562 nm was measured on a nanodrop ND-2000c spectrophotometer from 
THERMO SCIENTIFIC. Unknown concentrations were calculated by standard curve.  
 
Uncaging studies 
Photocleavage experiments of the Nvoc and DMNPB protecting group were performed using 
a mercury UV lamp from NEWPORT (Darmstadt, Germany) equipped with a mirror filter (280 - 
460 nm) at 650 W. Uncaging studies of DEACM protected peptides were carried out with 
 Experimental Part 129 
Streamline Laser from OSELA INC. (Lachine, Canada) at 405 nm, 100 mW and 70 mA. For 
irradiation, the caged peptide (40 µM) was transferred to a QS Micro Fluorescence Cell quartz 
cuvette (115F-QS, light path: 10 x 2 mm, volume: 400 µL, outer dimensions: 12.5 x 12.5 x 
40 mm) from HELLMA GMBH & CO. KG (Müllheim, Germany). The cuvette was centred ~ 5 cm 
in front of the light source and aliquots of 15 µL were taken after 30 sec, 1 min, 2 min, 3 min, 
5 min and 10 min. After irradiation, the samples were analysed by U-HPLC or LC-MS 
 
Protease Cleavage Studies 
Digestion experiments with TEV, Factor Xa (FXA) or cathepsin B protease were carried out 
under the following conditions. The peptides and peptide-PNA oligomers were dissolved in 
reaction buffer (TEV: 50 mM Tris-HCl, 0.5 mM EDTA and 1 mM DTT, pH 8.0; FXa: 20 mM 
Tris-HCl, 50 mM NaCl, 1 mM CaCl2, cathepsin B: 25 mM sodium acetate, 1 mM EDTA, pH 
5.0) to a concentration of 50-500 µM. Afterwards, the protease (TEV: 3.000 U/mg, FXa: 
20 U/mg, cathepsin B: 10 U/mg) was added and the reaction mixture was incubated at 37 °C. 
For cathepsin B treatment, the protease was activated prior usage with 30 mM DTT and 15 mM 
EDTA for 15 min at rt. Aliquots of 15 µL were taken at various time points in between 30 min 
and 48 h. After incubation, the protease cleavage process was analysed by U-HPLC or LC-MS. 
 
Programs 
NMR data were analysed by MestReNova (version 10) and graphs were plotted with OriginPro 
(version 8.5G). Chemical structures and calculations of molecular masses were performed by 
ChemBioDraw (version 16). Structures of the µ-conotoxin SIIIA were created by USCF 
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3.4 Standard Operating Protocols (SOPs) 
3.4.1 SOPS for the Synthesis of Peptide-PNA based Cl- sensors 
3.4.1.1 SOP1: Automated Solid-Phase Peptide Synthesis  
For the synthesis of different peptide sequences, a Liberty Blue peptide synthesizer from CEM 
(Matthews, North Carolina, USA) was used. For the synthesis, the following protected amino 
acids were prepared as 0.2 M solution in DMF: Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-
Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-
OH, Fmoc-His(Boc)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, 
Fmoc-Phe-OH, Fmoc-Pro-OH, Fmoc-Ser(OtBu)-OH, Fmoc-Thr(OtBu)-OH, Fmoc-Tyr(OtBu)-
OH, Fmoc-Val-OH, Fmoc-Lys(Alloc)-OH and Boc-Ala-OH. 
Depending on the synthesis scale, different coupling conditions were performed as well as 
different stock solutions for the amino acids, deprotection solution, activator and activator base 
were prepared (see table 4.2). In the following, the peptide synthesis is shown exemplarily for 
a synthesis scale of 0.10 mmol. For the deprotection of the Fmoc group, 20 % piperidine in 
DMF (v/v) was used. The amino acids were activated by DIC (0.50 M in DMF) as Activator 
and Oxyma (1.00 M in DMF) as Activator Base.  
The non-preloaded resin (1.0 eq loading density < 0.32 mmol/g) was placed in the reaction 
vessel of the peptide synthesizer and was swollen for 30 min in DMF. First, the N-terminal 
Fmoc protecting group was removed by addition of piperidine (20 % in DMF, v/v) under 
microwave irradiation (1: 75 °C, 90 W, 15 s; 2: 90 °C, 20 W, 50 s). To achieve a complete 
cleavage of the Fmoc-group, the deprotection step was repeated once. After washing of the 
resin with DMF (5 x 4 mL) the amino acid (0.20 M), DIC (0.50 M) as well as Oxyma (1.00 M) 
were transferred to the reaction vessel. The coupling reaction was performed under microwave 
irradiation (1: 75 °C, 170 W, 15 s; 2: 90 °C, 30 W, 110 s) and was repeated once. For the 
coupling of Fmoc-Arg(Pbf)-OH (75 °C, 30 W, 300 s) and Fmoc-His(Boc)-OH (50 °C, 30 W, 
1500 min) specialised coupling cycles were used to suppress the γ-lactam formation for 
arginine and epimerization of histidine.  
After the peptide synthesis was completed, the resin was transferred into a BD Syringe with 
PE-frit and was washed with DMF (6 x 4 mL) as well as DCM (6 x 4 mL). Following, the resin 
was dried under reduced pressure.  
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Table 3.2: Overview of coupling and deprotection conditions depending on the synthesis scale. 
 
3.4.1.2 SOP2: Automated SPPS for PNA Oligomers 
The synthesis of different peptide-PNA sequences was performed with a Liberty Blue peptide 
synthesizer from CEM (Matthews, North Carolina, USA) in a 0.01 mmol scale. For the 
synthesis the following protected aeg-PNA monomers were prepared as 0.08 M solution in 
DMF: Fmoc-a(Bhoc)-aeg-OH, Fmoc-c(Bhoc)-aeg-OH, Fmoc-g(Bhoc)-aeg-OH and Fmoc-
t(Bhoc)-aeg-OH. The Fmoc-group was removed with piperazine in DMF (2 %) and the PNA 
monomers (0.08 M) were activated with DIC (0.05 M) as activator as well as Oxyma (0.10 M) 
as activator base. 
The resin containing the peptide sequence was placed in the reaction vessel and was swollen in 
DMF for 30 min. First the Fmoc-group was removed by addition of the deprotection solution 
(3 mL) under microwave irradiation (50 C, 25 W, 300 s). In order to achieve a complete 
cleavage of the Fmoc-group, the deprotection step was repeated once. After washing of the 
resin with DMF (4 x 4 mL) the aeg-PNA monomer (0.08 M), DIC (0.05 M) as well as Oxyma 
(0.10 M) were transferred to the reaction vessel. The coupling was performed under microwave 
irradiation (50 °C, 25 W, 1500 s) and was repeated once. Following, the resin was washed with 
DMF (4 x 4 mL) and free amine groups were capped with a solution of DMF/DIPEA/Ac2O 
(2.79/0.15/0.6, v/v/v) for 5 min at rt. Following, the resin was washed with 5 % DIPEA in DMF 
and DMF (4 x4 mL). After the synthesis was completed, the resin was transferred into a BD 
syringe with a polyethylene (PE) frit and was washed with DMF (6 x 2 mL) as well as DCM 
(6 x 2 mL). Afterwards the resin was dried under reduced pressure.  
 0.01 mmol 0.025 mmol 0.05 mmol 0.1 mmol 
Deprotection 2 % Piperazine 20 % Piperidine 20 % Piperidine 20 %Piperidine 
Amino acids 0.08 M 0.2 M 0.2 M 0.2 M 
Activator 0.05 M DIC 0.13 M DIC 0.25 M DIC 0.5 M DIC 
Activator Base 0.1 M Oxyma 0.25 M Oxyma 0.5 M Oxyma 1.0 M Oxyma 
Deprotection 1.: 
                      2.: 
75 °C, 155 W, 15 s 
90 °C, 30 W, 165 s 
75 °C, 155 W, 15 s 
90 °C, 30 W, 50 s 
75 °C, 210 W, 15 s 
90 °C, 30 W, 50 s 
75 °C, 260 W, 15 s 
90 °C, 60 W, 50 s 
Coupling       1.: 
                      2.: 
75 °C, 170 W, 15 s 
90 °C, 30 W, 465 sec 
75°C, 170 W, 15 s 
90°C, 30 W, 225 s 
75°C, 170 W, 15 s 
90°C, 30 W, 110 s 
75°C, 170 W, 15 s 
90°C, 30 W, 110 s 
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3.4.1.3 SOP3: Alloc Deprotection 
According to the procedure of WILSON et al. the peptide-bound resin (5.00 µmol) was incubate 
with DCM (300 µl) and phenylsilane (10.8 µL, 75.0 µmol, 15.0 eq, ρ = 0.88 g/mL) for 
1 min.[122] Afterwards, Pd(PPh3)4 (2.84 mg, 2.50 µmol, 0.50 eq) was added and the cleavage 
reaction was performed under microwave irradiation (5 min, 38 °C, 15 W). After repeating the 
deprotection step twice the resin was washed with DMF (6 x 2 mL) as well as DCM (6 x 2 mL) 
and was dried under reduced pressure. 
 
3.4.1.4 SOP4: Labelling of Peptides-PNA Oligomers with the BAC-Fluorophore 
Labelling of the BAC fluorophore to the resin-bound peptide-PNA oligomer was performed in 
5.00 µmol scale. Therefore, BAC fluorophore (13.3 mg, 25.0 µmol, 5.00 eq) (4), PyAOP 
(26.1 mg, 50.0 µmol, 10.0 eq), HOAt (3.40 mg, 25.0 µmol, 5.00 eq) as well as DIPEA 
(8.73 µL, 50.0 µmol, 10.0 eq) were dissolved in DMF (400 µL) and added to the resin. The 
labelling reaction was performed under microwave irradiation for 3 h at 70 °C and 15 W. 
Afterwards the resin was washed with DMF (6 x 2 mL) as well as DCM (6 x 2 mL) and was 
dried under reduced pressure. 
 
3.4.1.5 SOP5: Labelling of Peptide-PNA Oligomers with the NBD Fluorophore 
Labelling of the NBD fluorophore to the resin-bound peptide-PNA hybrid was performed in 
5.00 µmol scale under argon atmosphere. Therefore, NBD-Cl (10.0 mg, 50.0 µmol, 10.0 eq) as 
well as DIPEA (17.4 µL, 100 µmol, 20.0 eq) were dissolved in DMF (400 µL) and added to the 
resin. The labelling reaction was performed for 12 h at rt. Afterwards the resin was washed with 
DMF (6 x 2 mL) as well as DCM (6 x 2 mL) and was dried under reduced pressure. 
 
3.4.1.6 SOP 6 Labelling of peptides with the AlexaFluor488 Fluorophore 
Labelling of the AlexaFluor488 fluorophore to the resin-bound peptide was performed in 
5.00 µmol scale under argon atmosphere. Therefore, AlexaFluor488-NHS ester (10.0 mg, 
50.0 µmol, 10.0 eq) as well as DIPEA (17.4 µL, 100 µmol, 20.0 eq) were dissolved in DMF 
(400 µL) and added to the resin. The labelling reaction was performed for 12 h at rt. Afterwards 
the resin was washed with DMF (6 x 2 mL) as well as DCM (6 x 2 mL) and was dried under 
reduced pressure. 
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3.4.1.7 SOP 7 Cleavage of Peptides and Peptide-PNA Oligomers from the Resin 
The cleavage of the peptide from the resin was performed in a BD syringe with a PE frit. The 
resin was shaken at room temperature for 2 h in TFA/TIS/H2O (95/2.5/2.5, v/v/v). After 
cleavage the solution was concentrated under a nitrogen stream and the crude peptide was 
precipitated from -20 °C methyl tert-butyl ether. The crude peptide was isolated by 
centrifugation (9000 rpm, -10 °C, 10 min), washed two times with ether and dried under 
reduced pressure.  
 
3.4.2 SOPS for the Synthesis of Modified µ-Conotoxin SIIIA 
3.4.2.1 SOP8: Preloading Resin with RAMAGE Linker 
2-Chlorotrityl chloride resin (385 mg, 0.58 mmol, 100-200 mesh, 1.50 mmol/g) was swollen in 
an argon flushed flask in dry DCM (4 mL) for 30 min. RAMAGE Linker (147 mg, 290 µmol, 
0.50 eq), DIPEA (237 µL, 1.39 mmol, 2.40 eq) were dissolved in DCM (4 mL), DMF (0.5 mL) 
and added to the resin. The mixture was stirred for 30 min and afterwards the resin was washed 
with DCM/MeOH/DIPEA (17:2:1, v/v/v), 3 x 5 mL), DCM (3 x 5 mL), DMF (3 x 5 mL), DCM 
(3 x 5 mL) and dried under reduced pressure.  
 
3.4.2.2 SOP9: Coupling of the First Amino Acid  
For 2-chlorotrityl chloride resin the first amino acid was coupled with manual SPPS. The resin 
was swollen in a BD discardit syringe with PE frit in DMF (5 mL) for 30 min. The Fmoc-group 
was removed with 20% piperidine in DMF (3 mL) under microwave assisted conditions (30 s, 
50 °C, 25 W) and was washed with DMF (3 x 3 mL). To receive a complete deprotection of the 
Fmoc-group the cleavage with 20 % Piperidine in DMF (3 mL) was repeated (3 min, 50 °C, 
25 W). After the resin was washed with DMF (3 x 5 mL), DCM (3 x 5 mL) and DMF (3 x 
5 mL) the first amino acid (5.00 eq) was coupled with DIC (4.90 eq) as well as HOBt (5.00 eq) 
in DMF (3 mL) under microwave assisted conditions (10 min, 50 °C, 25 W). To receive a 
complete loading of the first amino acid the coupling step was repeated once. Following, the 
resin was washed with DMF (3 x 5 mL), DCM (3 x 5 mL), DMF (3 x 5 mL) and DCM (3 x 
5 mL) and dried under reduced pressure.  
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3.4.2.3 SOP10: Determination of the Occupancy 
The resin loading was measured using UV absorption recordings. A small amount of the resin 
(5-10 mg) was placed in a graduated flask (10 mL) and DBU (2 % in NMP, 4.0 mL) were 
added. After gentle shaking for 1 h MeCN was added (6 mL). Afterwards the mixture was 
diluted with MeCN (1/12.5) and transferred in a 10.0 mm cuvette. The absorption was measured 
at 304 nm (ε304 = 7624 L‧mol
-1‧cm-1) and corrected by the reference. The Fmoc loading was 




] =  
1
m resin[g]
 ∙  (
A∙V[L]∙𝑓
𝜀 [L mol−1 cm−1]∙d[cm]
∙ 106)   (4.2) 
Thereby, ρresin is the loading density of resin, mresin is the mass of the analysed resin, A = 
absorption, V is the volume of the graduated flask (0.01 L), f the thinning factor (f = 12.5), ε 
the absorption coefficient of the dibenzofulvene and d the pathlength of the cuvette (10.0 mm). 
 
3.4.2.4 SOP11: Automated SPPS of the µ-Conotoxin SIIIA 
Automated synthesis of the modified µ-Conotoxin SIIIA derivates were performed with a 
Liberty Blue as well as Liberty Prime peptide synthesizer connected to a Discover microwave 
unit by CEM (Matthews, North Carolina, USA). The protected amino acids were used as a 
0.20 M solution in DMF, depending on the synthesis scale. The Fmoc-group was deprotected 
with piperidine in DMF (20 % + 0.10 M HOBt). The amino acids were activated with DIC 
(0.50 M) as activator and Oxyma (1.00 M) as the activator base. 
Prior usage the resin was swollen for 30 min in DMF. In the first step the Fmoc-group was 
removed by addition of the deprotection solution (3 mL) under microwave irradiation (1: 75 °C, 
90W, 15 s; 2: 90 C, 20 W, 50 s). To get a complete removal of the Fmoc-group the deprotection 
step was repeated once. After several washing steps (4 x 4 mL) the amino acids (0.20 M), DIC 
(0.50 M) as well as Oxyma (1.00 M) were transferred to the reaction vessel and the coupling 
was performed under microwave irradiation (1: 75 °C, 170 W, 15 s; 2: 90 °C, 30 W, 110 s). To 
prevent the formation of truncated sequences the coupling step was repeated. For the coupling 
of Fmoc-Arg(Pbf)-OH modified coupling conditions were used (75 °C, 30 W, 300 s) to prevent 
γ-lactam formation. Also Fmoc-His(Boc)-OH were coupled under mild conditions (50 °C, 
30 W, 1500 min) to reduce epimerization. 
After the synthesis was completed, the resin was transferred into a BD syringe with a 
polyethylene (PE) frit and was washed with DMF and DCM. Afterwards the resin was dried 
under reduced pressure.  
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3.4.2.5 SOP 12: Cleavage of µ-Conotoxin SIIIA Derivates from the Resin 
Test-cleavage of the conotoxin derivates or caged test peptides were performed in a BD syringe 
with a PE frit. Therefore, the resin was shaken at rt for 2 h in a cleavage solution A for conotoxin 
derivates (TFA/H2O/1,2-ethanedithiol/phenol/thioanisole, 82.5/5/2.5/5/5, v/v/v/v/v) or in 
cleavage solution B for caged test peptides (TFA/TIS/H2O, 95/2.5/2.5, v/v/v). After cleavage 
the solution was concentrated under a nitrogen stream and the crude peptide was precipitated 
from -20 °C methyl tert-butyl ether. The crude peptide was isolated by centrifugation 
(9000 rpm, 10 min, - 10 °C) and dried under reduced pressure. 
 
3.4.2.6 SOP 13: Synthesis of µ-SIIIA: Formation of the First Disulphide Bridge 
The µ-conotoxin SIIIA was synthesised in a scale of 0.10 mmol. Prior usage the resin was 
swollen in DMF for 30 min. 
1.) The StBu protecting group was removed using 20 % 2-mercaptoethanol and 1 % DBU 
in DMF (12 ml, 3 x 4 mL, 20 min each) followed by washing with DMF (3 x 5 mL), 
DCM (3 x 5 mL), DMF (3 x 5 mL), DCM (3 x 5 mL).  
2.) Activation of the free thiol by using 2,2’-dipyridyl disulphide (270 mg, 0.61 mmol) in 
DCM (12 mL, 3 x 4 mL, 20 min each) followed by washing with DCM (3 x 5 ml), DMF 
(3 x 5 mL), DCM (3 x 5 ml). 
3.) Cleavage of the peptide from the resin was performed using 10 % AcOH, 20 % TFE in 
DCM (12 mL, 3 x 4 mL, 20 min each). 
4.) Under argon atmosphere the cleavage mixture was added to a solution of 0.2 % TFA, 
0.4 % TES in DCM. The reaction was stirred for 4 h at rt. 
5.) Under argon atmosphere this solution was added dropwise over 30 min to a solution of 
NEt3/DCM (10:90, v/v) and was stirred for 2 h. The mixture was concentrated and the 
peptide was precipitated from -20 °C cold methyl tert-butyl ether (25 mL), isolated by 
centrifugation (9000 rpm, 10 min, -10  C), washed two times with -20 °C cold methyl 
tert-butyl ether and dried under reduced pressure.  
6.) For the deprotection of all acid-labile protecting groups TFA/H2O/TIS (95:2.5:2.5, 
v/v/v) was added to the peptide and agitate for 2 h at rt. The cleavage mixture was 
concentrated under a nitrogen stream and the crude peptide was precipitated from -20 °C 
cold ether, isolated by centrifugation (9000 rpm, 10 min, -10 °C) and dried under 
reduced pressure. 
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3.4.2.7 SOP 14: Synthesis of µ-SIIIA: Formation of the Second Disulphide Bridge 
According to the procedure of TAM et al. the crude peptide (0.10 mmol) was added to a solution 
of 5 % acetic acid in water (50 mL, pH 6, adjust with (NH4)2CO3).
[232] DMSO (12.5 mL) was 
added to the reaction mixture and it was stirred for 4 h at rt. Afterwards the solvent was removed 
under reduced pressure. The crude peptide was dissolved in TFA (2 mL) and precipitated with 
-20 °C cold ether, isolated by centrifugation (9000 rpm, 10min, -10 °C) and dried under reduced 
pressure. The resulting colourless solid was purified by semipreparative HPLC. 
 
3.4.2.8 SOP 15: Synthesis of Thiol or Amine Modified µ-Conotoxin SIIIA 
The thiol or amine modified µ-conotoxin SIIIA was synthesised in a scale of 0.10 mmol. Due 
to the incorporation of the StBu, Mmt and Trt groups a modified regioselective folding strategy 
compared to SOP13 and SOP14 was required. Prior usage the resin was swollen in DMF for 
30 min. protected with the  
1.) The StBu protecting groups were removed using 20 % 2-mercaptoethanol and 1 % DBU 
in DMF (12 ml, 3 x 4 mL, 20 min each) followed by washing with DMF (3 x 5 mL), 
DCM (3 x 5 mL), DMF (3 x 5 mL), DCM (3 x 5 mL).  
2.) Activation of the free thiol by using 2,2’-dipyridyl disulphide (540 mg, 1.22 mmol) in 
DCM (12 mL, 3 x 4 mL, 20 min each) followed by washing with DCM (3 x 5 ml), DMF 
(3 x 5 mL), DCM (3 x 5 ml). 
3.) Cleavage of the peptide from the resin was performed using 10 % AcOH, 20 % TFE in 
DCM (12 mL, 3 x 4 mL, 20 min each). 
4.) For the formation of the first disulphide bridge, the cleavage mixture was transferred to 
a basic solution of NEt3/DCM (10:90, v/v) under argon atmosphere and the mixture was 
stirred for 2 h. Following, the solvent was removed under reduced pressure and the 
peptide was precipitated from cold methyl tert-butyl ether (25 mL), isolated by 
centrifugation (9000 rpm, 10 min, -10 min) and dried under reduced pressure.  
5.) Cleavage of the Mmt protecting groups were performed with TFA/TES/DCM 
(0.2:0.4:100, v/v/v) for 2 h. Next, the reaction mixture was dried under reduced pressure.  
6.) The crude peptide was added to solution of 5 % acetic acid in water (50 mL, pH 6, adjust 
with (NH4)2CO3) and DMSO (12.5 mL). After stirring for 4 h, the reaction mixture was 
concentrated under reduced pressure. 
7.) For the deprotection of all acid-labile protecting groups TFA/H2O/TIS (95:2.5:2.5, 
v/v/v) was added to the peptide and agitate for 2 h at rt. The cleavage mixture was 
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concentrated under a nitrogen stream and the crude peptide was precipitated from -20 °C 
cold ether, isolated by centrifugation (9000 rpm, 10 min, -10 °C), washed two times 
with cold ether and dried under reduced pressure. 
8.) For the formation of the third disulphide bridge, the peptide was dissolved in a solution 
of 5 % acetic acid in water (50 mL, pH 6, adjust with (NH4)2CO3) and DMSO 
(12.5 mL). Following the mixture was stirred for 4 h and was concentrated under 
reduced pressure. The crude peptide was dissolved in TFA (2 mL) and precipitated with 
cold ether, isolated by centrifugation (9000 rpm, 10 min, -10 °C) and dried under 
reduced pressure. The resulting colourless solid was purified by semipreparative HPLC. 
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Synthesis Peptide-PNA based Cl- sensors 
Synthesis of 4-(9-oxoacridin-10(9H)-yl)butanoic acid (9) 
 
 
The synthesis was performed according to a protocol modified by LITT et al.[272] A solution of 
acridone (5.00 g, 25.6 mmol, 1.00 eq) (7) and KOH (1.80 g, 32.0 mmol, 1.30 eq) in ethanol 
(80 mL) was stirred at reflux for 2 h. Afterwards the solvent was removed under reduced 
pressure. The residue was dissolved in butyrolactone (39.1 mL, 512 mmol, 20.0 eq, 
δ = 1.13 g/mL) (8) and was stirred at reflux for 24 h. The reaction mixture was allowed to cool 
to room temperature, filtered and the solvent was removed under reduced pressure. The 
resulting brown oil was purified by flash column chromatography (EtOAc/n-pentane/NEt3 
1:1:0.01 → EtOAc/MeOH/AcOH 1:0.1:0.01, v/v/v) to yield the product 9 (2.99 g, 10.6 mmol, 
42 %) as yellow solid. 
1H-NMR (300 MHz, DMSO-d6); δ [ppm] = 1.94 – 2.08 (m, 2H, CH2-CH2-CH2), 2.57 (t, 
3JH,H = 6.8 Hz, 2H, CH2-COOH), 4.43 – 4.54 (m, 2H, CH2-CH2-CH2), 7.30 – 7.37 (m, 2H, 
CHArom.), 7.81 – 7.88 (m, 2H, CHArom.), 7.96 (d, 
3JH,H = 8.8 Hz, 2H, CHArom.), 8.36 (dd, 
3JH,H = 
8.0 Hz, 4JH,H = 1.7 Hz, 2H, CHArom.).  
13C-NMR (126 MHz, DMSO-d6); δ [ppm] = 22.4 (CH2-CH2-CH2), 30.9 (CH2-COOH), 45.3 
(N-CH2-CH2), 116.3 (2C, 2 x CAr.), 121.7 (2C, 2 x CAr.), 122.0 (2C, 2 x CAr), 127.2 (2C, 2 x 
CAr.), 134.7 (2C, 2 x CHAr.), 141.9 (2, 2 x CHAr.), 174.9 (CO.), 176.9 (COOH).  
MS (ESI): m/z (%) = 282.1 (12) [M+H]+, 304.1 (13) [M+Na]+. 
HRMS (ESI):  calc. for: C17H16NO3: 282.1125, found.: 282.1124 [M+H]
+,   
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Synthesis 4,4'-(10H,10'H-[9,9'-biacridinylidene]-10,10'-diyl)dibutyric acid (10) 
 
 
The synthesis was performed according to a protocol modified by MASSON et al.[273] 4-(9-
oxoacridin-10(9H)-yl)butanoic acid (1.63 g, 5.79 mmol, 1.00 eq) (9) and zinc powder (3.82 g, 
58.0 mmol, 10.0 eq) were dissolved in anhydrous ethanol (20 ml) under argon atmosphere at 
0 °C. Subsequently, hydrogen chloride ethanolic solution (2.50 M, 47.0 mL, 115 mmol, 
19.9 mmol) was added over 30 min and the solution was stirred at rt for 12 h. After addition of 
water (100 mL), the mixture was filtered and recrystallized from hot ethanol. The product 10 
(1.63 g, 3.07 mmol, 53 %) was obtained as a yellow solid. 
1H-NMR (300 MHz, DMSO-d6); δ [ppm] = 1.96 – 2.12 (m, 4H, 2x CH2-CH2-CH2), 2.40 – 2.48 
(m, 4H, 2 x CH2-COOH), 4.04 – 4.21 (m, 4H, 2 x CH2-CH2-CH2), 6.57 – 6.78 (m, 8H, CHArom.), 
7.02 – 7.26 (m, 4H, CHArom.), 7.27 – 7.33 (d, 
3JH,H = 8.4 Hz, 4H, CHArom.).  
13C-NMR (126 MHz, DMSO-d6); δ [ppm] = 21.7 (2C, 2 x CH2-CH2-CH2), 31.1 (2C, 2 x CH2-
COOH), 44.7 (2C, N-CH2-CH2), 114.3 (4C, 4 x CHAr.), 120.1 (4C, 4 x CHAr.), 123.5 (2C, C=C), 
124.4 (4C, 4 x CHAr.), 127.7 (4C, 4 x CHAr.), 127.8 (4, 4 x CHAr.), 143.8 (4C, 4 x CHAr.), 175.0 
(2C, 2 x COOH).  
MS (ESI): m/z (%) = 530.2 (3) [M+H]+, 265.1 (100) [M+2H]2+. 
HRMS (ESI):  calc. for: C34H31N2O4: 530.2200, found.: 530.2188 [M+H]
+
,   
  calc. for: C34H32N2O4: 265.1095, found.: 265.1099 [M+2H]
2+
.  
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Synthesis 10,10'-bis(3-carboxypropyl)-[9,9'-biacridine]-10,10'-diium (4) 
 
 
The synthesis was performed according to a protocol modified by MASSON et al.[273] 4,4'-
(10H,10'H-[9,9'-biacridinylidene]-10,10'-diyl)dibutyric acid (1.63 g, 3.07 mmol, 1.00 eq) (10) 
was suspended in nitric acid (2.00 M, 150 mL) and was stirred at reflux for 2 h at 120 °C. The 
reaction mixture was allowed to cool to rt, filtered and recrystallized from diluted nitric acid. 
The product 4 (0.84 g, 1.58 mmol, 52 %) was obtained as a yellow solid. 
 
1H-NMR (300 MHz, CD3OD); δ [ppm] = 2.59 – 2.82 (m, 4H, 2x CH2-CH2-CH2), 2.90 – 3.03 
(m, 4H, 2 x CH2-COOH), 5.57 – 5.86 (m, 4H, 2 x CH2-CH2-CH2), 7.68 – 7.84 (m, 8H, CHArom.), 
8.36 – 8.66 (m, 4H, CHArom.), 9.18 (d, 
3JH,H = 9.4 Hz, 4H, CHArom.). 
13C-NMR (126 MHz, DMSO-d6); δ [ppm] = 24.5 (2C, 2 x CH2-CH2-C), 30.7 (2C, 2 x CH2-
CH2-C), 50.9 (2C, 2 x N-CH2-CH2), 119.7 (4C, 4 x CArom.), 127.2 (4C, 4 x CArom.), 129.3 (4C, 
4 x CArom.), 129.7 (4C, 4 x CArom.), 139.7 (4C, 4 x CArom.) 141.6 (4C, 4 x CArom.), 152.0 (2C, 
2 x CArom..), 174.8 (2C, 2 x CO) 
MS (ESI): m/z (%) = 529.2 (28) [M+H]+. 
HRMS (ESI):  calc. for: C34H29N2O4: 529.2122, found.: 529.2112 [M+H]
+,   
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Synthesis of Cholest-5-en-3β-yl mesylate (13) 
 
 
The synthesis was performed according to a protocol modified by SUN et al.[130] Cholesterol 
(8.00 g, 20.7 mmol, 1.00 eq) (11) was dissolved in anhydrous DCM (110 mL) and 
triethylamine (4.30 mL, 31.0 mmol, 1.50 eq, δ = 0.73 g/mol) under argon atmosphere at 0 °C. 
Subsequently, methanesulfonyl chloride (2.48 mL, 32.1 mmol, 1.60 eq, δ = 1.48 g/mol) was 
added dropwise and the reaction mixture was stirred for 12 h at rt. Afterwards, the solvent was 
removed under reduced pressure. The residue was dissolved in DCM (10 mL) and recrystallized 
from methanol. The product 13 (10.2 g, 21.7 mmol, quant.) was obtained as a colourless solid. 
1H-NMR (300 MHz, CDCl3); δ [ppm] = 0.69 (s, 3H, 27-CH3), 0.88 (dd, 
3JH,H = 6.6 Hz, 
4JH,H = 
1.3 Hz, 6H, 23-CH3, 24-CH3), 0.93 (d, 
3JH,H = 6.5 Hz, 3H, 25-CH3), 0.98 – 2.64 (m, 31H, 1-
CH2, 3-CH2, 6-CH2, 8-CH2, 9-CH, 10 CH, 11-CH, 13-CH2, 14-CH2, 15-CH2, 16-CH2, 17-CH, 
18-CH, 19-CH2, 20-CH2, 21-CH2, 22-CH, 28-CH3), 3.02 (s, 3H, 34-CH3), 4.43 – 4.65 (m, 1H, 
2-CH), 5.40 – 5.48 (m, 1H, 7-CH).  
MS (ESI): m/z (%) = 487.3 (6) [M+Na]+, 951.7 (3) [2M+Na]+. 
HRMS (ESI):  calc. for: C28H48O3Na: 487.3216, found.: 487.3230 [M+Na]
+,   
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Synthesis of 3β-Azido-5-cholestene (14) 
 
 
The synthesis was performed according to a protocol modified by SUN et al.[130] Cholest-5-en-
3β-yl mesylate (4.00 g, 8.61 mmol, 1.00 eq) (13) was dissolved in anhydrous DCM (40 mL) 
under argon atmosphere at 0 °C. Trimethylsilyl azide (1.25 mL, 9.47 mmol, 1.10 eq, 
δ = 0.87 g/mL) as well as boron trifluoride etherate (2.18 mL, 17.2 mmol, 2.00 eq, 
δ = 1.12 g/mL) were added dropwise and the solution was stirred for 24 h at rt. The reaction 
mixture was transferred into aqueous NaOH (2.00 M, 50 mL) and the aqueous phase was 
extracted with DCM (100 mL). The organic layer was washed with brine (100 mL) and dried 
over Na2SO4. The solvent was removed under reduced pressure and the resulting colourless oil 
was purified by flash column chromatography (DCM/MeOH 98:2, v/v). The product 14 (1.04 g, 
2.53 mmol, 30 %) was obtained as a colourless oil. 
1H-NMR (300 MHz, CDCl3); δ [ppm] = 0.70 (s, 3H, 27-CH3), 0.88 (dd, 
3JH,H = 6.6 Hz, 
4JH,H = 1.4 Hz, 6H, 23-CH3, 24-CH3), 0.93 (d, 
3JH,H = 6.5 Hz, 3H, 25-CH3), 0.98 – 2.64 (m, 
31H, 1-CH2, 3-CH2, 6-CH2, 8-CH2, 9-CH, 10 CH, 11-CH, 13-CH2, 14-CH2, 15-CH2, 16-CH2, 
17-CH, 18-CH, 19-CH2, 20-CH2, 21-CH2, 22-CH, 28-CH3), 3.15 – 3.30 (s, 1H, 2-CH), 5.33 – 
5.49 (m, 1H, 7-CH).  
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Synthesis of 3β-Amino-5-cholestene (15) 
 
 
The synthesis was performed according to a protocol modified by SUN et al.[130] 3β-Azido-5-
cholestene (1.04 g, 2.53 mmol, 1.00 eq) (14) was dissolved in anhydrous Et2O (12 ml) under 
argon atmosphere at 4 °C and LiAlH4 (0.11 g, 3.10 mmol, 1.22 eq) was added slowly. The 
solution was stirred at 4 °C for 30 min and at rt for 2 h. After quenching the excess of hydride 
with water, the organic layer was separated, and the aqueous phase was extracted with EtOAc 
(3 x 50 mL). The organic layer was washed with brine (100 mL) and dried over Na2SO4. The 
solvent was removed under reduced pressure and the resulting colourless oil was purified by 
flash column chromatography (n-pentane/EtOAc 2:1, v/v). The product 15 (0.58 g, 1.52 mmol, 
60 %) was obtained as a colourless solid. 
1H-NMR (300 MHz, CDCl3); δ [ppm] = 0.69 (s, 3H, 27-CH3), 0.85 – 0.91 (m, 6H, 23-CH3, 24-
CH3), 0.93 (d, 
3JH,H = 6.4 Hz, 3H, 25-CH3), 0.98 – 2.64 (m, 31H, 1-CH2, 3-CH2, 6-CH2, 8-CH2, 
9-CH, 10 CH, 11-CH, 13-CH2, 14-CH2, 15-CH2, 16-CH2, 17-CH, 18-CH, 19-CH2, 20-CH2, 21-
CH2, 22-CH, 28-CH3), 3.10 – 3.30 (s, 1H, 2-CH), 5.30 – 5.49 (m, 1H, 7-CH).  
13C-NMR (126 MHz, DMSO-d6); δ [ppm] = 11.9 (C), 18.7 (C), 19.3 (C), 21.2 (C), 22.6 (C), 
22.8 (C), 23.8 (C), 24.3 (C), 28.0 (2C), 28.2 (C), 31.8 (2C), 35.8 (C), 36.2 (C).37.6 (C), 38.2 
(C), 39.5 (C), 39.7 (C), 42.3 (C), 50.1 (C), 56.1 (C), 56.7 (C), 61.2 (C), 122.5 (C), 140.1 (C) 
MS (ESI): m/z (%) = 386.4 (72) [M+H]+. 
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Synthesis of Fmoc-Asp(palmitoyl)-OH (23) 
 
 
The synthesis was performed according to a protocol modified by LINNING et al.[130]. Fmoc-
Asp-OtBu (2.00 g, 4.86 mmol, 1.00 eq) (20) was dissolved in anhydrous DCM (100 mL) under 
argon atmosphere at rt and MSNT (1.43 g, 5.35 mmol, 1.10 eq) as well as 1-methylimidazole 
(0.39 mL, 4.86 mmol, 1.00 eq, ρ = 1.03 g/mL) were added. After stirring for 10 min, 
hexadecanol (1.30 g, 5.35 mmol, 1.10 eq) (21) was added and the solution was stirred overnight 
at rt. Following, 2 % aqueous citric acid was added to the reaction mixture. The organic layer 
was washed with brine (100 mL) and dried over Na2SO4.The solvent was removed under 
reduced pressure and the resulting colourless oil was purified by flash column chromatography 
(Pen/EtOAc 2:1). The obtained Fmoc-Asp(palmitoyl)-OtBu (2.99 g, 4.71 mmol, 97 %) (22) 
was dissolved in TFA/DCM (20/30, v/v) and stirred for 3h at rt. The reaction mixture was 
diluted with DCM and washed with H2O (3 x 50 mL) as well as brine (1 x 50 mL). After drying 
over Na2SO4 and removal of the solvent under reduced pressure, the residue was purified by 
flash column chromatography (n-pentane/EtOAc/AcOH 1:1:0.01, v/v/v). The product 23 
(2.06 g, 3.55 mmol, 73 %) was obtained as a colourless solid. 
1H-NMR (300 MHz, DMSO-d6); δ [ppm] = 0.78 – 0.90 (m, 3H, CH3), 1.15 – 1.30 (m, 26H, 13 
x CH2), 1.49 – 1.53 (m, 2H, O-CH2-CH2), 2.58 – 2.90 (m, 2H, β-CH2), 3.96 – 4.07 (m, 2H, 
CH2), 4.18 – 4.31 (m, 3H, Fmoc-CH, Fmoc-CH2), 4.35 – 4.41 (m, 1H, α-CH), 7.32 (t, 
3JH,H = 
7.4 Hz, 1H, Fmoc-CHAr.), 7.41 (t, 
3JH,H = 7.4 Hz, 2H, Fmoc-CHAr.), 7.66 – 7.76 (m, 3H, NH, 
Fmoc-CHAr.), 7.89 (d, 
3JH,H = 7.5 Hz, 2H, Fmoc-CHAr.) 
13C-NMR (126 MHz, CDCl3); δ [ppm] = 14.2 (CH3), 22.7 (CH2-CH3), 25.9 (CH2), 28.5 (CH2), 
29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (2C, 2 x CH2), 29.8 (4C, 4 x CH2), 32.0 
(CH2), 36.4 (CH2), 47.1 (Fmoc-CH), 50.2 (α-CH), 65.5 (O-CH2), 67.5 (Fmoc-CH2), 120.0 (2C, 
2 x Fmoc-CAr.), 125.1 (2C, 2 x Fmoc-CAr.), 127.1 (2C, 2 x Fmoc-CAr.), 127.8 (2C, 2 x Fmoc-
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CAr.), 141.3 (2C, Fmoc-CAr.), 143.6 (Fmoc-CAr.), 143.8 (Fmoc-CAr.)156.2 (NH-C=O), 171.3 
(CH2-CO), 175.7 (CO2H). 
MS (ESI): m/z (%) = 580.4 (32) [M+H]+, 602.4 (100) [M+Na]+. 
HRMS (ESI):  calc. for: C35H50NO6: 580.3633, found.: 580.3635 [M+H]
+,    
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Synthesis of a BAC-labelled PNA Oligomer (11) 
 
 
The synthesis of the peptide-PNA oligomer was performed on a Rink Amide MBHA resin 
(10.0 µmol, 0.17 mmol/g) by automated SPPS according to SOP1 and SOP2. After 
deprotection of the Alloc group following SOP3 the lysine side chain was labelled with the 
BAC-fluorophore (4) as described in SOP4. The cleavage of the peptide-PNA oligomer from 
the resin was carried out as outlined in SOP7. The crude product was purified by semi-
preparative HPLC, yielding the peptide-PNA sensor 11 (0.98 mg, 0.24 µmol) as a yellow solid. 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 1-30 % B in 30 min, λ [nm]: 215, 260, 368): 
tR = 22.2 min. 
MS (ESI): m/z (%) = 1354.2 (4) [M+3H]3+, 1015.9 (33) [M+4H]4+, 813.0 (88) [M+5H]5+, 
677.6 (100) [M+6H]6+, 581.0 (58) [M+7H]7+.  
HRMS (ESI):  calc. for: C177H219N78O39: 1354.2533, found.: 1354.2539 [M+3H]
3+, 
  calc. for: C177H220N78O39: 1015.9418, found.: 1015.9432 [M+4H]
4+, 
  calc. for: C177H221N78O39: 812.9549, found.: 812.9562 [M+5H]
5+,  
  calc. for: C177H222N78O39: 677.6312, found.: 677.6303 [M+6H]6+,  
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Synthesis of a Palmitoyl Modified Peptide-PNA Sensor (25) 
 
 
The synthesis of the peptide-PNA oligomer was performed on a Rink Amide MBHA resin 
(10.0 µmol, 0.17 mmol/g) by automated SPPS according to SOP1 and SOP2. After 
deprotection of the Alloc group following SOP3 the lysine side chain was labelled with the 
BAC-fluorophore (4) as described in SOP4. The cleavage of the peptide-PNA oligomer from 
the resin was carried out as outlined in SOP7. The crude product was purified by semi-
preparative HPLC, yielding the peptide-PNA sensor 25 (0.30 mg, 0.85 µmol) as a yellow solid. 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 260, 368): 
tR = 23.5 min. 
MS (ESI): m/z (%) = 1171.8 (10) [M+4H]4+, 937.7 (38) [M+5H]5+,781.5 (75) [M+6H]6+. 
HRMS (ESI):  calc. for: C211H285N83O44: 1171.8162, found.: 1171.8198 [M+4H]
4+, 
  calc. for: C211H286N83O44: 937.6544, found.: 937.6566 [M+5H]
5+,  
  calc. for: C211H287N83O44: 781.5465, found.: 781.5486 [M+6H]
6+,  
  calc. for: C211H288N83O44: 670.0409, found.: 670.0420 [M+7H]7+,  
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The synthesis of the peptide-PNA oligomer was performed on a Rink Amide MBHA resin 
(10.0 µmol, 0.17 mmol/g) by automated SPPS according to SOP1 and SOP2. After 
deprotection of the Alloc group following SOP3 the lysine side chain was labelled with the 
BAC-fluorophore (4) as described in SOP4. The cleavage of the peptide-PNA oligomer from 
the resin was carried out as outlined in SOP7. The crude product was purified by semi-
preparative HPLC, yielding the peptide-PNA sensor 27 (0.25 mg, 0.04 µmol) as a yellow solid. 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 260, 368): 
tR = 17.8 min. 
MS (ESI): m/z (%) = 962.0 (32) [M+5H]5+. 
HRMS (ESI):  calc. for: C258H347N94O63: 1154.5382, found.: 1154.5382 [M+4H]
4+, 











 Experimental Part 149 
Synthesis of a Palmitoyl Modified Test Peptide with a TEV Recognition Sequence (28) 
 
 
The synthesis of the peptide was performed on a Rink Amide MBHA resin (25.0 µmol, 
0.17 mmol/g) by automated SPPS according to SOP1. The cleavage of the peptide sequence 
from the resin was carried out as outlined in SOP7. The crude product was purified by semi-
preparative HPLC, yielding the peptide 28 (2.42 mg, 1.24 µmol) as a colourless solid. 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 17.4 min. 
MS (ESI): m/z (%) = 977.0 (52) [M+2H]2+.  
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Synthesis of a Palmitoyl Modified Test Peptide with a TEV Recognition Sequence and 
Increased Linker Sequence (29) 
 
 
The synthesis of the peptide was performed on a Rink Amide MBHA resin (25.0 µmol, 
0.17 mmol/g) by automated SPPS according to SOP1. The cleavage of the peptide sequence 
from the resin was carried out as outlined in SOP7. The crude product was purified by semi-
preparative HPLC, yielding the peptide 29 (1.86 mg, 0.83 µmol) as a colourless solid. 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 15.9 min. 
MS (ESI): m/z (%) = 1121.1 (100) [M+2H]2+, 747.7 (21) [M+3H]3+. 
HRMS (ESI):  calc. for: C102H168N24O32: 1121.1138, found.: 1121.1144 [M+2H]
2+, 
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The synthesis of the peptide was performed on a Rink Amide MBHA r 
esin (25.0 µmol, 0.17 mmol/g) by automated SPPS according to SOP1. The cleavage of the 
peptide sequence from the resin was carried out as outlined in SOP7. The crude product was 
purified by semi-preparative HPLC, yielding the peptide 30 (3.76 mg, 1.89 µmol) as a yellow 
solid. 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 5-60 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 16.9 min. 
MS (ESI): m/z (%) = 995.0 (100) [M+2H]2+, 663.3 (78) [M+3H]3+. 
HRMS (ESI):  calc. for: C84H132N24O32: 994.9730, found.: 994.9729 [M+2H]
2+,  
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Synthesis of a Test Peptide with a TEV Recognition Sequence (31) 
 
 
The synthesis of the peptide was performed on a Rink Amide MBHA resin (25.0 µmol, 
0.17 mmol/g) by automated SPPS according to SOP1. The cleavage of the peptide sequence 
from the resin was carried out as outlined in SOP7. The crude product was purified by semi-
preparative HPLC, yielding the peptide 31 (4.20 mg, 3.73 µmol) as a colourless solid. 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 12.6 min. 
MS (ESI): m/z (%) = 1125.6 (12) [M+H]+, 563.3 (100) [M+2H]2+. 
HRMS (ESI):  calc. for: C52H81N14O14: 1125.6051, found.: 1125.6027 [M+H]
+,  
  calc. for: C52H82N14O14: 563.3062, found.: 563.3063 [M+2H]
2+,  
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Synthesis of a Test Peptide with a Factor Xa Recognition Sequence (32) 
 
 
The synthesis of the peptide was performed on a Rink Amide MBHA resin (25.0 µmol, 
0.17 mmol/g) by automated SPPS according to SOP1. The cleavage of the peptide sequence 
from the resin was carried out as outlined in SOP7. The crude product was purified by semi-
preparative HPLC, yielding the peptide 32 (2.93 mg, 1.40 µmol) as a colourless solid. 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 17.8 min. 
MS (ESI): m/z (%) = 1045.6 (7) [M+2H]2+, 697.4 (100) [M+3H]3+, 523.3 (6) [M+3H]3+. 
HRMS (ESI):  calc. for: C96H155N25O27: 1045.5771, found.: 1045.5757 [M+2H]
2+,  
  calc. for: C96H156N25O27: 697.3872, found.: 697.3870 [M+3H]
3+,  
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The synthesis of the peptide-PNA oligomer was performed on a Rink Amide MBHA resin 
(10.0 µmol, 0.17 mmol/g) by automated SPPS according to SOP1 and SOP2. After 
deprotection of the Alloc group following SOP3 the lysine side chain was labelled with the 
BAC-fluorophore (4) as described in SOP4. The cleavage of the peptide-PNA oligomer from 
the resin was carried out as outlined in SOP7. The crude product was purified by semi-
preparative HPLC, yielding the peptide-PNA sensor 34 (0.28 mg, 0.05 µmol) as a yellow solid. 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 260, 368): 
tR = 25.6 min. 
MS (ESI): m/z (%) = 1424.2 (6) [M+4H]4+, 1139.5 (19) [M+5H]5+,949.8 (38) [M+6H]6+, 
814.2 (44) [M+7H]7+, 712.6 (42) [M+8H]8+, 633.5 (19) [M+9H]9+. 
HRMS (ESI):  calc. for: C252H345N95O62: 1424.1710, found.: 1424.1699 [M+4H]
4+, 
  calc. for: C252H346N95O62: 1139.5382, found.: 1139.5374 [M+5H]
5+, 
  calc. for: C252H347N95O62: 949.7831, found.: 949.7827 [M+6H]
6+,  
  calc. for: C252H348N95O62: 814.2437, found.: 814.2426 [M+7H]7+,  
  calc. for: C252H349N95O62: 712.5891, found.: 712.5866 [M+8H]
8+,  







 Experimental Part 155 




The synthesis of the peptide-PNA oligomer was performed on a Rink Amide MBHA resin 
(10.0 µmol, 0.17 mmol/g) by automated SPPS according to SOP1 and SOP2. After 
deprotection of the Alloc group following SOP3 the lysine side chain was labelled with the 
BAC-fluorophore (4) as described in SOP4. The cleavage of the peptide-PNA oligomer from 
the resin was carried out as outlined in SOP7. The crude product was purified by semi-
preparative HPLC, yielding the peptide-PNA sensor 35 (0.91 mg, 0.17 µmol) as a yellow solid. 
 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 260, 368): 
tR = 18.1 min. 
MS (ESI): m/z (%) = 1330.6 (8) [M+4H]4+, 1064.9 (29) [M+5H]5+,887.6 (61) [M+6H]6+, 
760.9 (100) [M+8H]8+, 665.9 (98) [M+H], 592.1 (78)[M+9H]9+. 
HRMS (ESI):  calc. for: C245H334N90O49: 1330.6611, found.: 1330.6591 [M+4H]
4+, 
  calc. for: C245H335N90O49: 1064.7303, found.: 1064.7277 [M+5H]
5+, 
  calc. for: C245H336N90O49: 887.6105, found.: 887.6093 [M+6H]
6+,  
  calc. for: C245H337N90O49: 760.9529, found.: 760.9490 [M+7H]7+,  
  calc. for: C245H338N90O49: 665.9597, found.: 665.9574 [M+8H]
8+,  






Experimental Part  156 




The synthesis of the peptide-PNA oligomer was performed on a Rink Amide MBHA resin 
(10.0 µmol, 0.17 mmol/g) by automated SPPS according to SOP1 and SOP2. After 
deprotection of the Alloc group following SOP3 the lysine side chain was labelled with the 
BAC-fluorophore (4) as described in SOP4. The cleavage of the peptide-PNA oligomer from 
the resin was carried out as outlined in SOP7. The crude product was purified by semi-
preparative HPLC, yielding the peptide-PNA sensor 38 (0.64 mg, 0.10 µmol) as a yellow solid. 
 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 30-90 % B in 30 min, λ [nm]: 215, 260, 368): 
tR = 11.5 min. 
MS (ESI): m/z (%) = 1317.3 (6) [M+5H]5+, 1097.9 (25) [M+6H]6+, 823.8 (69) [M+7H]7+, 
732.3 (100) [M+8H]8+, 659.1 (75) [M+9H]9+. 
HRMS (ESI):  calc. for: C303H438N107O63: 1317.2883, found.: 1317.2898 [M+5H]
5+, 
  calc. for: C303H439N107O63: 1097.9081, found.: 1097.9088 [M+6H]
6+, 
  calc. for: C303H440N107O63: 823.6829, found.: 823.6836 [M+7H]
7+,  
  calc. for: C303H441N107O63: 732.2745, found.: 732.2708 [M+8H]8+,  
  calc. for: C303H442N107O63: 659.1478, found.: 659.1470 [M+9H]
9+,  








 Experimental Part 157 
Synthesis of TMD Modified peptide Labelled with NBD (42) 
 
 
The synthesis of the peptide was performed on a Rink Amide MBHA resin (10.0 µmol, 
0.17 mmol/g) by automated SPPS according to SOP1. After deprotection of the Alloc group 
following SOP3 the lysine side chain was labelled with the NBD-fluorophore as described in 
SOP5. The cleavage of the labelled peptide from the resin was carried out as outlined in SOP7. 
The crude product was purified by semi-preparative HPLC, yielding the peptide-PNA oligomer 
42 (0.95 mg, 0.31 µmol) as a yellow solid. 
 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 30-70 % B in 30 min, λ [nm]: 215, 260, 467): 
tR = 16.6 min. 
MS (ESI): m/z (%) = 1010.6 (11) [M+3H]3+, 758.2 (51) [M+4H]4+, 606.8 (100) [M+5H]5+. 
HRMS (ESI):  calc. for: C147H252N38O30: 1515.4690, found.: 1515.4688 [M+2H]
2+, 
  calc. for: C147H253N38O30: 1010.6484, found.: 1010.6494 [M+3H]
3+, 
  calc. for: C147H254N38O30: 758.2381, found.: 758.2386 [M+4H]
4+,  
  calc. for: C147H255N38O30: 606.7920, found.: 606.7921 [M+5H]5+,  










Experimental Part  158 
Synthesis of His14 Modified Peptide-PNA sensor (47) 
 
 
The synthesis of the peptide-PNA oligomer was performed on a Rink Amide MBHA resin 
(10.0 µmol, 0.17 mmol/g) by automated SPPS according to SOP1 and SOP2. After 
deprotection of the Alloc group following SOP3 the lysine side chain was labelled with the 
BAC-fluorophore (4) as described in SOP4. The cleavage of the peptide-PNA oligomer from 
the resin was carried out as outlined in SOP7. The crude product was purified by semi-
preparative HPLC, yielding the peptide-PNA sensor 47 (0.53 mg, 0.08 µmol) as a yellow solid. 
 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 5-35 % B in 30 min, λ [nm]: 215, 260, 368): 
tR = 18.4 min. 
MS (ESI): m/z (%) = 1370.2 (2) [M+5H]5+, 1141.8 (10) [M+6H]6+, 979.0 (10) [M+7H]7+, 
856.7 (11) [M+8H]8+, 685.5 (31) [M+10H]10+, 623.4 (40) [M+11H]11+, 571.5 (44) 
[M+12H]12+, 
HRMS (ESI):  calc. for: C292H370N131O71: 1369.9884, found.: 1369.9902 [M+5H]
5+, 
  calc. for: C292H371N131O71: 1141.8248, found.: 1141.8258 [M+6H]
6+, 
  calc. for: C292H372N131O71: 978.8509, found.: 978.8471 [M+7H]
7+,  
  calc. for: C292H373N131O71: 856.6205, found.: 856.6208 [M+8H]
8+,  
  calc. for: C292H374N131O71: 761.5523, found.: 761.5533 [M+9H]9+,  
  calc. for: C292H375N131O71: 685.4978, found.: 685.4961 [M+10H]
10+, 
  calc. for: C292H376N131O71: 623.2714, found.: 623.2707 [M+11H]
11+, 






 Experimental Part 159 
Synthesis of ALFA-tag Modified Peptide-PNA sensor (49) 
 
 
The synthesis of the peptide-PNA oligomer was performed on a Rink Amide MBHA resin 
(10.0 µmol, 0.17 mmol/g) by automated SPPS according to SOP1 and SOP2. After 
deprotection of the Alloc group following SOP3 the lysine side chain was labelled with the 
BAC-fluorophore (4) as described in SOP4. The cleavage of the peptide-PNA oligomer from 
the resin was carried out as outlined in SOP7. The crude product was purified by semi-
preparative HPLC, yielding the peptide-PNA sensor 49 (0.37 mg, 0.06 µmol) as a yellow solid. 
 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 16.0 min. 
MS (ESI): m/z (%) = 1060.6 (3) [M+5H]5+, 795.0 (8) [M+7H]7+. 
HRMS (ESI):  calc. for: C270H378N110O73S: 1272.5788, found.: 1272.5761 [M+4H]
4+,  
  calc. for: C270H379N110O73S: 1060.6502, found.: 1060.6520 [M+5H]
5+,  
  calc. for: C270H380N110O73S: 909.2726, found.: 909.2699 [M+6H]
6+,  
  calc. for: C270H381N110O73S: 795.7395, found.: 795.7419 [M+7H]
7+, 
  calc. for: C270H382N110O73S: 707.4359, found.: 707.4376 [M+8H]8+, 








Experimental Part  160 
Synthesis of an ALFA-tag Modified Peptide labelled with the AlexaFluor488 (51) 
 
 
The synthesis of the peptide-PNA oligomer was performed on a Rink Amide MBHA resin 
(10.0 µmol, 0.17 mmol/g) by automated SPPS according to SOP1 and SOP2. After 
deprotection of the Alloc group following SOP3 the lysine side chain was labelled with the 
BAC-fluorophore (4) as described in SOP4. The cleavage of the peptide-PNA oligomer from 
the resin was carried out as outlined in SOP7. The crude product was purified by semi-
preparative HPLC, yielding the peptide-PNA sensor 51 (0.64 mg, 0.19 µmol) as a yellow solid. 
 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 15.3 min. 
MS (ESI): m/z (%) = 1652.6 (2) [M+2H]2+, 1102.1 (6) [M+6H]6+. 
HRMS (ESI): calc. for: C134H210N42O50S3: 1652.2180, found.: 1652.2150 [M+2H]
2+,  
  calc. for: C134H211N42O50S3: 1101.8144, found.: 1101.8125 [M+3H]
3+, 











 Experimental Part 161 
Synthesis of His6-PNA-BAC (100) 
 
 
The synthesis of the peptide-PNA oligomer was performed on a Rink Amide MBHA Resin 
(10.0 µmol, 0.17 mmol/g) by automated SPPS according to SOP1 and SOP2. After 
deprotection of the Alloc group following SOP3 the lysine side chain was labelled with the 
BAC-fluorophore (4) as described in SOP4. The cleavage of the peptide-PNA oligomer from 
the resin was carried out as outlined in SOP7. The crude product was purified by semi-
preparative HPLC, yielding the peptide-PNA sensor 100 (0.53 mg, 0.08 µmol) as a yellow 
solid. 
 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 5-35 % B in 30 min, λ [nm]: 215, 260, 368): 
tR = 16.5 min. 
MS (ESI): m/z (%) = 1009.6 (2) [M+5H]5+, 841.3 (6) [M+6H]6+, 721.3 (7) [M+7H]7+, 631.3 
(10) [M+8H]8+, 561.3 (13) [M+9H]9+. 
HRMS (ESI):  calc. for: C217H262N98O50: 1009.4277, found.: 1009.4270 [M+5H]
5+, 
  calc. for: C217H263N98O50: 841.3577, found.: 841.3565 [M+6H]
6+,  
  calc. for: C217H264N98O50: 721.3076, found.: 721.3061 [M+7H]
7+,  
  calc. for: C217H265N98O50: 631.2701, found.: 631.2684 [M+8H]
8+,  







Experimental Part  162 
Synthesis of modified µ-Conotoxin SIIIA  
Synthesis of 4,5-Diemthoxy-2-nitrobenzyl(4-nitrophenyl)carbonate (82) 
 
 
The synthesis was performed according to a protocol modified by FOMINA et al.[259] 
4,5-Dimethoxy-2-nitrobenzyl alcohol (2.50 g, 11.7 mmol, 1.00 eq.) (81) and 4-nitrophenyl 
chloroformate (4.70 g, 23.5 mmol, 2.00 eq) (80) were dissolved in anhydrous DCM (40 mL) 
under argon atmosphere. Subsequently, DIPEA (4.18 mL, 23.5 mmol, 2.00 eq) was added and 
the reaction mixture was stirred for 12 h at rt under exclusion of light. The solvent was removed 
under reduced pressure and the residue was recrystallized from EtOH. After drying under 
reduced pressure, the product 82 (3.75 g, 9.93 mmol, 85 %) was obtained as yellow solid.  
 
1H-NMR (300 MHz, DMSO-d6); δ [ppm] = 3.89 (s, 3H, O-CH3), 3.92 (s, 3H, O-CH3), 5.61 
(s, 2H, CH2), 7.26 (s, 1H, CHAr.), 7.59 (d, 
3JH,H = 9.3 Hz, 2H, CHAr.), 7.74 (s, 1H, CHAr.), 8.33 
(d, 3JH,H = 9.2 Hz, 2H, CHAr.).  
13C-NMR (126 MHz, DMSO-d6); δ [ppm] = 56.1 (OCH3), 56.2 (OCH3), 66.1 (CH2), 108.2 
(CAr.), 111.9 (CAr.), 122.3 (2 x CAr.), 124.1 (CAr.), 125.2 (2 x CAr.), 139.8 (CAr.), 145.1 (CAr.), 
148.1 (CAr.), 151.3 (C=O), 152.9 (CAr.), 154.9 (CAr.). 
MS (ESI): m/z (%) = 401.1 (100) [M+Na]+, 779.2 (46) [2M+Na]+. 
HRMS (ESI):  calc. for C16H14N2O9Na ([M+Na]
+): 401.0592, found: 401.0593;  
  calc. for C16H14N2O9 K ([M+K]





 Experimental Part 163 
Synthesis of Fmoc-Lys(Nvoc)-OH (83) 
 
 
The synthesis was performed according to a protocol modified by DE GARCIA LUX et al.[274] 
Fmoc-Lys-OH (1.10 g, 1.06 mmol, 1.50 eq) and Na2CO3 (0.78 g, 2.70 mmol, 1.00 eq) were 
dissolved in a mixture of dioxane, acetonitrile and H2O (36 mL, 1:1:1, v/v/v). 4,5-Diemthoxy-
2-nitrobenzyl(4-nitrophenyl)carbonate (1.02 g, 2.70 mmol, 1.00 eq) (82) was added and the 
reaction mixture was stirred for 12 h at rt under exclusion of light. Afterwards, the solvent was 
removed under reduced pressure and crude product was purified by flash column 
chromatography (DCM/MeOH/AcOH 10:0.02:0.01, v/v/v). The product 83 (1.17 g, 1.94 mmol, 
71%) was obtained as a yellow solid.  
1H-NMR (300 MHz, DMSO-d6); δ [ppm] = 1.28 – 1.51 (m, 4H, δ-CH2, γ- CH2), 1.55 – 1.75 
(m, 2H, β-CH2), 2.96 – 3.08 (m, 2H ε-CH2), 3.86 (s, 3H, O-CH3), 3.88 (s, 3H, O-CH3), 3.90 – 
3.96 (m, 1H, Fmoc-CH), 4.17 – 4.32 (m, 3H, Fmoc-CH2, α-CH), 5.32 (s, 2H, Nvoc-CH2), 7.17 
(s, 1H, Nvoc-CHAr.), 7.32 (t, 
3JH,H = 7.4 Hz, 2H, Fmoc-CHAr.), 7.37 – 7.49 (m, 3H, Fmoc-CHAr., 
Nvoc-CHAr.), 7.61 (d, 
3JH,H = 8.0 Hz, 1H, NH), 7.67 – 7.75 (m, 2H, Fmoc-CHAr.), 7.88 (d, 
3JH,H 
= 7.5 Hz, 2H, Fmoc-CHAr.). 
13C-NMR (126 MHz, DMSO-d6); δ [ppm] = 22.8 (γ-CH2), 28.8 (δ-CH2), 30.3 (β-CH2), 40.1 
(ε-CH2), 46.6 (Fmoc-CH) 53.7 (α-CH), 56.0 (2C, OCH3), 65.5 (CH2), 67.0 (Fmoc-CH2), 107.5 
(CAr.), 108.2 (CAr.), 120.0 (2C, 2 x CAr.), 125.2 (2C, 2 x CAr.), 127.0 (2C, 2 x CAr.), 127.6 (2C, 2 
x CAr.), 133.4 (CAr.), 139.3 (CAr.), 140.7 (2C, 2 x CAr.), 143.8 (2C, 2 x CAr.), 147.5 (CAr.), 153.4 
(CAr.), 155.1 (CO), 156,1 (CO), 173.9 (CO2H) 
MS (ESI): m/z (%) = 606.2 (100) [M-H]-. 
HRMS (ESI):  calc. for C31H33N3O10Na ([M+Na]
+): 630.2058, found: 630.2023;  
  calc. for C31H32N3O10 ([M-H]
-): 606.2093, found: 606.2090.  
 
Experimental Part  164 
Synthesis of 3-(3,4-Dimethoxyphenyl)butan-2-one (86) 
 
 
The synthesis was performed according to a protocol modified by SPECHT et al.[263] 
1-(3,4-Dimethoxyphenyl)propan-2-one (1.30 mL, 7.50 mmol, 1.00 eq, δ = 1.12 g/mL) (85) and 
sodium hydride (60% in paraffin oil, 0.30 g, 7.50 mmol, 1.00 eq) were dissolved in anhydrous 
THF (30 min) under argon atmosphere. After stirring at rt for 30 min, the mixture was cooled 
to 0 °C and methyl iodide (0.56 mL, 9.00 mmol, 1.20 eq, δ = 2.28 g/mL) was added. The 
reaction mixture was stirred for 6 h at rt and was quenched by addition of sat. NaHCO3 solution 
(100 mL). Following, the aqueous layer was extracted with EtOAc (3 x 50 mL) and the 
combined layers were dried over Na2SO4. The solvent was removed under reduced pressure 
and the product 86 (1.61 g, quant.). was obtained as colourless oil.  
1H-NMR (300 MHz, DMSO-d6); δ [ppm] = 1.26 (d, 
3JH,H = 7.0 Hz, 3H, CH-CH3), 2.00 (s, 3H, 
CH3), 3.73 (s, 3H, O-CH3), 3.75 (s, 3H, O-CH3), 3.74 – 3.83 (m, 1H, CH), 6.69 – 6.83 (m, 2H, 
CHAr.), 6.90 (d, 
3JH,H = 7.0 Hz, 1H, CHAr.). 
13C-NMR (126 MHz, DMSO-d6); δ [ppm] = 16.9 (CH-CH3), 27.9 (CH3), 51.7 (CH), 55.4 (2C, 
2 x O-CH3), 111.5 (CAr.), 112.1 (CAr.), 119.5(CAr.), 133.0 (CAr.), 147.6 (CAr.), 148.7 (CAr.), 207.9 
(CO) 
MS (ESI): m/z (%) = 209.1 (100) [M+H]+, 231.1(79) [M+Na]+. 
HRMS (ESI):  calc. for C12H17O3 ([M+H]
+): 209.1172, found: 209.1179;   
  calc. for C12H16O3Na ([M+Na]





 Experimental Part 165 
Synthesis of 3-(4,5-Dimethoxy-2-nitrophenyl)butan-2-one (87) 
 
 
The synthesis was performed according to a protocol modified by SCHIRMACHER.[275] 
3-(3,4-Dimethoxyphenyl)butan-2-one (1.56 g, 7.50 mmol, 1.00 eq) (86) was dissolved in acetic 
acid (15 mL), cooled to 0 °C and nitric acid (1.50 mL, 36.0 mmol, 4.80 eq.) was added 
dropwise. After stirring for 60 min at 0 °C, saturated NaHCO3 solution was added and the 
aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were 
washed with brine (3 x 50 mL) and were dried over Na2SO4. The solvent was removed under 
reduced pressure and the product 87 (1.83 g, 7.21 mmol, 96%) was obtained as brown oil. 
1H-NMR (300 MHz, DMSO-d6); δ [ppm] = 1.41 (d, 
3JH,H = 7.1 Hz, 3H, CH-CH3), 2.10 (s, 3H, 
CH3), 3.86 (s, 3H, O-CH3), 3.90 (s, 3H, O-CH3), 3.97 – 4.09 (m, 1H, CH), 6.92 (s, 1H, CHAr.), 
7.61 (s, 1H, CHAr.). 
13C-NMR (126 MHz, DMSO-d6); δ [ppm] = 16.0 (CH3), 28.1 (CH3), 48.6 (CH), 56.0 (2 x 
O-CH3), 108.1 (CAr.), 112.0 (CAr.), 129.9 (CAr.), 140.5 (CAr.) 147.1 (CAr.), 152.7 (CAr.), 206.3 
(CO) 
MS (ESI): m/z (%) = 254.1 (28) [M+H]+, 276.1 (100) [M+Na]+. 
HRMS (ESI):  calc. for C12H16NO5 ([M+H]
+): 254.1023, found: 254.1026,   
  calc. for C12H15NO5Na ([M+Na]







Experimental Part  166 
Synthesis of 3-(4,5-Dimethoxy-2-nitrophenyl)butan-2-ol (88) 
 
 
The synthesis was performed according to a protocol modified by SCHIRMACHER.[275] 
3-(4,5-dimethoxy-2-nitrophenyl)butan-2-one (1.14 g, 4.51 mmol, 1.00 eq) (87) was dissolved 
in THF/2-propanol (3.3 mL, 2 mL, v/v) and sodium borohydride (0.43 g, 11.3 mmol, 2.50 eq) 
was added. The reaction mixture was stirred for 2 h at rt and the excess of sodium borohydride 
was quenched with HCl (1 M) at 0 °C. Following, the aqueous layer was extracted with EtOAc 
(50 mL). The combined organic layers were washed with saturated brine (3 x 50 mL) and were 
dried over Na2SO4. The solvent was removed under reduced pressure and the product 88 
(0.97 g, 3.83 mmol, 85 %, erythro/threo (1:2)) was obtained as colourless solid.  
1H-NMR (300 MHz, DMSO-d6); δ [ppm] = 0.88 (d, 
3JH,H = 6.2 Hz, 1H, 1-CH3 (erythro)), 1.04 
(d, 3JH,H = 6.2 Hz, 2H, 1-CH3 (threo)), 1.23 (d, 
3JH,H = 7.0 Hz, 2H, 2-CH3 (threo)), 1.28 (d, 
3JH,H 
= 6.9 Hz, 1H, 2-CH3 (erythro)), 3.11 (q, 
3JH,H = 6.8 Hz, 
4JH,H = 0.3H, CH-CH3 (erythro)), 3.22 
(q, 3JH,H = 7.0 Hz, 
4JH,H = 0.7H, CH-CH3 (threo), 3.81 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 
– 3.97 (m, 1H, CH-OH), 6.99 (s, 0.3H, CHAr.(erythro)), 7.11 (s, 0.7H, CHAr.(threo)), 7.38 (s, 
0.7H, CHAr.(threo)), 7.39 (s, 0.3H, CHAr.(erythro). 
13C-NMR (126 MHz, DMSO-d6); δ [ppm] = 16.0 (CH3), 22.1 (CH3), 48.6 (CH), 56.0 (2C, O-
CH3), 72.3 (CH), 108.1 (CAr.), 112.0 (CAr.), 129.9 (CAr.), 140.5 (CAr.), 147.1 (CAr.), 152.7 (CAr.). 
MS (ESI): m/z (%) = 278.1 (100) [M+H]+, 533.2 (10) [2M+Na]+. 
HRMS (ESI): calc. for C12H17NO3Na ([M+Na]





 Experimental Part 167 
Synthesis of Fmoc-Asp(DMNPB)-OtBu (89) 
 
 
The synthesis was performed according to a protocol modified by SCHIRMACHER.[275] 
3-(4,5-Dimethoxy-2-nitrophenyl)butan-2-ol (0.97 g, 3.81 mmol, 1.00 eq) (88) was dissolved in 
anhydrous DCM (30 mL) under argon atmosphere. Following, Fmoc-Asp-OtBu (1.57 g, 
3.81 mmol, 1.00 eq), EDC ‧ HCl (0.80 g, 4.19 mmol, 1.10 eq) as well as DMAP (0.23 g, 
1.91 mmol, 0.50 eq) were added and the mixture was stirred at rt for 24 h. Afterwards, sat. 
NaHCO3 solution (100 mL) was added and the aqueous layer was extracted with EtOAc (3 x 
50 mL). The combined organic layers were washed with saturated brine (3 x 50 mL) and were 
dried over Na2SO4. The solvent was removed under reduced pressure and crude product was 
purified using flash column chromatography (n-pentane/EtOAc 1:0.2, v/v). The product 89 
(1.16 g, 1.79 mmol, 47%) was obtained as a colourless solid. 
1H-NMR (300 MHz, DMSO-d6); δ [ppm] = 0.96 – 1.15 (m, 3H, O-CH-CH3), 1.27 (d, 
3JH,H = 
7.0 Hz, 3H, CH3), 1.91 (s, 9H, 3 x CH3), 3.48 – 3.57 (m, 2H, β-CH2), 3.77 – 3.91 (m, 7H, 2 x 
O-CH3, CH), 4.16 – 4.44 (m, 4H, α-CH, Fmoc-CH, Fmoc-CH2), 5.05 – 5.15 (m, 1H, CH), 7.06 
– 7.10(m, 1H, CHAr.), 7.31 (t, 
3JH,H = 8.3 Hz, 2H, Fmoc-CHAr.), 7.37 – 7.48 (m, 3H, Fmoc-
CHAr., CHAr.), 7.63 – 7.72(m, 3H, Fmoc-CHAr., NH), 7.89 (d, 
3JH,H = 7.5 Hz, 2H, Fmoc-CHAr.).  
13C-NMR (126 MHz, DMSO-d6); δ [ppm] = 17.3 (CH3), 17.9 (CH3), 27.4 (3C, OC(CH3)3), 
36.0 (β-CH2), 37.7 (CH-CH3), 46.5 (Fmoc-CH), 50.9 (α-CH), 55.9 (O-CH3), 56.1 (O-CH3), 
65.6 (Fmoc-CH2), 73.7 (CH-CH3), 80.9 (OC(CH3)3), 107.25 (CAr.), 110.3 (CAr.), 119.8 (2C, 2 x 
CAr.), 124.9 (2C, 2 x CAr.), 126.8 (2C, 2 x CAr.), 127.4 (2C, 2 x CAr.), 130.6 (CAr.), 140.5 (2C, 2 
x CAr.), 142.5 (CAr.), 143.5 (2C, 2 x CAr.), 146.8 (CAr.), 151.9 (CAr.), 155.5 (Fmoc-CO), 168.8 
(CO2
tBu), 169.9 (δ-CO) 
MS (ESI): m/z (%) = 671.3 (100) [M+Na]+, 1319.5 (60) [2M+Na]+. 
Experimental Part  168 
HRMS (ESI):  calc. for C35H41N2O10 ([M+H]
+): 649.2756, found: 649.2742  
  calc. for C35H40N2O10Na ([M+Na]
+): 671.2575, found: 671.2561,  
  calc. for C35H40N2O10K ([M+K]























 Experimental Part 169 
Synthesis of Fmoc-Asp(DMNPB)-OH (90) 
 
 
The synthesis was performed according to a protocol modified by SCHIRMACHER et al.[275] 
Fmoc-Asp(DMNPB)-OtBu (1.16 g, 1.79 mmol, 1.00 eq) (89) was dissolved in TFA/DCM 
(35 mL, 35 mL, v/v) and was stirred for 2 h at rt.[263] Following, the solvent was removed in a 
nitrogen stream and dried under reduced pressure. The crude product was purified by flash 
column chromatography (n-pentane/EtOAc/AcOH 1:0.2:0.01, v/v/v). The product 90 (0.94 g, 
1.58 mmol, 89%) was obtained as a colourless solid. 
1H-NMR (300 MHz, DMSO-d6); δ [ppm] = 0.96 – 1.10 (m, 3H, O-CH- CH3), 1.27 (d, 
3JH,H = 
7.0 Hz, 3H, CH3), 2.53 – 2.61 (m, 2H, β-CH2), 3.76 – 3.91 (m, 7H, CH, 2 x O-CH3), 4.15 – 
4.35 (m, 4H, Fmoc-CH, Fmoc-CH2, α-CH), 5.05 – 5.15 (m. 1H, O-CH), 7.08 (d, 
4J H,H = 4.5 Hz, 
1H, CHAr.), 7.28 – 7.35 (m, 2H, Fmoc-CHAr.), 7.37 – 7.48 (m, 3H, Fmoc-CHAr., CHAr.), 7.60 – 
7.75(m, 3H, Fmoc-CHAr., NH), 7.89 (d, 
3JH,H = 7.5 Hz, 2H, Fmoc-CHAr.). 
13C-NMR (126 MHz, DMSO-d6); δ [ppm] = 14.0 (CH3), 17.3 (CH3), 36.0 (CH2), 37.7 (CH), 
46.6 (Fmoc-CH), 55.8 (2 x OCH3), 60.0 (α-CH), 65.5 (Fmoc-CH2), 73.4 (CH), 107.3 (CHArom.), 
110.4 (CAr.), 119.8 (2C, 2 x CAr.), 124.9 (2C, 2 xCAr.), 126.8 (2C, 2 x CAr..), 127.4 (2C, 2 x CAr.), 
130.6 (CArom.), 140.4 (2C, 2 x CAr.), 142.51 (CAr.), 143.5 (2C, 2 x CAr.), 146.7 (CAr.), 149.4 (CAr.), 
151.9 (Fmoc-CO), 168.8 (δ-CO), 169.3 (CO2H) 
MS (ESI): m/z (%) = 615.2 (100) [M+Na]+, 1207.4 (26) [2M+Na]+. 
HRMS (ESI):  calc. for C31H32N2O10Na ([M+Na]
+): 615.1949, found: 615.1948,  
  calc. for C31H31N2O10 ([M-H]




Experimental Part  170 
Synthesis of 7-(Diethylamino)-4-(hydroxymethyl)-2H-chromen-2-one (93) 
 
 
The synthesis was performed according to a protocol modified by ZHANG et al.[276] A solution 
of 7-dimethylamino-4-methylcoumarin (4.21 g, 18.2 mmol, 1.00 eq.) (92) and selenium 
dioxide (2.10 g, 18.9 mmol, 1.10 eq) in p-xylene (350 mL) was stirred at reflux for 48 h. 
Following, the reaction mixture was filtered and the solvent was removed under reduced 
pressure. The residue was dissolved in methanol (350 mL) and sodium borohydride (0.68 g, 
18.2 mmol, 1.00 eq) was added slowly added to the solution. The mixture was stirred at rt for 
4 h and was neutralized with by addition of HCl (1 M). The aqueous layer was extracted with 
DCM (3 x 100 mL) and the combined organic layers were washed with brine (3 x 50 mL). After 
drying over Na2SO4, the solvent was removed under reduced pressure and the crude product 
was purified by flash column chromatography (DCM/acetone 1:0.04 → 1:0.2, v/v). The product 
93 (2.02 g, 8.17 mmol, 44 %) was obtained as an orange solid.  
1H-NMR (300 MHz, DMSO-d6); δ [ppm] = 1.12 (t, 
3JH,H = 7.0 Hz, 6H, 2 x CH3), 3.42 (q, 
3JH,H 
= 7.3 Hz, 4H, 2 x CH2), 4.65 (d, 
4J = 1.5 Hz, 2H, CH2-OH), 5.54 (s, 1H, OH), 6.05 – 6.09 (m, 
1H, CH), 6.52 (d, 4JH,H = 2.5 Hz, 1H, CHAr.), 6.67 (dd, 
3JH,H = 9.0 Hz, 
4JH,H = 2.6 Hz, 1H, 
CHAr.), 7.43 (d, 
3JH,H = 9.0 Hz, 1H, CHAr.). 
13C-NMR (126 MHz, DMSO-d6); δ [ppm] = 12.3 (2C, 2 x CH3), 44.0 (2C, 2 x CH2), 59.1 (CH2-
OH), 96.8 (CAr.), 103.9 (CAr.), 105.7 (CAr.), 108.6 (CH-CO), 125.1 (CAr.), 150.2 (C-CH2), 155.6 
(CAr.), 156.9 (CAr.), 161.2 (C=O). 
MS (ESI): m/z (%) = 248.1 (86) [M+H]+, 270.1 (40) [M+Na]+, 495.3 (11) [2M+H]+, 517.3 
(100) [2M+Na]+, 764.4 (40) [3M+Na]+. 
HRMS (ESI):  calc. for C14H18NO3 ([M+H]
+): 248.1281, found: 248.1285;   
  calc. for C14H17NO3Na ([M+Na]
+): 270.1101, found: 270.1102.  
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The synthesis was performed according to a protocol modified by KOTZUR et al.[269] 
7-(Diethylamino)-4-(hydroxymethyl)-2H-chromen-2-one (0.87 g, 3.52 mmol, 1.00 eq) (93) 
was dissolved in DCM (25 mL) and cooled to 0 °C. Afterwards p-nitrophenyl chloroformate 
(1.49 g, 7.39 mmol, 2.10 eq) (80), dimethylaminopyridine (0.43 g, 3.52 mmol, 1.00 eq) as well 
as DIPEA (1.31 mL, 7.50 mmol, 1.50 eq, δ = 0.74 g/mL)were added and the reaction mixture 
was stirred for 12 h at rt under light exclusion. After removal of the solvent under reduced 
pressure, the residue was dissolved in EtOAc (100 mL) and washed with 1 M H3PO4 (3 x 
50 mL). The organic layer was collected and dried over Na2SO4. The crude product was purified 
by flash column chromatography (DCM/acetone 1:0.04 → DCM/acetone 1:0.2, v/v) and the 
product 94 (0.85 g, 2.06 mmol, 59 %) was obtained as an orange solid. 
 
1H-NMR (300 MHz, DMSO-d6); δ [ppm] = 1.13 (t, 
3JH,H = 7.0 Hz, 6H, 2 x CH3), 3.45 (q, 
3JH,H 
= 7.0 Hz, 4H, 2 x CH2), 5.50 (s, 2H, CH2-OH), 6.12 (s, 1H, CHAr.), 6.57 (d, 
4JH,H = 2.5 Hz, 1H, 
CHAr.), 6.73 (dd, 
3JH,H = 9.1 Hz, 
4JH,H = 2.7 Hz, 1H, CHAr.), 7.54 (d, 
3JH,H = 9.0 Hz, 1H, CHAr.), 
7.60 – 7.67 (m, 2H, CHAr.), 8.31 – 8.39 (m, 2H, CHAr.). 
13C-NMR (126 MHz, DMSO-d6); δ [ppm] = 12.3 (2C, 2 x CH3), 44.0 (2C, 2 x CH2), 65.9 (CH2-
O), 96.9 (CAr.), 105.5 (CAr.), 105.9 (CAr.), 108.8 (CH-CO), 122.6 (2C, 2 x CAr.), 125.4 (2C. 2 x 
CAr.), 126.2 (CAr.), 145.3 (CAr.), 148.9 (C-CH2), 150.2 (CAr.), 151.6 (O-C=O), 155.11 (CAr.), 
155.85 (CAr.), 160.5 (C=O).  
MS (ESI): m/z (%) = 413.1 (100) [M+H]+, 847.3 (40) [2M+Na]+. 
HRMS (ESI): calc. for C21H21N2O7 ([M+H]
+): 413.1343, found: 413.1334;   
  calc. for C21H21N2O7Na ([M+Na]
+): 435.1163, found: 435.1152.  
 
Experimental Part  172 
Synthesis of Fmoc-Lys(DEACM)-OH (95) 
 
The synthesis was performed according to a protocol modified by SCHIRMACHER et al.[269] 
(7-(Diethylamino)-2-oxo-2H-chromen-4-yl)methyl (4-nitrophenyl) carbonate (0.56 g, 
1.36 mmol, 1.00 eq) (94) was dissolved in a mixture of DCM/DMF (15 mL, 15 mL, v/v) and 
was transferred to a solution of Fmoc-Lys-OH (0.50 g, 1.36 mmol, 1.00 eq) in in toluene 
(40 mL). The reaction mixture was cooled to 0 °C and DIPEA (0.24 mL, 1.36 mmol, 1.00 eq, 
δ = 0.74 g/mL) was added. The solution was stirred for 24 h at rt under exclusion of light. 
Afterwards, the solvent was removed under reduced pressure and crude product was purified 
by flash column chromatography (DCM/MeOH/AcOH 1:0.05:0.01, v/v/v). The product 95 
(0.47 g, 0.73 mmol, 54 %) was obtained as a yellow solid.  
1H-NMR (300 MHz, DMSO-d6); δ [ppm] = 1.11 (t, 
3JH,H = 7.00 Hz, 6H, 2 x CH3), 1.28-1.79 
(m, 6H, β-CH2, γ-CH2, δ-CH2), 3.00 – 3.03 (m, 2H, ε-CH2), 3.42 (q, 
3JH,H = 7.00 Hz, 4H, 2 x 
CH2-CH3), 3.86-3.96 (m, 1H, α-CH), 4.17-4.36 (m, 3H, Fmoc-CH2, Fmoc-CH), 5.20 (s, 2H, O-
CH2), 5.97 (s, 1H, CHArom.), 6.53 (d, 
4JH,H = 2.50 Hz, 1H, CHArom.), 6.67 (dd, 
3JH,H = 9.10 Hz, 
4JH,H = 2.50 Hz, 1H, CHArom.), 7.29 – 7.33 (m, 2H, CHArom.), 7.38-7.46 (m, 3H, CHArom.), 7.49-
7.58 (m, 2H, CHArom., NH), 7.88 (d, 
3JH,H = 7.60 Hz, 2H, CHArom.), 7.89 (d, 
3JH,H = 7.60 Hz, 2H, 
CHArom.). 
13C-NMR (126 MHz, DMSO-d6); δ [ppm] = 12.8 (2 x CH3), 23.3 (γ-CH2), 29.4 (δ-CH2), 31.0 
(β-CH2), 44.4 (3C, 2 x CH2, ε-CH2), 47.1 (Fmoc-CH), 54.4 (α-CH), 61.3 (CH2-O), 66.0 (Fmoc-
CH2), 97.3 (CAr.), 104.9 (CAr.), 105.7 (CAr.), 109.2 (C-CO), 120.0 (CAr.), 120.5 (2C, 2 x CAr.), 
125.7 (2C, 2 x CAr.), 127.5 (2C, 2 x CAr.), 128.1 (2C, 2 x CAr.), 141.15 (2C, 2 x CAr.), 144.3 (2C, 
2 x CAr.), 150.9 (CAr.), 152. 4 (CAr.), 155.9 (CAr.),156.2 (O-CO), 156.5 (CO-NH), 161.2 (C=O), 
174.4 (COOH). 
MS (ESI): m/z (%) = 642.3 (14) [M+H]+, 664.3 (100) [M+Na]+, 1305.5 (11) [2M+Na]+. 
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HRMS (ESI):  calc. for: C36H40N3O8 ([M+H]
+): 642.2810, found.: 642.2808,  
  calc.: for C36H39N3O8Na ([M+Na]
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Synthesis of a Nvoc-protected test peptide (84) 
 
 
The peptide was synthesised on a Rink Amide MBHA resin (25.0 µmol, 0.76 mmol/g). Fmoc-
Ser(tBu)-OH was coupled as first amino acid according to SOP9. The peptide was synthesised 
with automated SPPS following SOP11. The cleavage of the peptide from the resin was 
performed as described in SOP12 (cleavage mixture B). The crude peptide was purified by 
semipreparative HPLC to yield the product 84 (2.43 mg, 2.57 µmol) as a yellow solid.  
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 0-50 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 26.1 min. 
MS (ESI): m/z (%) = 467.2 (50) [M+2H]2+, 933.5 (53) [M+H]+. 
HRMS (ESI):  calc. for: C41H61N10O15: 933.4312 found: 933.4310 [M+H]
+,  
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Synthesis of a DMNPB-protected test peptide (91) 
 
 
The peptide was synthesised on a Rink Amide MBHA resin (25.0 µmol, 0.76 mmol/g). Fmoc-
Ser(tBu)-OH was coupled as first amino acid according to SOP9. The peptide was synthesised 
with automated SPPS following SOP11. The cleavage of the peptide from the resin was 
performed as described in SOP12 (cleavage mixture B). The crude peptide was purified by 
semipreparative HPLC to yield the product 91 (1.83 mg, 1.90 µmol) as a yellow solid  
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 0-50 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 27.7 min. 
MS (ESI): m/z (%) = 483.3 (50) [M+2H]2+, 918.5 (74) [M+H]+. 
HRMS (ESI):  calc. for: C41H60N9O15: 918.4203 found: 918.4210 [M+H]
+, 
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Synthesis of a DEACM-protected test peptide (96) 
 
 
The peptide was synthesised on a Rink Amide MBHA resin (25.0 µmol, 0.76 mmol/g). Fmoc-
Ser(tBu)-OH was coupled as first amino acid according to SOP9. The peptide was synthesised 
with automated SPPS following SOP11. The cleavage of the peptide from the resin was 
performed as described in SOP12 (cleavage mixture B). The crude peptide was purified by 
semipreparative HPLC to yield the product 96 (2.02 mg, 2.06 µmol) as a yellow solid  
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 1-40 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 20.9 min. 
MS (ESI): m/z (%) = 967.5 (100) [M+H]+, 989.5 (35) [M+Na]+. 
HRMS (ESI):  calc. for: C46H67N10O13: 967.4884, found.: 967.4881 [M+H]
+,   
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Synthesis of Native µ-Conotoxin SIIIA by the Folding Strategy from RADZEY[220] 
 
 
2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded with the 
Ramage linker according to SOP8 and the occupancy (0.28 mmol/g) was determined following 
SOP10. The first amino acid Fmoc-Cys(Trt)-OH was coupled to the resin (238 mg, 0.10 mmol) 
as described in SOP9 and the peptide sequence was synthesised by automated SPPS following 
SOP11. The test cleavage of the native µ-SIIIA (101) was carried out with cleavage mixture A 
as outlined in SOP12, yielding the Acm and StBu protected peptide. 
 
 
MS (ESI): m/z (%) = 1222.5 (18) [M+2H]2+, 815.3 (100) [M+3H]3+, 611.7 (50) [M+4H]4+. 
HRMS (ESI):  calc. for: C93H149N35O29S7: 122.4664, found.: 1222.4666 [M+2H]
2+,  
  calc. for: C93H150N35O29S7: 815.3134, found.: 815.3130 [M+3H]
3+,  
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The formation of the first and second disulphide bridge was performed as described in SOP13 
and SOP14. The crude peptide was purified by semipreparative HPLC and the product 58 
(4.36 mg, 1.95 µmol) was obtained as a colourless solid. 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 1-40 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 20.2 min. 
MS (ESI): m/z (%) = 1176.4 (22) [M+2H]2+, 784.6 (100) [M+3H]3+, 588.7 (11) [M+4H]4+. 
HRMS (ESI):  calc. for: C89H137N35O29S6: 1176.4330, found.: 1176.4341 [M+2H]
2+,  
  calc. for: C89H138N35O29S6: 784.6244, found.: 784.6245 [M+3H]
3+,  
  calc. for: C89H139N35O29S6: 588.7201, found.: 588.7199 [M+4H]
4+. 
 
Synthesis of native µ-conotoxin SIIIA: formation of the third disulphide bridge 
 
 
For cleavage of the Acm protecting groups and formation of the third disulphide bridge, 58 
(4.36 mg, 1.95 µmol, 1.00 eq) and Ac-L-Trp-OMe (5.13 mg, 19.5 µmol, 10 eq) were dissolved 
in AcOH/H2O (0.92/0.46, v/v). Following, a solution of iodine (12.3 mg, 97.5 µmol, 50.0 eq), 
dissolved in acetic acid (0.95 mL), was added and the reaction mixture was stirred for 60 min 
at rt. The reaction was quenched by addition of L-ascorbic acid (100 mg in 0.75 mL H2O) and 
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the crude peptide was directly purified by semipreparative HPLC. Four isomers of the product 
59 were obtained as a colourless solid.  
1.) Isomer 59.1.1 (0.09 mg, 0.04 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 1-40 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 19.8 min. 
MS (ESI): m/z (%) = 1103.9 (11) [M+2H]2+, 736.6 (56) [M+3H]3+. 
HRMS (ESI):  calc. for: C83H125N33O27S6: 1103.8868, found.: 1103.8868 [M+2H]
2+,  
  calc. for: C83H126N33O27S6: 736.2603, found.: 736.2596 [M+3H]
3+,  
  calc. for: C83H127N33O27S6: 552.4470, found.: 552.4464 [M+4H]
4+. 
2.) Isomer 59.1.2 (0.04 mg, 0.02 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 1-40 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 20.9 min. 
MS (ESI): m/z (%) = 1104.4 (15) [M+2H]2+, 736.6 (79) [M+3H]3+. 
HRMS (ESI): calc. for: C83H125N33O27S6: 1103.8868, found.: 1103.8872 [M+2H]
2+,  
  calc. for: C83H126N33O27S6: 736.2603, found.: 736.2597 [M+3H]
3+,  
  calc. for: C83H127N33O27S6: 552.4470, found.: 552.4462 [M+4H]
4+. 
3.) Isomer 59.1.3 (0.08 mg, 0.04 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 1-40 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 21.5 min. 
MS (ESI): m/z (%) = 1104.4 (15) [M+2H]2+, 736.6 (53) [M+3H]3+. 
HRMS (ESI):  calc. for: C83H125N33O27S6: 1103.8868, found.: 1103.8863 [M+2H]
2+, 
  calc. for: C83H126N33O27S6: 736.2603, found.: 736.2593 [M+3H]
3+. 
4.) Isomer 59.1.4 (0.12 mg, 0.05 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 1-40 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 23.2 min. 
MS (ESI): m/z (%) = 1104.4 (6) [M+2H]2+, 736.6 (21) [M+3H]3+. 
HRMS (ESI):  calc. for: C83H125N33O27S6: 1103.8868, found.: 1103.8866 [M+2H]
2+,  
  calc. for: C83H126N33O27S6: 736.2603, found.: 736.2595 [M+3H]
3+. 
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Synthesis of Native µ-Conotoxin SIIIA by the Optimised Folding Strategy 
 
 
2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded with the 
Ramage linker according to SOP8 and the occupancy (0.24 mmol/g) was determined following 
SOP10. The first amino acid Fmoc-Cys(Acm)-OH was coupled to the resin (416 mg, 
0.10 mmol) as described in SOP9 and the peptide sequence was synthesised by automated SPPS 
following SOP11. The test cleavage of the native µ-SIIIA (102) was carried out with cleavage 
mixture A as outlined in SOP12, yielding the Acm and StBu protected peptide. 
 
 
MS (ESI): m/z (%) = 1222.4 (22) [M+2H]2+, 815.3 (100) [M+3H]3+, 611.7 (83) [M+4H]4+. 
HRMS (ESI):  calc. for: C93H149N35O29S7: 1221.4660, found.: 1221.4651 [M+2H]
2+,  
  calc. for: C93H150N35O29S7: 815.3131, found.: 815.3119 [M+3H]
3+,  
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Synthesis of Native µ-Conotoxin SIIIA: Formation of the Second Disulphide Bridge 
 
 
The formation of the first and second disulphide bridge was performed as described in SOP13 
and SOP14. The crude peptide was purified by semipreparative HPLC and the product 61 
(8.22 mg, 3.48 µmol) was obtained as a colourless solid. 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 1-40 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 18.7 min. 
MS (ESI): m/z (%) = 1176.4 (16) [M+2H]2+, 784.6 (87) [M+3H]3+, 588.7 (100) [M+4H]4+. 
HRMS (ESI):  calc. for: C89H137N35O29S6: 1176.4333, found.: 1176.4344 [M+2H]
2+,  
calc. for: C89H138N35O29S6: 784.6246, found.: 784.6266 [M+3H]
3+,   
calc. for: C89H139N35O29S6: 588.7203, found.: 588.7215 [M+4H]
4+. 
 
Synthesis of native µ-conotoxin SIIIA: formation of the third disulphide bridge 
 
 
For cleavage of the Acm protecting groups and formation of the third disulphide bridge, 61 
(8.22 mg, 3.71 µmol, 1.00 eq) and Ac-L-Trp-OMe (9.97 mg, 37.1 µmol, 10.0 eq) were 
dissolved in AcOH/H2O (1.82/0.91, v/v). Following, a solution of iodine (48.5 mg, 185 µmol, 
50.0 eq), dissolved in acetic acid (1.80 mL), was added and the reaction mixture was stirred for 
60 min at rt. The reaction was quenched by addition of L-ascorbic acid (400 mg in 1.5 mL H2O) 
and the crude peptide was directly purified by semipreparative HPLC. Two isomers of the 
product 59 were obtained as a colourless solid. 
Experimental Part  182 
1.) Isomer 59.2.1 (0.10 µg, 0.04 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 1-40 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 16.6 min. 
MS (ESI): m/z (%) = 1104.4 (11) [M+2H]2+, 736.6 (100) [M+3H]3+, 552.7 (56) [M+4H]4+. 
HRMS (ESI):  calc. for: C83H125N33O27S6: 1104.3884, found.: 1104.3880 [M+2H]
2+, 
  calc. for: C83H126N33O27S6: 736.5947, found.: 736.5957 [M+3H]
3+,  
  calc. for: C83H127N33O27S6: 552.6978, found.: 552.6984 [M+4H]
4+. 
2.) Isomer 59.2.2 (0.46 µg, 0.21 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 1-40 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 17.2 min. 
MS (ESI): m/z (%) = 1104.4 (15) [M+2H]2+, 736.6 (79) [M+3H]3+. 
HRMS (ESI):  calc. for: C83H125N33O27S6: 1104.3884, found.: 1104.3883 [M+2H]
2+,  
  calc. for: C83H126N33O27S6: 736.5947, found.: 736.5946 [M+3H]
3+,  
  calc. for: C83H127N33O27S6: 552.6978, found.: 552.6977 [M+4H]
4+. 
 
Synthesis of AlexaFluor488 modified µ-Conotoxin SIIIA 
 
2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded with the 
Ramage linker according to SOP8 and the occupancy (0.26 mmol/g) was determined following 
SOP10. The first amino acid Fmoc-Cys(Acm)-OH was coupled to the resin (385 mg, 
0.10 mmol) as described in SOP9 and the peptide sequence was synthesised by automated SPPS 
following SOP11. The test cleavage of the native µ-SIIIA (103) was carried out with cleavage 
mixture A as outlined in SOP12, yielding the Acm and StBu protected peptide. 
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MS (ESI): m/z (%) = 1241.4 (21) [M+2H]2+, 828.0 (100) [M+3H]3+, 621.2 (86) [M+4H]4+. 
HRMS (ESI):  calc. for: C96H151N35O29S7: 1241.4738, found.: 1241.4725 [M+2H]
2+, 
  calc. for: C96H152N35O29S7: 827.9850, found.: 827.9844 [M+3H]
3+,  
  calc. for: C96H153N35O29S7: 621.2406, found.: 621.2399 [M+4H]
4+. 
 




For cleavage of the Acm protecting groups and formation of the third disulphide bridge, 63 
(4.81 mg, 2.14 µmol, 1.00 eq) and Ac-L-Trp-OMe (5.23 mg, 21.4 µmol, 10.0 eq) were 
dissolved in AcOH/H2O (0.91/0.46, v/v). Following, a solution of iodine (25.0 mg, 107 µmol, 
50.0 eq), dissolved in acetic acid (0.91 mL), was added and the reaction mixture was stirred for 
15 min at rt. The reaction was quenched by addition of L-ascorbic acid (400 mg in 1.5 mL H2O) 
and the crude peptide was directly purified by semipreparative HPLC. The product 64 
(0.06 mg,0.03 µmol) was obtained as a colourless solid.  
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 20-50 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 14.7 min. 
MS (ESI): m/z (%) = 1123.4 (21) [M+2H]2+, 749.3 (100) [M+3H]3+, 562.2 () [M+4H]4+. 
HRMS (ESI):  calc. for: C86H127N33O27S6: 1123.3962, found.: 1123.3931[M+2H]
2+, 
  calc. for: C86H128N33O27S6: 749.2666, found: 749.2658 [M+3H]
3+,  
  calc. for: C86H129N33O27S6: 562.2017, found: 562.2003[M+4H]
4+. 
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Synthesis of AlexaFluor488-labelled µ-Conotoxin SIIIA 
 
The labelling reaction was performed according to a protocol modified by RINK et al.[241] The 
alkyne modified µ-SIIA (64.0 µg, 28.8 nmol, 1.00 eq) and AlexaFluor488 azide (1.64 mg, 
1.44 µmol, 50.0 eq) were dissolved in degassed MilliQ (200 µL) under argon atmosphere. 
Sodium ascorbate (10 µL, 100 mM), CuSO4/THPTA (10 µL,67.0 mM/10 µL,134 mM) were 
mixed in degassed tert-butanol/PBS (200 µL) and was transferred to the peptide solution. The 
reaction mixture was incubated at 37 °C for 48 h and was directly purified by analytical HPLC, 
yielding the product 65 (0.04 µg, 13.3 nmol) as yellow solid. 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 20-50 % B in 30 min, λ [nm]: 215, 280, 488): 
tR = 14.7 min. 
HRMS (ESI): calc. for: C113H154N39O37S8: 968.6381, found.: 968.6359 [M+3H]
3+. 
 
Synthesis of Allocam Protected Alkyne-modified µ-SIIIA 
 
 
2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded with the 
Ramage linker according to SOP8 and the occupancy (0.26 mmol/g) was determined following 
SOP10. The first amino acid Fmoc-Cys(Allocam)-OH was coupled to the resin (385 mg, 
0.10 mmol) as described in SOP9 and the peptide sequence was synthesised by automated SPPS 
following SOP11. The test cleavage of the alkyne-modified µ-SIIIA (104) was carried out with 
cleavage mixture A as outlined in SOP12, yielding the Allocam and StBu protected peptide. 
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MS (ESI): m/z (%) = 1283.4 (4) [M+2H]2+, 856.0 (12) [M+3H]3+, 642.2 (8) [M+4H]4+. 
HRMS (ESI):  calc. for: C100H156N35O31S7: 855.9920, found.: 855.9879 [M+3H]
3+,  
  calc. for: C100H157N35O31S7: 642.2458, found.: 642.2429 [M+4H]
4+. 
 
Synthesis of Allocam Protected Alkyne-modified µ-SIIIA: Formation of the First and 
Second Disulphide Bridge 
 
 
The formation of the first and second disulphide bridge was performed as described in SOP13 
and SOP14. The crude peptide was purified by semipreparative HPLC and the product 67 was 
obtained as a colourless solid. 
1.) Isomer 67.1 (1.07 mg, 0.43 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 14.2 min. 
MS (ESI): m/z (%) = 1237.5 (23) [M+2H]2+, 825.3 (100) [M+3H]3+, 619.2 (82) [M+4H]4+. 
HRMS (ESI):  calc. for: C96H143N35O31S6: 1237.4514, found.: 1237.4505 [M+2H]
2+,  
  calc. for: C96H144N35O31S6: 825.3034, found.: 825.3034 [M+3H]
3+,  
  calc. for: C96H145N35O31S6: 619.2293, found.: 619.2290 [M+4H]4+. 
2.) Isomer 67.2 (1.27 mg, 0.51 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 14.4 min. 
MS (ESI): m/z (%) = 1237.5 (10) [M+2H]2+, 825.3 (70) [M+3H]3+, 619.2 (63) [M+4H]4+. 
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HRMS (ESI):  calc. for: C96H143N35O31S6: 1237.4514, found.: 1237.4495 [M+2H]
2+, 
  calc. for: C96H144N35O31S6: 825.3034, found.: 825.3027 [M+3H]
3+,  




Synthesis of tBu Protected Alkyne-modified µ-SIIIA 
 
 
2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded with the 
Ramage linker according to SOP8 and the occupancy (0.26 mmol/g) was determined following 
SOP10. The first amino acid Fmoc-Cys(tBu)-OH was coupled to the resin (385 mg, 0.10 mmol) 
as described in SOP9 and the peptide sequence was synthesised by automated SPPS following 
SOP11. The test cleavage of the alkyne-modified µ-SIIIA (105) was carried out with cleavage 
mixture A as outlined in SOP12, yielding the tBu and StBu protected peptide. 
 
 
MS (ESI): m/z (%) = 1226.5 (18) [M+2H]2+, 818.0 (100) [M+3H]3+, 613.7 (68) [M+4H]4+. 
HRMS (ESI):  calc. for: C98H157N33O27S7: 1226.4993, found.: 1222.4967 [M+2H]
2+, 
  calc. for: C98H158N33O27S7: 818.0020, found.: 818.0008 [M+3H]
3+,  




 Experimental Part 187 




The formation of the first and second disulphide bridge was performed as described in SOP13 
and SOP14. The crude peptide was purified by semipreparative HPLC and the product 69 was 
obtained as a colourless solid. 
1.) Isomer 69.1 (2.7 mg, 1.1 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 12.9 min. 
MS (ESI): m/z (%) = 1180.4 (42) [M+2H]2+, 787.3 (100) [M+3H]3+, 590.7 (16) [M+4H]4+. 
HRMS (ESI): calc. for: C94H145N33O27S6: 1180.4664, found.: 11180.4657 [M+2H]
2+, 
  calc. for: C94H146N33O27S6: 787.3133, found.: 787.3133 [M+3H]
3+,  
  calc. for: C94H147N33O27S6: 590.7368, found.: 590.7364 [M+4H]
4+. 
2.) Isomer 69.2 (2.9 mg, 1.2 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 13.4 min. 
MS (ESI): m/z (%) = 1180.5 (30) [M+2H]2+, 787.3 (100) [M+3H]3+, 590.7 (37) [M+4H]4+. 
HRMS (ESI):  calc. for: C94H145N33O27S6: 1180.4664, found.: 11180.4667 [M+2H]
2+, 
  calc. for: C94H146N33O27S6: 787.3133, found.: 787.3133 [M+3H]
3+,  
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Synthesis of MeOBzl Protected Alkyne-modified µ-SIIIA 
 
2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded with the 
Ramage linker according to SOP8 and the occupancy (0.26 mmol/g) was determined following 
SOP10. The first amino acid Fmoc-Cys(MeOBzl)-OH was coupled to the resin (385 mg, 
0.10 mmol) as described in SOP9 and the peptide sequence was synthesised by automated SPPS 
following SOP11. The test cleavage of the alkyne-modified µ-SIIIA (106) was carried out with 
cleavage mixture A as outlined in SOP12, yielding the MeOBzl and StBu protected peptide. 
 
 
MS (ESI): m/z (%) = 1290.5 (5) [M+2H]2+, 860.6 (16) [M+3H]3+, 645.7 (18) [M+4H]4+. 
HRMS (ESI): calc. for: C106H157N33O29S7: 1290.4943, found.: 1290.4900 [M+2H]
2+, 
  calc. for: C106H158N33O29S7: 860.6653, found.: 860.6635 [M+3H]
3+, 
  calc. for: C106H159N33O29S7: 645.7508, found.: 645.7492 [M+4H]
4+. 
 
Synthesis of MeOBzl Protected Alkyne-modified µ-SIIIA: Formation of the First and 
Second Disulphide Bridge 
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The formation of the first and second disulphide bridge was performed as described in SOP13 
and SOP14. The crude peptide was purified by semipreparative HPLC and the product 71 was 
obtained as a colourless solid. 
1.) Isomer 71.1 (5.09 mg, 2.05 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 1-40 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 24.8 min. 
MS (ESI): m/z (%) = 1244.5 (12) [M+2H]2+, 830.0 (100) [M+3H]3+, 622.7 (97) [M+4H]4+. 
HRMS (ESI):  calc. for: C102H145N33O29S6: 1244.4613, found.: 1244.4607 [M+2H]
2+, 
  calc. for: C102H146N33O29S6: 829.9766, found.: 829.9767 [M+3H]
3+, 
  calc. for: C102H147N33O29S6: 622.7343, found.: 622.7342 [M+4H]
4+. 
2.) Isomer 71.2 (2.05 mg, 0.82 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 1-40 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 25.4 min. 
MS (ESI): m/z (%) = 1244.5 (17) [M+2H]2+, 830.0 (100) [M+3H]3+, 622.7 (97) [M+4H]4+. 
HRMS (ESI):  calc. for: C102H145N33O29S6: 1244.4613, found.: 1244.4600 [M+2H]
2+, 
  calc. for: C102H146N33O29S6: 829.9766, found.: 829.9765 [M+3H]
3+, 
  calc. for: C102H147N33O29S6: 622.7343, found.: 622.7339 [M+4H]
4+. 
 
Synthesis of Thiol-modified µ-SIIIA 
 
2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded with the 
Ramage linker according to SOP8 and the occupancy (0.26 mmol/g) was determined following 
SOP10. The first amino acid Fmoc-Cys(Trt)-OH was coupled to the resin (385 mg, 0.10 mmol) 
as described in SOP9 and the peptide sequence was synthesised by automated SPPS following 
SOP11. The test cleavage of the thiol-modified µ-SIIIA (107) was carried out with cleavage 
mixture A as outlined in SOP12, yielding the Acm and StBu protected peptide. 
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MS (ESI): m/z (%) = 1253.9 (16) [M+2H]2+, 836.3 (84) [M+3H]3+, 627.7 (100) [M+4H]4+. 
HRMS (ESI):  calc. for: C95H154N34O28S9: 1253.9586, found.: 1253.9548 [M+2H]
2+,  
  calc. for: C95H155N34O28S9: 836.3082, found.: 836.3071 [M+3H]
3+,  
  calc. for: C95H156N34O28S9 : 627.4830, found.: 627.4817 [M+4H]
4+. 
 




The formation of the first, second and third disulphide bridge was performed following SOP15 
and the crude peptide was directly purified by semipreparative HPLC. Two isomers of the 
product 74 were obtained as a colourless solid. 
1.) Isomer 74.1 (1.73 mg, 0.74 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 15.0 min. 
MS (ESI): m/z (%) = 1162.9 (23) [M+2H]2+, 775.6 (100) [M+3H]3+, 581.9 (16) [M+4H]4+. 
HRMS (ESI):  calc. for: C87H132N34O28S7: 1162.9008, found.: 1162.9001 [M+2H]
2+, 
  calc. for: C87H133N34O28S7: 775.6030, found: 775.6034 [M+3H]
3+,  
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2.) Isomer 74.2 (1.95 mg, 0.84 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 10-60 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 15.7 min. 
MS (ESI): m/z (%) = 1162.9 (9) [M+2H]2+, 775.6 (58) [M+3H]3+, 581.9 (21) [M+4H]4+. 
HRMS (ESI): calc. for: C87H132N34O28S7: 1162.9008, found.: 1162.8993 [M+2H]
2+, 
  calc. for: C87H133N34O28S7: 775.6030, found: 775.6019 [M+3H]
3+,  
  calc. for: C87H134N34O28S7: 581.9540, found: 581.9528 [M+4H]
4+. 
 
Synthesis of Amine-modified µ-SIIIA 
 
 
2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded with the 
Ramage linker according to SOP8 and the occupancy (0.26 mmol/g) was determined following 
SOP10. The first amino acid Fmoc-Cys(Trt)-OH was coupled to the resin (385 mg, 0.03 mmol) 
as described in SOP9 and the peptide sequence was synthesised by automated SPPS following 
SOP11. The test cleavage of the amine-modified µ-SIIIA (108) was carried out with cleavage 
mixture A as outlined in SOP12, yielding the Alloc and StBu protected peptide. 
 
 
MS (ESI): m/z (%) = 1272.9 (24) [M+2H]2+, 848.9 (100) [M+3H]3+, 637.0 (58) [M+4H]4+. 
HRMS (ESI): calc. for: C99H160N34O29S8: 1272.9936, found.: 1272.9907 [M+2H]
2+,  
  calc. for: C99H161N34O29S8: 848.9981, found.: 848.9975 [M+3H]
3+,  
  calc. for: C99H162N34O29S8: 637.0004, found.: 636.9993 [M+4H]
4+. 
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The formation of the first, second and third disulphide bridge was performed following SOP15. 
After formation of the second disulphide bridge, the Alloc protecting group was cleaved under 
argon atmosphere with Pd(PPh3)4 (14.4 mg, 0.01 µmol, 0.50 eq) and phenylsilane (46.2 µL, 
0.38 µmol, 15.0 eq) for 12 h at rt. The ε-amine group of the lysine was labelled with NHS-
activated TMR (65.9 mg, 0.13 µmol, 5.00 eq) in DMF (400 µL) and DIPEA (43.5 µL, 
0.25 µmol, 10.0 eq) for 12 h at rt. After labelling the third disulphide bridge was formed, 
following SOP15 and the crude peptide was directly purified by semipreparative HPLC. Two 
isomers of the product 79 were obtained as a colourless solid. 
1.) Isomer 79.1 (54.3 µg, 20.2 nmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 1-40 % B in 30 min, λ [nm]: 215, 280, 540): 
tR = 24.0 min. 
MS (ESI): m/z (%) = 673.8 [M+4H]4+. 
HRMS (ESI):  calc. for: C112H156N36O31S6: 673.5017, found.: 673.4994 [M+4H]
4+, 
  calc. for: C112H157N36O31S6: 539.0028, found.: 539.0008 [M+5H]
5+. 
2.) Isomer 79.2 (115µg, 42.8 nmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 1-40 % B in 30 min, λ [nm]: 215, 254, 540): 
tR = 24.6 min. 
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Synthesis of DEACM modified µ-Conotoxin SIIIA 
 
 
2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded with the 
Ramage linker according to SOP8 and the occupancy (0.26 mmol/g) was determined following 
SOP10. The first amino acid Fmoc-Cys(Acm)-OH was coupled to the resin (385 mg, 
0.10 mmol) as described in SOP9 and the peptide sequence was synthesised by automated SPPS 
following SOP11. The test cleavage of the native µ-SIIIA (109) was carried out with cleavage 
mixture A as outlined in SOP12, yielding the DEACM, Acm and StBu protected peptide. 
 
 
MS (ESI): m/z (%) = 1359.0 (33) [M+2H]2+, 906.3 (100) [M+3H]3+. 
HRMS (ESI):  calc. for: C108H164N36O33S7: 1359.0161, found.: 1359.0151 [M+2H]
2+, 
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Synthesis of DEACM modified µ-Conotoxin SIIIA: Formation of the First and Second 
Disulphide Bridge  
 
 
The formation of the first and second disulphide bridge was performed as described in SOP13 
and SOP14. The crude peptide was purified by semipreparative HPLC and the product 98 
(1.35 mg, 0.54 µmol) was obtained as a colourless solid. 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 20-50 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 16.0 min. 
MS (ESI): m/z (%) = 1359.0 (33) [M+2H]2+, 906.3 (100) [M+3H]3+. 
HRMS (ESI):  calc. for: C104H152N36O33S6: 1312.9831, found.: 1312.9847 [M+2H]
2+, 
  calc. for: C104H153N36O33S6: 875.6578, found.: 875.6592 [M+3H]
3+. 
 




For cleavage of the Acm protecting groups and formation of the third disulphide bridge, 98 
(1.35 mg, 0.54 µmol, 1.00 eq) and Ac-L-Trp-OMe (1.34 mg, 5.44 µmol, 10.0 eq) were 
dissolved in AcOH/H2O (0.33/0.17, v/v). Following, a solution of iodine (6.58 mg, 27.0 µmol, 
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50.0 eq), dissolved in acetic acid (0.26 mL), was added and the reaction mixture was stirred for 
20 min at rt. The reaction was quenched by addition of L-ascorbic acid (100 mg in 0.50 mL 
H2O) and the crude peptide was directly purified by semipreparative HPLC. Four isomers of 
the product 99 were obtained as a colourless solid. 
1.) Isomer 99.1 (0.25 mg, 0.10 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 20-50 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 13.5 min. 
MS (ESI): m/z (%) = 1240.9 (33) [M+2H]2+, 827.6 (100) [M+3H]3+. 
HRMS (ESI):  calc. for: C98H140N34O31S6: 1240.9382, found.: 1240.9386 [M+2H]
2+, 
  calc. for: C98H141N34O31S6: 827.6279, found.: 827.6292 [M+3H]
3+. 
2.) Isomer 99.2 (0.05 mg, 0.02 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 20-50 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 14.1 min. 
MS (ESI): m/z (%) = 1240.9 (33) [M+2H]2+, 827.6 (100) [M+3H]3+. 
HRMS (ESI):  calc. for: C98H140N34O31S6: 1240.9382, found.: 1240.9368 [M+2H]
2+, 
  calc. for: C98H141N34O31S6: 827.6279, found.: 827.6290 [M+3H]
3+. 
3.) Isomer 99.3 (0.08 mg, 0.02 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 20-50 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 14.7 min. 
MS (ESI): m/z (%) = 1240.9 (33) [M+2H]2+, 827.6 (100) [M+3H]3+. 
HRMS (ESI):  calc. for: C98H140N34O31S6: 1240.9382, found.: 1240.9389 [M+2H]
2+, 
  calc. for: C98H141N34O31S6: 827.6279, found.: 827.6291 [M+3H]
3+. 
4.) Isomer 99.4 (0.12 mg, 0.05 µmol) 
HPLC: (250 · 10 mm, 5 µm, C18, Gradient = 20-50 % B in 30 min, λ [nm]: 215, 254, 280): 
tR = 15.5 min. 
MS (ESI): m/z (%) = 1240.9 (16) [M+2H]2+, 827.6 (100) [M+3H]3+. 
HRMS (ESI):  calc. for: C98H140N34O31S6: 1240.9382, found.: 1240.9386 [M+2H]
2+, 
  calc. for: C98H141N34O31S6: 827.6279, found.: 827.6287 [M+3H]
3+. 
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4 Abbreviations  
 
Standard α-amino acids are abbreviated using the three- or one letter code. Nucleobases in aeg-
PNA sequences are abbreviated with small letter (a,c,g,t). 
 
Ac2O    acetic anhydride 
Acm   acetoamidomethyl  
AcOH    acetic acid 
aeg   N-(2-aminoethyl)glycine 
Alloc   allyloxycarbonyl  
Allocam  allyloxycarbonyl aminomethyl 
AO   acridine orange 
ATP   adenosine triphosphate 
AU    absorption unit 
BAC   10,10’-bis[3-carboxypropyl]-9,9’biacridinium dinitrate 
BD    syringe syringe by Becton Dickinson 
Bhoc   benzhydryloxycarbonyl protection group 
Boc   tert-butoxycarbonyl  
calc   calculated 
CFP   cyan fluorescent protein 
CNS   central nervous system 
COMU  (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino- 
CuAAC  copper(I)-catalysed azide-alkyne cycloaddition 
δ    chemical shift (NMR) 
DBU   1,8-diazabicyclo[5.4.0]undec-7-en  
DCM   dichlormethane  
DEACM  (7-(diethylamino)coumarin-4-yl)methyl 
DIC   N,Nˈ-diisopropylcarbodiimide  
DIPEA  N,N’-diisopropylethylamine  
DLS    dynamic light scattering 
DMAP   4-dimethylaminopyridine 
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DMF   N,N-dimethylformamide  
DMNPB  3-(4,5-Dimethoxy-2-nitrophenyl)-2-butyl 
DMSO   dimethyl sulfoxide   
DNA    deoxyribonucleic acid 
DOPC   1,2-dioleoyl-sn-glycero-3-phosphocholine  
DOPE   1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
DOPS   1,2-dioleoyl-sn-glycero-3-phospho-L-serine 
ΔpH   pH gradient 
DsRed   red fluorescent protein 
DTT    dithiothreitol 
ΔµH+   electrochemical gradient 
ΔΨ   membrane potential 
ε   extinction coefficient 
EDC   1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDT   1,2-ethanedithiole 
EDTA   ethylenediaminetetraacetic acid 
eq    equivalents 
ESI   electrospray-ionisation  
EtOAc   ethyl acetate 
EtOH   ethanol 
FCCS    fluorescence cross-correlation spectroscopy 
FDA   Food and Drug Administration (US) 
Fmoc   fluorenylmethoxycarbonyl  
FRET   fluorescence resonance energy transfer  
G   BAC fluorescence intensity 
GABA   γ-aminobutyric acid 





HEK   human embryonic kidney 
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HOAt   1-hydroxy-7-azabenzotriazole  
HOBt   1-hydroxybenzotriazole 
HPLC   high performance liquid chromatography  
HR-MS  high resolution mass spectrometry  
J   coupling constant 
KALP   peptides of general sequence: GKK(LA) n LKKA 
KD   dissociation constant 
kobs   observed association rate 
koff    dissociation rate 
kon   association rate 
KSV   STERN-VOLLMER quenching constant 
LC-MS  liquid chromatography mass spectrometry 
LUV   large unilamellar vesicle  
m/z   mass-to-charge ratio 
MeCN   acetonitrile 
MeIm   methylimidazole 
MeOH   methanol 
MEQ   6-methoxy-N-ethylquinolinium iodide 
morpholino-carbenium hexafluorophosphate 
MQAE  N-(ethoxycarbonylmethyl)-6-methoxyquninolinium bromide 
MS   mass spectrometry 
MSNT   1-(mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole 
NaV   voltage gated sodium channels 
NBD   7-nitrobenz-2-oxa-1,3-diazol-4-yl  
NHS-ester   N-hydroxysuccinimide ester 
NMR   nuclear magnetic resonance  
nt    nucleotides 
NTA   Nitrilotriacetic acid 
NVOC   6-nitroveratryloxycarbonyl 
Oxyma   ethyl cyanohydroxyiminoacetate 
PAGE    polyacrylamide gel electrophoresis 
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Pbf   2,2,4,6,7-pentamethyldihydrofurane-5-sulphonyl 
Pd(PPh3)4  Tetrakis(triphenylphosphine)palladium 
PG   protecting group  
pGlu   pyroglutamate 
PNA    peptide nucleic acid 
PNS   peripheral nervous system 
PPG   photoremovable protecting group 
Ppm   parts per million  
PTMs   post-translational modifications 
PyAOP 7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate  
R   AlexaFluor 647 fluorescence intensity 
RNA   ribonucleic acid 
Rpm   rotations per minute 
rrp   readily releasable pool 
rt   room temperature  
SLC17   solute carrier transmembrane transporters 
SNARE   soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
SOP   standard operating procedure  
SPPS   solid phase peptide synthesis  
SPQ   6-methoxy-N-(3-sulfopropyl)quinolinium 
SPyr    2-pyridinesulphenyl 
StBu   tert-butylthio 
STX   saxitoxin 
SUV   small unilamellar vesicle  
SV   synaptic vesicles 
tBu   tert-butyl 
Tert   tertiary  
TES   triethylsilane 
TEV   tobacco etch virus 
TFA   trifluoroacetic acid  
Abbreviations  200 
TFE   trifluoroethanol  
TFMSA  trifluoromethanesulfonic acid 
THPTA  tris((1-hydroxy-propyl-1H-1,2,3-triazol-4-yl)methyl)amine 
TIRF   total internal reflection fluorescence 
TIS   triisopropylsilan 
TLC   thin layer chromatography 
TMD    transmembrane domain 
TMR   tetramethylrhodamine  
TMS   trimethylsilan  
TMSN3  trimethylsilyl azide 
tR    retention time  
TR   Texas Red 
Trt    trityl  
TTX   tetrodotoxin 
U   units 
U-HPLC  ultra-high performance liquid chromatography 
UV   ultraviolet  
v/v   volume to volume  
VAchT  vesicular acetylcholine transporter 
V-ATPase  vacuolar-type H+-ATPase 
VGLUT  vesicular glutamate transporter 
VGSC   voltage-gated sodium channel 
VIAAT  vesicular inhibitory amino acid transporter 
VIS   visual  
VMATs  vesicular monoamine transporters 





  Bibliography 201 
5 Bibliography 
 
[1] T. C. Südhof, Annu. Rev. Neurosci. 2004, 27, 509–547. 
[2] S. Takamori, M. Holt, K. Stenius, E. A. Lemke, M. Grønborg, D. Riedel, H. Urlaub, S. Schenck, 
B. Brügger, P. Ringler, et al., Cell 2006, 127, 831–846. 
[3] J. Preobraschenski, J. F. Zander, T. Suzuki, G. Ahnert-Hilger, R. Jahn, Neuron 2014, 84, 1287–
1301. 
[4] S. Schenck, S. M. Wojcik, N. Brose, S. Takamori, Nat. Neurosci. 2009, 12, 156–162. 
[5] S. Saha, V. Prakash, S. Halder, K. Chakraborty, Y. Krishnan, Nat. Nanotechnol. 2015, 10, 645–
651. 
[6] V. Prakash, S. Saha, K. Chakraborty, Y. Krishnan, Chem. Sci. 2016, 7, 1946–1953. 
[7] N. D. Sonawane, J. R. Thiagarajah, A. S. Verkman, J. Biol. Chem. 2002, 277, 5506–5513. 
[8] M. Zajac, K. Chakraborty, S. Saha, V. Mahadevan, D. T. Infield, A. Accardi, Z. Qiu, Y. 
Krishnan, J. Cell Sci. 2020, 133, 1–13. 
[9] M. De Lera Ruiz, R. L. Kraus, J. Med. Chem. 2015, 58, 7093–7118. 
[10] S. D. Dib-Hajj, Y. Yang, J. A. Black, S. G. Waxman, Nat. Rev. Neurosci. 2013, 14, 49–62. 
[11] S. J. Sanders, M. T. Murtha, A. R. Gupta, J. D. Murdoch, M. J. Raubeson, A. J. Willsey, A. G. 
Ercan-Sencicek, N. M. Di Lullo, N. N. Parikshak, J. L. Stein, et al., Nature 2012, 485, 237–241. 
[12] G. Bulaj, P. J. West, J. E. Garrett, M. Marsh, M. M. Zhang, R. S. Norton, B. J. Smith, D. 
Yoshikami, B. M. Olivera, Biochemistry 2005, 44, 7259–7265. 
[13] C. I. Schroeder, J. Ekberg, K. J. Nielsen, D. Adams, M. L. Loughnan, L. Thomas, D. J. Adams, 
P. F. Alewood, R. J. Lewis, J. Biol. Chem. 2008, 283, 21621–21628. 
[14] K. B. Akondi, R. J. Lewis, P. F. Alewood, Biopolymers 2014, 101, 347–354. 
[15] L. Qu, Y. Akbergenova, Y. Hu, T. Schikorski, J. Comp. Neurol. 2009, 514, 343–352. 
[16] J. S. Bonifacino, B. S. Glick, Cell 2004, 116, 153–166. 
[17] T. C. Südhof, R. Jahn, Neuron 1991, 6, 665–677. 
[18] C. Rosenmund, C. F. Stevens, Neuron 1996, 16, 1197–1207. 
[19] P. S. Kaeser, W. G. Regehr, Curr. Opin. Neurobiol. 2017, 43, 63–70. 
[20] N. L. Chanaday, M. A. Cousin, I. Milosevic, S. Watanabe, J. R. Morgan, J. Neurosci. 2019, 39, 
Bibliography  202 
8209–8216. 
[21] B. Katz, Science 1971, 173, 123–126. 
[22] R. H. Edwards, Neuron 2007, 55, 835–858. 
[23] Z. Farsi, J. Preobraschenski, G. Van Den Bogaart, D. Riedel, R. Jahn, A. Woehler, Science 2016, 
351, 981–984. 
[24] M. Beinlich, Mechanisms Underlying Biphasic Synaptic Vesicle Acidification in Glutamatergic 
Synapses, Dissertation, Heinrich-Heine Universität Düsseldorf, 2018. 
[25] H. Fei, A. Grygoruk, E. S. Brooks, A. Chen, D. E. Krantz, Traffic 2008, 9, 1425–1436. 
[26] D. Peter, J. Jimenez, Y. Liu, J. Kim, R. H. Edwards, J. Biol. Chem. 1994, 269, 7231–7237. 
[27] J. D. Erickson, M. K. H. Schäfer, T. I. Bonner, L. E. Eiden, E. Weihe, Proc. Natl. Acad. Sci. U. 
S. A. 1996, 93, 5166–5171. 
[28] M. L. Nguyen, G. D. Cox, S. M. Parsons, Biochemistry 1998, 37, 13400–13410. 
[29] R. G. Johnson, Physiol. Rev. 1988, 68, 232–307. 
[30] J. D. Erickson, H. Varoqui, M. K. H. Schafer, W. Modi, M. F. Diebler, E. Weihe, J. Rand, L. E. 
Eiden, T. I. Bonner, T. B. Usdin, J. Biol. Chem. 1994, 269, 21929–21932. 
[31] S. L. McIntire, R. J. Reimer, K. Schuske, R. H. Edwards, E. M. Jorgensen, Nature 1997, 389, 
870–876. 
[32] N. Juge, A. Muroyama, M. Hiasa, H. Omote, Y. Moriyama, J. Biol. Chem. 2009, 284, 35073–
35078. 
[33] P. R. Maycox, T. Deckwerth, J. W. Hell, R. Jahn, J. Biol. Chem. 1988, 263, 15423–15428. 
[34] E. E. Bellocchio, R. J. Reimer, J. Fremeau, R. H. Edwards, Science 2000, 289, 957–960. 
[35] S. Takamori, J. S. Rhec, C. Rosenmund, R. Jahn, Nature 2000, 407, 189–194. 
[36] R. T. Fremeau, S. Voglmaier, R. P. Seal, R. H. Edwards, Trends Neurosci. 2004, 27, 98–103. 
[37] S. M. Wojcik, J. S. Rhee, E. Herzog, A. Sigler, R. Jahn, S. Takamori, N. Brose, C. Rosenmund, 
Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 7158–7163. 
[38] Å. Wallén-Mackenzie, H. Gezelius, M. Thoby-Brisson, A. Nygård, A. Enjin, F. Fujiyama, G. 
Fortin, K. Kullander, J. Neurosci. 2006, 26, 12294–12307. 
[39] D. Balschun, D. Moechars, Z. Callaerts-Vegh, B. Vermaercke, N. Van Acker, L. Andries, R. 
D’Hooge, Cereb. Cortex 2010, 20, 684–693. 
  Bibliography 203 
[40] R. M. Tordera, S. Totterdell, S. M. Wojcik, N. Brose, N. Elizalde, B. Lasheras, J. Del Rio, Eur. 
J. Neurosci. 2007, 25, 281–290. 
[41] E. E. Benarroch, Neurology 2018, 91, 125–132. 
[42] A. Kashani, È. Lepicard, O. Poirel, C. Videau, J. P. David, C. Fallet-Bianco, A. Simon, A. 
Delacourte, B. Giros, J. Epelbaum, et al., Neurobiol. Aging 2008, 29, 1619–1630. 
[43] W. S. Van Der Hel, S. A. M. W. Verlinde, D. H. M. Meijer, M. De Wit, M. G. Rensen, K. L. I. 
Van Gassen, P. C. Van Rijen, C. W. M. Van Veelen, P. N. E. De Graan, Epilepsia 2009, 50, 
1717–1728. 
[44] N. Pietrancosta, M. Djibo, S. Daumas, S. El Mestikawy, J. D. Erickson, Mol. Neurobiol. 2020, 
57, 3118–3142. 
[45] K. Disbrow, J. Gershten, J. A. Ruth, Biochem. Biophys. Res. Commun. 1982, 108, 1221–1227. 
[46] P. R. Maycox, J. W. Hell, R. Jahn, Trends Neurosci. 1990, 13, 83–87. 
[47] M. Martineau, R. E. Guzman, C. Fahlke, J. Klingauf, Nat. Commun. 2017, 8, 1–13. 
[48] S. Takamori, J. S. Rhee, C. Rosenmund, R. Jahn, J. Neurosci. 2001, 21, 1–6. 
[49] S. Takamori, P. Malherbe, C. Broger, R. Jahn, EMBO Rep. 2002, 3, 798–803. 
[50] S. El Mestikawy, Å. Wallén-Mackenzie, G. M. Fortin, L. Descarries, L. E. Trudeau, Nat. Rev. 
Neurosci. 2011, 12, 204–216. 
[51] S. M. Voglmaier, K. Kam, H. Yang, D. L. Fortin, Z. Hua, R. A. Nicoll, R. H. Edwards, Neuron 
2006, 51, 71–84. 
[52] S. De Gois, E. Jeanclos, M. Morris, S. Grewal, H. Varoqui, J. D. Erickson, Cell. Mol. Neurobiol. 
2006, 26, 679–693. 
[53] T. S. Hnasko, N. Chuhma, H. Zhang, G. Y. Goh, D. Sulzer, R. D. Palmiter, S. Rayport, R. H. 
Edwards, Neuron 2010, 65, 643–656. 
[54] C. Gras, B. Amilhon, È. M. Lepicard, O. Poirel, J. Vinatier, M. Herbin, S. Dumas, E. T. Tzavara, 
M. R. Wade, G. G. Nomikos, et al., Nat. Neurosci. 2008, 11, 292–300. 
[55] F. Li, J. Eriksen, J. Finer-Moore, R. Chang, P. Nguyen, A. Bowen, A. Myasnikov, Z. Yu, D. 
Bulkley, Y. Cheng, et al., Science 2020, 368, 893–897. 
[56] J. Almqvist, Y. Huang, A. Laaksonen, D.-N. Wang, S. Hovmöller, Protein Sci. 2007, 16, 1819–
1829. 
[57] J. B. Leano, S. Batarni, J. Eriksen, N. Juge, J. E. Pak, T. Kimura-Someya, Y. Robles-Colmenares, 
Bibliography  204 
Y. Moriyama, R. M. Stroud, R. H. Edwards, PLoS Biol. 2019, 17, 1–25. 
[58] H. H. Füldner, H. Stadler, Eur. J. Biochem. 1982, 121, 519–524. 
[59] H. Wolosker, D. O. De Souza, L. De Meis, J. Biol. Chem. 1996, 271, 11726–11731. 
[60] J. S. Tabb, P. E. Kish, R. Van Dyke, T. Ueda, J. Biol. Chem. 1992, 267, 15412–15416. 
[61] J. Preobraschenski, C. Cheret, M. Ganzella, J. F. Zander, K. Richter, S. Schenck, R. Jahn, G. 
Ahnert-Hilger, Cell Rep. 2018, 23, 535–545. 
[62] G. Y. Goh, H. Huang, J. Ullman, L. Borre, T. S. Hnasko, L. O. Trussell, R. H. Edwards, Nat. 
Neurosci. 2011, 14, 1285–1292. 
[63] J. Eriksen, R. Chang, M. McGregor, K. Silm, T. Suzuki, R. H. Edwards, Neuron 2016, 90, 768–
780. 
[64] S. Naito, T. Ueda, J. Neurochem. 1985, 44, 99–109. 
[65] J. Hartinger, R. Jahn, J. Biol. Chem. 1993, 268, 23122–23127. 
[66] G. Ahnert-Hilger, M. Höltje, I. Pahner, S. Winter, I. Brunk, Rev. Physiol. Biochem. Pharmacol. 
2003, 150, 140–160. 
[67] S. M. Stobrawa, T. Breiderhoff, S. Takamori, D. Engel, M. Schweizer, A. A. Zdebik, M. R. Bösl, 
K. Ruether, H. Jahn, A. Draguhn, et al., Neuron 2001, 29, 185–196. 
[68] T. Maritzen, D. J. Keating, I. Neagoe, A. A. Zdebik, T. J. Jentsch, J. Neurosci. 2008, 28, 10587–
10598. 
[69] X. Li, T. Wang, Z. Zhao, S. A. Weinman, Am. J. Physiol. - Cell Physiol. 2002, 282, 1483–1491. 
[70] M. Hara-Chikuma, B. Yang, N. D. Sonawane, S. Sasaki, S. Uchida, A. S. Verkman, J. Biol. 
Chem. 2005, 280, 1241–1247. 
[71] R. E. Guzman, M. Grieschat, C. Fahlke, A. K. Alekov, ACS Chem. Neurosci. 2013, 4, 994–1003. 
[72] R. E. Guzman, A. K. Alekov, M. Filippov, J. Hegermann, C. Fahlke, Front. Cell. Neurosci. 2014, 
8, 1–9. 
[73] M. Yoshikawa, S. Uchida, J. Ezaki, T. Rai, A. Hayama, K. Kobayashi, Y. Kida, M. Noda, M. 
Koike, Y. Uchiyama, et al., Genes to Cells 2002, 7, 597–605. 
[74] R. Chang, J. Eriksen, R. H. Edwards, Elife 2018, 7, 1–16. 
[75] J. Eriksen, F. Li, R. H. Edwards, BBA - Biomembr. 2020, 104743. 
[76] T. Y. Chen, T. C. Hwang, Physiol. Rev. 2008, 88, 351–387. 
  Bibliography 205 
[77] U. F. Aslanova, T. Morimoto, E. I. Farajov, N. Kumagai, M. Nishino, N. Sugawara, A. Ohsaga, 
Y. Maruyama, S. Tsuchiya, S. Takahashi, et al., Tohoku J. Exp. Med. 2006, 210, 291–300. 
[78] T. Stauber, T. J. Jentsch, Annu. Rev. Physiol. 2013, 75, 453–477. 
[79] A. Di, M. E. Brown, L. V. Deriy, C. Li, F. L. Szeto, Y. Chen, P. Huang, J. Tong, A. P. Naren, 
V. Bindokas, et al., Nat. Cell Biol. 2006, 8, 933–944. 
[80] T. O. Neild, R. C. Thomas, J. Physiol. 1974, 242, 453–470. 
[81] R. A. Harris, A. M. Allan, Science 1985, 228, 1108–1110. 
[82] D. Arosio, G. M. Ratto, Front. Cell. Neurosci. 2014, 8, 1–12. 
[83] R. M. Wachter, S. J. Remington, Curr. Biol. 1999, 9, 628–629. 
[84] L. J. V. Galietta, P. M. Haggie, A. S. Verkman, FEBS Lett. 2001, 499, 220–224. 
[85] S. Jayaraman, P. Haggie, R. M. Wachter, S. J. Remington, A. S. Verkman, J. Biol. Chem. 2000, 
275, 6047–6050. 
[86] O. Markova, M. Mukhtarov, E. Real, Y. Jacob, P. Bregestovski, J. Neurosci. Methods 2008, 170, 
67–76. 
[87] T. Kuner, G. J. Augustine, Neuron 2000, 27, 447–459. 
[88] D. Arosio, F. Ricci, L. Marchetti, R. Gualdani, L. Albertazzi, F. Beltram, Nat. Methods 2010, 7, 
516–518. 
[89] D. Arosio, G. Garau, F. Ricci, L. Marchetti, R. Bizzarri, R. Nifosì, F. Beltram, Biophys. J. 2007, 
93, 232–244. 
[90] T. Wasiluk, M. Roueinfar, K. Hiryak, M. Torsiello, A. Miner, J. Lee, M. Venditto, W. Terzaghi, 
D. Lucent, A. L. VanWert, Biol. Open 2019, 8, 1–8. 
[91] C. D. Geddes, Meas. Sci. Technol. 2001, 12, 53–88. 
[92] S. Saha, V. Prakash, S. Halder, K. Chakraborty, Y. Krishnan, Nat. Nanotechnol. 2015, 10, 645–
651. 
[93] R. Y. Tsien, Biochemistry 1980, 19, 2396–2404. 
[94] A. Minta, J. P. Y. Kao, R. Y. Tsien, J. Biol. Chem. 1989, 264, 8171–8178. 
[95] A. S. Verkman, Am. J. Physiol. - Cell Physiol. 1990, 259, 375–388. 
[96] T. D. Ashton, K. A. Jolliffe, F. M. Pfeffer, Chem. Soc. Rev. 2015, 44, 4547–4595. 
[97] N. P. Illsley, A. S. Verkman, Biochemistry 1987, 26, 1215–1219. 
Bibliography  206 
[98] A. S. Verkman, M. C. Sellers, A. C. Chao, T. Leung, R. Ketcham, Anal. Biochem. 1989, 178, 
355–361. 
[99] L. J. MacVinish, T. Reancharoen, A. W. Cuthbert, Br. J. Pharmacol. 1993, 108, 469–478. 
[100] N. Chub, G. Z. Mentis, M. J. O’Donovan, J. Neurophysiol. 2006, 95, 323–330. 
[101] M. K. Mansoura, J. Biwersi, M. A. Ashlock, A. S. Verkman, Hum. Gene Ther. 1999, 10, 861–
875. 
[102] R. G. Painter, G. Wang, Anal. Chem. 2006, 78, 3133–3137. 
[103] Y. Şener, G. Tosun, F. Kahvecioğlu, A. Gökalp, H. Koç, Eur. J. Dent. 2007, 01, 21–24. 
[104] H. A. Olszowy, J. Rossiter, J. Hegarty, P. Geoghegan, M. Haswell-Elkins, J. Anal. Toxicol. 1998, 
22, 225–230. 
[105] A. M. Gbadebo, C. O. Nwufoh, J. Geochemical Explor. 2010, 107, 169–174. 
[106] N. D. Sonawane, A. S. Verkman, J. Cell Biol. 2003, 160, 1129–1138. 
[107] S. Modi, M. G. Swetha, D. Goswami, G. D. Gupta, S. Mayor, Y. Krishnan, Nat. Nanotechnol. 
2009, 4, 325–330. 
[108] S. Modi, C. Nizak, S. Surana, S. Halder, Y. Krishnan, Nat. Nanotechnol. 2013, 8, 459–467. 
[109] S. Surana, J. M. Bhat, S. P. Koushika, Y. Krishnan, Nat. Commun. 2011, 2, 1–7. 
[110] J. R. Lakowicz, Principles of Fluorescence Spectroscopy, Springer 3rd Edition, 2006. 
[111] A. M. Hansen, G. Bonke, W. F. J. Hogendorf, F. Björkling, J. Nielsen, K. T. Kongstad, D. 
Zabicka, M. Tomczak, M. Urbas, P. E. Nielsen, et al., Eur. J. Med. Chem. 2019, 168, 134–145. 
[112] P. E. Nielsen, M. Egholm, R. H. Berg, O. Buchardt, Science 1991, 254, 1497–1500. 
[113] G. T. Hwang, Y. J. Seo, B. H. Kim, J. Am. Chem. Soc. 2004, 126, 6528–6529. 
[114] P. E. Nielsen, Curr. Opin. Struct. Biol. 1999, 9, 353–357. 
[115] J. C. Wu, Q. C. Meng, H. M. Ren, H. T. Wang, J. Wu, Q. Wang, Acta Pharmacol. Sin. 2017, 38, 
798–805. 
[116] P. E. Nielsen, Appl. Biochem. Biotechnol. - Part B Mol. Biotechnol. 2004, 26, 233–248. 
[117] S. Siddiquee, Adv. Tech. Biol. Med. 2015, 03, 1–10. 
[118] U. Giesen, W. Kleider, C. Berding, A. Geiger, H. Ørum, P. E. Nielsen, Nucleic Acids Res. 1998, 
26, 5004–5006. 
[119] J. Tailhades, H. Takizawa, M. J. Gait, D. A. Wellings, J. D. Wade, Y. Aoki, F. Shabanpoor, 
  Bibliography 207 
Front. Chem. 2017, 5, 1–7. 
[120] S. Middel, C. H. Panse, S. Nawratil, U. Diederichsen, ChemBioChem 2017, 18, 2328–2332. 
[121] B. E. Hubrich, P. M. Menzel, B. Kugler, U. Diederichsen, Pept. Nucleic Acids Methods Protoc. 
Springer, 3rd Edition, 2020. 
[122] K. R. Wilson, S. Sedberry, R. Pescatore, D. Vinton, B. Love, S. Ballard, B. C. Wham, S. K. 
Hutchison, E. J. Williamson, J. Pept. Sci. 2016, 22, 622–627. 
[123] U. Rost, C. Steinem, U. Diederichsen, Chem. Sci. 2016, 7, 5900–5907. 
[124] D. Pahlke, Synthesis , characterisation and sensor-functionalisation of transmembrane β -
peptides, Dissertation, Georg-August Universität Göttingen, 2018. 
[125] E. I. Vrettos, N. Sayyad, E. M. Mavrogiannaki, E. Stylos, A. D. Kostagianni, S. Papas, T. 
Mavromoustakos, V. Theodorou, A. G. Tzakos, RSC Adv. 2017, 7, 50519–50526. 
[126] G. A. Höger, M. Wiegand, B. Worbs, U. Diederichsen, ChemBioChem 2020, 21, 2599–2603. 
[127] G. Höger, Self-Organization of β -Peptide Nucleic Acid Helices for Membrane Scaffolding, 
Dissertation, Georg-August-Universität Göttingen, 2019. 
[128] Q. Sun, S. Cai, B. R. Peterson, Org. Lett. 2009, 11, 567–570. 
[129] R. Ramage, S. Irving, C. McInnes, Tetrahedron Lett. 1993, 354, 6599–6602. 
[130] P. Linning, U. Haussmann, I. Beyer, S. Weidlich, H. Schieb, J. Wiltfang, H. W. Klafki, H. J. 
Knölker, Org. Biomol. Chem. 2012, 10, 8216–8235. 
[131] C. S. Bennett, C. H. Wong, Chem. Soc. Rev. 2007, 36, 1227–1238. 
[132] T. J. Tolbert, D. Franke, C. H. Wong, Bioorganic Med. Chem. 2005, 13, 909–915. 
[133] H. Nam, B. J. Hwang, D. Y. Choi, S. Shin, M. Choi, FEBS Open Bio 2020, 10, 619–626. 
[134] David S. Waugh, Protein Expr. Purif. 2011, 80, 283–293. 
[135] J. Zerweck, B. S. Venkata, J. M. Pittman, A. K. Srivastava, P. C. Moore, J. R. Sachleben, G. 
Thinakaran, S. C. Meredith, Protein Expr. Purif. 2019, 162, 72–82. 
[136] G. M. Dubowchik, R. A. Firestone, L. Padilla, D. Willner, S. J. Hofstead, K. Mosure, J. O. Knipe, 
S. J. Lasch, P. A. Trail, Bioconjug. Chem. 2002, 13, 855–869. 
[137] M. K. Shim, Y. Moon, S. Yang, J. Kim, H. Cho, S. Lim, H. Y. Yoon, J. K. Seong, K. Kim, 
Biomaterials 2020, 261, 1–14. 
[138] J. D. Bargh, A. Isidro-Llobet, J. S. Parker, D. R. Spring, Chem. Soc. Rev. 2019, 48, 4361–4374. 
Bibliography  208 
[139] J. D. Wehland, A. S. Lygina, P. Kumar, S. Guha, B. E. Hubrich, R. Jahn, U. Diederichsen, Mol. 
Biosyst. 2016, 12, 2770–2776. 
[140] K. Halbmair, J. Wegner, U. Diederichsen, M. Bennati, Biophys. J. 2016, 111, 2345–2348. 
[141] A. Holt, J. A. Killian, Eur. Biophys. J. 2010, 39, 609–621. 
[142] V. Vasic, Reconstitution of retrotranslocation by the Hrd1 ubiquitin ligase with purified 
components, Dissertation, Georg-August Universität Göttingen, 2019. 
[143] W. van den Nest, S. Yuval, F. Albericio, J. Pept. Sci. 2001, 120, 115–120. 
[144] N. Hartrampf, A. Saebi, M. Poskus, Z. P. Gates, A. J. Callahan, A. E. Cowfer, S. Hanna, S. 
Antilla, C. K. Schissel, A. J. Quartararo, et al., Science 2020, 368, 980–987. 
[145] S. Lata, A. Reichel, R. Brock, R. Tampé, J. Piehler, J. Am. Chem. Soc. 2005, 127, 10205–10215. 
[146] R. Wieneke, N. Labòria, M. Rajan, A. Kollmannsperger, F. Natale, M. C. Cardoso, R. Tampé, J. 
Am. Chem. Soc. 2014, 136, 13975–13978. 
[147] J. L. Douglas, C. A. Trieber, M. Afara, H. S. Young, Protein Expr. Purif. 2005, 40, 118–125. 
[148] P. Bannas, J. Hambach, F. Koch-Nolte, Front. Immunol. 2017, 8, 1–13. 
[149] M. M. Harmsen, H. J. De Haard, Appl. Microbiol. Biotechnol. 2007, 77, 13–22. 
[150] H. Götzke, M. Kilisch, M. Martínez-Carranza, S. Sograte-Idrissi, A. Rajavel, T. Schlichthaerle, 
N. Engels, R. Jungmann, P. Stenmark, F. Opazo, et al., Nat. Commun. 2019, 10, 1–12. 
[151] M. Petukhov, Y. Tatsu, K. Tamaki, S. Murase, H. Uekawa, S. Yoshikawa, L. Serrano, N. 
Yumoto, J. Pept. Sci. 2009, 15, 359–365. 
[152] G. V. Los, L. P. Encell, M. G. McDougall, D. D. Hartzell, N. Karassina, C. Zimprich, M. G. 
Wood, R. Learish, R. F. Ohana, M. Urh, et al., ACS Chem. Biol. 2008, 3, 373–382. 
[153] R. S. Erdmann, S. W. Baguley, J. H. Richens, R. F. Wissner, Z. Xi, E. S. Allgeyer, S. Zhong, A. 
D. Thompson, N. Lowe, R. Butler, et al., Cell Chem. Biol. 2019, 26, 584-592.e6. 
[154] E. I. Vrettos, G. Mező, A. G. Tzakos, Beilstein J. Org. Chem. 2018, 14, 930–954. 
[155] J. R. McCombs, S. C. Owen, AAPS J. 2015, 17, 339–351. 
[156] K. Tsuchikama, Z. An, Protein Cell 2018, 9, 33–46. 
[157] M. J. Roberts, M. D. Bentley, J. M. Harris, Adv. Drug Deliv. Rev. 2002, 54, 459–476. 
[158] H. Duclohier, BBA - Biomembr. 2009, 1788, 2374–2379. 
[159] W. A. Catterall, J. Physiol. 2012, 590, 2577–2589. 
  Bibliography 209 
[160] A. L. Hodgkin, A. F. Huxley, J. Physiol. 1952, 116, 473–496. 
[161] A. L. Hodgkin, A. F. Huxley, J. Physiol. 1952, 116, 449–472. 
[162] D. A. Beneski, W. A. Catterall, J. Supramol. Cell. Biochem. 1980, 12, 639–643. 
[163] R. P. Hartshorne, W. A. Catterall, Proc. Natl. Acad. Sci. U. S. A. 1981, 78, 4620–4624. 
[164] E. C. McCusker, C. Bagnéris, C. E. Naylor, A. R. Cole, N. D’Avanzo, C. G. Nichols, B. A. 
Wallace, Nat. Commun. 2012, 3, 1–8. 
[165] J. Payandeh, T. Scheuer, N. Zheng, W. A. Catterall, Nature 2012, 475, 353–358. 
[166] W. A. Catterall, Exp Physiol. 2014, 99, 1–7. 
[167] D. L. Bennett, X. A. J. Clark, J. Huang, S. G. Waxman, S. D. Dib-Hajj, Physiol. Rev. 2019, 99, 
1079–1151. 
[168] S. A. Pless, F. D. Elstone, A. P. Niciforovic, J. D. Galpin, R. Yang, H. T. Kurata, C. A. Ahern, 
J. Gen. Physiol. 2014, 143, 645–656. 
[169] W. A. Catterall, A. L. Goldin, S. G. Waxman, Pharmacol. Rev. 2005, 57, 397–409. 
[170] W. A. Catterall, Neuron 2000, 26, 13–25. 
[171] M. D. L. Ruiz, R. L. Kraus, J. Med. Chem. 2015, 58, 7093–7118. 
[172] T. Dudev, C. Lim, Acc. Chem. Res. 2014, 47, 3580–3587. 
[173] S. H. Heinemann, H. Terlau, W. Stuhmer, K. Imoto, S. Numa, Nature 1992, 356, 441–443. 
[174] W. A. Catterall, A. L. Goldin, S. G. Waxman, Pharmacol. Rev. 2005, 57, 397–409. 
[175] K. Jurkat-Rott, B. Holzherr, M. Fauler, F. Lehmann-Horn, Pflugers Arch. Eur. J. Physiol. 2010, 
460, 239–248. 
[176] C. Antzelevitch, V. Nesterenko, J. Shyrock, S. Rajamani, Y. Song, L. Belardinelli, Handb. Exp. 
Pharmacol. 2014, 221, 137–168. 
[177] A. Moreau, P. Gosselin-Badaroudine, M. Chahine, Front. Pharmacol. 2014, 5, 1–19. 
[178] A. Nardi, N. Damann, T. Hertrampf, A. Kless, ChemMedChem 2012, 7, 1712–1740. 
[179] K. Nakamura, M. Kato, H. Osaka, S. Yamashita, E. Nakagawa, K. Haginoya, J. Tohyama, M. 
Okuda, T. Wada, S. Shimakawa, et al., Neurology 2013, 81, 992–998. 
[180] J. W. Theile, T. R. Cummins, Front. Pharmacol. 2011, 2, 1–14. 
[181] K. S. Walia, E. A. Khan, D. H. Ko, S. S. Raza, Y. N. Khan, Pain Pract. 2004, 4, 194–203. 
Bibliography  210 
[182] J. P. Meeks, S. Mennerick, J. Neurophysiol. 2007, 97, 3460–3472. 
[183] D. A. Wollner, W. A. Catterall, Proc. Natl. Acad. Sci. 1986, 83, 8424–8428. 
[184] C. M. Colbert, E. Pan, Nat. Neurosci. 2002, 5, 533–538. 
[185] T. A. Stanly, M. Fritzsche, S. Banerji, E. Garcia, J. B. De La Serna, D. G. Jackson, C. Eggeling, 
Biol. Open 2016, 5, 1343–1350. 
[186] E. G. Moczydlowski, Toxicon 2013, 63, 165–183. 
[187] R. Chen, S. H. Chung, Biochem. Biophys. Res. Commun. 2014, 446, 370–374. 
[188] H. M. Garraffo, T. F. Spande, Heterocycles 2009, 79, 195–205. 
[189] J. Wang, V. Yarov-Yarovoy, R. Kahn, D. Gordon, M. Gurevitz, T. Scheuer, W. A. Catterall, 
Proc. Natl. Acad. Sci U.S.A. 2011, 108, 15426–15431. 
[190] J. K. Klint, S. Senff, D. B. Rupasinghe, S. Y. Er, V. Herzig, G. M. Nicholson, G. F. King, Toxicon 
2012, 60, 478–491. 
[191] B. G. Livett, K. R. Gayler, Z. Khalil, Curr. Med. Chem. 2004, 11, 1715–1723. 
[192] K. B. Akondi, M. Muttenthaler, S. Dutertre, Q. Kaas, D. J. Craik, R. J. Lewis, P. F. Alewood, 
Chem. Rev. 2014, 114, 5815–5847. 
[193] I. Vetter, R. J. Lewis, Curr. Top. Med. Chem. 2012, 12, 1546–1552. 
[194] K. B. Akondi, M. Muttenthaler, S. Dutertre, Q. Kaas, D. J. Craik, R. J. Lewis, P. F. Alewood, 
Chem. Rev. 2014, 114, 5815–5847. 
[195] J. Davis, A. Jones, R. J. Lewis, Peptides 2009, 30, 1222–1227. 
[196] B. Gao, C. Peng, B. Lin, Q. Chen, J. Zhang, Q. Shi, Toxins (Basel). 2017, 9, 1–10. 
[197] Q. Kaas, J. C. Westermann, D. J. Craik, Toxicon 2010, 55, 1491–1509. 
[198] S. D. Robinson, R. S. Norton, Mar. Drugs 2014, 12, 6058–6101. 
[199] F. Y. Dao, H. Yang, Z. D. Su, W. Yang, Y. Wu, H. Ding, W. Chen, H. Tang, H. Lin, Molecules 
2017, 22, 1–20. 
[200] J. E. Pope, T. R. Deer, Expert Opin. Pharmacother. 2013, 14, 957–966. 
[201] J. G. McGivern, Neuropsychiatr. Dis. Treat. 2007, 3, 69–85. 
[202] E. Leipold, R. Markgraf, A. Miloslavina, M. Kijas, J. Schirmeyer, D. Imhof, S. H. Heinemann, 
Neuropharmacology 2011, 61, 105–111. 
[203] B. R. Green, B. M. Olivera, Curr. Top. Membr. 2016, 78, 65–86. 
  Bibliography 211 
[204] E. Tosti, R. Boni, A. Gallo, Mar. Drugs 2017, 15, 1–16. 
[205] R. S. Norton, Molecules 2010, 15, 2825–2844. 
[206] R. Chen, A. Robinson, S. H. Chung, PLoS One 2014, 9, 1–8. 
[207] B. R. Green, G. Bulaj, R. S. Norton, Futur. Med. Chem. 2014, 6, 1677–1698. 
[208] S. Yao, M. M. Zhang, D. Yoshikami, L. Azam, B. M. Olivera, G. Bulaj, R. S. Norton, 
Biochemistry 2008, 47, 10940–10949. 
[209] C. Z. Wang, H. Zhang, H. Jiang, W. Lu, Z. Q. Zhao, C. W. Chi, Toxicon 2006, 47, 122–132. 
[210] B. R. Green, P. Catlin, M. M. Zhang, B. Fiedler, W. Bayudan, A. Morrison, R. S. S. Norton, B. 
J. Smith, D. Yoshikami, B. M. Olivera, et al., Chem. Biol. 2007, 14, 399–407. 
[211] D. Chelius, K. Jing, A. Lueras, D. S. Rehder, T. M. Dillon, A. Vizel, R. S. Rajan, T. Li, M. J. 
Treuheit, P. V. Bondarenko, Anal. Chem. 2006, 78, 2370–2376. 
[212] E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng, T. E. 
Ferrin, J. Comput. Chem. 2004, 25, 1605–1612. 
[213] A. M. Steiner, K. J. Woycechowsky, B. M. Olivera, G. Bulaj, Angew. Chemie - Int. Ed. 2012, 
51, 5580–5584. 
[214] A. Walewska, M. M. Zhang, J. J. Skalicky, D. Yoshikami, B. M. Olivera, G. Bulaj, Angew. 
Chemie - Int. Ed. 2009, 48, 2221–2224. 
[215] K. K. Khoo, M. J. Wilson, B. J. Smith, M.-M. Zhang, J. Gulyas, D. Yoshikami, J. E. Rivier, G. 
Bulaj, R. S. Norton, J. Med. Chem. 2011, 54, 7558–7566. 
[216] C. Pi, J. Liu, L. Wang, X. Jiang, Y. Liu, C. Peng, S. Chen, A. Xu, J. Biotechnol. 2007, 128, 184–
193. 
[217] A. H. Jin, M. Muttenthaler, S. Dutertre, S. W. A. Himaya, Q. Kaas, D. J. Craik, R. J. Lewis, P. 
F. Alewood, Conotoxins: Chemistry and Biology, 2019. 
[218] A. M. Steiner, G. Bulaj, J. Pept. Sci. 2011, 17, 1–7. 
[219] A. A. Miloslavina, E. Leipold, M. Kijas, A. Stark, S. H. Heinemann, D. Imhof, J. Pept. Sci. 2009, 
15, 72–77. 
[220] H. A. Radzey, Synthesis of fluorescent toxin and nucleotide derivatives to specifically address 
membrane proteins, Dissertation, Georg-August Universität Göttingen, 2015. 
[221] L. Moroder, H. J. Musiol, M. Götz, C. Renner, Biopolym. - Pept. Sci. Sect. 2004, 80, 85–97. 
[222] G. Bulaj, B. M. Olivera, Antioxid. Redox Signal. 2008, 10, 141–155. 
Bibliography  212 
[223] C. Boulègue, H. J. Musiol, V. Prasad, L. Moroder, Chim. Oggi 2006, 24, 24–36. 
[224] T. M. Postma, F. Albericio, European J. Org. Chem. 2014, 2014, 3519–3530. 
[225] A. Cuthbertson, B. Indrevoll, Org. Lett. 2003, 5, 2955–2957. 
[226] A. I. Kuzmenkov, A. A. Vassilevski, Neurosci. Lett. 2018, 679, 15–23. 
[227] A. J. Hone, M. Scadden, J. Gajewiak, S. Christensen, J. Lindstrom, J. M. Mcintosh, 2012, 82, 
972–982. 
[228] D. S. Kudryavtsev, I. V. Shelukhina, L. V. Son, L. O. Ojomoko, E. V. Kryukova, E. N. 
Lyukmanova, M. N. Zhmak, D. A. Dolgikh, I. A. Ivanov, I. E. Kasheverov, et al., J. Biol. Chem. 
2015, 290, 22747–22758. 
[229] Z. Zhang, D. Yomo, C. Gradinaru, BBA - Biomembr. 2017, 1859, 1242–1253. 
[230] P. Heimer, A. A. Tietze, C. A. Bäuml, A. Resemann, F. J. Mayer, D. Suckau, O. Ohlenschläger, 
D. Tietze, D. Imhof, Anal. Chem. 2018, 90, 3321–3327. 
[231] M. Ieronymaki, M. E. len. Androutsou, A. Pantelia, I. Friligou, M. Crisp, K. High, K. Penkman, 
D. Gatos, T. Tselios, Biopolymers 2015, 104, 506–514. 
[232] J. P. Tam, C. R. Wu, W. Liu, J. W. Zhang, J. Am. Chem. Soc. 1991, 113, 6657–6662. 
[233] B. Kamber, A. Hartmann, K. Eisler, B. Riniker, H. Rink, P. Sieber, W. Rittel, Helv. Chim. Acta 
1980, 63, 899–915. 
[234] M. J. Espiritu, Disulfide Bond and Topological Isomerization of the Conopeptide PNID: 
Disulfide Bonds with a Twist, Dissertation, University of Hawaii, 2017. 
[235] Y. Shimonishi, Y. Hidaka, M. Koizumi, M. Hane, S. Aimoto, T. Takeda, T. Miwatani, Y. 
Takeda, FEBS Lett. 1987, 215, 165–170. 
[236] M. Okumura, S. Shimamoto, Y. Hidaka, FEBS J. 2012, 279, 2283–2295. 
[237] M. J. Wilson, D. Yoshikami, L. Azam, J. Gajewiak, B. M. Olivera, G. Bulaj, M. M. Zhang, Proc. 
Natl. Acad. Sci. U. S. A. 2011, 108, 10302–10307. 
[238] L. D. Hughes, R. J. Rawle, S. G. Boxer, PLoS One 2014, 9, 1–8. 
[239] P. Thirumurugan, D. Matosiuk, K. Jozwiak, Chem. Rev. 2013, 113, 4905–4979. 
[240] F. Saito, H. Noda, J. W. Bode, ACS Chem. Biol. 2015, 10, 1026–1033. 
[241] W. M. Rink, F. Thomas, Org. Lett. 2018, 20, 7493–7497. 
[242] M. Empting, O. Avrutina, R. Meusinger, S. Fabritz, M. Reinwarth, M. Biesalski, S. Voigt, G. 
  Bibliography 213 
Buntkowsky, H. Kolmar, Angew. Chemie - Int. Ed. 2011, 50, 5207–5211. 
[243] T. D. Kondasinghe, H. Y. Saraha, S. B. Odeesho, J. L. Stockdill, Org. Biomol. Chem. 2017, 15, 
2914–2918. 
[244] T. D. Kondasinghe, H. Y. Saraha, S. T. Jackowski, J. L. Stockdill, Tetrahedron Lett. 2019, 60, 
23–28. 
[245] F. Wu, J. P. Mayer, V. M. Gelfanov, F. Liu, R. D. Dimarchi, J. Org. Chem. 2017, 82, 3506–
3512. 
[246] F. Czerny, Development of Zinc-Finger-Based Artificial Restriction Endonucleases and 
Fluorescent Peptidyl Metal Sensors, Dissertation, Georg-August Universität Göttingen, 2016. 
[247] E. J. Ste.Marie, R. J. Hondal, J. Pept. Sci. 2018, 24, 1–8. 
[248] A. Otaka, T. Koide, A. Shide, N. Fujii, Tet 1991, 32, 1223–1226. 
[249] A. Schulz, E. Klüver, S. Schulz-Maronde, K. Adermann, Biopolym. - Pept. Sci. Sect. 2005, 80, 
34–49. 
[250] B. H. Northrop, S. H. Frayne, U. Choudhary, Polym. Chem. 2015, 6, 3415–3430. 
[251] J. S. Nanda, J. R. Lorsch, Methods Enzymol. 2014, 536, 87–94. 
[252] C. González-Cabrera, R. Meza, L. Ulloa, P. Merino-Sepúlveda, V. Luco, A. Sanhueza, A. Onate-
Ponce, J. P. Bolam, P. Henry, J. Comp. Neurol. 2017, 1–37. 
[253] H. Yu, J. Li, D. Wu, Z. Qiu, Y. Zhang, Chem. Soc. Rev. 2010, 39, 464–473. 
[254] H.-M. Lee, D. R. Larson, D. S. Lawrence, ACS Chem. Biol. 2009, 4, 409–427. 
[255] M. J. Hansen, W. A. Velema, M. M. Lerch, W. Szymanski, B. L. Feringa, Chem. Soc. Rev. 2015, 
44, 3358–3377. 
[256] W. H. So, C. T. T. Wong, J. Xia, Chinese Chem. Lett. 2018, 29, 1058–1062. 
[257] P. Klán, T. Šolomek, C. G. Bochet, A. Blanc, R. Givens, M. Rubina, V. Popik, A. Kostikov, J. 
Wirz, Chem. Rev. 2013, 113, 119–191. 
[258] Y. V. Il’ichev, M. A. Schwörer, J. Wirz, J. Am. Chem. Soc. 2004, 126, 4581–4595. 
[259] N. Fomina, C. Mcfearin, M. Sermsakdi, O. Edigin, A. Almutairi, J. Am. Chem. Soc. 2010, 132, 
9540–9542. 
[260] M. Quast, Synthesis and Analyis of Modified SNARE Proteins with Respect to Assembly and 
Disassembly of the SNARE Complex, Dissertation, Georg-August Universität Göttingen, 2016. 
Bibliography  214 
[261] S. Zhou, O. Mozziconacci, B. A. Kerwin, C. Schöneich, Pharm. Res. 2013, 30, 1291–1299. 
[262] S. Bourgault, M. Létourneau, A. Fournier, Peptides 2007, 28, 1074–1082. 
[263] A. Specht, J. S. Thomann, K. Alarcon, W. Wittayanan, D. Ogden, T. Furuta, Y. Kurakawa, M. 
Goeldner, ChemBioChem 2006, 7, 1690–1695. 
[264] S. B. Cambridge, D. Geissler, S. Keller, B. Cürten, Angew. Chemie - Int. Ed. 2006, 45, 2229–
2231. 
[265] V. Hagen, J. Bendig, S. Frings, T. Eckardt, S. Helm, D. Reuter, B. Kaupp, Angew. Chem. Int. 
Ed. 2001, 40, 1046–1048. 
[266] L. Fan, R. W. Lewis, G. P. Hess, B. Ganem, Bioorg. Med. Chem. Lett 2010, 19, 3932–3933. 
[267] D. Geißler, W. Kresse, B. Wiesner, J. Bendig, H. Kettenmann, V. Hagen, ChemBioChem 2003, 
4, 162–170. 
[268] R. O. Schönleber, J. Bendig, V. Hagen, B. Giese, Bioorganic Med. Chem. 2002, 10, 97–101. 
[269] N. Kotzur, B. Briand, M. Beyermann, V. Hagen, J. Am. Chem. Soc. 2009, 131, 16927–16931. 
[270] J. Gonzales, P. Demetrio De Souza Franca, Y. Jiang, G. Pirovano, S. Kossatz, N. Guru, D. 
Yarilin, A. J. Agwa, C. I. Schroeder, S. G. Patel, et al., Bioconjug. Chem. 2019, 30, 2879–2888. 
[271] A. E. Ondrus, H. L. D. Lee, S. Iwanaga, W. H. Parsons, B. M. Andresen, W. E. Moerner, J. Du 
Bois, Chem. Biol. 2012, 19, 902–912. 
[272] M. H. Litt, J. Kim, J. M. Rodriguezparada, J. Polym. Sci. Polym. Chem. Ed. 1985, 23, 1307–
1319. 
[273] E. Masson, Y. M. Shaker, J. Masson, M. E. Kordesch, Org. Lett. 2011, 13, 3872–3875. 
[274] C. De Gracia Lux, J. Olejniczak, N. Fomina, M. L. Viger, A. Almutairi, J. Polym. Sci. Part A 
Polym. Chem. 2013, 51, 3783–3790. 
[275] A. Schirmacher, Modification of transmembrane peptides to probe SNARE-induced membrane 
fusion and cross-presentation membrane-buried epitopes. Dissertation, Georg-August-
Universität Göttingen, 2020. 




  List of Figures 215 
6 List of Figures 
 
Figure 1.1: Cycling of Neurotransmitters and Synaptic vesicles. ........................................................... 4 
Figure 1.2: Proton-dependent neurotransmitter transport into vesicles. .................................................. 5 
Figure 1.3: Structure of VGLUT. ............................................................................................................ 7 
Figure 1.4: Functional residues of VGLUT. ........................................................................................... 8 
Figure 1.5: Cl- dependence of vesicular glutamate uptake. .................................................................... 9 
Figure 1.6: Proteoliposome model for Cl- transport mechanism. .......................................................... 10 
Figure 1.7: Proposed mechanism of glutamate uptake in the synaptic vesicle. .................................... 12 
Figure 1.8: Model of the VGLUT transport mechanism. ...................................................................... 13 
Figure 1.9: Elevated model of the VGLUT transport mechanism. ....................................................... 14 
Figure 1.10: Schematic representation of CL-SENSOR. ......................................................................... 16 
Figure 1.11: Schematic presentation of the CLOPHENSOR. ................................................................... 16 
Figure 1.12: Examples for the first-generation Cl--sensitive small molecules. ..................................... 18 
Figure 1.13: Structure of a ratiometric Cl- sensor. ................................................................................ 20 
Figure 1.14: Structure of the I-switch sensor. ....................................................................................... 20 
Figure 1.15: Schematic structure of various DNA based sensor. .......................................................... 22 
Figure 1.16: Schematic presentation of the CLENSOR. .......................................................................... 24 
Figure 1.17: Structure and function of the Cl- sensors. ......................................................................... 26 
Figure 1.18: Target structure of Cl- sensitive PNA module. ................................................................. 27 
Figure 1.19: Structure of the aeg-PNA. ................................................................................................. 28 
Figure 1.20: Synthesis and analysis of PNA oligomer. ......................................................................... 29 
Figure 1.21: Synthesis of the Cl- sensitive BAC fluorophore (4). ......................................................... 30 
Figure 1.22: Synthesis and Analysis of BAC labelled PNA oligomer. ................................................. 31 
Figure 1.23: Synthesis of amino-5-cholestene (X). ............................................................................... 32 
Figure 1.24: Synthesis approach of cholesterol modified peptide-PNA oligomers. ............................. 33 
Figure 1.25: Synthesis approach of cholesterol modified peptide-PNA oligomer in solution. ............. 33 
Figure 1.26: Synthesis of Fmoc-Asp(palmitoyl)-OH (X) over two steps. ............................................ 34 
Figure 1.27: Synthesis and analysis of palmitoyl and BAC modified PNA oligomer. ......................... 35 
Figure 1.28: Synthesis of palmitoyl, TEV and BAC modified peptide-PNA oligomer. ....................... 36 
Figure 1.29: TEV-protease cleavage experiments of the palmitoyl modified PNA sensor. .................. 37 
Figure 1.30: TEV-cleavage experiments of different test peptides. ...................................................... 38 
Figure 1.31: Structure and cleavage of Factor Xa test peptides. ........................................................... 39 
Figure 1.32: Synthesis and Factor Xa cleavage of palmitoyl-modified PNA sensors........................... 40 
Figure 1.33: Synthesis and cathepsin B cleavage of palmitoyl-modified PNA sensors. ....................... 41 
Figure 1.34: Separation of incorporated sensors by density-gradient centrifugation. ........................... 42 
Figure 1.35: Incorporation of the palmitoyl-modified PNA sensor in liposomes. ................................ 42 
Figure 1.36: Synthesis and Cathepsin B cleavage of TMD-modified PNA sensors. ............................ 44 
Figure 1.37: Incorporation assay of the TMD-modified PNA sensor in liposomes. ............................. 45 
Figure 1.38: Quenching experiments in fluorophore labelled TMD peptides. ...................................... 45 
Figure 1.39: Synthesis and incorporation assay of NBD labelled TMD peptides. ................................ 46 
Figure 1.40: Gel mobility shift assay for visualisation of  the Cl- sensor formation. ............................ 47 
Figure 1.41: Strategy for a more effective Cl--sensor encapsulation..................................................... 49 
Figure 1.42: Epimerization of Fmoc-His(PG)-OH during SPPS activation. ......................................... 50 
Figure 1.43: Synthesis and analysis of His14-PNA sensors. .................................................................. 51 
Figure 1.44: Gel mobility assay visualizing the His14 Clensor formation. ............................................ 52 
Figure 1.45: Cl- sensitivity measurements of the His14 Cl- sensor......................................................... 53 
Figure 1.46: Integrity analysis of His14 Cl- sensor by gel mobility shift assay. ..................................... 54 
Figure 1.47: Encapsulation and cleavage of His14-Cl- sensor in Ni2+ modified liposomes. .................. 55 
Figure 1.48: Purification and Cl- measurements of encapsulated His14 sensors in liposomes. ............. 56 
List of Figures  216 
Figure 1.49: Activity measurements of encapsulated VGLUT TF0F1 His14 in liposomes. ................... 58 
Figure 1.50: Time-dependent BAC fluorescence intensity of His14-Cl--sensor. ................................... 59 
Figure 1.51: Strategy for Cl--sensor incorporation in synaptic vesicles. ............................................... 60 
Figure 1.52: Structure of the nanobody fairy. ....................................................................................... 61 
Figure 1.53: Synthesis and analysis of ALFA-tag modified PNA sensor. ............................................ 62 
Figure 1.54: Gel mobility shift assay of the ALFA-Cl--sensor formation with the ALFA-nanobody. . 63 
Figure 1.55: Synthesis of AlexaFluor 488 labelled ALFA-tag peptides. .............................................. 64 
Figure 1.56: Gel mobility shift assay visualizing the AFLA-peptide nanobody formation. ................. 64 
Figure 1.57: Structure of the PNA-DNA based Cl- sensor. ................................................................... 66 
Figure 1.58: Overview of the results of the TMD and Cathepsin B modified PNA sensor. ................. 68 
Figure 1.59: Overview of the results of the His14-PNA sensor. ............................................................ 69 
Figure 2.1: Structure of NaV channels. .................................................................................................. 72 
Figure 2.2: Tissue expression of the nine different voltage gated sodium channel subtypes.[158] ......... 73 
Figure 2.3: Non-peptidic toxins inhibiting the NaV channels. ............................................................... 74 
Figure 2.4: Peptidic toxins that inhibit NaV channels. ........................................................................... 75 
Figure 2.5: Classification of conotoxins. ............................................................................................... 76 
Figure 2.6: Structure and sequence of µ-conotoxin SIIIA. ................................................................... 79 
Figure 2.7: Formation possibilities in a peptide containing two-disulphide bonds. .............................. 80 
Figure 2.8: Comparison of oxidative one-step folding and regioselective synthesis strategy. .............. 81 
Figure 2.9: 3D Structure of the µ-SIIIA modified with AlexaFluor 488. ............................................. 84 
Figure 2.10: Schematic overview of the µ-SIIIA synthesis into a fluorescent labelled toxin. .............. 85 
Figure 2.11: Formation of the first disulphide bridge of the native µ-SIIIA. ........................................ 86 
Figure 2.12: Formation of the second disulphide bridge of the native µ-SIIIA. ................................... 87 
Figure 2.13: Formation of the third disulphide bridge of the µ-SIIIA. ................................................. 88 
Figure 2.14: Folding strategy of disulphide bonds. ............................................................................... 89 
Figure 2.15: Synthesis and purification of native µ-SIIIA. ................................................................... 90 
Figure 2.16: Patch-clamp measurements of isomer 2.1......................................................................... 92 
Figure 2.17: Patch-clamp measurements of isomer 2.2......................................................................... 93 
Figure 2.18: Synthesis and purification of alkyne modified µ-SIIIA. ................................................... 95 
Figure 2.19: Synthesis and purification of AlexaFluor 488 labelled µ-SIIIA. ...................................... 96 
Figure 2.20: Synthesis strategy for the Allocam-protected alkyne-modified µ-SIIIA. ......................... 98 
Figure 2.21: Synthesis strategy of tert-butyl-protected and alkyne modified µ-SIIIA. ......................... 99 
Figure 2.22: Synthesis strategy of MeOBzl-protected and alkyne modified µ-SIIIA. ........................ 100 
Figure 2.23: Synthesis approach for Cys(Acm)-modified µ-SIIIA. .................................................... 102 
Figure 2.24: Synthesis and purification of TMR labelled µ-SIIIA. .................................................... 104 
Figure 2.25: Overview of the synthesis and application of caged neurotoxins. .................................. 105 
Figure 2.26: 3D Structure of the µ-conotoxin SIIIA. .......................................................................... 106 
Figure 2.27: Synthesis of the caged Fmoc-Lys(Nvoc)-OH building block for SPPS over two steps. 107 
Figure 2.28: Structure and uncaging experiments of Nvoc modified peptides. .................................. 108 
Figure 2.29: Synthesis of the caged Fmoc-Asp(DMNPB)-OH building block for SPPS. .................. 109 
Figure 2.30: Structure and uncaging experiments of DMNPB modified peptides. ............................. 110 
Figure 2.31: Three step synthesis of Fmoc-Lys(DEACM)-OH building block for SPPS................... 111 
Figure 2.32: Structure and uncaging experiments of DEACM modified peptides. ............................. 111 
Figure 2.33: Synthesis and purification of the DECAM caged µ-SIIIA. ............................................ 113 
Figure 2.34: Photocleavage experiments of DEACM caged µ-SIIIA. ................................................ 114 
Figure 2.36: Patch-clamp experiments of isomer 4.2. ......................................................................... 117 
Figure 2.37: Patch-clamp experiments of isomer 4.3. ......................................................................... 118 
Figure 2.38: HPLC analysis of irradiated isomer 4.1 and 4.2. ............................................................ 119 
Figure 2.39: Overview of the results of the native µ-SIIIA. ............................................................... 121 
Figure 2.40: Overview of the results of the AlexaFluor 488 labelled µ-SIIIA. .................................. 121 
Figure 2.41: Overview of the results of the PPG modified µ-SIIIA. .................................................. 123 
 
  List of Tables 217 
7 List of Tables 
 
Table 1.1: Overview of the fluorescent Cl--sensitive small molecule dyes. .......................................... 18 
Table 1.2: Overview of the photophysical characteristics of different BAC-labelled constructs. ........ 23 
Table 1.3: Overview of the different test peptides with the TEV recognition sequence. ...................... 38 
Table 1.4: Sequence of the peptide-PNA and DNA oligomers. ............................................................ 47 
Table 2.1: µ-Conotoxin sequences and characteristics.......................................................................... 78 
Table 2.2: Overview of frequently used thiol protecting groups for SPPS. .......................................... 82 
Table 3.1:The extinction coefficients used for concentration estimations. ......................................... 128 


























Acknowledgements  218 
8 Acknowledgements 
 
Mein besonderer Dank gilt Prof. Dr. Ulf Diederichsen für die Möglickeit meine Dissertation 
bei Ihnen im Arbeitskreis anfertigen zu dürfen, sowie für die sehr gute Betreeung, ständige 
Diskussionsbereitschaft und die wissenschaftliche Freiheit. Ich bin sehr dankbar für das 
Vertrauen und die enge Zusammenarbeit nicht nur in wissenschaftlichen Fragen, sondern auch 
in der Betreung von Bachelorstudenten und in der Organisation von Praktika. 
Meiner Zweitgutachterin Prof. Dr. Claudia Steinem möchte ich danken für die Übernahme des 
Koreferats, sowie für die jährlichen Treffen und die daraus resultierenden Diskussionen und 
hilfreichen Vorschläge für mein Projekt.  
Darüber hinaus danke ich Prof. Dr. Reinhard Jahn, Prof. Dr. Silvio Rizzoli, Dr. Stefan Glöggler 
und Dr. Holm Frauendorf für die Bereitschaft meiner Prüfungskommsission anzugehören.  
Mein besonderer Dank gilt Rashi Goel und Jennifer Struck für die intensive Kooperiation, die 
Diskussions- und Hilfsbereitschaft bei biologischen und physikalischen Fragestellungen, sowie 
für die enge und gute Zusammenarbeit auf dem Chlorid-Sensor Thema. Zusätzlich möchte ich 
mich bei Benjamin Ide und Frederike Maaß für die Durchführung von Experimenten bedanken. 
Bei Vivien Kistmacher und Prof. Dr. Enrico Leipold möchte ich mich für die Messungen der 
Conotoxin Proben sowie für ausführlichen Diskussionen und Erklärungen zur den Toxin 
Eigenschaften bedanken. 
Dr. Michael John und dem Team der NMR Abteilung danke für die Anfertigung der 
Kernresonanzspektren. Bei Dr. Holm Frauendorf und seinen Mitarbeitern aus der 
Massenspektrometrie Abteilung möchte ich mich ganz besonders bedanken, für die schnelle 
und gewissenhafte Bearbeitung meiner unzähligen Proben. 
Ganz besonders möchte ich mich bei Angela Heinemann bedanken: für die ständige 
Unterstützung in allen Situationen, dein offenes Ohr und dafür, dass du dir immer Zeit für meine 
kleinen und großen Probleme genommen hast. Besonders dankbar bin ich, dass du mir das 
Verlegen von Rechnungen oder das Chaos im Labor nie übel genommen hast.  
Allen aktuellen und ehemaligen Mitgliedern des Arbeitskreises Diederichsen danke ich für die 
vielen schönen Stunden, beim Mittagessen, der Kaffeepause oder auf den AK-Fahrten.  
Meinen Laborkollegen Dr. Matthias Krull und Ilze Lace danke ich für die schöne und lustige 
Zeit im Labor 106.  
  Acknowledgements 219 
Bei Dr. Denis Pahlke, Dr. Geralin Höger, Dr. Anastasiya Schirmacher, Mathis Rink und 
Benedikt Kugler möchte ich mich für die vielen hilfreichen wissenschaftlichen Diskussionen 
und Ratschläge bedanken.  
Ein unendlich großer Dank gehört den von mir betreuten Bachelorstudenten Lina Kopp, Lucas 
Hensen, Manuel Müller und Katharina Overhoff für die großartige Unterstützung im Labor, die 
vielen schönen Stunden und euren Beitrag zu meinen Projekten . 
Für das Korrekturlesen meiner Arbeit möchte ich mich ganz besonders bei Iriyna Portnova, 
Benedikt Kugler, Tobias Schmidt, Lina Kopp, Florian Grimm, Dr. Julia Menzel und Katharina 
Ewers bedanken. Vielen Dank für eure hilfreichen Korrekturvorschläge  
Ein besonderes großer Dank geht an Florian Grimm für all die Laufrunden am Donnerstagabend 
im Regen und bei Schneefall. Zusätzlich danke ich dir für alle Mittagspausen am Freitag, deine 
Hilfsbeitschaft in allen Lebenslagen und deine Freundschaft.  
Den Handballern vom NSC danke ich für die unzähligen schönen Stunden in der Halle und auf 
dem Sportplatz , sowie für die Ablenkung und den Ausgleich zum Laboralltag.  
Meinen „Schwiegereltern“ in spe möchte ich danken für all die gemeinsame Zeit sowie eure 
Unterstützung und Hilfe während der letzten Jahre. Auch bei Maximilian und Alexander 
möchte ich mich bedanken für eurer Hilfsbereitschaft und die vielen lustigen Studen. Ganz 
besonderer Dank geht an Constantin, für die beste WG aller Zeiten, fürs gemeinsame Handball 
spielen, Football schauen und für all die schönen Stunden.  
Bei Julia und Marcel möchte ich mich bedanken für die unfassbar schöne Zeit, sowie für eure 
Unterstützung und Hilfe in allen Lebenslagen. Danke für all die Grillabende, Laufrunden, für 
das Anfeuern bei Heimspielen, Spieleabende und Urlaube.  
Ein unendlich großer Dank geht an meine Eltern. Danke für die Ermöglichung des Studiums, 
sowie eure bedingungslose Unterstützung und euren Rückhalt, die mich so weit gebracht haben.  
Mein größter Dank geht an Katharina, für all die Unterstützung, Hilfsbereitsschaft, gute Laune 
in den letzten Jahren, in allen guten und schlechten Augenblicken. Vielen Dank für deine 
Begeisterung für all unsere Abenteuer und dafür, dass du immer an meiner Seite bist und warst. 
 
 
Curriculum Vitae  220 
9 Curriculum Vitae 
 
Patrick Matthias Menzel 




01/2017-11/2020 PhD thesis in the working group of Prof. Dr. Ulf Diederichsen at 
the Institute of Organic and Biomolecular Chemistry (IOBC), 
Georg-August University Göttingen 
Synthesis of Modified Biomolecules to Investigate Neuronal 
Processes 
10/2014-11/2016  M. Sc. Chemistry Philipps University Marburg 
Overall grade: very good (1.1)  
Master Thesis (04-11/2016) in the working group of Prof. Dr. 
Martin Schlitzer at the Institute of Pharmaceutical Chemistry 
Synthesis and Investigation of Sulfonamide-Derivates as 
Inhibitors of the eIF4F Complex 
06/2014-10/2014 IRTG Research student at the IOBC in the working group of Prof. 
Dr. Ulf Diederichsen 
    Synthesis and Modification of Zinc Finger Zif268 
10/2011-06/2014  B.Sc. Biochemistry Georg-August-University Göttingen 
Overall grade: good (1.7)  
Bachelor Thesis (04-06/2014) in the working group of Prof. Dr. 
Ulf Diederichsen at the IOBC 
    Synthesis and Investigation of Modified β-Peptides 







  Curriculum Vitae 221 
Scientific Contributions 
2020 Oral Presentation, 12th Göttinger Chemie Forum, Synthesis of 
Fluorescent Neurotoxins to Investigate Neuronal Processes 
2019  Poster Presentation, 14th German Peptide Symposium, Cologne, 
Germany, Modified Biomolecules to Address Membrane 
Proteins and to Quantify Ion Concentrations 
2018 Poster Presentation, 8th Peptide Engineering Meeting, Berlin, 
Germany, Peptide Nucleic Acid (PNA) as a Reaction Template 
and Recognition Motif in Bioorganic Chemistry  
 
Selected Teaching Experience 
01/2017-11/2020   Supervision of four bachelor theses and one student internship 
01/2017-11/2020  Senior assistant: practical course Biological Chemistry 
01/2017-11/2020 Senior assistant: practical course Enzyme catalysis and 
biological chemistry  
 
Awards 
2020    Travel Grand, 12th International Peptide Symposium, Barcelona,
    Spain 
2018    Poster Award, 8th Peptide Engineering Meeting, Berlin, Germany 
Publications 
B. E. Hubrich, P. M. Menzel, B. Kugler, U. Diederichsen, Peptide Nucleic Acids: Methods and 
Protocols, P. Nielsen (Ed.), 3rd Edition, Springer Verlag, Wiesbaden, 2020. 
 
